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1 Introduction 
1.1 Neuronal cell death mechanisms 
Neuronal viability is maintained through a complex interactive network of signaling pathways 
and can be disturbed in response to multiple cellular stress factors and pathologies. Although 
neuronal death is required for the normal development of the central nervous system (CNS), 
as well as for the removal of dysfunctional cells in pathological conditions, excessive loss of 
neurons underlies the symptoms of many human neurological disorders, including acute 
brain injury as well as neurodegenerative diseases, such as Alzheimer´s disease (AD), 
Parkinson´s diseases (PD), Huntington´s disease (HD) and amyotrophic lateral sclerosis 
(ALS)1, 2. Oxidative stress and perturbed calcium homeostasis are environmental factors of 
neuronal death that ultimately compromise mitochondrial function, energy metabolism and 
nuclear integrity2. Although extensive research has provided insights into several key factors 
and targets that play important roles in mediating neuronal injury, and recent advances have 
improved the management of the neurological diseases mentioned above, there is no 
effective treatment available so far that prevents neuronal death. Since current treatments 
are mostly symptomatic and achieve only mild to moderate effects in patients, it is 
indispensable to further explore the biological pathways of neuronal disorders and to validate 
novel therapeutic perspectives against the progressive loss of brain function in both acute 
and chronic brain injury3, 4.  
Although it is well recognized that neurons die after acute brain damage and in 
neurodegenerative diseases, the mode of cell death is not always clear. Neuronal cell death 
has been commonly delineated into two distinct categories: apoptosis and necrosis. 
However, limitations of such nomenclature became apparent when apoptotic mechanisms 
were associated with necrotic cell death features, leading to an expanding number of 
additional neuronal cell death classifications based on morphological and biochemical 
considerations5. Therefore, neuronal cell death has also been described in terms of regulated 
necrosis or necroptosis and authophagy. 
Necrosis is an acute and passive form of cell death associated with the loss of ATP, loss of 
ionic homeostasis, membrane disruption, and organelle and cell swelling. Thus, necrosis 
causes inflammation in the surrounding region due to the release of cellular contents into the 
environment6. As there is no defined biochemical pathway, necrosis is not termed as a 
programmed form of cell death in contrast to the recently identified forms of regulated 
necrosis or necroptosis that occur in a RIP1 and/or RIP3-dependent manner5, 7. However, 
both pathways are described in neurons and have been associated to several 
neurodegenerative diseases, indicating their relevance for further therapeutic interventions8-
11.  
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In contrast to necrosis, apoptosis is a highly conserved and uniform type of programmed cell 
death, characterized by nuclear condensation and DNA fragmentation as well as membrane 
blebbing and formation of apoptotic bodies12. Cells undergoing apoptosis secrete signals that 
initiate their phagocytic removal by macrophages or neighboring cells, thereby preventing 
cell lysis and inflammatory response1. Thus, apoptosis serves as an important physiological 
function in the replacement of senescent and excessive cells. In the nervous system, 
apoptosis is essential during development, removing unnecessary cells thereby controlling 
the formation of synapses and neuronal plasticity1, 13. In contrast to its physiological role, 
pathological pathways of apoptosis have been associated with the progressive neuronal loss 
during several neuronal disorders including AD and PD as well as with delayed cell death 
after acute brain damage caused by cerebral ischemia or traumatic brain injury (TBI)2, 14-16.  
Apoptosis can result from the activation of two biochemical cascades, which are known as 
the extrinsic pathway and the intrinsic mitochondrial pathway (Figure 1). The extrinsic 
apoptotic pathway is initiated by the activation of specific cell surface receptors, specifically 
by the members of the tumor necrosis factor (TNF) family. Fas-ligand (FasL) activation of the 
Fas receptor leads to the association with the adaptor protein FADD (Fas-associated protein 
death domain) and the initiator caspases 8 or 10 to form a complex known as DISC (death-
inducing signaling complex)17. The activation of downstream effector caspases (3, 6, or 7) 
triggers the proteolytical cleavage of many cellular substrates and the activation of nucleases 
like caspase-activated desoxyribonuclease (CAD), thereby mediating DNA cleavage and cell 
death5, 18. While extrinsic apoptosis can occur irrespective of any contribution by 
mitochondria, caspase-8 can also cleave and activate the pro-apoptotic protein Bid to its 
active truncated form tBid. tBid in turn causes changes in mitochondrial permeability, thereby 
initiating the cascade of intrinsic apoptosis5, 17. 
In contrast, intrinsic apoptosis involves a cascade of molecular events occurring within the 
cells, independent of plasma membrane receptor stimulation. Various conditions trigger 
intrinsic cell death pathways, including accelerated oxidative stress, intracellular [Ca2+] 
deregulation and DNA damage, but converge at mitochondria where the permeabilization of 
the mitochondrial outer membrane (MOMP) is considered as the ´point of no return´ in the 
cell’s commitment to die5, 19. Breakdown of the mitochondrial membrane potential (Δψm) is 
associated with impaired oxidative phosphorylation and diminished energy supplies, 
enhanced production of reactive oxygen species (ROS), and the release of mitochondrial 
proteins, such as cytochrome c, Omi/HtrA2, Smac/DIABLO, and apoptosis-inducing factor 
(AIF)5, 17, 20-24. Upon mitochondrial release, AIF rapidly translocates to the nucleus and 
induces chromatin condensation and large-scale DNA fragmentation, resulting in the final 
execution steps of caspase-independent intrinsic cell death25. 
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In contrast, intrinsic apoptotic pathways can also occur in a caspase-dependent manner as 
cytosolic cytochrome c might interact with the apoptosis protease-activating factor-1 
(APAF-1) as well as with pro-caspase-9 to form the apoptosome. This results in the 
sequential activation of execution caspases 3, 6 and 7, which in turn induce the breakdown 
of the framework through degradation of several substrates, executing the final cell death 
process5, 18. Alternatively, caspase activation is mediated by the mitochondrial release of 
Omi/HtrA2 or Smac/DIABLO, which are capable of blocking the anti-apoptotic protein XIAP 
(x-chromosomal linked inhibitor of apoptosis) and other IAPs (inhibitors of apoptosis), 
thereby releasing caspase-3 from its physiological inhibitors17.  
 
Figure 1: Intrinsic and extrinsic pathways of apoptotic cells death. 
Apoptosis can result from the activation of two biochemical cascades, the extrinsic pathway and the intrinsic 
(mitochondrial) pathway. The extracellular extrinsic pathway is initiated at the plasma membrane: The death 
receptor Fas is activated by its ligand (FasL), which in turn leads to the association of the Fas associated death 
domain (FADD). Procaspase-8 is bound by the death effector domain (CED) and activated through FADD 
complex binding. Activation of caspase-8 triggers the cleavage and activation of downstream effector caspase-3, 
inducing the release of CAD (caspase-activated desoxyribonuclease) from its inhibitory ligand ICAD. This induces 
the CAD-mediated nuclear DNA fragmentation, accelerating cell death. The intrinsic mitochondrial pathway is 
triggered by intracellular stimuli such as Ca
2+
 overload and increased generation of reactive oxygen species 
(ROS). Caspase-8 mediated cleavage of the pro-apoptotic protein Bid into its active truncated form tBid links the 
extrinsic and intrinsic pathway. tBid translocation to the mitochondria induces the detrimental mitochondrial outer 
membrane permeabilization (MOMP), which marks the point of no return in the intrinsic cell death machinery.  
Permeabilization of MOM allows the mitochondrial release of death promoting proteins such as AIF, 
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Smac/DIABLO (Smac), Omi /HtrA2 and cytochrome c (C) in the cytosol. Smac/DIABLO or Omi/HtrA2 scavenge 
the inhibitors of apoptosis (IAPs) such as XIAP, thereby enhancing the activation of caspase-3. Further, cytosolic 
cytochrome c, APAF-1 and procaspase-9 interact to form the apoptosome that additionally drives the activation of 
caspase-3. Upon mitochondrial release, AIF translocates into the nucleus where it induces chromatin 
condensation and DNA fragmentation thereby resulting in caspase-independent cell death. 
 
1.1.1 Oxidative stress, mitochondria and the point of no return 
In humans, oxidative stress has been associated with a variety of pathologies, including 
chronic inflammatory processes, cancer, type II diabetes or arteriosclerosis, as well as 
ischemic injury, brain trauma and several neurodegenerative diseases26. Under physiological 
conditions, low levels of ROS are involved in signaling processes mediating cellular growth 
and adaptation responses27. However, the imbalance of excessive ROS production over 
antioxidant defense can lead to oxidation of macromolecules and has been implicated in the 
damage of intracellular structures, mitochondrial dysfunction and cell death28. In neurons, 
enhanced production of ROS occurs in both, developmental apoptosis as well as in various 
neuropathological conditions29-34, indicating the relevance of oxidative stress in neuronal 
damage. Given the importance of mitochondria as the prime source of intracellular ROS, 
mainly generated at complex I and III of the respiratory chain, mitochondria are at the same 
time important targets of ROS-mediated damaging effects and placed in the focus of cell 
death regulation1, 35, 36. Extensive formation of ROS and lipid peroxides affect vital 
mitochondrial functions, such as respiration and oxidative phosphorylation and perturb the 
maintenance of the mitochondrial membrane potential (Δψm)
28. Thus, besides their essential 
role in the cells` ATP supply and their involvement in several metabolic reactions20, 37, 
mitochondria play a central role in intrinsic pathways of apoptosis triggered by oxidative 
stress38. Furthermore, increasing evidence points to a crucial role of mitochondrial dynamics 
and integrity for the maintenance of cellular viability. Mitochondrial fission and fusion defects 
limit mitochondrial motility, decrease energy production and enhance oxidative stress, 
thereby promoting cell death20, 24. Thus, it is obvious, that the preservation of mitochondrial 
integrity and function, called mitoprotection, is essential for cell survival. 
Mitochondria consist of two membranes, the outer and the inner membrane, composed of 
phospholipid bilayers and proteins. While the mitochondrial outer membrane (MOM) is freely 
permeable to small molecules such as ions and sugar, the inner mitochondrial membrane 
(IMM) is highly impermeable. The permeabilization of MOM allows the release of protein 
from the intermembrane space (IMS), such as cytochrome c, Smac/DIABLO and AIF, which 
immediately initiate the cell death machinery21. While it is likely, that the permeabilization is 
achieved by the formation of membrane-spanning pores, the involvement of appropriate 
pore-forming proteins as well as the correlation between MOMP and the breakdown of Δψm is 
not well defined.  
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It is well described that MOMP is initiated by multi-domain pro-apoptotic members of the 
Bcl-2 family, such as Bax and Bak as well as BH3-only proteins, such as tBid or Bim, that 
directly activate Bax or Bak21, 23, 39. However, the precise mechanisms of how Bcl-2 family 
proteins trigger MOMP and subsequent mitochondrial impairment are still not fully 
understood. An alternative model for the initiation of MOMP is the opening of the 
mitochondrial permeability transition pore (mPTP), consisting of the voltage-dependent anion 
channel (VDAC) present in the outer membrane, the adenine nucleotide transporter (ANT) 
located in the inner membrane and the matrix protein cyclophilin D (CypD), among other 
proteins23, 40. Under normal conditions, CypD is reported to reside in the mitochondrial matrix 
and the mPTP remains closed. Opening of the mPTP upon cell death stimuli such as calcium 
overload or intracellular oxidative stress, results in a sudden increase in the IMM 
permeability, loss of Δψm, mitochondrial swelling and rupture of the MOM
41, 42. The present 
thesis addresses the disputed question, how these proposed mechanisms of MOMP are 
related to each other. 
 
1.2 Bcl-2 family proteins – regulators of life and death 
An important regulatory mechanism of mitochondrial integrity and function is represented by 
the B-cell lymphoma-2 (Bcl-2) family proteins36. An imbalance between multiple pro- and anti-
apoptotic members of this family has been explored for their involvement in the underlying 
mechanisms of diverse pathologies such as tumor formation as well as autoimmune 
pathologies, infectious diseases and neurological disorders43. The Bcl-2 family includes more 
than 20 members and is subdivided into three groups on the basis of their pro- or anti-
apoptotic action and the presence of conserved Bcl-2 homology (BH1-BH4) domains (Figure 
2)44. The first group includes the anti-apoptotic proteins (e.g. Bcl-2, Bcl-xl, Bcl-w, Mcl-1, and 
A1/Bfl-1), which contain all four Bcl-2-homology domains (BH1-4) and preserve MOM 
integrity by directly binding and inhibiting either pro-apoptotic Bax/Bak or activator BH3-
proteins. They are generally integrated within the MOM, but also displaced in the cytosol or 
ER membranes36, 45. In contrast, the second and third group contain the pro-apoptotic 
members, which are divided into multi-domain proteins with all four homology regions (e.g. 
Bax, Bak and Bok) and those that contain only the BH3 domain (e.g tBid, Bim, Bad, Bik/Nbk, 
Noxa, Puma)46. While the multi-domain proteins Bax and Bak are thought to undergo 
conformational changes and oligomerization thereby promoting pore-formation and MOMP, 
the BH3-only proteins are described to either interact with anti-apoptotic proteins to inhibit 
their function and/or to directly interact with the effector proteins Bax/Bak to provoke their 
apoptotic activity21, 44, 47. In healthy cells pro-apoptotic Bcl-2 family members are cytosolic, 
whereas cell death stimuli can trigger their translocation (e.g Bid or Bim) to membranes. In 
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contrast to the BH3-only protein tBid, full-length Bid shares structural similarities with the 
multi-domain family members as described in detail below44. Opposed to their abundant 
presence in non-neuronal cells, neuronal cells reveal highly dynamic expression of the main 
family members Bcl-xl, Bcl-2, Bax, Bak, Mcl-1 and Bid during neuronal development. While 
Bid, Bax and Bcl-xl continue to be highly expressed in the adult brain, significant expression 
levels of Bcl-2 and Mcl-1 as well as full-length Bak have not been observed48-52. In contrast, 
neurons express an unusual splice variant of Bak depicting anti-apoptotic functions when 
over-expressed52. In regard to the expanding interest in the BH3-only proteins and their pro-
apoptotic effects within neurons, this thesis focuses on the pro-apoptotic protein Bid and 
addresses Bid-dependent mechanisms of neuronal cell death. 
 
 
Figure 2: Simplified overview of the Bcl-family proteins. 
Bcl-2 family proteins can be classified into three subtypes based on structural and functional features. To date, 
four Bcl-2 homology (BH)-domains have been identified (BH1-BH4). The anti-apoptotic family members Bcl-2, 
Bcl-xl, A1, MCL-1 and Bcl-w contain four BCL-2 homology domains and are thought to exert their effect at the 
mitochondrial outer membrane where they contribute to maintenance of membrane integrity. The pro-apoptotic 
proteins are subdivided into the multi-domain proteins Bax, Bak, Bok and the BH3-only proteins e.g. tBid, Bim, 
Bad, Bik, Noxa, Puma, Bik and Bnip3. Pro-apoptotic members such as Bax and Bak oligomerize and 
permeabilize the MOM, whereas tBid, Bim, Bad or Noxa are thought to either activate Bax or Bak or inhibit the 
anti-apoptotic proteins. In contrast to tBid, full-length Bid shares structural and functional similarities to the pro-
apoptotic protein Bax. Most members of the Bcl-2 family consist of a carboxy-terminal membrane-binding region 
(MBR) that triggers the translocation and binding of the proteins to membranes. (modified from Chikpuk et al., 
2010 and Shamas-Din et al., 2013)
53, 54
.  
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1.2.1 The BH3-only protein Bid 
The BH3-interacting domain death agonist, Bid, first reported by Wang et al. 199655, is a 
widely expressed cytosolic pro-apoptotic protein, consisting of 195 amino acid residues 
(22 kDa) in its full length form. Although Bid has been reported to participate in a mitosis 
checkpoint and maintenance of genomic stability56, 57, the main function of Bid appears to be 
its crucial involvement in the regulation of mitochondrial cell death pathways. Even though 
some pro-apoptotic function is reported for full-length Bid58, 59, detrimental activation of Bid is 
accelerated by proteolytic cleavage of the native protein to a truncated C-terminal p15 
fragment (tBid), which translocates to the mitochondria60. There, tBid mediates mitochondrial 
membrane permeabilization and the subsequent release of apoptotic factors from the 
mitochondrial intermembrane space to the cytosol61-63. 
The structure of Bid, which has been elucidated using NMR spectroscopy64, 65, consists of 
eight α helices arranged in three layers, with two central hydrophobic helices (α 6 and α 7) 
surrounded by the amphipatic helices on either side66. Beside this highly ordered core 
structure, Bid contains a large unstructured loop between the helices α 2 and α 3 (amino 
acids 42-79), as well as a disordered N-terminal region (Figure 3 A).The structural 
arrangement of Bid shares high similarity to the structure of multi-domain Bcl-2 family 
proteins, such as Bcl-2, Bcl-xl, Mcl-1 and Bax, and is thereby contrasting the unstructured 
composition of almost all BH3-only proteins44, 66, 67. In accordance to the structures of Bax 
and Bak, recent studies further suggested a redefined BH4 region at the N-terminus of Bid, a 
feature that was previously observed only by the anti-apoptotic Bcl-2 family proteins61. 
Further, the structural arrangement of Bid is similar to that of bacterial toxins such as the 
colicins and diphtheria toxin65, 68 and implies the role of Bid in pore-formation. This suggestion 
has been substantiated by reports describing high similarities between Bid and Bax 
regarding their migration to and insertion into the MOM, thereby indicating Bid as a ´Bax-like 
protein´ 61. While the BH3-domain of Bid, located in helix 3, is required for its interactions with 
the Bcl-2 family proteins Bax and Bcl-xl, the unstructured loop contains a variety of sites that 
are subjected to post-translation modifications regulating Bid localization and apoptotic 
function (Figure 3 B)66, 68.  
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Figure 3: Molecular structure and protease-cleavage sites of Bid. 
A, NMR- solution structure of mouse Bid (PDB entry 1DDB)
65
. The flexible loop region between helix α 2 and α 3 
and the flexible N-terminal region are marked in red. The core structure consisting of 8 α-helices is stained in 
grey. The schematic drawing reveals one of 20 NMR solution structures of mouse Bid. B, Human Bid (hu) and 
mouse Bid (mu) consists of 195 amino acids and 8 α-helices. Numbers below each α-helix indicates the starting 
and ending amino acid sequence of the helix. The BH3-domain is domain is required for interactions with other 
Bcl-2 family members, whereas helix α 2 is thought to interact with membrane lipids, particularly cardiolipin. 
Mostly all proteases cleave Bid in the loop region, cleavage sites are indicated with black arrows (modified from 
billen et al 2009)
61
. 
Within this highly flexible region, proteolytic activation and cleavage of Bid can be exerted by 
different proteases (Figure 3 B). The first mentioned and best studied example of Bid 
activation is its cleavage by caspase-860, which itself is activated by the engagement of 
Fas/TNF death receptors. Caspase-8 cleavage of Bid, resulting in the C-terminal p15 tBid 
fragment, triggers the exposure of the BH3-domain and drives the membrane binding of tBid 
by relieving its auto-repression mediated by the un-cleaved N-terminal p7 fragment61, 64, 65, 69. 
Upon cleavage, the smaller p7 fragment of tBid is not necessarily completely separated from 
the active C-terminal moiety66, as both fragments are held together by hydrophobic 
interactions70. However, recent studies revealed that in the presence of a membrane, both 
fragments of caspase-8 cleaved Bid (cBid) spontaneously dissociate, thereby exposing 
sufficient hydrophobicity to drive the insertion of tBid into membranes71, 72. Beside caspase-8, 
Bid can also be cleaved by the effector caspase-361, as well as by caspase-1066, caspase-2 
and caspase-1. In addition, Bid cleavage has also been shown to be exerted by several non-
caspase proteases, namely granzyme B73, calpains74, 75 or lysosomal hydrolases such as 
cathepsins76, and finally by a JNK-dependent unknown protease61. Mostly all of them cleave 
Bid in the loop region between helices α 1 and α 2 and notably all proteases trigger the 
accumulation of the C-terminal cleavage product at mitochondria44, 61.  
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1.2.1.1 Bid interactions with lipids and proteins - recruitment to mitochondrial 
membranes  
There are several hypotheses proposed to explain the recruitment of Bid and tBid to 
mitochondrial membranes and the subsequent MOMP. While protein-protein interactions are 
discussed in being involved in the specific translocation of Bid and tBid to mitochondria66, 
increasing evidence indicates that mitochondrial lipids might play an important role in the 
molecular cell death pathway driven by pro-apoptotic Bcl-2 family members culminating with 
MOMP and the release of apoptogenic factors77.  
For example it has been postulated that post-transcriptional myristinylation of tBid enhances 
its targeting to mitochondria70, and many in vitro studies revealed Bid-lipid binding and a 
membrane destabilization or even a pore-forming ability of tBid on artificial lipid 
membranes66, 69. Furthermore, a relevance of a Bid-lipid interaction was also suggested for 
the activation of mitochondria and a tBid-induced mitochondrial dysfunction in the absence of 
Bak or Bax78. In particular, the glycerol-based phospholipid cardiolipin (CL) has been shown 
to play a crucial role for the specific targeting of tBid to mitochondria79, 80. Cardiolipin is 
synthesized and exclusively present in the IMM, but also found in the MOM and even more 
at the contact sites connecting the outer with inner mitochondrial membrane. A Bid-
cardiolipin interaction was initially demonstrated by in vitro studies, revealing the necessity of 
CL in liposome membranes for the effective tBid-induced release of trapped indicators71, 79 
and confirmed by cell based assays demonstrating the requirement of CL for tBid-induced 
cytochrome c release80-82. In accordance to the mitochondrial localization of CL, it has been 
suggested that tBid binds to CL at the contact sites of the IMM and MOM81, 83 and further 
studies have linked the Bid-CL interaction to mitochondrial cristae reorganization, 
permeability transition and the subsequent release of CL-bound cytochrome c84, 85. Notably, 
also full-length Bid as well as the non-separated cBid retain the capacity of binding tightly to 
CL and display interactions with other Bcl-2 family proteins and lipid membranes86-89. 
Therefore it is obvious, that CL plays a role in the modulation of the pro-apoptotic action of 
Bid90, 91, although it remains unclear whether the pro-apoptotic action of Bid is directly 
dependent on CL. 
Despite the apparent important role of mitochondrial lipids, it is well accepted that the pro-
apoptotic activity of Bid, and in particular tBid-mediated membrane permeabilization and the 
release of cytochrome c, is based on its interactions with other Bcl-2 family members or 
mitochondrial proteins. tBid can interact with the anti-apoptotic proteins Bcl-2 and Bcl-xl, 
thereby releasing Bax to promote Bax activation, but is also able to directly activate the 
apoptotic effector proteins Bax and Bak to trigger their oligomerization and mitochondrial 
activation61, 92. Besides the necessity of other Bcl-2 family members, it has also been shown 
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that the voltage-dependent anion channel 2 (VDAC2) is required for tBid-induced 
mitochondrial apoptosis by inducing Bak translocation to mitochondria66, 93. Furthermore, the 
mitochondrial carrier homolog 2 (Mtch2) has been recently reported as a binding partner for 
tBid and appears to be important for its mitochondrial recruitment72, 94, 95. After cleavage of 
Bid and the spontaneous separation of the p7 and p15 fragment upon the initial binding of 
tBid to MOM, Mtch2 is thought to act as a direct receptor for tBid, catalyzing its 
conformational change and anchoring the membrane binding helices of tBid in the 
membrane72. Finally, latest reports demonstrated a direct interaction of tBid with caspase-
cleaved arrestin-2, which does not induce tBid recruitment to mitochondria but enhances the 
ability of tBid to induce cytochrome c release96.  
These studies suggest the importance of both, mitochondrial lipids and other proteins for the 
crucial role of Bid in the mitochondrial cell death machinery. However, it is not clear if the 
described Bid-lipid and –protein interactions depend on each other, occur in parallel or if 
there are multiple mechanisms for the mitochondrial recruitment of Bid and its apoptotic 
function depending on cell type and cell death stimuli. It is therefore of interest to address the 
precise mechanism of Bid participation in MOMP and especially to explore the essential 
binding partners that facilitate the mitochondrial recruitment and pro-apoptotic action of Bid in 
neurons.  
1.2.1.2 Involvement of Bid in neuronal cell death 
In contrast to other cells where Bax and Bak are reported to be the key players of intrinsic 
cell death pathways, recent studies highlighted a pivotal role of Bid in mitochondrial demise, 
the subsequent acceleration of oxidative stress and neuronal cell death. It has been shown 
that Bid-deficient neurons are highly resistant to cell death stimuli including oxygen-
glucose deprivation (OGD), glutamate-induced excitotoxicity or oxidative stress in vitro97, 98. 
Pharmacological Bid inhibition and Bid gene silencing using small interfering RNA (siRNA) 
provides neuroprotective effects by inhibiting tBid-induced mitochondrial fragmentation, 
loss of mitochondrial membrane integrity, mitochondrial AIF release, and cell death 97, 99. 
In vivo, a pivotal role for Bid in mechanisms of delayed neuronal death has been 
confirmed in models of cerebral ischemia and brain trauma, where Bid knockout mice 
revealed significantly reduced brain damage compared to wild-type controls98, 100, 101. In 
addition, activation of Bid and tBid translocation to mitochondria has been detected in 
seizure-induced neuronal death and in human brain tissue after temporal lobe 
epilepsy102, 103, indicating a key role of Bid in neurological disorders.  
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1.2.2 Pharmacological Bid inhibition – a strategy for mitoprotection 
The findings above highlight the pivotal role of Bid in the control point of life and death and 
identified Bid as a key regulator of mitochondrial injury and mitochondrial pathways of 
neuronal cell death. The transactivation of Bid to mitochondria, Bid-induced mitochondrial 
fragmentation and MOMP and the accelerated production of reactive oxygen species (ROS) 
mediate the release of death promoting factors into the cytosol that trigger the final steps of 
the mitochondrial cell death machinery. Bid deficiency and pharmacological Bid inhibition 
were shown to provide protection against such mitochondrial demise, indicating Bid as a 
target for mitoprotection and cell survival. Therefore, inhibition of Bid may serve as a 
promising strategy for the development of novel therapeutic approaches for neuroprotection 
with high relevance for the treatment of age-related diseases of the nervous system, where 
intrinsic death pathways cause impaired mitochondrial integrity and neuronal death.  
While several selective inhibitors for other members of the Bcl-2 family proteins, such as Bcl-
2, Bcl-xl or Mcl-1 have been described104-113, so far, only a few small molecules targeting Bid 
have been developed by Becattini et al.99, 114. While the discovery of Bcl-2 and Bcl-xl 
inhibitors has been based on the structural knowledge of their molecular function104, 106, 115, 
analogous strategies for Bid were missing so far as the molecular basis for its function is not 
fully understood99. In contrast, the design of small-molecules targeting Bid was based on the 
abovementioned NMR-solution structure of mouse Bid (PDB entry, 1DDB)65, revealing the 
presence of a deep hydrophobic crevice on the surface of the Bid protein. First Bid-targeting 
ligands (1-3), capable of occupying this hydrophobic pocket, were identified by an NMR-
based approach named “structure-activity relationships by interligand-Nuclear-Overhauser 
Effects” (SAR-by-ILOE) (Figure 4). Combination of these small Bid-binding fragments (1-3) 
resulted in several substances with diverse potentials for Bid-binding and inhibition of 
mitochondrial Smac/DIABLO release99, 114. The most promising substances obtained from 
this strategy were the 4-phenylsulfanyl-phenylamine derivatives BI-11A7 (4) and BI-6c9 (5) 
(Figure 4). Both BI-6c9 and BI-11A7 demonstrated protective efficiency, positively influencing 
cell survival and mitochondrial integrity. Furthermore, these small-molecule Bid inhibitors 
provided protection against neuronal cell death in models of glutamate toxicity and oxygen-
glucose deprivation (OGD) in neuronal cell lines in vitro24, 97, 99, 114, 116 and attenuated gentoxic 
drug induced apoptosis in HeLa cells117, 118. However, the protective activities of the Bid-
inhibiting compounds developed so far, were only achieved at high micromolar 
concentrations and the small-molecules were only applicable in enzyme assays and in cell 
culture. Applications of BI-6c9 in model systems of neuronal degeneration in vivo have failed 
so far, likely due to a limited affinity and bioavailability of the compound. Based on these 
findings the first part of this thesis focused on Bid as a molecular druggable target and the 
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screening of novel small Bid inhibitors which were developed based on further optimization of 
the available Bid-targeting molecules. 
 
 
 
Figure 4: Structures of Bid-binding fragments and the resulting Bid inhibitors. 
By the combined approaches of NMR-fragment-based screening and in vitro assays, Becatiini et al. identified the 
fragments BI-2A7, BI-2A2 and BI-2A1 as binding ligands for Bid. Combinations of these fragments yielded in the 
Bid inhibitors BI-11A7 and BI-6c9 
99, 114
 
Another aspect in the demanding development of novel small-molecules that selectively 
target Bid is the absence of an appropriate crystal structure of isolated Bid. It is well accepted 
that elucidation of the atomic structure of proteins is not only a powerful tool for 
understanding the macromolecular function but has undoubtedly an important role in drug 
discovery and pharmacological research119, 120. So far, only small Bid-BH3 peptides have 
been crystallized in complex with the Bax protein and were used to explore the pro-apoptotic 
activation of Bax121, but no crystal structure of the Bid helical core has been obtained to date. 
However, deep structural knowledge would enable the structure-guided drug design as it has 
been performed for the related Bcl-2 family proteins Bcl-xl or Mcl-1109, 122-124. Thus, a crystal 
structure of Bid would facilitate the rational design of lead candidates with acceptable 
physicochemistry, selectivity, and affinity properties.   
 
  
Introduction | 13 
 
 
 
1.3 Voltage-dependent anion channels (VDAC) and their role in 
mitochondrial apoptosis 
Voltage-dependent anion channels, also known as mitochondrial porins, are the most 
abundant proteins in the outer mitochondrial membrane and can be subdivided into three 
isoforms: VDAC1, VDAC2 and VDAC3. All three proteins have a similar molecular weight 
(30-35 kDa) and are highly conserved across species, albeit in different amounts, with 
VDAC1 being the most prevalent sub-type and the least common form being VDAC3125, 126. 
While so far very little is known about the three-dimensional structure of VDAC2 and VDAC3, 
intensive structural investigations were performed on the isoform VDAC1 in recent years127-
129. X-ray structures revealed VDAC1 as an atypical 19 stranded β-barrel with a 25 residue-
long N-terminal α-helical region spanning the middle of the pore which is supposed to be 
involved in channel gating behavior127-129. Beside their abundant presence in the MOM, 
VDACs are also localized in compartments other than mitochondria, such as plasma 
membranes and the endoplasmatic reticulum (ER), yet the exact functions of extra-
mitochondrial VDAC remain unclear125. The physiological function of mitochondrial VDACs is 
their involvement in the cross-talk between mitochondria and the cytosol by regulating the 
exchange of energy carrying molecules like ATP, ADP, pyruvate or succinate and other small 
molecules130-132. Further reports connect VDACs to many physiological and 
pathophysiological processes, including Ca2+ homeostasis133-136 or energy metabolism135-140 
and increasing evidence points to VDAC as a key protein in the regulation of intrinsic cell 
death pathways130, 135, 136, 138, 141-144. Several lines of experimental data suggested the isoform 
VDAC1 as the most likely candidate involved in mitochondrial apoptosis, as siRNA mediated 
VDAC1 gene silencing efficiently prevented Bax activation, cytochrome c release and cell 
death induced by various stimuli, such as cisplatin145, endostatin146 or selenite147. In contrast, 
VDAC1 over-expression triggers apoptotic cell death132, 141, 148, 149, and release of cytochrome 
c could be induced by purified VDAC1 reconstituted into cytochrome c containing 
liposomes132, 150. Although these data indicate the critical involvement of VDAC1 in cell death, 
the precise mechanisms of how VDAC1-mediated apoptosis is regulated is a matter of 
controversial discussion126, 130, 131, 151.  
VDAC1 is regarded as the major pore-forming component of the mPTP, suggesting that its 
activation by apoptotic stimuli, such as over-production of Ca2+ and ROS, results in mPTP 
opening and subsequent cell death125, 130, 131, 152. Another hypothesis indicates that VDAC1 
closure prevents the efficient exchange of ATP and ADP between mitochondria and cytosol, 
thereby leading to osmotic matrix swelling, rupture of MOM and the non-specific diffusion of 
intermembrane proteins that trigger cell death132, 153. Alternatively, it has been suggested that 
VDAC1 oligomerization mediates the release of apoptogenic factors154-156, as an increase in 
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VDAC1 homo-oligomers was observed upon STS-induced apoptosis and could be blocked 
by the anion channel blocker 4,4´-diisothiocyanostilbene-2,2´-disulfonic acid (DIDS)136, 155. 
Finally, both VDAC1 and VDAC2 have been reported as key functional targets of the Bcl-2 
family proteins and increasing evidence indicates that both anti- and pro-apoptotic proteins 
are involved in the regulation of VDAC mediated apoptosis142, 157-160. Although a close 
interplay of VDAC with Bcl-2 family proteins such as Bcl-xl, Bax or Bid has been proposed157, 
159, 161, 162, a direct interaction of VDAC with any of these Bcl-2 family members has not yet 
been demonstrated at the cellular level. Furthermore, the relationship between Bcl-2 family 
proteins and the VDAC gating behavior is contradictious. While it has been described that 
the pro-apoptotic proteins triggers VDAC channel closure thereby leading to MOM rupture 
and cell death, and anti-apoptotic proteins maintains the functional open state of VDAC 
channels153, 161, other reports claim, that the pro-apoptotic members Bax and Bak induce 
VDAC channel opening and the formation of a large pore permeable for cytochrome c144, 159 
in contrast to the anti-apoptotic proteins Bcl-xl and Bcl-2 which facilitate the close state of 
VDACs144, 160. Despite all abovementioned indications, it should be noted, that VDAC 
isoforms were also reported to be dispensable for mitochondria-dependent cell death163, 
suggesting that multiple pathways and mechanisms of mPTP opening and cytochrome c 
release can co-exist within the proposed cell death models depending on the cell type and 
death stimulus151, 163. 
The particular involvement of VDAC1 and VDAC2 in intrinsic cell death pathways and 
especially their connection to the pro-apoptotic activity of the Bcl-2 family protein Bid will be 
elucidated in the last part of the present thesis. 
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1.4 HT-22 cells – a model for and Bid-mediated cell death 
In order to investigate the mechanisms of Bid-mediated neuronal cell death, immortalized 
mouse HT-22 neurons were used as a well established model system to study intrinsic cell 
death pathways triggered by oxidative stress. Since HT-22 cells lack functional ionotropic 
glutamate receptors, glutamate induced cell death occurs independently of NMDA-receptor 
stimulation through competitive inhibition of the glutamate/cystine antiporter system Xc
-, 
which exchanges extracellular cystine and intracellular glutamate across the plasma 
membrane. High extracellular glutamate concentrations at millimolar ranges consequently 
reduce the intracellular cystine levels required for glutathione (GSH) synthesis164-167. As 
glutathione serves as a radical scavenger that sequesters free radicals and ROS, GSH 
depletion results in a pronounced and significant increase in free radicals and detrimental 
reactive oxygen species (ROS) within a few hours after glutamate treatment of cells164. The 
dramatic GSH depletion leads to the loss of function of glutathione peroxidase 4 (GPX4) and 
an increased activity of 12/15-lipoxygenases (12/15-LOX), resulting in ROS-mediated lipid 
peroxidation. Upon 12/15-LOX activation, the pro-apoptotic protein Bid translocates to 
mitochondria, induces mitochondrial fragmentation and mitochondrial membrane 
permeabilization and thereby accelerates the glutamate-induced ATP depletion, the second 
pronounced increase in ROS production and, finally, the release of death-promoting factors, 
such as AIF in the cytosol. Nuclear translocation of AIF induces the DNA fragmentation and 
nuclear condensation, ultimately triggering the final execution step of caspase-independent 
cell death within a few minutes97. 
This delayed form of glutamate-induced toxicity is clearly different from glutamate-induced 
excitotoxicity in primary neurons, where excessive or even prolonged physiological 
glutamate-mediated activation of ionotropic NMDA-receptors leads to a massive calcium 
influx and rapid neuronal cell death168, 169. However, despite the absence of functional NMDA-
receptors, it has also been shown that glutamate-induced cell death signaling is 
accompanied with increases in cyclic GMP and cytosolic calcium levels34, 170, 171. Although the 
initial signaling of glutamate-induced cell death in primary neurons and HT-22 cells are 
different, they both share a high similarity in the downstream cell death pathways. Since 
enhanced ROS formation, increased Ca2+ levels as well as Bid-mediated mitochondrial 
dysfunction are well established features of neuronal toxicity, the glutamate-treatment of the 
present HT-22 cells serves as a valuable and applicable in vitro model for studying molecular 
mechanisms of PCD triggered by oxidative stress and the activation of the pro-apoptotic 
protein Bid. 
16 | Introduction 
 
 
 
 
Figure 5: Simplified model of glutamate-induced toxicity in HT-22 cells. 
In HT-22 cells, the xCT- antiporter mediates the import of extracellular cystine and the export of intracellular 
glutamate. Exposure to high concentrations of glutamate triggers oxidative stress by a competitive inhibition of the 
cystine import, resulting in a GSH depletion, which reduces GPX4 activity and increases the 12/15-LOX 
activation. These events enhance the generation of highly detrimental ROS and increase the formation of lipid 
peroxides. Downstream of the first ROS formation, the pro-apoptotic protein Bid is activated to its truncated form 
tBid, which subsequently translocates to mitochondria, where tBid induces the permeabilization of the 
mitochondrial outer membrane, mitochondrial dysfunction and the accelerated ROS production, consequently 
releasing death promoting factors, such as AIF, into the cytosol. AIF in turn immediately translocates to the 
nucleus, leading to DNA fragmentation and nuclear condensation, thereby causing the final execution of caspase-
independent cell death. Red arrows indicate the increases and decreases in cellular molecule levels caused by 
the exposure of HT-22 cells to glutamate. (modified from Tobaben et al., 2011).  
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1.5 Aims of the thesis 
The pivotal role of the pro-apoptotic Bcl-2 family protein Bid in intrinsic cell death pathways 
has become increasingly apparent over the last couples of years, as Bid has been identified 
as a key regulator of mitochondrial integrity and function and detrimental accumulation of 
reactive oxygen species (ROS). Previous studies revealed an important role of Bid in 
delayed neuronal death after oxygen-glucose-deprivation, glutamate-induced excitotoxicity or 
oxidative stress in vitro. In vivo, major roles of Bid-dependent cell death mechanisms were 
confirmed in models of cerebral ischemia and traumatic brain injury. These data highlight Bid 
as a potential target for novel therapeutic strategies aiming at preserved mitochondrial 
function and neuronal survival with high relevance for the treatment of age-related diseases 
of the nervous system, where mitochondrial injury and associated neuronal dysfunction are 
prominent.   
To achieve efficient pharmacological strategies to inhibit Bid-mediated cell death pathways, 
novel drug discovery campaigns are required to overcome the limitations of the few Bid 
inhibiting compounds developed so far. While other Bcl-2 family members are intensively 
investigated in various structure-guided drug development approaches, until now similar 
strategies for Bid were hampered by the absence of appropriate crystal structures of isolated 
Bid. Moreover, a better knowledge of mechanisms involved in Bid activation and Bid-
dependent impairments of mitochondrial membrane integrity are mandatory for sustaining 
the therapeutic potential of Bid inhibition. 
Therefore, the present thesis is aimed to bridge crucial gaps of knowledge regarding the 
precise mechanisms of Bid-dependent mitochondrial demise and cell death and to initiate 
important requisites for Bid crystallization with the principal purpose of identifying novel Bid-
targeting compounds for mitoprotection and cell survival: 
 
1) Evaluation of new chemical compounds that target Bid for mitoprotection and cell 
survival  
The first aim of the present thesis was the identification of novel Bid-targeting molecules that 
provide protection against mitochondrial cell death. Based on the structure of available Bid 
inhibitors, compounds of three chemical classes of were developed. These molecules were 
screened in this thesis for their protective efficiency in the model of glutamate toxicity in HT-
22 neurons. In order to investigate the interference with the pro-apoptotic activities of Bid, the 
effects of the novel structures were further examined after tBid over-expression. Moreover, 
the work addresses the ability of the most promising compounds to prevent Bid-mediated 
impairments in mitochondrial integrity and function. 
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1) Design, expression and purification of different Bid constructs for crystallization 
and functional assays 
In order to provide insights into the structural properties of Bid and its pro-apoptotic activities, 
the second aim of this thesis was the design of different Bid constructs and the establishment 
of protocols for expression and purification of recombinant Bid protein. Highly pure protein 
was used for initiation of the first Bid crystallization studies and the development of primary 
assays of Bid activity, and Bid-interactions with other proteins. 
 
2) Development of model systems for membrane permeabilization 
Since Bid was identified as a key trigger of apoptotic cell death via detrimental effects at the 
mitochondrial membrane, the third goal of the project was to investigate the effect of 
recombinant full length Bid and cBid on artificial lipid bilayer structures which mimic the 
mitochondrial membrane. For this approach, a liposome channel activity assay was validated 
as a screening system for membrane permeabilization. As many previous studies claimed 
the pro-apoptotic protein Bax as the main pore-forming protein required for MOMP, a further 
purpose during this research was to examine the role of Bax in Bid/cBid-mediated 
permeabilization of fluorescent liposomes. Another question of interest was the role of 
cardiolipin in Bid-mediated membrane integration and permeabilization. 
 
3) Mechanisms of Bid mediated mitochondrial dysfunction and cell death and the link 
to the voltage-dependent anion channel VDAC 
So far, the precise mechanism by which Bid initiates MOMP and the subsequent 
mitochondrial demise is not fully understood. Therefore, the thesis was proposed to 
investigate whether the voltage-dependent anion channel VDAC1 is a direct mitochondrial 
receptor for activated Bid at the control point of life and death. The approach of the anion 
channel blocker DIDS as well as VDAC1 gene silencing was used to explore the impact of 
VDAC in glutamate-induced and Bid-accelerated cell death pathways in cultured neurons. 
The interplay between Bid and VDAC was additionally verified in a model of ischemic brain 
injury in vivo as well as by in vitro studies using recombinant proteins.   
As previous studies reported a direct interplay between the isoform VDAC2, tBid and Bak in 
non-neuronal cells, the last part of the work was aimed at the role of VDAC2 in glutamate-
induced cell death in HT-22 neurons. 
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2 Materials and methodes 
2.1 Chemicals and reagents 
All standard chemicals were obtained from Sigma-Aldrich (Taufkirchen, Germany) and Roth 
(Karlsruhe, Germany), if not described otherwise. All buffers and solutions were prepared 
using demineralized, ultrapure water that was prepared with the SG Ultra Clear UV plus pure 
water system (VWR, Darmstadt, Germany).  
Ultrapure, demineralized water for aseptic preparation of solutions was sterilized before use 
by a steam autoclave (Systec V-40, Systec GmbH, Wettenberg, Germany). In addition, all 
media and solutions that were used in cell culture were sterilized by filtration using 0.22 μm 
filter sets (Sarstedt, Nümbrecht, Germany). 
2.1.1 Transfection reagents  
Opti-MEM I (Invitrogen, Karlsruhe, Germany) was used to allow formation of DNA- or siRNA 
transfection complexes. For siRNA transfections, the cationic lipid formulation Lipofectamine 
RNAiMax (Invitrogen, Karlsruhe, Germany) was used. Transfection of plasmid vectors were 
performed using the attractene transfection reagent (Qiagen, Hilden, Germany).  
2.1.1.1 Plasmid vectors 
Plasmid pCDNA 3.1+ was obtained from Invitrogen (Karlsruhe, Germany). The mitoGFP 
(mGFP) vector was a kind gift from Andreas Reichert (Goethe University Frankfurt, Frankfurt, 
Germany). The tBid vector (pIRES-tBid) was generated as previously described172. The 
ApoAlert® pDSRed2-Bid vector which encodes a biologically active fluorescent fusion protein 
of Bid and DsRed monomer was derived from Clontech (Palo Alto, California, USA). The 
mouse VDAC1 plasmid (mVDAC1) was kindly provided by Dr. Jeff Abramson (University of 
California LA). For the generation of Flag-VDAC1, full-length mouse VDAC1 was amplified 
with two primers (VDAC1-fwd and VDAC1-Flag-rev, see 2.1.2) of which the C-terminal one 
encoded also a Flag epitope. The PCR product was subcloned into pcDNA3 (Invitrogen) 
using the inserted BamHI and NotI sites. Plasmids containing either the gene sequence for 
full length Bid or truncated Bid were ordered from Addgene (Cambridge, MA): pET15b Bid 
p22 (Addgene plasmid 8784) encodes full-length mouse Bid, pET15b Bid p15 (Addgene 
plasmid 8782) encodes mouse tBid173. A plasmid containing the caspase 8 gene was also 
purchased from Addgene in a pET15b vector (Addgene plasmid 11827, pET15b-Casp8 delta 
DED). The plasmid vector encoding the Bax sequence was ordered from Addgene in a 
pCEP4-HA vector (Addgene plasmid 16587, pCEP4-HA-Bax). The construction of plasmids 
encoding GST fusion proteins of various Bid constructs is described in more detail in section 
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2.14.3. The following plasmids were constructed: pGEX Δ12-Y47 (also called Bid 1), 
pGEX Δ12-D51 (Bid 2), pGEX Δ13-Y47 (Bid 3) and pGEX Δ13-D51 (Bid 4).  
All plasmids were amplified using a Quiagen Plasmid Plus Midi kit (Quiagen, Hilden, 
Germany) according to the manufacturer´s protocol. Prior to use, the plasmid DNA-
concentrations were determined using the NanoVue Plus Spectrophotometer (Implen, GE 
Healthcare Europe GmbH, Freiburg, Germany), and digestion by restriction enzymes with 
subsequent gel electrophoresis analysis was performed. Additionally all plasmid constructs 
were verified by sequencing. 
2.1.1.2 SiRNA  
VDAC1 and VDAC2 siRNA sequences were synthesized by Eurofins MWG Operon (Eurofins 
MWG Operon, Ebersberg, Germany). Specific VDAC1 knockdown was achieved by the 
following siRNA sequences: 5´-GAUUGGCUUAGG GUACACUCA- 3´ (VDAC1 siRNA 1) and 
5´-GUGAAUGACGGGACAGAGUUU-3´ (VDAC1 siRNA 2). For specific knockdown of 
VDAC2 the following siRNA sequences were used: 5´-UGAUAUUCGUUCCCAGAGGUU-3´ 
(VDAC2 siRNA a) and 5´-AGAGUGUUAUCGGUGUUCCUU-3´ (VDAC2 siRNA b). For 
knockdown of Bid two siRNA sequences were purchased from Sigma-Aldrich 
(Taufkirchen, Germany): 5´-GAGUGUAUCUAAGAGUUU[dT][dT]-3´ (SASI_Mm01_0011519) 
and 5´-AAACUCUUCAGAUACACUC[dT][dT]-3´ (SASI_Mm01_00115200). Non-functional 
scrambled siRNA (scr siRNA, 5’-AAGAGAAAAAGCGAAGAGCCA-3’) was purchased from 
Dharmacon (Thermo Scientific, Bonn, Germany). 
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2.1.2 PCR-primer 
For RT-PCR all primers were synthesized at by Eurofins MWG Operon (Eurofins MWG 
Operon, Ebersberg, Germany). Primer sequences were used as listed in Table 1: 
 
Table 1: Primers used for RT-PCR 
Primers Sequences 
VDAC1 fwd 5´-GGACTGAGTATGGGCTGACG -3´ 
VDAC1 rev 5´-AAGTTGCTCTGGGTCACTCG-3´ 
VDAC2 fwd 5´-ACTTTGCAGTCGGCTACAGG-3´ 
VDAC2 rev 5´-CTCTTCCCGTCTACCAGAGC-3´ 
Bid fwd 5´-GGGAACTGCCTGTGCAAGCTTAC-3´ 
Bid rev 5´-CAGTGAGGCCTTGTCTCTGAA-3´ 
GAPDH fwd  5′-AGGCCGGTGCTGAGTAT-3′ 
GAPDH rev 5′-TGCCTGCTTCACCACCTTCT-3′ 
Primers used for the construction of expression vectors: 
Primer Sequence 
mVDAC fwd 5´-TTA ATA CTC GAG TTA TGC TTG AAA TTC CAG TCC TAG GC-3´ 
mVDAC rev 5´-ATA AAT CAT ATG GCC GTG CCT CCC AC-3´ 
VDAC1 fwd 5´-AAA TAA _GGA TCC_ ATG GCC GTG CCT CCC-3´ 
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VDAC1-Flag 
rev 
5´-AAA ATT _GCG GCC GC_T TAC TTA TCA TCA TCA TCC TTA TAA 
TC_T CTA GA_T GCT TGA AAT TCC AGT CC-3´ 
G12-mBid fwd 5´-AAAAAAGGATCCGGGGCCGAGCACATCACAGACC-3´ 
A13-mBid fwd 5´-AAAAAAGGATCCGCCGAGCACATCACAGACCTGCTGG-3´ 
mBid-EcoRI 5´-AAAAAAGAATTCTCAGTCCATCTCGTTTCTAACCAAGTTCC-3´ 
Y47-mBid fwd 
5´-AAAAAAAAGCTTACAGTCAGGAAGAAATCATCCACAACATTGCC-
3´ 
D51-mBid fwd 
5´-AAAAAAAAGCTTACTGGGAGGCAGACAGTCAGGAAGAAATCATC
CACAACATTGCC-3´ 
KpnI-M13Bid 5’-AAAAAA GGTACC ATG GCCGAGCACATCACAGACCTGCTGG-3’ 
 
 
2.1.3 Primary antibodies 
All primary antibodies were diluted in Tris-buffered saline containing 0.05 % Tween 20 
(TBST) and 5 % skim milk powder or Tris-buffered saline containing 5 % BSA (all Sigma-
Aldrich) as indicated in the company´s protocol. For Western blot analysis in this study, the 
VDAC1-antibody (VDAC1-N18, polyclonal, Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
was diluted 1:200, of monoclonal and polyclonal Flag-antibody (Flag M2 monoclonal, Flag 
polyclonal both Sigma-Aldrich, Munich, Germany) 1:1000. VDAC2-, Bid-, Bax and Bak- 
antibodies (all polyclonal, Cell Signaling, Danvers, Massachusetts, USA, and New England 
Biolabs GmbH, Frankfurt, Germany) were diluted 1:1,000. The dilution of the Drp1-antibody 
(BD Bioscience Laboratories, Heidelberg, Germany) was 1:500 and the anti-actin antibody 
(Cell Signaling, Danvers, Massachusetts, USA, and New England Biolabs GmbH, Frankfurt, 
Germany) was used at a dilution of 1:10,000. 
For immunoprecipitation experiments the Bid-antibody (polyclonal, Cell Signaling, Danvers, 
Massachusetts, USA) and Flag-antibody (polyclonal Sigma-Aldrich, Munich, Germany) were 
used at concentrations of 7.5 µg/sample and the VDAC1(N18)-antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) was used at concentrations of 10 µg/sample (see also 
2.8.4) 
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2.1.4 Secondary antibodies 
All secondary antibodies were purchased from Vector Labs (Burlingame, California, USA), if 
not otherwise described. Horse radish peroxidase (HRP) labeled anti-mouse IgG (H+L), anti-
goat IgG (H+L) and anti-rabbit IgG (H+L) secondary antibodies were used for Western blot 
analysis at dilutions of 1:2,500 - 1:5,000 in Tris-buffered saline with 0.05 % Tween 20 and 
5 % skim milk powder (Sigma-Aldrich). For immunocytochemistry biotinylated anti-rabbit IgG 
(H+L) antibody was used in a 1:200 dilution in phosphate buffered saline (1 x PBS, Table 5) 
containing 3 % horse serum (Invitrogen, Karlsruhe, Germany) and DyLight 649 anti-mouse 
antibody (Merck Millipore, Darmstadt, Germany) in a dilution of  1:200 in phosphate buffered 
saline (1 x PBS) containing 3 % heat inactivated fetal calf serum (FCS).  
 
2.2 Supplies 
2.2.1 Kits  
All kits used in this work are provided in Table 2 and were applied following the 
manufacturer´s instructions: 
Table 2: Kits 
Kit Company 
Annexin-V-FITC Detection Kit Promokine, Heidelberg, Germany 
 BODIPY (581/591 C11) Invitrogen, Karlsruhe, Germany 
MitoPTTM TMRE kit 
Immunochemistry Techonolgies, Hamburg, 
Germany 
ViaLightTM Plus-Kit Lonza, Verviers, Belgium 
XF Cell Mito Stress Kit Seahorse Biosciences ,North Billerica, MA 
Pierce BCA Kit Perbio Science, Bonn, Germany 
NucleoSpin RNA II Kit Machery & Nagel, Düren, Germany 
SuperScript III One Step RT-PCR System 
with Platinum® Taq 
Invitrogen, Karlsruhe, Germany 
QIAGEN Plasmid Plus Midi Qiagen, Hilden, Germany 
QIAGEN Gel Extraction Kit Qiagen, Hilden, Germany 
Ultra Free DNA Extraction Kit Millipore, Schwalbach, Germany 
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2.2.2 Materials for recombinant proteins 
Consumables used for purification and concentration of recombinant proteins are provided in 
Table 3.  Materials for crystallographic methods are depicted in Table 4.  
Table 3: Materials for protein purification 
Columns and filters Company  
His-Catcher Nickel Gravity columns PJK GmbH, Kleinbittersdorf, Germany 
HisTrapTM FF, 1 ml and 5 ml column 
GE Healthcare Bio-Science AB, Uppsala, 
Sweden 
GSTrapTM FF, 5 ml column 
GE Healthcare Bio-Science AB, Uppsala, 
Sweden 
Glutathione HiCap Cartridge, 5 ml Qiagen, Hilden, Germany 
HiTrap Q HP, 1 ml and 5 ml column 
GE Healthcare Bio-Science AB, Uppsala, 
Sweden 
HiLoad 16/600 Superdex 75 prep grade 
GE Healthcare Bio-Science AB, Uppsala, 
Sweden 
Collection tubes 14 ml, 105x16 mm, 
Polystyrol 
Sarstedt, Newton, NC, USA 
Poly-Prep® Chromatography column BioRad Laboratories, Munich, Germany 
PD MidiTrap G-25 column 
GE Healthcare Europe GmbH, Freiburg, 
Germany 
3 kDa Amicon® Ultra Centrifugal Filter  
Units – 4 ml 
Millipore, Schwalbach, Germany 
3 kDa and 10 kDa Amicon® Ultra 
Centrifugal Filter  Units – 15 ml 
Millipore, Schwalbach, Germany 
0.22 μm Whatman PuradiscTM sterile-filter Whatman, Dassel, Germany 
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Table 4: Materials for protein crystallization 
Crystal equipment  Company 
MRC2 96-well crystallization plate  Jena Bioscience GmbH, Jena, Germany 
24-well EasyXtal plate Quiagen, Hilden Germany 
VIEWseelTM adhesive sheets Greiner Bio-one, Frickenhausen, Germany 
96-Deep well plate Abgene,  Schwerte, Germany 
CrystalWand MagneticTM Hampton Research, Aliso Viejo, CA, USA 
CrystalCapHTTM Hampton Research, Aliso Viejo, CA, USA 
Mounted CryoLoop™ - 10 and 20 micron 
with EasySnap Micro Tube 
Hampton Research, Aliso Viejo, CA, USA 
CrystalCap™ Copper MagneticTM  Hampton Research, Aliso Viejo, CA, USA 
CrystalCap MagneticTM Hampton Research, Aliso Viejo, CA, USA 
Micro-Tools Hampton Research, Aliso Viejo, CA, USA 
 
2.2.3 Cell culture materials  
Sterile plastic ware was used as indicated in Table 5. 
Table 5: Sterile plastic ware 
Plastic ware Company  
T75 flasks Greiner, Frickenhausen, Germany  
T175 flasks  Greiner, Frickenhausen, Germany 
6-well plates Greiner, Frickhausen, Germany 
24-well plates Greiner, Frickenhausen, Germany 
96-well plates Greiner, Frickenhausen, Germany 
IbiTreat 8-well Ibidi, Munich, Germany  
6 cm dishes Sarstedt, Newton, NC, USA 
10 cm dishes Sarstedt, Newton, NC, USA 
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96-well plates white  Greiner, Frickenhausen, Germany 
96- well plates black  Greiner, Frickenhausen, Germany 
XF96-well microplates Seahorse Biosciences, North Billerica, MA 
E-plate 96 well Roche, Applied Science, Penzberg, Germany 
15 ml tubes  Greiner, Frickenhausen, Germany  
50 ml tubes  Greiner, Frickenhausen, Germany  
0.5, 1.5, 2 ml tubes Sarstedt, Nümbrecht, Germany  
0.22 μm Whatman PuradiscTM sterile-
filter 
Whatman, Dassel, Germany 
0.45 μm filter   Whatman, Dassel, Germany 
Cell scraper Sarstedt, Nümbrecht, Germany  
1, 5, 10 ml Injekt® Braun, Melsungen, Germany 
 
2.3 Cell culture  
2.3.1 Cell culture media and cultivation of HT-22 cells  
HT-22 cells were obtained from Gerald Thiel (Homburg/Saar) with kind permission of David 
Schubert (Salk Institute, San Diego, California, USA). The HT-22 cell line was originally 
selected from HT-4 cells based on glutamate sensitivity. HT-4 cells were immortalized from 
primary hippocampal neurons using a temperature-sensitive SV-40 T antigen174.  
HT-22 cells were cultured in Dulbeccos´s modified Eagle medium (DMEM, Invitrogen, 
Karlsruhe, Germany) supplemented with 10 % heat-inactivated fetal calf serum, 100 U/ml 
penicillin, 100 µg/ml streptomycin and 2 mM glutamine (all from PAA Laboratories GmbH, 
Germany) as indicated in Table 6. For standard cultivation HT-22 cells were kept in 75 cm2 
culture flasks in a standard unified incubator at 37°C and 5 % CO2. Cells were split twice per 
week in a ratio 1:10 - 1:20. Splitting of HT-22 cells was perfomed as follows: Growth medium 
was removed and cells were washed once with 2 ml phosphate buffered saline (1 x PBS, 
Table 7) to fully remove the growth media. For detachment of cells from the bottom of the 
flasks, 2 ml of trypsin/EDTA solution (Table 8) was added and cells were incubated 2-5 min. 
at 37°C. After detaching of the cells, the protease activity was stopped by adding the 3-fold 
amount of DMEM growth medium (Table 6). Afterwards, the cell suspension was centrifuged 
at 1.000 x rpm for 5 minutes and the cell pellet resuspended in fresh growth medium. For 
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determination of cell number a counting chamber (Neubauer Zählkammer, Brand, Wertheim, 
Germany) was used. Afterwards, cells were seeded into the appropriate culture dishes with a 
cell density of 6 x 103 – 6 x 104 cells per well or 5 x 105 – 1.5 x 106 cells per dishes, 
depending on the respective experiments (Table 9). 
 
 
Table 6: HT-22 standard growth medium 
DMEM-medium with 4.5mg/l glucose and 110 mg/l sodium pyruvate 440 ml 
Heat inactivated fetal calf serum (FCS) 50 ml 
L-alanyl-L-glutamine 200 mM 5 ml 
Penicillin 10.000 U/ml / Streptomycin 10 mg/ml (Pen/Strep) 5 ml 
 
 
Table 7: Phosphate buffered saline (PBS), pH 7.4 
NaCl 9 g 
Na2HPO4 0.527 g 
KH2PO4 0.144 g 
HCl (0.1M) q.s. for pH adjustment 
Aqua demin add to a final volume of 1,000 ml 
 
 
Table 8: Standard Trypsin/EDTA solution 
Trypsin (7.500 U/mg) 100 mg 
Ethylenediamine-tetra-acetic acid (EDTA) 40 mg 
PBS Table 3 
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Table 9: HT-22 cells – cell densities 
Cell culture format cell density cells/cm2 (cells/well) 
96-well plate ~ 6,000 – 12,000 cells/well 
24-well plate ~ 40,000 – 60,000 cells/well 
6-well plate ~ 180,000 cells/well 
ibidi μ-slide 8-well plates ~ 16,000 – 20,000 cells/well 
6 cm dish ~ 500,000 cells/dish 
10 cm dish ~ 1,000,000 – 1,500,000 cells/ dish 
XF96-well microplates ~ 10,000 cells/well 
E-Plate 96-well ~ 10,000 cells/well 
 
2.3.2 Cell culture medium and cultivation of primary mouse embryonic cortical 
neurons  
For culturing of primary mouse embryonic cortical neurons, cell culture dishes were coated 
one day before preparation with 5 % polyethylenimine (PEI, Table 10). Coating was 
performed by incubation with 5 % PEI for 2-3 h at 37°C. Afterwards the dishes were washed 
three times with sterile bidest water and dried for 30 min under UV-light. Cell dishes were 
filled up with MEM+ and incubated overnight in the cell incubator at 37 °C and 5 % CO2. 
 
Table 10: 5% PEI 
Borac acid 3.1 g 
Borax  9.0 g 
PEI 1 ml 
Aqua demin add to a final volume of 1,000 ml 
 
Cortices were removed from embryonic day 14-16 wild type C57BL/6 mice (Charles River 
Laboratories, Sulzfeld, Germany) and dissociated by trypsinization and trituation as followed: 
Isolated cortices were incubated in Hank’s balanced salt solution (HBSS, diluted from 
10 x HBSS, Invitrogen, Karlsruhe, Germany, Table 12 ) containing 1 mg/ml trypsin (Sigma-
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Aldrich,Taufkirchen, Germany) for 15 min. at 37°C. Afterwards, DNAse was added for 30 
seconds and the cortices were washed with HBSS and mixed with HBSS containing 1 mg/ml 
trypsin inhibitor (Sigma-Aldrich,Taufkirchen, Germany), and the cell suspension was 
incubated for further 2 min. at room temperature. Afterwards, the cortices were washed once 
with HBSS, and triturated in MEM+ obtained from Eagle’s minimum essential medium 
(Invitrogen, Germany, Table 13) by addition of 1 mM HEPES (Biomol, Hamburg, Germany), 
26 mM NaHCO3, 40 mM glucose, 20 mM KCl, 1.2 mM L-glutamine (each Sigma-Aldrich, 
Taufkirchen, Germany), 1 mM sodium pyruvate (Biochrom, Berlin, Germany), 10% (v/v) fetal 
calf serum (FCS) (Invitrogen, Karlsruhe, Germany) and 10 mg/l gentamicin sulfate (Sigma-
Aldrich, Taufkirchen, Germany). The titurated cells were centrifuged at 1,000 x g for 5 min. at 
room temperature. The supernatant was removed and cells cultured in neurobasal medium 
supplemented with 2 % (v/v) B-27 (Table 11). Afterwards, cells were counted in a cell 
counting chamber (Neubauer Zählkammer) and seeded into T75 flasks with a density of 10 
to 15 x 106 cells per flask containing 20 ml MEM+. One day after incubation, the medium was 
exchanged with neurobasal medium (Table 11) containing 0.5 µM cytosine 
arabinofuranoside (CAF) to avoid glia cell growth. On day 5 and 7 after seeding of cells, half 
of the medium was exchanged with fresh neurobasal medium, respectively. Since cultures of 
primary neurons develop functional NMDA receptors after 6-8 days in culture and are 
therefore susceptible to glutamate-induced excitotoxicity, experimental treatments were 
performed with 7-9 day old cultures.  
All mediums were obtained from Invitrogen (Karlsruhe, Germany), if not described otherwise. 
Chemical substances were obtained from Sigma-Aldrich (Taufkirchen. Germany). 
 
Table 11:  Neurobasal medium 
Neurobasal medium (Gibco®) 490 ml 
2 % (v/v) B-27 (Gibco®) 10 ml 
1 % (v/v) L-glutamine 5 ml 
1 % (v/v) Pen/Strep 5 ml 
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Table 12: Hank´s balanced salt solution (1 x HBSS) ph 7.2 
10 x HBSS 50 ml 
HEPES 1.2 g 
1 % (v/v) Pen/Strep 5 ml 
Aqua demin add to a final volume of 500 ml 
 
 
Table 13: Eagle´s minimum essential medium (MEM) 
MEM- Phenolrot 4.695 mg 
1 mM HEPES 4.75 mg 
26 mM NaHCO3 1.1 g 
40 mM Glucose 5.0 g 
20 mM KCL 0.605 g 
1 mM Na-pyruvate 0.6 g 
1.2 mM L-glutamine 0.088 g 
10 % (v/v) FCS 50 ml 
1% (v/v) Pen/Strep 5 ml 
Aqua demin add to a final volume of 500 ml 
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2.3.3 Induction and inhibition of cell death in HT-22 neurons 
2.3.3.1 Induction of neuronal cell death 
Neuronal cell death was induced 24 – 48 h after seeding of the HT-22 cells. Induction of cell 
death was either performed by glutamate-induced toxicity or by tBid over-expression. 
2.3.3.1.1 Glutamate-induced toxicity 
Glutamate-induced toxicity in HT-22 cells was performed when cells reached about 70-80 % 
confluency. For induction of cell death, glutamate solution at a final concentration range from 
3-7 mM was used. For glutamate stock solution, D,L-glutamic acid monohydrate (Sigma-
Aldrich, Taufkirchen, Germany) was dissolved in Dulbeccos´s modified eagle medium 
(DMEM; PAA Laboratories GmbH; Cölbe, Germany) to a stock concentration of 1 M. The pH 
was adjusted to 7.2 with concentrated sodium hydroxid solution (NaOH). The stock solution 
was stored at -20°C. For measuring glutamate toxicity the stock solution was diluted in 
DMEM to final concentrations of 3 mM to 7 mM instantaneously before treatment, and cell 
growth medium was removed and replaced by the final glutamate solution. To investigate 
neuroprotective properties of the inhibitors used in this study (0), growth medium of HT-22 
cells was exchanged with cell culture medium containing glutamate and/or substances in the 
final concentrations, respectively. Between 4 h and 24 h after treatment, cells were analyzed 
following the the described procedures for protein or RNA analysis, cell viability, flow 
cytometry, epi- and confocal microscopy or immunoprecipitation and immunoblots.  
2.3.3.1.2 tBid induced-toxicity 
For induction of tBid-mediated cell death, HT-22 cells were seeded in 24-well plates with a 
density of 40,000 cells per well. Twenty-four hours after seeding, tBid overexpression was 
induced by transfection of cells with a tBid- encoding plasmid (pIRES-tBid, 2.3.5.1). Between 
17 h to 24 h after tBid overexpression cell morphology, cell viability and mitochondrial 
membrane potential (Δψm) was analyzed as described below.  
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2.3.3.2 Inhibition of neuronal cell death 
To inhibit neuronal cell death in HT-22 cells, the Bid inhibitor BI-6c9 (Sigma-Aldrich, 
Taufkirchen, Germany; Figure 6) was dissolved in dimethyl sulfoxide (DMSO) to a stock 
concentration of 10 mM. The stock solution was stored at -20°C. To achieve neuroprotection 
against glutamate- and tBid-induced toxicity BI6c9 was used at final concentrations of 10 µM 
in DMEM (Table 6). The Bid inhibitor BI-6c9 was used as a positive control for 
neuroprotection in all experiments performed in this study. 
 
                    
                    Figure 6: Chemical structure of the Bid inhibitor BI-6c9 
 
Novel small-molecule Bid inhibitors used in this study (3.1.3) were dissolved in dimethyl 
sulfoxide (DMSO) to a stock concentration of 100 mM and stored at -20°C, respectively. To 
screen the newly synthesized structures for their ability to provide neuroprotection against 
glutamate- and tBid-induced toxicity, compounds were diluted in cell culture medium to final 
concentration ranges of 0.1 µM to 100 µM. Chemical structures of all novel small-molecule 
inhibitors are provided in Table 67 - Table 70 (Appendix). 
The unspecific anion channel blocker and VDAC inhibitor 4,4´- Diisothio-cyanatostilbene-
2,2´-disulfonic acid (DIDS; Figure 2) was dissolved in DMSO to a stock concentration of 
100 mM. The stock solution was stored at -20°C and diluted with cell culture medium prior to 
each experiment to final concentrations of 100 µM up to 1 mM.  
 
                                               
Figure 7: Chemical structure of 4,4´- Diisothio-cyanatostilbene-2,2´-disulfonic acid (DIDS).  
DIDS was used to analyze the impact of the voltage-dependent anion channel (VDAC) in glutamate- and tBid-
induced toxicity in HT-22 cells.  
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In order to exclude specific effects of the solvent of the different chemical substances and 
inhibitors, vehicle controls (DMSO controls) were always treated with medium containing the 
highest concentration of the solvent that was present at the highest applied concentration of 
the active compounds during the experiment. 
 
2.3.4 Induction of cell death in primary cortical neurons (PCN) 
Cell death in primary cortical neurons was performed by glutamate-induced excitotoxicity via 
activation of NMDA receptors that are functionally expressed at 6-8 days in vitro (DIV). 
Therefore treatments of primary cortical neurons were performed with 7-9 old cell cultures 
and excitotoxicity was induced by glutamate (20-25 µM) in neurobasal medium 
supplemented with 2 % B-27 (Table 11). Cultured neurons were harvest 4 h and 22- 24 h 
after glutamate exposure, and 30-45 x 106 cells per treatment condition were analyzed 
following the described procedures for immunoprecipitation studies. 
 
2.3.5 Transfection protocols 
HT-22 neurons were transfected either in 96-well plates, 24-well plates, ibidi µ-slide 8-well 
plates, 6 cm2 or 10 cm2 dishes, depending on the respective experiments. Plasmid 
transfections were performed 24 h after seeding of cells and siRNA transfections were 
performed as reverse transfections instantaneous prior to seeding of cells. 
2.3.5.1 Plasmid and gene transfection 
For plasmid transfections HT-22 cells/well were seeded in 24-well plates at a density of 
4 x 104 or in ibidi µ-slide 8-well plates (Ibidi, Munich, Germany) at a density of 
16.000 cells/well 24 h before transfection, and incubated under normal growth conditions 
(37°C, 5% CO2). On the day of transfection growth medium was replaced with 500 µl fresh 
standard growth medium and substance pre-treatment (BI-6c9, DIDS, novel Bid inhibitors) 
was performed 1 h before the following plasmid transfection. The plasmids pIRES-tBid, 
pDSRed2-Bid, pc-mBid13-y47, pc-mBid13-D51,FLAG-VDAC1, FLAG-control or empty vector 
pcDNA 3.1+ were dissolved separately in antibiotic- and serum-free medium and Attractene 
transfection reagent (Qiagen, Hilden, Germany) was added to the DNA solution. To allow 
complex formation samples were incubated for 10 to 15 minutes at RT. 24-60 µl of the 
transfection mixture was added to the cell culture medium to a final concentration of 0.5-2 µg 
DNA/well and 0.75-4.5 µl Attractene/well. Controls were treated with 24-60 µl antibiotic- and 
serum-free cell culture medium only and vehicle controls additionally with 0.75-4.5 µl 
Attractene/well. Cells were incubated under normal growth conditions until further 
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experiments. Cell morphology and cell viability was analyzed 16 h to 20 h after over-
expression tBid or novel Bid constructs, respectively. Immunostaining and 
immunoprecipitation of FLAG-VDAC1 was performed 24 h – 48 h after over-expression of 
FLAG-VDAC1. Immuno-analysis of pDSRed2-Bid was performed 24 h – 48 h after 
transfection. 
2.3.5.2 SiRNA transfection 
For siRNA transfections Lipofectamine RNAiMax (Invitrogen, Karlsruhe, Germany) was used. 
VDAC1 siRNA (VDAC1 siRNA1 and VDAC1 siRNA2), VDAC2 siRNA (VDAC2 siRNA a and 
VDAC2 siRNA b), Bid siRNA (SASI 115198 and SASI 115200) or non-functional scrambled 
siRNA were separately dissolved in Opti-MEM I (Invitrogen, Karlsruhe, Germany). After 10 
min. of equilibration at RT, each siRNA solution was combined with the respective volume of 
the Lipofectamine RNAiMax solution and mixed gently. For reverse transfection the 
transfection mixture was filled into the cell culture wells or dishes, depending on the 
respective experiments, and allowed to form siRNA liposome complexes for further 20 min. 
at room temperature. After addition of antibiotic-free cell suspension, a final concentration of 
20 nM to 80 nM siRNA and 2 µl/ml Lipofectamine was reached. Controls were treated with 
100 µl/ml Optimem only, and vehicle controls additionally with 2µl/ml Lipofectamine 
RNAiMax. SiRNA sequences see 2.3.5.2.  
SiRNA transfections were performed in 10 cm2 dishes for protein analysis or in 24-well plates 
for RNA analysis. Gene silencing was verified by RT-PCR and Western blotting. For 
functional analysis of protein depletion, siRNA transfections were carried out in cell culturing 
formats depending on the respective experiment. 
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2.4 Cell viability assays 
2.4.1 Analysis of cell morphology 
After different cell death stimuli, such as glutamate- or tBid-induced toxicity, HT-22 neurons 
show excessive alterations in cell morphology: Cells clearly appear shrunken, rounded up 
and detached from the bottom of the culture plate. Therefore, analysis of cell morphology can 
be used for estimating cell viability of HT-22 cells. 
For analysis of cellular morphology, transmission light microscopy of living HT-22 cells, 
growing as monolayers, was performed using an Axiovert 200 microscope (Carl Zeiss, Jena, 
Germany) equipped with a Lumenera Infinity 2 digital camera (Lumenera Corporation, 
Ottawa, Canada). Light was collected through a 10 x 0.25 NA objective (Carl Zeiss, Jena, 
Germany), and images were captured using phase contrast. The INFINITY ANALYZE 
software (Lumenera Corporation, Ottawa, Canada) was used for digital image recording and 
image analysis. Images were captured using phase contrast. 
2.4.2 MTT assay 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay is a well 
accepted colorimetric method to determine cell proliferation, cell viability and cytotoxicity. The 
cellular reduction of the yellow colored monotetrazolium salt MTT to purple colored formazan 
is performed by either a lyosomal/endosomal cell compartment or active mitochondria in 
living cells175. Since only viable cells with active metabolism convert MTT into a purple 
formazan product with an absorbance maximum near 570 nm that can be easily detected by 
absorptive spectroscopy, color formation serves as a useful and convenient marker of the 
metabolic activity in viable cells. 
                         
                  Figure 8: Reduction of yellow MTT to purple colored formazan
 
 
Cell viability of HT-22 cells was evaluated 16-24 h after glutamate- or tBid-induced toxicity 
and respective substance pre-or co-treatments. Quantification of cell viability in HT-22 cells 
was performed either in standard 96-well plates or standard 24-well plates. MTT (Sigma-
Aldrich, Munich, Germany) was dissolved in 1 x PBS at a concentration of 2.5 mg/ml. When 
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morphological changes of the cells indicated cell death, the MTT reagent was added to the 
media at final concentrations of 0.25 mg/ml, followed by 1 h incubation at 37°C. After 
terminating the reaction was terminated by removing the media from cells and freezing the 
plate at -80 °C for at least 1 h. The formazan crystals were dissolved in dimethyl sulfoxide 
(DMSO) and absorbance was determined at 570 nm (FluoStar OPTIMA, BMG Labtech, 
Offenburg, Germany). Background was detected at 630 nm and subtracted accordingly. Cell 
viability levels were demonstrated as percentage of absorption levels in untreated control 
cells (100 % cell viability). A DMSO control was used as solvent control. For statistical 
analysis the experiments were repeated at least three times. 
2.4.3 Real-time measurements of cell impedance (xCELLigence) 
Impedance-based real-time detection of cellular events was conducted using the 
xCELLigence system Real-Time Cell Analyzer RTCA-MP (Roche Diagnostics, Penzberg, 
Germany), which measures the electrical impedance between gold micro-electrodes 
integrated into the bottom of custom made tissue culture plates (E-plates 96)176. Due to a 
high electrical resistance of cells, the electrical impedance is the higher the more cells are 
attached to the bottom of the E-plates. Therefore this system allows for monitoring changes 
in cell proliferation, cell viability and morphology as well as alterations in cell number and cell 
adhesion, and especially the kinetics of these processes in a large number of tissue culture 
wells simultaneously throughout the experiments. Differences in the electrical impedance of 
cells are displayed as cell index (CI) as function of time.  
HT-22 cells were cultured with a density of 10,000 – 12,000 cells/well in 96- well E-plates 
and recordings were started immediately after seeding. At twenty-four hours after seeding of 
cells, when the cell index exceeded a value of about one, cells were treated with glutamate 
(3-7 mM) and/or with different inhibitor substances dependent on the experiment. Since the 
system is very sensitive to changes in temperature, a complete removal of the medium was 
avoided to prevent a persistent breakdown of the impedance. Recording of cell index (CI) 
values and normalization was performed using the RTCA Software 1.2 (Roche Diagnostics, 
Penzberg, Germany). Background impedance caused by the media was recorded before 
seeding of the cells and subtracted automatically by the RTCA software.  
After concluding each experiment, E-plates were recycled by removing media, washing the 
plates twice with aqua demin. and adding standard Trypsin/EDTA for 15-20 minutes. 
Afterwards 1xTE was removed, plates were washed 3 times. To reassure sterility the plates 
were irradiated with UV light for 30 minutes. For statistical analysis the experiments were 
repeated at least three times. 
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2.4.4 ATP- luminescence measurements 
Adenosinetriphosphate (ATP) can be used to assess the functional integrity of living cells 
since all cells require ATP for survival and their energy-dependent specialized functions. Any 
form of cell injury results in a rapid decrease in cytoplasmic ATP-levels. The detection of 
cellular ATP is based on a bioluminescent assay, which utilizes an enzyme, luciferase, to 
catalyze the formation of light from ATP and luciferin according to the following reaction: 
 
               
 
 
 
Figure 9: Formation of light from ATP and luciferin 
 
The emitted light intensity is linearly related to the cellular ATP concentration and can be 
easily detected by a plate reader measuring the luminescence. As each individual cell 
contains ATP, the method can not only be used for detection of cellular ATP-levels, but also 
for the direct assessment of cell numbers.  
For analysis of total ATP levels, HT-22 neurons were seeded in white 96-well plates 
(Greiner, Frickenhausen, Germany) for luminescence measurements. Twenty four hours 
after seeding, cells were treated with 5 mM glutamate and when indicated additionally with 
the Bid inhibitor BI-6C9 (10 µM), novel compounds (20 µM) or the VDAC inhibitor DIDS 
(500 µM – 1000 µM) respectively. Cellular ATP levels were detected approximately 20 h after 
glutamate exposure using the ViaLightTM Plus-Kit (Lonza, Verviers, Belgium) according to the 
manufacturer’s protocol. Briefly, the culture plate was allowed to cool down to room 
temperature for at least 5 minutes. In this time all reagents were prepared following the 
manual instructions. Afterwards, cells were treated with the nucleotide releasing reagent, and 
incubated for 5 min. at room temperature. The ATP monitoring reagent was then injected into 
each well and luminescence was detected immediately by the FluoStar plate reader (BMG 
Labtech, Offenburg, Germany). The emitted light intensity was recorded for quantification of 
ATP-levels and values were given as relative values in % to control cells. The experiments 
were repeated at least three times with an n=8 per treatment condition.  
 
ATP + Luciferin + O2 Oxyluciferin + AMP + PPi + CO2 + LIGHT 
Mg
2+ 
Luciferase
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2.4.5 Measurements of oxygen consumption (Seahorse Bioscience) 
Measurement of oxygen consumption form intact cells enables evaluation of mitochondrial 
bioenergetics and metabolism under conditions that are more physiologically realistic 
compared to isolated mitochondria. Metabolic substrate uptake (oxygen, glucose, fatty acids) 
and energy conversion through oxidation and reduction reactions are executed by several 
intracellular biochemical processes (glycolysis, Krebs cycle, electron transport, OXPHOS) 
that result in the production of ATP and the release of heat and chemical by-products (lactate 
and CO2) into the extracellular environment. Using the Extracellular Flux Analyzer (Seahorse 
Bioscience, North Billerica, MA, USA) the uptake and excretion of metabolic end products 
can be measured in real-time. The XF Cell Mito Stress Test Kit (Seahorse Bioscience) was 
used to detect extracellular flux changes of oxygen and protons in the media immediately 
surrounding adherent cells by using fluorescent biosensors (oxygen and pH) and a sensor 
cartridge coupled to a fiber-optic waveguide177. From this waveguide light at various 
excitation wavelength (oxygen = 532 nm, pH = 470 nm) is delivered and a fluorescent signal 
is transmitted to a set of highly sensitive photodetectors177. In cells, oxygen consumption and 
proton extrusion cause rapid but measurable changes in oxygen tension and pH which are 
detected within a transient micro chamber in each well of a microplate. Additionally, each 
sensor cartridge is equipped with four reagent delivery chambers per well for injection of 
different reagents to analyze the respective mitochondrial bioenergetics Thereby, four key 
parameters of mitochondrial function, namely basal respiration, ATP production, proton leak, 
and maximal respiration, were measured in a microplate (Figure 10). Thus a complete 
mitochondrial stress profile can be recorded: 
 
                            
Figure 10: Mito Stress Profile 
Key parameters of mitochondrial function: basal respiration, ATP turnover, proton leak, and maximal respiration, 
and spare respiratory. (Picture from Seahorse Bioscience, www.seahorsebio.com) 
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Measurements of oxygen consumption rate (OCR) in HT-22 cells were assessed using an 
XF96 Extracellular Flux Analyzer (Seahorse Biosciences, North Billerica, MA, USA), which 
directly records the OCR in cells that remain attached to the culture plate by using calibrated 
optical sensors. The OCR recordings were carried out as previously described with minor 
modifications178. Briefly, HT-22 cells were seeded in XF96-well cell culture microplates 
(Seahorse Bioscience, North Billerica, MA) at a density of 10,000 cells/well in standard 
growth medium and incubated at 37°C and 5 % CO2 for ~24 h. For measuring effects of 
gene depletion on OCR of HT-22 cells, siRNA transfections were performed in the XF96-well 
microplates instantaneously prior to seeding of cells. Twenty-four hours after seeding, cells 
were treated with glutamate (5-7 mM) and/or BI-6c9 (10 µM), novel compounds (20 µM) or 
DIDS (500 µM and 1000 µM) for 20 h, respectively. Before starting the measurements, the 
growth medium was washed and replaced with ~180 μl of assay medium (with 4.5 g/L 
glucose as the sugar source, 2 mM glutamine,  1 mM pyruvate, pH 7.35) and cells were 
incubated at 37°C for 60 min. Three baseline measurements were recorded before the 
addition of compounds. To assess mitochondrial dysfunction, respiratory chain poisons were 
used. The ATP synthase inhibitor Oligomycin was injected in Port A at a final concentration 
of 3 µM to measure OCR in the absence of oxidative phosphorylation. The protonophore 
FCCP was subsequently injected in Port B at a concentration of 0.4 µM to dissipate the 
proton gradient across the inner mitochondrial membrane and thereby to assess maximal 
respiratory capacity (MRC). Co-injection of the complex I/III inhibitors Rotenone/Antimycin A 
in Port C at concentrations of 1 µM, respectively, was used to inhibit O2 consumption by the 
mitochondrial electron transport chain and thus to address non-mitochondrial respiration. 
Three measurements were performed after the addition of each compound by a 4-minute mix 
cycle used to oxygenate the medium and 3-minute measurement cycle to asses respiration. 
For comparing OCR after compound exposure to OCR in non-treated cells, the absolute cell 
number is insignificant since the same population of cells is compared. Therefore, most of 
the results are indicated as normalized OCR (% baseline rate) for each individual cell 
population to minimize variability due to slight differences in plating and viability during 
culture and treatment time (~48 h). The experiments were independently repeated at least 
three to five times. 
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2.5 Flow cytometric measurements (FACS) 
For Fluorescence-activated cell sorting (FACS) the Guava Easy Cyte 6-2 L system (Merck 
Millipore, Schwalbach, Germany) was used. For FACS measurements cells were treated 
with glutamate (3-5 mM) or transfected with pIRES-tBid 24 h after seeding in 24-well plates. 
SiRNA transfections were directly performed in the 24-well plates. Treatment of cells with the 
Bid inhibitor BI-6c9 (10 µM), novel compounds (20 µM) or DIDS (500 µM, 1000 µM) was 
performed simultaneously or 1 h prior to the cell death stimulus, dependent on the respective 
experiments. Seventeen to twenty hours after treatment, cells were analyzed as further 
described. Data were always collected from 10,000 cells per sample and 3-4 samples per 
condition were measured for each experiment. For quantitative analysis the GuavaSoft 
Software package was used. Measurements shown in this thesis are representative of at 
least three to five independent experiments, each with n = 3-4.  
2.5.1 Analysis of apoptotic and necrotic cell death with Annexin-V-FITC 
staining 
To determine apoptotic and necrotic cell death, cells were stained with Annexin-V-FITC and 
propidium iodide (PI) and subsequently analyzed by flow cytometry. In apoptotic cells, the 
membrane phospholipid phosphatidylserin (PS) is translocated from the inner to the outer 
leaflet of the plasma membrane, thereby exposing PS to the external cellular environment. 
Annexin-V (AV) is a calcium dependent phospholipid-binding protein with high affinity for PS 
on the cell surface in early phases of apoptosis. The conjugation of annexin-V to the green-
fluorescent FITC dye allows for flow cytometric analysis of cells that undergo apoptosis. The 
red-fluorescent propidium iodide dye (PI) is used to stain late apoptotic or necrotic cells. 
Viable cells with intact membranes exclude PI, whereas the membranes of dead and 
damaged cells are permeable to PI. After treatment of cells with both AV and PI, apoptotic 
cells show green fluorescence (AV+), dead cells show red and green fluorescence (AV+/PI+) 
and viable cells depict no fluorescence. 
After respective treatments, HT-22 cells from 3 wells per condition were harvest using 
trypsin/EDTA, washed once with 1 x PBS and loaded with 2 ul of annexin V-fluorescein 
isothiocyanate (FITC) and 2 µl of propidium iodide (PI) according to the manufacturer´s 
protocol (Annexin-V-FITC Detection Kit, Promokine, Heidelberg, Germany). After incubation 
for 5 min. at RT in the dark, cells were analyzed by FACS. Annexin-V-FITC was excited at 
488 nm and emission was detected with the green filter at 525/530 nm. Fluorescence of PI 
was excited at 488 nm and fluorescence emission was detected with the red filter at 
690/650 nm. To exclude cell debris and doublets, cells were appropriately gated by forward 
versus side scatter and pulse width, and 10,000 gated events per sample were collected.  
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2.5.2 Analysis of lipid peroxidation with BODIPY 
For detection of cellular lipid peroxidation, BODIPY 581/591 C11 (Invitrogen, Karlsruhe, 
Germany) was used. BODIPY is a sensitive fluorescent reporter for lipid peroxidation, 
undergoing a shift from red to green fluorescence emission upon oxidation of the 
phenylbutadiene segment of the fluorophore. This oxidation-dependent emission shift 
enables fluorescence ratio imaging of lipid peroxidation in living cells. For detection of cellular 
lipid peroxidation cells were stained with 2 mM BODIPY 581/591 C11 (Invitrogen, Karlsruhe, 
Germany) for 60 minutes in standard growth medium at indicated time points after glutamate-
or tBid-induced toxicity and/or substance treatment. Afterwards, cells were harvest by using 
trypsin/EDTA, washed once with 1 x PBS and resuspended in 1 x PBS. Flow cytometry was 
performed using 488 nm UV line argon laser for excitation, and BODIPY emission was 
recorded at 530 nm (green) and 585 nm (red) by flow cytometry (FACS). Data were collected 
from at least 10,000 events per sample at three independent experiments each with n = 3-4. 
Increases in green fluorescence indicated formation of lipid peroxides.  
2.5.3 Analysis of mitochondrial membrane potential with TMRE 
For detection of mitochondrial membrane potential (Δψm) in whole cells the MitoPT
TM TMRE 
kit (Immunochemistry Technologies, Hamburg, Germany) followed by flow cytometric 
measurements (FACS) was used. The kit contains tetramethylrhodamin ethyl ester (TMRE) 
which is a lipophilic, cationic fluorescent redistribution dye. This dye has a delocalized 
positive charge dispersed throughout its molecular structure, and due to its lipophilic 
solubility TMRE is able to penetrate into living cells. As the mitochondrial membrane potential 
collapses and cells enter apoptosis or other oxidative stress driven mechanism, the amount 
of fluorescence will drop as the concentrated TMRE dye equilibrates back out of the 
mitochondria and into the cytosol, where it is diluted to a lower dye concentration. Therefore, 
cells with healthy mitochondria appear red (high TMRE fluorescence), whereas dead cells 
are depicted by a reduced magnitude of red fluorescence, indicating loss of Δψm. 
When cell death occurred after the respective treatments (see outlined above), HT-22 cells 
were collected and washed with 1 x PBS. After incubation of cells with 0.2 µM TMRE for 
30 min at 37 °C, cells were washed and resuspended in assay buffer. As a positive control 
for a complete loss of Δψm, the protonophore carbonyl cyanide m-chlorophenylhydrazone 
(CCCP, 50 µM) was applied to intact cells 30 min. prior to harvesting. To exclude auto-
fluorescence of the cells a non-treated negative control, which was not stained by TMRE, 
was prepared. Flow cytometry was performed using fluorescence excitation at 488 nm and 
TMRE emission at 680 nm. To exclude cell debris and doublets, cells were appropriately 
gated by forward versus side scatter and pulse width, and 10,000 events were gated per 
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sample and data were collected from 3-4 independent samples per treatment condition and 
the experiments were repeated at least three times.  
 
2.6 Immunocytochemistry 
2.6.1 Visualization of mitochondria 
For detection of mitochondrial morphology changes during cell death, HT-22 neurons were 
seeded in ibidi μ-slide 8-well plates (Ibidi, Munich, Germany) at a density of 16,000 – 20,000 
cells per well 24 hours before treatment. For visualization of mitochondria, cells were 
transfected with the green fluorescent mGFP plasmid. Alternatively, mitochondria were 
visualized by MitoTracker Green/DeepRed according to the manufacturer’s protocol 
(Invitrogen, Karlsruhe, Germany). Nuclei were stained with DAPI (4´,6- diamidino-2-
phenylindole dihydrochloride) for endpoint analysis on a fluorescence microscope 
(DMI6000B, Leica, Wetzlar, Germany). MitoTracker DeepRed was dissolved in DMSO at a 
final stock concentration of 50 μM and kept protected from light. For applications on cells the 
MitoTracker reagent was diluted 1:250 in culture medium (final working concentration 
200 nM) together with DAPI (1 μg/ml) for counterstaining of the nuclei. Staining solution was 
added to the cells and incubated for 20-30 minutes at 37°C before starting the respective 
treatment. After completing the experiment, cells were washed with 1 x PBS, fixed with 4 % 
paraformaldehyde (PFA) and washed again twice with PBS. Mitochondria were visualized by 
epiflourescence microscopy (DMI6000B Leica, Wetzlar, Germany) for characterization and 
counting of mitochondria (see 2.6.2). Images were taken using a confocal laser scanning 
microscope (Leica SP5, Leica, Wetzlar, Germany). 
2.6.2 Characterization of mitochondrial morphology 
For evaluation and classification of mitochondrial morphology, mitochondria of HT-22 cells, 
cells were seeded in ibidi μ-slide 8-well plates (Ibidi, Munich, Germany) at a density of 
16,000 – 20,000 cells per well. Twenty-four hours after seeding, cells were treated with 
glutamate (3-5 mM) and/or BI-6c9 (10 µM) or DIDS (500 µM and 1000 µM) for 17-20 h, 
respectively. Mitochondria and nuclei were visualized as described before (2.6.1). Endpoint 
pictures were taken after fixation of cells with 4% paraformaldehyde (PFA) using confocal 
fluorescence microscopy (Leica SP5, Leica, Wetzlar, Germany). Three categories of 
mitochondrial morphology were defined as follows: Healthy cells display category I: 
elongated tubulin-like mitochondria, which are equally distributed throughout the cytosol. 
Category II mitochondria are defined as intermediate and round mitochondria, the cells do 
not show apoptotic features, e.g. shrunken nuclei, and are not detached. In contrast, 
damaged and dying cells contain category III mitochondria, which are strongly fragmented. In 
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these cells, mitochondrial fragmentation is accompanied by an apoptotic phenotype, showing 
nuclear condensation and the peri-nuclear arrangement of the mitochondrial fragments. For 
quantification of mitochondrial morphology, at least 500 cells per condition were counted by 
two investigators blinded towards the treatment condition in at least three independent 
experiments. 
2.6.3 Immunocytochemistry of Bid and VDAC1 
For detection of Bid and VDAC1 localization in healthy cells and during cell death, HT-22 
neurons were seeded in ibidi μ-slide 8-well plates (Ibidi GmbH, Munich, Germany) at a 
density of 16,000-20,000 cells/well and transfected with the pDSRed2-Bid or the FLAG-
VDAC1 plasmid. Twenty-four hours after transfection cells were treated with glutamate 
(5 mM) or in case of Flag-VDAC1 transfection with BI-6c9 (10 µM). To visualize 
mitochondria, cells were co-transfected with mGFP or alternatively, mitochondria were 
stained with MitoTracker Green as described before. For fixation of cells, culture medium 
was removed, cells were washed once with 1x PBS and fixed with 4 % PFA for 20 min. and 
washed again with 1 x PBS. After fixation, pDSRed2-Bid and mGFP-transfected cells were 
instantaneously analyzed by confocal fluorescence microscopy. In contrast, membranes of 
cells transfected with Flag-VDAC1 were permeabilized by exposure for 5 min. to 0.4 % Triton 
X-100 (Sigma-Aldrich, Taufkirchen, Germany) in 1x PBS. After fixation, cells were placed in 
blocking solution (3 % horse serum (Invitrogen, Karlsruhe, Germany) in 1x PBS) for 30-60 
minutes. To visualize FLAG-VDAC1, cells were exposed to a monoclonal anti-FLAG antibody 
(1:200 in block solution, Sigma-Aldrich, Munich, Germany), for 2 h at room temperature. 
Afterwards, cells were washed three times with 1 x PBS followed by incubation for 1-2 hours 
with the secondary Dylight 649 anti-mouse antibody (1:200, Merck Millipore, Darmstadt, 
Germany). After washing of cells three times with 1 x PBS, cells were analyzed by confocal 
fluorescence microscopy. For immunocytochemistry of endogenous Bid, cells were exposed 
to a polyclonal anti-Bid antibody (1:200, Cell signaling, Danvers, Massachusetts, USA) 
overnight at 4°C and subsequent 2.5 h at room temperature, followed by an incubation for 2 
hours with a secondary biotinylated anti-rabbit IgG antibody (1:200, Vector Labs, 
Burlinghame, CA. USA) and 30 min. in the presence of streptavidin oregon green 514 
conjugate (Invitrogen, Karlsruhe, Germany) according to the manufacturers protocol. The 
specificity of the respective Bid or FLAG-VDAC1 immune reactivity was controlled by 
emission of the primary antibody in parallel staining of negative controls. Images were 
acquired using a confocal laser scanning microscope (Leica SP5, Leica, Wetzlar, Germany) 
as described below.  
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2.7 Epifluorescence and confocal laser scanning microscopy (CLSM) 
2.7.1 Epifluorescence microscopy 
Imaging of mitochondrial morphology or TMRE stained HT-22 neurons was performed using 
a Leica DMI6000B fluorescence microscope, equipped with a DCF360FX-camera (both 
Leica, Wetzlar, Germany). TMRE red fluorescence and MitoTracker Deep Red fluorescence 
were excited using a 620 ± 60 nm band pass filter and fluorescence emission was collected 
using a 700 ± 75 nm band pass filter (Filter Cy5, Leica, Wetzlar, Germany). DAPI 
fluorescence was excited using 360 ± 40 nm band pass filter, and emission was collected 
using a 470 ± 40 nm band pass filter (Filter A4, Leica, Wetzlar, Germany). MitoTracker Green 
and mGFP fluorescence was excited at a wavelength of 488 nm and emission was detected 
using a 560 nm long pass filter. For digital imaging the software LAS AF (Leica, Wetzlar, 
Germany) was used. 
2.7.2 Confocal laser scanning microscopy 
For detection of mitochondrial morphology changes, VDAC1-induced toxicity as well as 
VDAC1 and Bid localization in healthy and dead cells, HT-22 neurons were immunostained 
as described before. Images were acquired using a confocal laser scanning microscope 
(Leica SP5, Leica, Wetzlar, Germany) equipped with a diode (405 nm), an argon laser 
(458/476/488/496/514 nm) and two helium-neon lasers (543 nm and 633 nm). An Acousto-
Optical-Beam-Splitter (AOBS) serves as tunable dichroic for all lasers.  Light was collected 
through a 63 x 1.4 NA, oil immersion objective. MGFP, MitoTracker Green and oregon green 
fluorescence was excited at 488 nm and emissions were detected between 500 nm and 
535 nm bandwidth. DyLight-stained Flag-VDAC1 was excited at 543 nm and  emission was 
detected between 555 nm and 620 nm. MitoTracker DeepRed fluorescence was detected by 
excitation at 633 nm and emission between 640 nm and 750 nm. For digital imaging the 
software LSM Image Browser 4.2.0 (Carl Zeiss, Jena, Germany) was used. 
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2.8 Protein analysis 
2.8.1 Protein sample preparation from HT-22 cells 
For obtaining total protein extracts from HT-22 cells, cells were seeded either at a density of 
7 x 104 cells per well in 24-well plates or at a density of 1-1.5 x 106 cells per dish in 10 cm2 
dishes for western blot analysis, and at a density of 1.5 x 106 cells per flask in T75 flask or at 
a density of 4 x 106 cells per T175 flask for immunoprecipitation experiments. After 
respective treatments, cells were washed with cold 1 x PBS, lysed with protein lysis buffer 
(Table 14) supplemented with 1 mM DTT, 1% Triton-X-100,  Complete Mini Protease 
Inhibitor Cocktail and Phosstop Phosphatase Inhibitor Cocktail (1 tablet per 10 ml, both 
Roche, Mannheim, Germany) and detached with a cell scraper. For immunoprecipitation 
studies, cells from 3 flasks per condition were pooled. All steps were performed at 4°C. After 
centrifugation at 15.000 x g for 15 min at 4 °C supernatants were stored at -80 °C until further 
use.  
 
Table 14: Protein lysis stock-buffer for HT-22 cells; pH 7.8 
0.25 M D-Mannitol 4.56 g 
0.05 M Tris 0.788 g 
1 M EDTA 0.038 g 
1 M EGTA 0.038 g 
Bidest H2O ad 100 ml 
 
2.8.2 Protein sample preparation from primary mouse cortical neurons (PCN)  
For total protein extracts form primary mouse cortical neurons (PCN), neurons were cultured 
in PEI-coated T75 flask at a density of 10-15 x 106 cells per flask. For immunoprecipitation 
studies and western blot analysis, neurons from three flasks per conditions were pooled. 
After respective glutamate treatment, cells were washed in warm 1 x PBS, and lysed in lysis 
buffer for primary neurons and brain tissue samples (Table 15) supplemented with Complete 
Mini Protease Inhibitor Cocktail and Phosstop Phosphatase Inhibitor Cocktail (1 tablet per 
10 ml, both Roche, Mannheim, Germany). Lysis and scratching of cells was performed at 
4°C. Protein extracts were frozen 3 times with liquid nitrogen and thawed again at room 
temperature before extracts were centrifuged at 13.000 g for 10 min at 4°C. The supernatant 
was placed in a new tube and stored at -80°C until further use.  
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Table 15: Protein Lysis Buffer for primary neurons and brain tissue; pH 7.4 
50 mM HEPES  119.15 mg 
150 mM NaCl 87.66 mg 
4 mM EGTA 80 µl (0.5 M EGTA-stock solution) 
10 mM EDTA 100 µl (1 M EDTA-stock solution) 
15 mM Na4O7P2 75 µl (2 M Na4O7P2 -stock solution) 
50 mM NaF 20.99 mg 
5 mM Na3VO4 25 µl (2 M Na3VO4-stock solution) 
1 mM DTT 100 µl (100 mM DTT-stock solution) 
1 mM PMSF 100 µl (100 mM PMSF-stock solution) 
0.2% NP-40 20 µl 
Bidest H2O ad 10 ml 
Lysis buffer was always prepared fresh before starting the experiment and stored at 4°C in 
the dark during use.  
2.8.2 Protein sample preparation from cortex and hippocampal mice brain 
tissue  
For obtaining total protein extracts from mice brain tissue, brains were isolated from 
untreated control C57BL/6 mice and from male C57BL/6 mice subjected to transient middle 
cerebral artery occlusion (MCAo, see 2.10). Cortex homogenates for immunoprecipitation 
and western blot analysis were generated from 4 mm sections of the ipsi-and contralateral 
parietal cortex (2 mm +/- bregma) respectively at 2 h, 6 h and 24 h after the onset of 
ischemia. Hippocampal homogenates were generated from approximately half of the 
hippocampus of the respective mice. After isolation of brain tissue, brain slices were 
separately transferred in a pre-cooled clean glas-douncer filled with 500 µl lysis buffer for 
brain tissue (Table 15), supplemented with Complete Mini Protease Inhibitor Cocktail and 
Phosstop Phosphatase Inhibitor Cocktail (1 tablet per 10 ml, both Roche, Mannheim, 
Germany), respectively. Each tissue sample was homogenized by douncing it 10 times 
followed by centrifugation at 800 x g for 5 min. at 4°C. Tissue homogenates were stored on 
ice until further use. For immunoprecipitation and western blot analysis, samples were used 
immediately without freezing at -80°C.  
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2.8.3 Determination of protein amount in cell lysates 
For determination of protein amounts, the principle of the bicinchoninic acid (BCA) assay, 
which is well accepted for colorimetric detection and quantification of total protein, was used. 
This method is based on the reduction of Cu2+ ions to Cu+ ions by the peptide bonds in 
proteins in an alkaline medium (Biuret-reaction). The amount of reduced Cu2+ is proportional 
to the amount of protein present in the solution. The following purple-colored reaction product 
of this assay is formed by the chelation of two molecules of BCA with on cuprous ion. This 
water-soluble complex exhibits a strong absorbance at 562 nm that is nearly linear with 
increasing protein concentrations in ranges up to 2,000 µg/ml. The macromolecular structure 
of the protein, the amount of peptides, and the four amino acids cysteine, cystine, tryptophan 
and tyrosine are reported to be responsible for the color formation with BCA. This provides a 
basis to monitor the reduction of alkaline Cu2+ by proteins and, thus determine the protein 
concentration in biochemical samples and cell extracts 179. 
Using the Pierce BCA kit (Perbio Science, Bonn, Germany) protein amounts in extracts were 
determined as follows: 5 μl of each sample were diluted in 95 μl 1x PBS. A standard curve 
containing 0-150 μg bovine serum albumin (Perbio Science, Bonn, Germany) per 100 μl, 5 μl 
of the respective lysis buffer and 1 x PBS add to 100 μl was prepared. Next, 200 μl of a 1:50 
mixture of reagent B : reagent A (Perbio Science, Bonn, Germany) was added to each 
sample. Samples were incubated for 30 minutes at 60 °C.  At this temperature, peptide 
bonds assist in the formation of the reaction product, so the assay sensitivity is increased 
since the variances caused by unequal amino acid composition are minimized. One hundred 
micro liter of each sample were added into a 96-well plate (Nunc, Wiesbaden, Germany). 
Absorption was determined at 590 nm using a plate reader (FluoStar OPTIMA, BMG 
Labtech, Offenburg, Germany) and protein amounts of the test samples were calculated from 
the standard curve. 
2.8.4 Immunoprecipitation of Bid, VDAC1 and FLAG-VDAC1 
Immunoprecipitation of Bid, VDAC1 and Flag-VDAC1 was performed by pull-down of the 
proteins from total protein lysates of HT-22 cells exposed to glutamate at the indicated time 
points 0 h to 16 h, primary mouse cortical neurons exposed to glutamate (0 h, 4 h and 22 h) 
and tissue homogenates of mice subjected to MCAo (see 2.8.2 and 2.10), according to the 
manufacturer´s protocol (Invitrogen, Karlsruhe, Germany). Briefly, magnetic Dynabeads 
Protein A were prepared for each condition for effective binding of the respective antibodies: 
anti-Bid antibody (7.5 µg, polyclonal, Cell Signaling, Danvers, Massachusetts, USA), anti-
VDAC1 (N18) antibody (7.5 µg to 10 µg, polyclonal, Santa Cruz, Biotechnology, Santa Cruz, 
CA, USA) or anti-Flag antibody (7.5 μg, polyclonal, Sigma-Aldrich, Munich, Germany). The 
respective antibodies were separately added to the Dynabeads Protein A for 30 min. to bind 
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the Dynabeads via their Fc-region. For all washing steps the tube was placed on a 
Dynamagnet, where the beads migrate to the side of the tube facing the magnet and allow 
for removal of the supernatant. A cross linking reaction with BS3 was performed according to 
the manufacturer’s protocol to avoid co-elution of the antibodies. 
For each immunoprecipitation of Bid, VDAC1 or Flag-VDAC1, 2.5 mg of total protein lysate 
from HT-22 cells and 1-2 mg of total protein lysates from primary neurons and brain tissue 
samples of each treatment condition was incubated with the respective bead-bound 
antibodies for one hour at room temperature followed by a second hour at 4 °C. To elute the 
proteins with their binding partners, 70 μl of 2.5x sodium dodecyl sulfate (SDS)-sample buffer 
was added to each condition and the Dynabead-protein lysate-mix was boiled for 10 min. at 
95 °C. Afterwards the Dynabeads were removed and the supernatant was stored at -80 °C 
until further use. To detect protein-interaction partners of Bid and VDAC1, 30 µl of the eluat 
was analyzed by electrophoresis followed by western blot analysis. The regular protein 
extract with 30-150 μg of total protein lysate per treatment condition was used as a control in 
the SDS-PAGE. 
2.8.5 Gel electrophoresis and western blot  
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a well 
established technique to separate proteins according to their different electrophoretic mobility 
depending on their molecular mass. SDS is an anionic detergent that is applied to the protein 
sample and binds to polypeptide chain, imparting an identical protein charge per unit mass 
and thereby allowing a fractionation by size. Gels were prepared using a polyacrylamide 
separation gel with a concentration of 12.5 % and a stacking gel with 3.5 % and casting of 
gels was performed using BIO-RAD gel casting stands and frames. The specific buffers used 
for gels preparation, subsequent electrophoresis and western blot analysis are provided in 
Table 16 – Table 24: Stripping buffer, pH 2Table 24. 
Prior to electrophoresis, an amount of 30-150 μg of each protein extract samples was mixed 
with 5 x SDS sample buffer and samples were filled up to an equal sample volume with 
bidest water. Afterwards, samples were boiled at 95°C for 10 minutes, cooled down to room 
temperature and loaded onto the gel. For comparative evaluation of molecular-mass, 5 μl of 
PageRulerTM Plus Prestained Ladder (Fermentas, St. Leon-Rot, Germany) were loaded 
next to the samples. Electrophoresis was performed initially at 60 V for about 30 minutes to 
allow for sample collection and subsequently at 125 V in electrophoresis buffer. Following 
electrophoretic separation, proteins were blotted on a polyvinylidenfluorid membrane (PVDF, 
Bio-Rad, Munich, Germany) by Semi-Dry blotting according to the Bio-Rad protocol at 15 V 
for 90 minutes. PVDF-membranes were first activated in methanol and then incubated for 10 
minutes in 1 x transfer buffer before blotting. Meanwhile, Whatman blotting paper and the 
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acrylamide gel were incubated for 10 minutes in transfer buffer. Blotting was carried out by 
stacking one layer of Whatman paper on top of the anodic plate, followed by the PVDF 
membrane, the acrylamide gel as the third, and another final layer of Whatman paper on top. 
Blotting was carried out in a Trans-Blot SD semi-dry transfer cell (Bio-Rad, Munich, 
Germany) using extra thick Whatman filter paper (Bio-Rad, Munich, Germany) and 1x 
transfer buffer. Alternatively, proteins were blotted on a PVDF membrane by Tank-Blotting 
(wet-blotting) at 20 mA per Gel for approximately 20 h over night according to the Bio-Rad 
Tank-Blotting protocol. Therefore, a Mini-Trans-Blot Cell (Bio-Rad, Munich, Germany), in 
which the gel and membrane sandwich was entirely submerged under 1 x transfer buffer 
within a buffer tank, was used. Blotting was performed over night and temperature controlled 
by cooling the system with one ice pack per buffer tank.  
After blotting, the PVDF-membranes were transferred directly into 5 % blocking buffer and 
incubated for 1 h at RT. The blots were then probed with the respective primary antibodies 
(2.1.3) at 4 °C overnight, followed by 1 h incubation at RT. The next day, membranes were 
washed three times with TBST for 5 minutes and exposed to the appropriate HRP-
conjugated secondary antibody (2.1.4) in 5 % blocking solution for 1 h at RT. After washing 3 
times with TBST for 15 minutes, membranes were incubated with chemiluminescence 
substrate solution HRP-Juice (PJK GmbH, Kleinblittersdorf, Germany) at RT in the dark. 
Chemiluminescence signals were recorded and quantified by densitometric analysis using 
the semi-automated Chemidoc-XRS Imaging System and the dedicated Quantity One 
software package (both, Bio-Rad, Munich, Germany). Equal protein loading and quality was 
controlled by re-probing the membranes with the anti-actin antibody (1:10.000, MB 
Biomedicals, Illkirch Cedex, France) and the respective anti-mouse HRP-conjugated 
secondary antibody.  
For SDS gel electrophoresis following solutions were used: 
Table 16: Stacking gel 3.5 % 
0.5 M Tris-HCl solution pH 8.8 2.5 ml 
Acrylamide/bisacrylamide (37.5 : 1) 30% 1.2 ml 
Sodium dodecyl sulfate solution 10% 0.1 ml 
Ammoniumpersulfate solution 10% 0.05 ml 
Tetramethylethylenediamine TEMED 0.01 ml 
Aqua demin.    ad 10 ml 
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Table 17: Running gel 12.5 % 
1.5 M Tris-HCl solution pH 8.8 2.5 ml 
Acrylamide/bisacrylamide (37,5:1) 30 % 3.34 ml 
Sodium dodecyl sulfate solution 10 % 0.1 ml 
Ammoniumpersulfate solution 10 %  0.05 ml 
Tetramethylethylenediamine TEMED 0.01 ml 
Aqua demin. ad 10 ml 
 
Table 18: 5 x SDS-loading buffer 
1 M Tris-HCl pH 6.8   7 ml 
Glycerol 3 ml 
D,L-dithiotreitol (DTT) 0.93 g 
SDS 1 g 
β-Mercaptoethanol 0.1 ml 
Bromophenol blue sodium salt 1.2 mg 
 
Table 19: 1 x Electrophoresis buffer 
Tris base   3 g 
Glycine   14.4 g 
Sodium dodecyl sulfate (SDS) 1 g 
Aqua demin.   ad 1,000 ml 
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For western blot analyses following buffers were used: 
Table 20: 1 x 10 % Transfer buffer (Semi-Dry-Blotting), pH 8.3 
Tris base 3 g 
Glycine 14.4 g 
Methanol   100 ml 
HCl 0.1 M q.s. 
Aqua demin.    ad 1,000 ml 
 
Table 21: 1 x 20% Transfer buffer (Tank-Blotting), pH 8.3 
Tris base 3 g 
Glycine 14.4 g 
Methanol   200 ml 
HCl 0.1 M q.s. 
Aqua demin.    ad 1,000 ml 
 
Table 22: 1 x TBS/Tween 20, pH 7.5 
Tris Base   2.4 g 
Sodium chloride    29.2 g 
Tween 20 0.5 ml 
HCl 0.1 M q.s. 
Aqua demin.   ad 1,000 ml 
 
Table 23: 5 % Blocking buffer 
Skim milk powder   25 g 
TBST    ad 500 ml 
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Table 24: Stripping buffer, pH 2 
Glycine 15 g 
Sodium dodecyl sulfate (SDS) 1 g 
Tween 20   10 ml 
HCl conc. q.s. 
Aqua demin.    ad 1,000 ml 
 
2.8.6 Dot blot analysis 
Dot blotting is a technique similar to the western blot technique but differing in that protein or 
antibody samples are not separated electrophoretically but are spotted directly onto the 
membrane. Therefore a grid was drawn by pencil on a PVDF membrane to indicate the 
region for sample point plotting. The membrane was activated in methanol and then 
incubated for 5 minutes in 1 x 20 % transfer buffer. Afterwards 0.5-2 µl of the respective 
sample was spotted on the wet membrane at the center of the grid. The area that the 
solution penetrates was minimized by applying the sample slowly. The membrane was dried 
and then reactivated in methanol followed by 5 min. of TBST incubation. To block non-
specific sites the membrane was incubated in 5 % blocking solution for 1 h at room 
temperature and afterwards incubated with the appropriate primary antibody in blocking 
solution for 1-2 h at room temperature. After washing three times with TBST for 5 min., the 
HRP-conjugated secondary antibody was added to the membrane for 1 h at room 
temperature. Detection of proteins was performed by chemiluminescence as described in 
2.8.5.  
2.8.7 Coomassie staining 
To investigate the purity of recombinant proteins (2.14.1) and for determining protein-protein 
interactions after pull down experiments using recombinant proteins, gel electrophoresis 
(SDS-PAGE) was followed by staining the gels with Coomassie Blue R250, which binds 
nonspecific to all proteins. The detection limit is 0.3-1 ug/protein band. For protein staining 
the gels were incubated for 1 h in coomassie staining solution containing 0.1 % R250, 45 % 
methanol, 45 % aqua bidest. and 10 % pure acetic acid. Afterwards, the gels were discolored 
at least 1 h - overnight in destaining solution containing 30 % methanol, 10 % pure acetic 
acid and 60 % aqua bidest., until single blue proteins bands were visible. Images of 
coomassie stained gels were taken using the semi-automated Chemidoc-XRS Imaging 
System (Bio-Rad, Munich, Germany) using white transmission light. The gels were stored in 
7 % acetic acid.  
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2.8.8 Ponceau S staining 
Ponceau S is a rapid and reversible stain for detecting proteins bands on cellulose acetate, 
PVDF or nitrocellulose membranes, and is especially used to check for success of transfer 
after western blotting. The negative stain binds to the positively charged amino groups of a 
protein and also non-covalently to non-polar regions in the protein. Microgram quantities of 
transferred protein can be detected with Ponceau S stain, which generates reddish pink 
protein bands with a clear background. Since staining with Ponceau S is reversible it allows 
further immunological detection. To detect proteins after blotting on a PVDF membrane, the 
blotted membranes were washed shortly in TBST and immersed in a sufficient amount of 
Ponceau S Staining solution (5 ml, AppliChem, Darmstadt, Deutschland) for 5-10 min. at 
room temperature. After staining, the membranes were washed with water until the water 
was clear and the reddish pink protein bands were well-defined and visible. For imaging, 
membranes were subsequently scanned. For further immunological detection, the 
membranes were discolored completely by repeated washing in water and TBST. Afterwards 
the membrane was re-activated with methanol and washed again in TBST before blocking in 
5 % blocking solution and the following standard protocol for western blotting (2.8.5).  
 
2.9 RNA analysis 
For RNA extraction HT-22 cells were grown either in 24-well plates at an average density of 
60,000 cells/well and 2-4 wells per condition were pooled for RNA preparation. Alternatively, 
cells were grown in 6 well plates at a density of 180,000 cells/well and 4 wells per condition 
were pooled. For RNA extraction of HT-22 cells transfected with siRNA, cells were harvest 
48 h after siRNA transfection. For determination of mRNA amount in glutamate-treated cells, 
cells were grown in T75 flask at a density of 1 x 106 cells/flask and harvest 15 h after 
glutamate treatment. 
2.9.1 RNA preparation and determination of RNA amount 
Total RNA was extracted from HT-22 cells using the NucleoSpin RNA II kit (Macherey-Nagel, 
Düren, Germany) according to the manufacturer´s instructions. Briefly, HT-22 cells were 
washed with 1 x PBS and harvested in 350 µl cell lysis buffer RA1 supplemented with 1 % 2-
Mercaptoethanol. Before continuing with the extraction, all samples were shock-frozen in 
liquid nitrogen and left to thaw slowly on ice. Next, the raw extracts were filtered through 
NucleoSpin-RNA II columns to remove cellular debris. The supernatant was supplemented 
with ethanol, mixed carefully and loaded on a NucleoSpin RNA II column to extract nucleic 
acids by adsorption to the silica matrix of the column. Excessive electrolytes were removed 
by washing with MDB buffer (supplied with the kit). To remove possible contaminations with 
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genomic DNA, recombinant DNAse was added. Further, purification of the column-bound 
RNA was achieved by subsequent purification, using RA2 and RA3 buffers. RNA was eluted 
in 70 µl RNAse free water supplied with the NucleoSpin Kit II. RNA-concentration was 
determined by UV-Vis absorption spectroscopy, using the NanoPhotometerTM (Implen, GE 
Healthcare Europe GmbH, Freiburg, Germany) at a wavelength of 260 nm. For intermediate 
storage, RNA-extracts were transferred to the -80°C freezer. 
2.9.2 One Step reverse transcriptase polymerase chain reaction (RT-PCR) 
Following RNA purification, mRNA was amplified by one-step RT-PCR using the SuperScript 
III One Step PCR kit with Platinum Taq (Invitrogen, Karlsruhe, Germany). Sequence specific 
primers were used as described in Table 1 in section 0. Sample preparation was performed 
according to the following scheme given in Table 25 and Table 26. For amplification of PCR 
products the respective cycler programs provided in Table 27 - Table 30 were used. The RT-
PCR products were visualized under UV illumination after electrophoresis on a 1.5 % 
agarose gel containing ethidium bromide or SYBR Gold (Invitrogen Karlsruhe). The resulting 
gen products had a length of 400 (GAPDH), 316 (VDAC1), 289 (VDAC2), 1250 (Bid) base 
pairs, respectively. 
 
Table 25: PCR sample preparation: VDAC1, VDAC2, Bid 
2x reaction buffer  12.5 µl 
Sample (0.1 μg)  x µl 
fwd primer (10μM)  0.5 µl 
rev primer (10μM)  0.5 µl 
SuperScript III enzyme (Platinum Taq) 0.5 µl 
Nuclease free water ad 25 µl 
 
Table 26: PCR sample preparation GAPDH 
2x reaction buffer  12.5 µl 
Sample (0.1 μg)  x µl 
fwd primer (5 μM)  1.0 µl 
rev primer (5 μM)  1.0 µl 
SuperScript III enzyme (Platinum Taq) 0.5 µl 
Nuclease free water ad 25 µl 
For amplification the following cycler programs were used: 
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Table 27: RT-PCR cycler program – murine GAPDH 
60° C 30 min  
95° C 2 min 
95° C 30 sec 
57° C 1 min 
70° C 2 min 
70° C 10 min 
4° C ∞ 
 
Table 28: RT-PCR cycler program – murine VDAC1 
60° C 30 min  
95° C 2 min 
95° C 30 sec 
59,3° C 1 min 
70° C 2 min 
70° C 10 min 
4° C ∞ 
 
Table 29: RT-PCR cycler program – murine VDAC2 
60° C 30 min  
95° C 2 min 
95° C 30 sec 
60,4° C 1 min 
70° C 2 min 
70° C 10 min 
4° C ∞ 
 
 
 
 
 
30 cycles 
25 cycles 
27-28 cycles 
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Table 30: RT-PCR cycler program – murine Bid 
60° C 30 min  
95° C 2 min 
95° C 30 sec 
53° C 1 min 
70° C 2 min 
70° C 10 min 
4° C ∞ 
 
 
2.9.3 Agarose gel electrophoresis 
Analysis of PCR products were performed by agarose gel electrophoresis and subsequent 
fluorescence detection of ethidium bromide or SYBR Gold (Invitrogen), both intercalating 
agents that increase their fluorescent emission upon DNA binding.  For gel preparation, 
1.5 % agarose (Sigma-Aldrich) was suspended in Tris/Borate/EDTA (TBE) buffer (10 x stock, 
Invitrogen) and dissolved by heating up the suspension in a microwave oven. After 
dissolving, 2 µl of SYBR Gold or 5 µl of stock solution ethidium bromide (1 % in water) was 
added into 100 ml suspension, stirred carefully and the solution was filled into the gel 
cartridge to allow gel formation. For subsequent gel loading, a comb was inserted in the gel, 
to generate the pockets. Samples were loaded using 1-5 μl of PCR product, 2 μl of Blue 
Juice sample buffer (Sigma Aldrich) added with nuclease-free water up to a total volume of 
7 μl. In addition to the samples, 4 μl of a pre-prepared 100 bp reference marker (Fermentas, 
St. Leon-Roth, Germany) was loaded on the gel. Electrophoresis was conducted at 100 V for 
about 1 hour. Stained PCR-products were detected by UV light excitation and fluorescent 
emission using the Chemidoc Imaging System (Bio-Rad, Munich, Germany). Pictures were 
taken and analyzed using Quantity One software (Bio-Rad, Munich, Germany). 
 
 
 
 
 
 
 
27 cycles 
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2.10 Transient focal cerebral ischemia in mice 
The middle cerebral artery occlusion (MCAo) experiments were kindly performed by Uta 
Mamrak (Ludwig-Maximilians-University, Munich, Germany). Male C57BL/6 mice (n = 6) 
(body weight, 18–22 g; Charles River Laboratories, Sulzfeld, Germany) were subjected to 60 
min transient MCAo as described previously180, 181. Surgery was performed in isoflurane/N2O 
anesthesia (1.5% isoflurane, 68.5% N2O, 30% O2) with controlled ventilation. A silicon coated 
nylon monofilament was inserted into the internal carotid artery and gently pushed forward 
until blood flow in the MCA territory decreased to less than 20 % of baseline. Ischemia and 
reperfusion were verified by laser Doppler measurements. Tissue homogenates for 
immunoprecipitation and western blot analysis were generated from 4 mm sections of the 
ipsi- and contralateral parietal cortex (2 mm +/- bregma) respectively at 2 h, 6 h and 24 h 
after the onset of ischemia. For each experimental group, six animals were used. Statistical 
analysis was performed using the Kruskal-Wallis test. All procedures described are in 
accordance with local laws and were approved by the animal protection committee of the 
Government of Upper Bavaria. 
 
2.11 Concentration-response curves and EC50 values 
Half maximal effective concentrations (EC50) for all thiazolidindiones provided in Table 69 
(Appendix) were determined based on the concentration-response curves for each 
compound (see also 0). To determine the concentration required to achieve maximal 
neuroprotective effects, initially all compounds were screened by their ability to prevent 
glutamate-induced cell death at concentrations of 10, 20, 30, 40 and 50 µM. Since 
quantification of cell viability (MTT assay) revealed maximal protective effects of the 
compounds in a concentration of 20 µM and higher, generation of concentration ranges for 
these measurements were not satisfying. Therefore compounds with an EC50 < 10 µM were 
screened in lower concentrations of 0.1 µM up to 50 µM for maximum protection. Cell viability 
data were normalized between untreated control conditions (0 %) and maximum amplitude at 
50 µM (100 %). Using OriginPro8.5 Software, the resulting data were fitted with a sigmoid 
function following the equation y=A1+(A2-A1)/(1+10^((LOGx0-x)*p)) and EC50 values for all 
substances were calculated.  
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2.12 Molecular docking 
Molecular docking is a method used in the field of molecular modeling, to predict the 
preferred orientation of one molecule to another molecule when bound to each other to form 
a stable complex. It is frequently used to reveal the binding orientation of small-molecule 
drug candidates to their protein targets. Thereby, the affinity and activity of novel compounds 
can be predicted, and, hence docking plays an important role in the rational design of novel 
drugs. In this thesis, docking analyses were performed to investigate the possible binding 
mode of novel small-molecule inhibitors to the pro-apoptotic protein Bid. 
Molecular docking analyses were kindly performed by Dr. Wegscheid-Gerlach 
(Pharmaceutical chemistry, Philipps-University Marburg, Marburg, Germany). According to 
Becattini et al.114 docking studies were conducted using the NMR solution structure of mouse 
BID from the PDB entry 1DDB65. All compounds were converted from SMILES notation into 
Sybyl mol2 format using CORINA. Protein preparation and docking was performed using 
FlexX182, available within the LeadIT version 2.1.3 from BioSolveIT. All obtained docking 
solutions were re-ranked with HYDE-score183, 184. Pictures for 2D-representation of the 
docking solution were generated with pose view185, as implemented in LeadIT, and exported 
in the same way as the 3D representation, from the program.  
 
2.13 Statistical analysis 
All data are given as means ± standard deviation (SD). For statistical comparison between 
two groups Mann-Whitney-U-test was used. Multiple comparisons were performed by 
analysis of variance (ANOVA) followed by Scheffé's post hoc test or Kruskal-Wallis test, as 
indicated. Calculations were performed with the Winstat standard statistical software 
package (R. Fitch Software, Bad Krozingen, Germany). 
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2.14 Molecular Biology 
2.14.1 Recombinant proteins 
Human recombinant caspase 8, mouse recombinant tBid and mouse recombinant His-Bax 
were kindly provided by Prof. Dr. Jean-Claude Martinou (University of Geneva, Switzerland). 
In addition human recombinant full-length Bax with an N-terminal GST-tag was ordered from 
Abnova (Heidelberg, Germany). Mouse recombinant VDAC1, VDAC1 Δ11 and mouse 
recombinant VDAC2 were kindly provided by Barbara Mertins (Group of Prof. Essen, 
Department of Chemistry, University of Marburg). Full-length mouse Bid, truncated Bid (tBid) 
as well as different Bid constructs were expressed and purified in this thesis as described 
below.  
2.14.2 Competent cells 
For bacterial expression of recombinant proteins Escherichia coli RosettaTM2 (DE3) single 
competent cells (Novagen/Merck Millipore, Darmstadt, Germany) were used. Rosetta™2 
host strains are BL21 derivatives designed to enhance the expression of eukaryotic proteins 
that contain codons rarely used in E. coli. The original Rosetta strains supply tRNAs for 7 
rare codons (AGA, AGG, AUA, CUA, GGA, CCC, and CGG) on a compatible 
chloramphenicol-resistant plasmid. The tRNA genes are driven by their native promoters. 
DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy 
of the T7 RNA polymerase gene under control of the lacUV5 promoter (see Novagen User 
protocol TB009). Such strains are suitable for protein production from target genes cloned in 
pET vectors amongst others by induction with IPTG.  
2.14.3 Culture medium for bacteria 
For bacterial growth Luria-Bertani (LB) broth medium was used, which is the most widely 
used medium for the growth of bacteria. For liquid LB medium 100 g Luria Broth Base 
powder (AppliChem, Darmstadt, Germany), containing 10 g peptone 140, 5 g yeast extract 
and 5 g sodium chloride per liter, was dissolved in 5 l Aqua demin. and aliquoted in 500 ml 
bottles. Afterwards, LB bottles were autoclaved for 21 min and stored at room temperature. 
For preparation of LB Agar plates, 7.5 g of agar powder (Lennox L agar, AppliChem, 
Darmstadt, Germany) was added to 500 ml of LB medium. After autoclaving 0.5 ml of 
ampicillin (100 mg/ml) and/or 0.5 ml of chloramphenicol (30 mg/ml, dissolved in ethanol) was 
added to 500 ml LB agar and the LB agar was poured into petri-dishes. After hardening, 
petri-dishes were inverted and stored at 4°C in the dark.   
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2.14.4 Cloning and site-directed mutagenesis of Bid constructs 
Different Bid constructs were expressed as GST fusion proteins. Based on the NMR 
structure of Bid, we reasoned that crystallization could be facilitated by removing the mobile 
N-terminus and loop. This was accomplished by first cloning N-terminally truncated mouse 
Bid constructs starting with Gly12 or Ala13 (designated 12 and 13, respectively), 
respectively, into pGEX1λT (GE Healthcare Bio-Science AB, Uppsala, Sweden) by PCR. The 
loop was removed in a second step by employing an endogenous HindIII site spanning 
Gln45 to Tyr47. The distal part of mouse Bid before Ser78 was amplified using primers 
encoding the HindIII site (and sometimes bases encoding for amino acids 49-52) followed by 
bases encoding for Ser78 and beyond. This part was then cloned into the constructs made in 
the first step. Detailed cloning procedure was performed as follows.  
For the first step PCR samples were prepared and amplified in a Sensoquest-Cycler as 
described in Table 31- Table 34. Primer sequences are provided in Table 1. 
 
Table 31: PCR sample preparation - G12-mBid, A13-mBid 
5x Phusion HF reaction buffer  10 µl 
Template (pET15b-Bid-p22, 50 ng)  1.0 µl 
G12-mBid / A13-mBid fw primer (1 μM)  0.5 µl 
mBid-EcoRI rev primer (1 μM)  0.5 µl 
dNTP (10 mM) 1.0 µl 
Phusion 0.5 µl 
Nuclease free water 35.5 µl 
 
Table 32: PCR sample preparation - Y47-mBid, D51-mBid 
5x Phusion HF reaction buffer  10 µl 
Template (pET15b-Bid-p22, 50 ng)  1.0 µl 
Y47-mBid / D51-mBid fw primer (1 μM)  0.5 µl 
mBid-EcoRI rev primer (1 μM)  0.5 µl 
dNTP (10 mM) 1.0 µl 
Phusion 0.5 µl 
Nuclease free water 35.5 µl 
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Table 33: RT-PCR Cycler program – G12-mBid and A13-mBid 
Pre-heating  
94° C   5 sec 
95° C 30 sec 
66° C 30 sec 
72° C 2 min 
72° C 15 min 
4° C ∞ 
 
Table 34: RT-PCR Cycler program – Y47-mBid and D51-mBid 
Pre-heating  
94° C   5 sec 
95° C 30 sec 
60° C 30 sec 
72° C 2 min 
72° C 15 min 
4° C ∞ 
 
The obtained PCR products were analyzed by agarose gel electrophoresis and subsequent 
fluorescence detection with ethidium bromide (Promega, Mannheim, Germany) as described 
in 2.9.  
Afterwards PCR products were purified using the QIAquick Gel Extraction Kit (Quiagen, 
Hilden, Germany) according to the manufacturer’s protocol. Briefly, PCR samples were filled 
up with 3 volumes (150 µl) of QG buffer, respectively, and incubated at 50°C for 10 min. 
Afterwards 50 µl of isopropanol was added and samples mixed gently. Samples were 
transferred to a QIAquick spin column in a provided 2 ml collection tube and centrifuged for 
1 min. at 13,000 rpm. After discarding the flow-through, 750 µl PE buffer was added and 
samples centrifuged twice at 13,000 rpm for 1 min. To elute DNA, 50 μl of Buffer EB (10 mM 
Tris-HCl, pH 8.5) was added to the center of the QIAquick membrane and columns 
centrifuged at 13,000 rpm for 1 min. 
Digestion and ligation of DNA products: 
The eluted G12-mBid and A13-mBid were digested with BamHI-HF and EcoRI-HF in NEB4 
buffer overnight at 37°C and products were isolated by agarose gel electrophoresis followed 
by gel extraction with Ultra Free DNA gel extract kit (Millipore, Darmstadt, Germany) 
30 cycles 
30 cycles 
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according to the manufacturer’s protocol. Products were cloned into the pGEX1λT vector to 
obtain the pGEX-Δ12-Bid and pGEX-Δ13-Bid constructs by DNA ligation for 5 h at 16°C. The 
pGEX-Δ12-Bid, pGEX-Δ13-Bid, Y47-mBid and D51-mBid products were digested with HindII-
HF and EcoRI-HF in NEB4 buffer overnight at 37°C and the digestion products isolated as 
described above. In the last step Y47-mBid and D51-mBid were cloned into the pGEX-Δ12-
Bid and pGEX-Δ13-Bid, respectively by DNA ligation for 2 h at 16°C. After DNA ligation all 
constructs were transformed into competent cells186 and afterwards plated on appropriate 
agar plates containing ampicillin (Amp). Amplification of the obtained plasmids was 
performed using the Quiagen Plasmid Plus Midi kit (Qiagen, Hilden, Germany) according to 
the manufacturer´s protocol. Plasmid DNA-concentrations were determined using the 
NanoPhotmeterTM (Implen, Freiburg, Germany). 
To confirm the successful cloning of all constructs, the plasmids were digested with Pstl 
(Fermentas) for 1 h at 37°C and digestion products analyzed by agarose gel electrophoresis. 
Furthermore, all constructs were verified by sequencing. Thereby, four different Bid 
constructs were obtained, namely pGEX Δ12-Y47 (Bid1), pGEX Δ12-D51 (Bid2), pGEX Δ13-
Y47 (Bid 3) and pGEX Δ13-D51 (Bid 4). 
2.14.4.1 Cloning of Bid constructs for expression in eukaryotic cells 
The A13-mBid constructs were also expressed in eukaryotic cells. To this end, a KpnI site 
followed by a start codon was introduced in front of Ala13 by PCR using the KpnI-M13Bid 
primer (Table 1). mBid-EcoRI was used as the reverse primer (see Table 1). PCR conditions 
are described in Table 35 and Table 36. PCR products were digested with KpnI and EcoRI 
and ligated into pcDNA3 that had been digested with the same enzymes. 
 
Table 35: PCR sample preparation- A13-mBid constructs 
5x Phusion HF reaction buffer  10 µl 
Template (100 ng)  1.0 µl 
Kpn-M13Bid fw primer (100 mM)  1.0 µl 
mBid-EcoRI rev primer (100 mM)  1.0 µl 
dNTP (10 mM) 1.0 µl 
Phusion 0.5 µl 
Nuclease free water 35.5 µl 
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Table 36: RT-PCR Cycler program A13-mBid constructs 
Pre-heating  
94° C   5 sec 
95° C 30 sec 
55° C 30 sec 
72° C 1 min 
72° C 15 min 
4° C ∞ 
 
Cloning and site-directed mutagenesis were performed together with Cornelius Krasel. 
 
2.14.5 Transformation of plasmids in Rosetta2 (DE3) 
For the expression of the recombinant proteins full-length Bid, tBid, Bid constructs Bid1-4, 
Bax and caspase 8, Escherichia coli Rosetta2 (DE3) singles were transformed with the 
respective plasmids provided in 2.1.1.1. All plasmids contain an Ampicillin-resistance gene. 
Rosetta2 (DE3) singles carry a chloramphenicol resistance. Transformation of Rosetta2 
(DE3) singles was performed according to the protocol recommended by Novagen (User 
protocol TB009 Rev.G0609), with an appreciated transformation efficiency of 2x106 cfu/µg 
plasmid. Bacteria and plasmids were thawed on ice for 2-5 min. and gently resuspended. 
Afterwards, 20 µl of Rosetta2 (DE3) were transferred to a 1.5 ml tube for each plasmid 
sample, respectively and 0.5-1 µl of the purified plasmid DNA was added directly to the cells. 
The samples were stirred gently and the tubes incubated on ice for 5 min. to allow 
transformation. The mixture of DNA and cells was afterwards heated for exactly 30 s to 42°C 
in a water bath without shaking. After heating, the tubes were placed on ice for another 2 
min. before adding 250 µl room temperature SOC medium to each tube. The mixtures were 
incubated at 37°C while shaking at 250 rpm for 60 min. Before plating the bacteria on LB-
Amp agar plates, the plates were treated with 50 µl of chloramphenicol (30mg/ml in ETOH). 
Then 50 µl of each transformation was spread on the LB agar plates, now containing the 
appropriate antibiotics, chloramphenicol and ampicillin. The agar plates were incubated at 
37°C overnight until bacterial colonies were grown.  
2.14.6 Inoculating a liquid bacterial culture 
The LB agar plates prepared as described in 2.15 were frequently used to isolate individual 
colonies of bacteria carrying the specific plasmid. To support a higher density of bacteria a 
liquid culture was used to grow up sufficient numbers of bacteria necessary to isolate enough 
30 cycles 
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plasmid DNA for experimental use, for generating cryo-stocks for long term storage of 
plasmid as well as for further expression of the recombinant proteins.  
For inoculating an overnight culture of liquid LB with Rosetta2 (DE3), 2.5 ml liquid LB 
medium was added into a 15 ml falcon for each plasmid and each bacterial colony and 
supplemented with 2.5 µl chloramphenicol (30 mg/ml in ETOH) and 2.5 µl ampicillin 
(100 mg/ml in H2O), respectively. Afterwards a single bacterial colony was picked from the 
LB agar plate using a sterile pipette tip, transferred to the liquid LB medium containing the 
appropriate antibiotics and swirled gently. The bacterial culture was incubated at 37°C in a 
shaking incubator overnight. After incubation, bacterial growth was characterized by turbidity 
of the media. The liquid LB culture containing bacteria, transformed with the respective 
plasmids, was used for preparing cryo-stocks (2.14.7) and for further expression of specific 
recombinant protein (2.14.9).  
2.14.7 Long-term storage of plasmids via Cryo-stocks 
For long-term storage of plasmids bacterial cryo-stocks, containing the respective bacterial 
culture and the cryo-protectant dimetyolsulfoxid (DMSO), were prepared. The optical density 
(OD600) of the liquid bacterial culture used for the cryo-stocks should not exceed 0.6 AU. For 
each stock 930 µl of the respective bacterial overnight culture were mixed with 70 µl sterile 
DMSO and transferred into sterile cryo-vials, labeled with the bacterial strain and the 
plasmid, respectively. Afterwards, the cryo-vials were frozen in liquid nitrogen and stored 
at -80°C.  
2.14.8 Determination of optical density of bacteria (OD600) 
Optical density was measured using the BioRad SmartSpecTM Plus spectrophotometer 
(BioRad laboratories, Munich, Germany) to determine the concentration of bacteria in a 
suspension. To measure bacteria which are in their mid-log phase of growth, the bacterial 
suspension was measured at a wavelength of 600 nm (OD600). All samples were measured 
in BioRad trUViewTM cuvets (single use). The spectrophotometer was blanked to zero using 
100 µl fresh LB medium. Afterwards, OD600 of each bacterial suspension was determined 
using 100 µl sample volume, respectively. Determination of OD600 was repeated until an 
OD600 of 0.6 AU was reached and protein expression was induced.  
2.14.9 Expression of recombinant proteins 
Recombinant proteins with a hexa-histidine tag at the N-terminus (His6-Bid, His6-tBid, His6-
caspase 8) and GST-tagged Bid constructs (Bid1-Bid4) were expressed in competent 
Escherichia coli Rosetta 2 (DE3) cells (Novagen). After transformation of bacteria with the 
respective plasmids (2.14.5) and generation of a liquid bacterial culture (2.14.6), 5 ml of 
overnight culture was inoculated into 400 ml of standard LB medium containing ampicillin 
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(100 μg/ml) and chloramphenicol (100 μg/ml) in 1 L flasks. Three to four cultures were 
prepared in parallel. Bacteria were grown at 37°C in a shaking incubator for approximately 
4.5 h and the optical density (OD600) was checked at regular intervals to evaluate cell growth. 
At an OD600 of 0.6, 400 μl of isopropyl ß–D-1-thiogalactopyranoside (IPTG) was added to 
each 400 ml culture to induce protein production. IPTG is a molecular mimic of allolactose 
and allows the transcription of gens in the lac-operon and is thereby commonly used as 
effective inducer of protein expression, where genes are under control of the lac-operator. 
Protein expression was induced for 4-6 h at 37 °C while shaking. Afterwards cells were 
harvest by centrifugation (Sorvall GSA rotor, 5000 g, 15 min, 4 °C) using the Sorvall RC 5B 
Plus centrifuge (Sorvall, Bad Homburg, Deutschland). All pellets of a 1.2-1.6 L culture were 
pooled and resuspended in 20 ml standard protein lysis buffer (Table 37). For GST-tagged 
proteins cells were resuspended in 20 ml protein lysis buffer provided in Table 38. Bacterial 
lysates were frozen in liquid nitrogen, and stored at -80 °C until further use. 
2.14.10 Expression tests 
Before large-scale expression of recombinant proteins, every protein construct was checked 
for expression efficiency and protein solubility. For this approach, 200-500 µl of the bacterial 
overnight culture was inoculated into 5-10 ml of standard LB medium containing ampicillin 
(100 μg/ml) and chloramphenicol (100 μg/ml) in a 15-100 ml flask. The bacterial culture was 
grown at 37°C until an OD600 > 0.6 was reached and protein expression was induced by 1 M 
IPTG addition. Afterwards, 1 ml samples were taken at different time points from 0 h up to 
19 h after IPTG induction. Samples were centrifuged at 15,300 rpm for 15 min. at 4°C, the 
supernatant discarded and the cell pellet resuspended in 20 mM Tris buffer (pH 7.5). Cells 
were lysed without detergent by sonication using the Sonifier Cell Disrupter S-450D (Branson 
Ultrasonics, Dietzenbach, Deutschland) equipped with a 3 mm micro-tip. Sonication of each 
sample was performed on ice for 15-20 times using 10% amplitude in pulses of 1 sec with 
1 sec break between pulses. To separate soluble and membrane bound proteins, cells were 
centrifuged at 15,300 rpm for 15 min. at 4°C. The supernatant of each sample was 
transferred into a new sample tube and protein concentration was determined by the 
Bradford assay (2.20.1). All supernatant samples were acetone precipitated according to the 
pierce protocol (2.21). The cell pellets were resuspended in 20 mM Tris buffer (pH 7.5), 
respectively. Afterwards, all samples were analyzed for protein expression by gel 
electrophoresis followed by coomassie staining. In addition, respective protein expression 
was confirmed by western blot.  
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2.15 Purification of recombinant proteins  
For purification bacterial cell lysates (either recently centrifuged and resuspended in lysis 
buffer or thawed) were subjected to sonication (Branson Sonifier Cell Disrupter S-450D, 
Branson Ultrasonics, Dietzenbach, Deutschland).For 20 ml bacterial cell lysate a macro-tip 
was used and sonication was performed at 20% maximum power (20 % amplitude). To avoid 
protein degradation due to heat produced by the sonicator’s sound waves, samples were 
treated using a sonication interval of 1 sec. puls on and 2 sec. puls off for 7-10 min. total 
time. The solution was then centrifuged at 30,000 rpm for at least 30 minutes (Beckman 
Optima XE-90, Ti70 rotor, Beckman Coulter, Krefeld, Deutschland) at 4°C. All proteins 
purified in this thesis were recovered in the soluble bacteria fraction. The supernatant was 
subsequently filtered through a 0.45 μm filter (Whatman, Dassel, Germany) and stored on ice 
until further purification. 
2.15.1 Buffers for protein purification 
Buffers used for purification of recombinant proteins are provided in Table 37–Table 43. 
 
Table 37: Protein standard lysis buffer 
20 mM Tris base 1.21 g 
250 mM NaCl 7.3 g 
10 mM β-Mercaptoethanol 0.39 g (eq. 11 drops) 
Aqua demin. ad 500 ml 
Complete Mini Protease Inhibitor Cocktail 
(Roche, Mannheim, Germany)  
2 tablets per 20 ml instantaneously prior to 
use 
 
Table 38: Protein lysis buffer for GSTrap purification 
20 mM Tris base 1.21 g 
100 mM NaCl 2.92 g 
1 mM EDTA 0.15 g 
1 mM DTT 0.5 ml DTT stock solution (1 M DTT) 
Aqua demin. ad 500 ml 
Complete Mini Protease Inhibitor Cocktail 
(Roche, Mannheim, Germany) 
2 tablets per 20 ml instantaneously prior to 
use 
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Table 39: Buffer for His-Catcher Nickel Gravity Columns (PJK GmbH) 
IMAC binding buffer, pH 7.5 
20 mM Tris base 1.21 g 
200 mM NaCl 5.84 g 
10 mM β-Mercaptoethanol 0.39 g (eq. 11 drops) 
Aqua demin. ad 500 ml 
Wash buffer, pH 7.5 
20 mM Tris base 1.21 g 
20 mM NaCl 0.584 g 
10 mM Imidazole 0.34 g 
10 mM β-Mercaptoethanol 0.39 g (eq. 11 drops) 
Aqua demin.  ad 500 ml 
Elution buffer, pH 7.5 
20 mM Tris base 1.21 g 
20 mM NaCl 0.584 g 
250 mM Imidazole 8.51 
10 mM β-Mercaptoethanol 0.39 g (eq. 11 drops) 
Aqua demin.  ad 500 ml 
 
For purification of proteins by chromatography using the ÄKTAprime plus (GE Healthcare 
Bio-Science AB, Uppsala, Sweden) the following buffers were used: 
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Table 40: Buffer for HisTrap affinity columns (HisTrapTM FF 5 ml) 
Buffer A: Binding buffer, pH 7.5 
20 mM Tris base 1.21 g 
250 mM NaCl 7.3 g 
10 mM β-Mercaptoethanol 0.39 g (eq. 11 drops) 
Aqua demin.  ad 500 ml 
Buffer B: Elution buffer pH 7.5  
20 mM Tris base 1.21 g 
20 mM NaCl 0.584  g 
400 mM Imidazole 13.62 g 
10 mM β-Mercaptoethanol 0.39 g (eq. 11 drops) 
Aqua demin.  ad 500 ml 
 
Table 41: Buffer for GSTrap affinity columns and Glutathione and HiCap Cartridges  
Buffer A: Binding buffer, pH 7.5 
20 mM Tris base 1.21 g 
100 mM NaCl 2.92 g 
1 mM EDTA 0.15 g 
1 mM DTT 0.5 ml DTT stock solution (1 M DTT) 
Aqua demin.  ad 500 ml 
Buffer B: Elution buffer pH 8.0 
50 mM Tris base 3.92 g 
10 mM L-Glutathione red. 1.54 g 
1 mM EDTA 0.15 g 
1 mM DTT 0.5 ml DTT stock solution (1 M DTT) 
Aqua demin.  ad 500 ml 
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Table 42: Buffer for HiTrap ion exchange columns (HiTrap Q HP, 5 ml) 
Buffer A: Binding buffer, pH 8.0 
20 mM Tris base 1.21 g 
10 mM β-Mercaptoethanol 0.39 g (eq. 11 drops) 
Aqua demin.  ad 500 ml 
Buffer B: Elution buffer pH 8.0 
20 mM Tris base 1.21 g 
500 mM NaCl 14.61 g 
10 mM β-Mercaptoethanol 0.39 g (eq. 11 drops) 
Aqua demin.  ad 500 ml 
 
Table 43: Buffer for HiLoad gel filtration columns (HiLoadTM 16/600 Superdex 75 pg) 
Buffer A; pH 7.5 
20 mM Tris base 2.42 g 
50 mM NaCl 2.92 g 
Aqua demin.  ad 1000 ml 
 
To avoid bacterial growth, all buffers were supplemented with 0.03 % sodium azide. After 
buffer preparation, all buffers were sterile filtered through a 0.22 µM cellulose filter and 
completely degassed under vacuum for at least 1-2 hours before use. All buffers were stored 
at 4°C.  
2.15.2 Protein purification using the ÄKTA prime plus  
ÄKTA prime plus is a compact liquid chromatography system used for one-step purification 
of proteins at laboratory scale. All methods applied for protein purification using the ÄKTA 
prime plus system where extensively established during this thesis and respectively 
customized for each of the purified protein constructs. The methods were programmed line-
by-line using the PrimeView 5.0 software. Using this software all purification runs were 
monitored and results were presented by the respective chromatograms. 
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Prior to start of the protein purification the system was pre-equilibrated. Since the system and 
columns were stored in 20% ethanol, all components had to be flushed with water before 
working with buffers or protein. Therefore, the system, inlet tubing, sample loops and 
columns were purged 2-3 times with degassed aqua demin using the “system wash” 
program. Afterwards the system was rinsed with water for at least 2 volumes of the required 
column (CV) by manual run using a flow rate of 1-1.5 ml/min. For equilibrating the system for 
the intended purification method, it was subsequently purged with the appropriate binding 
buffer, followed by a manual buffer wash with 2 CV of binding buffer. The system was then 
ready for the following protein purification (2.15.3 and 2.15.4). The maximum pressure was 
fixed to 0.3 kPa for all purification methods. 
At the end of the purification run, the system was rinsed with at least 2-3 CV of aqua demin. 
to remove all buffers in order to avoid precipitations. For storage, the system as well as 
sample loops and columns were rinsed with 20% ethanol. The washing procedure was 
performed either by manual run with a flow rate of 1-2 ml/min or by the programmed wash 
method provided in Table 44 overnight. 
 
Table 44: Programmed method for ÄKTA- wash and storage 
Action Breakpoint 
Volume 
[ml] 
Conc 
Buffer B 
[%] 
Flow rate 
[ml/min] 
Fraction 
size [ml] 
Inject 
valve 
position 
Equilibration 1 0 0 2 0 Load 
Water wash (A) 2 10 0 1 0 Load 
Water wash End 3 130 0 1 0 Load 
Priming B 4 130.1 100 1 0 Load 
20% ETOH wash (B) 5 250 100 1 0 Load 
Method end 6 260 100 1 0 Load 
 
2.15.3 Purification of recombinant His6-tagged proteins  
Purification of His6-tag proteins was performed by three consecutive chromatography steps 
as described below.   
2.15.3.1 Nickel-Affinity chromatography  
Immobilized metal ion affinity chromatography (IMAC) is based on the specific binding 
properties of amino acids, particularly histidines, towards immobilized metals for purification 
purposes. Nickel-nitriloacetic (Ni-NTA) contains chelated nickel, which is able to specifically 
bind to poly-histidine in proteins and therefore used in this thesis for purification of His6-
tagged proteins. For elution, an excess amount of a compound able to act as a metal ion 
ligand, such as Imidazole, is used and displaces the tagged protein from column resin. 
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Recombinant full length Bid with a hexa-histidine tag at the N-terminus was initially purified 
manually using His-Catcher Nickel Gravity Columns (PJK GmbH, Kleinbittersdorf, Germany) 
according to the manufacturer’s protocol. Before starting, all buffers provided in Table 39 
were prepared and the required buffer volumes as well as protein solution filtered through a 
0.45 µm filter (Whatman, Dassel, Germany). The column was released from storage buffer 
and equilibrated twice with 3 ml aqua demin. followed by three times equilibration with 6 ml of 
IMAC binding buffer. Afterwards 6 ml of protein solution was applied to the column by gravity 
flow to allow binding of His6-tagged proteins. Sample application was repeated until the entire 
sample had been processed. For subsequent analysis, an unprocessed sample as well as a 
sample of the effluent was stored at 4°C until further use. After sample loading, the column 
was washed three times with 6 ml wash buffer, containing 10 mM imidazole to elute 
unspecifically bound proteins. Elution of the specifically bound protein was achieved by 
adding 4 volumes of 1.5 ml elution buffer, containing 250 mM imidazole thereby displacing 
the His6-tagged protein from the nickel ions. Elution fractions were collected drop-wise and 
stored at 4°C for further processing. All purification steps were performed on ice. Protein 
purity was confirmed by analyzing collected samples by SDS-PAGE. 
Alternatively, affinity chromatography purification of His6-tagged full-length Bid was 
performed using a HisTrapTM FF column (GE Healthcare Bio-Science AB, Uppsala, Sweden) 
connected to the ÄKTA prime plus instrument. All buffers used for the following method are 
provided in Table 40. Before equilibration with binding buffer, the system was pre-
equilibrated as described in 2.15.2. Depending on the protein sample size, chromatography 
was performed using either a 1 ml or 5 ml HisTrap TM FF column, which was likewise pre-
equilibrated with binding buffer prior to sample loading. Final equilibration, sample injection, 
wash, sample elution as well as re-equilibration of the system were performed automatically 
by the applied program provided in Table 45. Protein sample was applied to the respective 
column by repeated injections using a 5 ml sample loop. During sample loading, flow through 
was collected in volumes of 8 ml. Elution of His6-tagged protein was performed using a 
continuous gradient of 0-300 mM imidazole followed by a wash out step up to concentrations 
of 400 mM imidazole. Elution fractions were collected in volumes of 1-5 ml and stored at 4°C 
until further use. The respective purification run was monitored using PrimeView5.0 and the 
resulting chromatogram was analyzed for elution peaks. Elution fractions collected within 
peak areas were analyzed by SDS- gel electrophoresis followed by coomassie staining. 
Afterwards, Bid-containing fractions were pooled and stored at 4°C until further purification 
by ion exchange.  
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Table 45: Programmed method for ÄKTA - IMAC- Ni-Affinity chromatography 
                 (1 ml HisTrap column, 5 ml sample loop, < 25 ml sample volume) 
Action Breakpoint 
Volume 
[ml] 
Conc 
Buffer B 
[%] 
Flow 
rate 
[ml/min] 
Fraction 
size 
[ml] 
Inject 
valve 
position 
Equilibration 1 0 0 1 0 Load 
Sample injection 1 2 5 0 1 8 Inject 
Equilibration/Buffer A wash 3 13 0 1 0 Load 
Sample injection 2 4 15 0 1 8 Inject 
Equilibration/Buffer A wash 5 23 0 1 0 Load 
Sample injection 3 6 25 0 1 8 Inject 
Equilibration/Buffer A wash 7 33 0 1 0 Load 
Sample injection 4 8 35 0 1 8 Inject 
Equilibration/Buffer A wash 9 43 0 1 0 Load 
Sample injection 5 10 55 0 1 8 Inject 
Wash 7% imidazole 11 63 0 1 5 Load 
Elution  12 73 5 1 1 Load 
Elution wash out 13 93 75 1 1 Load 
End wash 14 103 75 1 5 Load 
Re-equilibration 15 113 100 1 5 Load 
End method 16 123 0 1 0 Waste 
 
2.15.3.2 Ion exchange chromatography 
Ion exchange chromatography is based on electrostatic properties of proteins, which can 
bind to the charged groups exposed on the surface of the exchanger. In this thesis anion 
exchange chromatography was performed by using HiTrap columns containing Q-
Sepharose, which is composed of cross-linked 6% agarose beads with quaternary 
ammonium (Q) strong anion exchange groups. Q-Sepharose is commonly used for 
separation of proteins during purification.  
Ion exchange chromatography was performed using pre-packed 5 ml HiTrap Q HP columns 
(GE Healthcare Bio-Science AB, Uppsala, Sweden) and the ÄKTA prime plus system. The 
appropriate buffers are provided in Table 42. To ensure ionic binding of full-length Bid, the 
total ionic strength of the protein buffer (Table 39; Buffer B, Table 40) needed to be reduced. 
Therefore, the Bid-containing fractions achieved by Ni-affinity chromatography were pooled 
and either four-times diluted with binding buffer A or desalted using ZebaTM Spin Desalting 
columns (Thermo Scientific, Langenselbold, Germany).  After equilibrating the system 
(2.15.2) and connection of the column to the ÄKTA, ion exchange was started by applying 
the programmed method depicted in Table 46. During the process, the protein sample was 
applied to a 5 ml sample loop and sample injection was repeated 3-5 times depending on the 
particular sample volume. Throughout purification, elution fractions were collected in 2-5 ml 
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sizes and stored at 4°C until further use. Elution fractions collected within peak areas were 
analyzed by SDS- gel electrophoresis followed by coomassie staining. Bid-containing 
fractions were pooled and stored at 4°C. 
 
Table 46: Programmed method for ÄKTA – Ion Exchange Gradient elution 
                    (5 ml HiTrap column, 5 ml sample loop, < 25 ml sample volume)  
Action Breakpoint 
Volume 
[ml] 
Conc 
Buffer B 
[%] 
Flow 
rate 
[ml/min] 
Fraction 
size  
[ml] 
Inject 
valve 
position 
Equilibration 1 0 0 5 0 Load 
Sample injection 1 2 25 0 5 5 Inject 
Equilibration/Buffer A wash 3 30 0 5 2 Load 
Sample injection 2 4 32 0 5 5 Inject 
Equilibration/Buffer A wash 5 37 0 5 2 Load 
Sample injection 3 6 39 0 5 5 Inject 
Equilibration/Buffer A wash 7 44 0 5 2 Load 
Sample injection 4 8 46 0 5 5 Inject 
Equilibration/Buffer A wash 9 51 0 5 2 Load 
Sample injection 5 10 53 0 5 5 Inject 
Buffer A wash 11 58 0 5 5 Load 
Elution  12 85 0 5 2.5 Load 
Elution wash out 13 185 100 5 2.5 Load 
End wash 14 205 100 5 2.5 Load 
Re-equilibration 15 210 0 5 0 Waste 
End method 16 215 0 5 0 Waste 
 
When indicated, the Bid-containing fractions were subjected to proteolytic cleavage of the 
His6-tag (see 2.16) and in either case concentrated prior to the subsequent size exclusion 
chromatography. 
2.15.3.3 Gel filtration 
Gel filtration (size exclusion chromatography, SEC) is used for fractionation of proteins by 
their size and/or molecular weight. The macromolecule solution is separated by flowing 
through porous, inert matrices which are characterized by an exclusion limit indicating the 
molecular weight of the largest protein that is still delayed in the column.  
In this thesis a HiLoad 16/600 column (GE Healthcare Bio-Science AB, Uppsala, Sweden) 
was used with a Superdex 75 prep grade matrix composited of dextran and highly cross-
linked agarose. Due to different pore sizes within the matrix, molecules of different sizes 
elute through the stationary phase at different rates. The column allows for separation of 
proteins in the molecular weight range of 3,000 up to 70,000 Da.  
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Since separation efficiency increases with smaller sample volumes, the pooled Bid-
containing fractions were concentrated using 3-kDa cut-off Amicon filters (Millipore, 
Schwalbach, Germany) up to a sample volume < 2 ml (2.18) and filtered through a 0.45 µm 
filter.  Afterwards, gel filtration was performed using the ÄKTA prime plus system. After pre-
equilibrating the system and column (2.15.2) with aqua demin. followed by gel filtration buffer 
(Table 43), the sample was applied to a 2 ml sample loop and the programmed method 
depicted in Table 47 was started. Elution fractions were collected in volumes of 2 ml. Due to 
gel filtration, highly pure Bid protein was yielded as shown by gel electrophoresis and 
coomassie staining. The protein was finally concentrated with 3-kDa cut-off Amicon filters 
(Millipore, Schwalbach, Germany) up to concentrations required for respective functional 
experiments or crystallization studies. Protein samples were stored at 4°C until use, or 
supplemented with 30% glycerol for long-term storage. 
 
Table 47: Programmed method for ÄKTA – Gel filtration (full-length Bid) 
                 (HiLoad 16/600 Superdex 75 pg column, 2 ml sample loop, < 2 ml sample volume) 
Action Breakpoint 
Volume 
[ml] 
Conc 
Buffer B 
[%] 
Flow 
rate 
[ml/min] 
Fraction 
size [ml] 
Inject 
valve 
position 
Equilibration 1 0 0 1 0 Load 
Sample injection 2 10 0 1 0 Inject 
Buffer wash 3 12 0 1 0 Load 
Elution 4 35 0 1 2 Load 
Re-equilibration 5 140 0 1 2 Load 
 
2.15.4 Purification of recombinant GST-tagged proteins 
2.15.4.1 GSH-Affinity chromatography 
Glutathione S-transferase (GST) is a 26 kDa protein, which is used as N-terminal tag of 
target proteins to allow simple purification by affinity chromatography based on the high 
affinity of GST for immobilized glutathione. When applied to the affinity medium, GST-tagged 
proteins bind to the glutathione ligand, and impurities can be removed by washing with 
binding buffer. Elution of tagged proteins from chromatography medium is performed under 
mild, non-denaturing conditions that preserve both protein structure and function. Due to the 
positive influence of the GST-tag on protein solubility, expression efficiency and detection 
especially of small proteins, GST-tags are commonly used to generate proteins for 
crystallization and molecular immunology studies involving protein-protein interactions. 
Therefore, in this thesis, all truncated Bid constructs were fused to GST to allow highly pure 
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protein purification. To avoid interference of the GST-tag during crystallization, the tag was 
removed after affinity purification by proteolytic (thrombin) cleavage (2.16). 
GSH-affinity chromatography was performed with the ÄKTA prime plus system using pre-
packed 5 ml columns containing a matrix composed of highly cross-linked 4-6% agarose 
beads and a glutathione ligand. Depending on the protein amount, either GSTrapTM FF 
columns (GE Healthcare Bio-Science AB, Uppsala, Sweden) with a binding capacity of 
approximately 11 mg GST-tagged protein/ml, or Glutathione HiCap Cartridges (Quiagen, 
Hilden, Germany) with a binding capacity up to 100 mg GST-tagged protein were used.  
To increase binding capacity, usually two 5 ml HiCap Cartridges were connected on after 
another. All buffers used for this method are provided in Table 41. After pre-equilibration of 
columns and the ÄKTA system (2.15.2), protein sample was loaded to the column through 
tube B using the programmed method provided in Table 48. Afterwards GSH-affinity 
chromatography was performed using the ÄKTA installed application template “GST-tag 
purification GSTrap”, as provided in Table 49. Elution was performed with buffer containing 
10 mM glutathione and fractions were collected and stored at 4°C until SDS-gel 
electrophoresis. Fractions containing the respective Bid construct were pooled and subjected 
to further cut-off concentration and buffer exchange followed by proteolytic cleavage of the 
GST-tag. 
Alternatively, sample application and purification of Bid construct 4 was performed in a one-
step process by applying the programmed method in Table 50 to the ÄKTA system. Using 
this method, application of 25 ml sample volume was performed by repeated injection steps 
using a 5 ml sample loop. Fractions were collected in volumes of 2-5 ml. Elution and fraction 
analysis was performed as outlined above. 
 
Table 48: Programmed method for ÄKTA – sample application  
Action Breakpoint 
Volume 
[ml] 
Sample 
tube B 
[%] 
Flow 
rate 
[ml/min] 
Fraction 
size 
[ml] 
Inject valve 
position 
Equilibration 1 0 0 1 0 Load 
Sample injection 2 2 100 1 5 Load 
Buffer wash 3 44 100 1 0 Load 
Re-equilibration 4 50 0 1 0 Load 
End method 5 65 0 0 0 Load 
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Table 49: ÄKTA installed method – GST-tagged purification GSTrap  
                    (5 ml GSTrapTM column) 
Action Breakpoint 
Volume 
[ml] 
Conc 
Buffer B 
[%] 
Flow 
rate 
[ml/min] 
Fraction 
size 
[ml] 
Inject 
valve 
position 
Priming A1 0 0 0 40 0 Waste 
Equilibration 1 35 0 1 0 Load 
Autozero 2 45 
    
Sample injection 2 45 0 0.3 0 Inject 
Buffer wash 3 50 0 1 0 Load 
End wash 4 60 0 1 0 Load 
Priming B 5 60.1 100 40 0 Waste 
Elution 6 95 100 1 1 Load 
End elution 7 105 100 1 0 Laod 
Priming A1 8 105.1 0 40 0 Waste 
Re-equilibration 9 120 0 1 0 Load 
End method 10 125 0 0 0 Load 
 
Table 50: Programmed method for ÄKTA – GST-affinity chromatography 
                (2 x 5 ml HiCap Catridge, 5 ml sample loop, < 25 ml sample volume) 
Action Breakpoint 
Volume 
[ml] 
Conc 
Buffer B 
[%] 
Flow 
rate 
[ml/min] 
Fraction 
size 
[ml] 
Inject 
valve 
position 
Pre-equilibration 1 0 0 1 0 Load 
Equilibration 2 10 0 1 0 Load 
Sample injection 1 3 12 0 1 5 Inject 
Equilibration/Buffer A wash 4 17 0 1 2 Load 
Sample injection 2 5 19 0 1 5 Inject 
Equilibration/Buffer A wash 6 24 0 1 2 Load 
Sample injection 3 7 26 0 1 5 Inject 
Equilibration/Buffer A wash 8 31 0 1 2 Load 
Sample injection 4 9 33 0 1 5 Inject 
Equilibration/Buffer A wash 10 38 0 1 2 Load 
Sample injection 5 11 40 0 1 5 Inject 
Equilibration/Buffer A wash 12 45 0 1 2 Load 
Sample injection 6 13 47 0 1 5 Inject 
Buffer A wash 14 52 0 1 2 Load 
Pre-elution 15 72 0 1 2 Load 
Elution 16 74 100 1 2 Load 
Elution wash out 17 104 100 1 2 Load 
Reequilibration 18 110 0 1 2 Load 
Method end 19 120 0 1 0 Load 
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2.15.4.2 Gel filtration 
To achieve highly pure recombinant Bid constructs suitable for further crystallization studies, 
Bid construct-containing fractions were finally purified by gel filtration. After buffer exchange 
to gel filtration buffer, provided in Table 43, and cleavage of the GST-tag (2.16), protein 
samples were concentrated using 3-kDa cut-off Amicon filters (Millipore, Schwalbach, 
Germany) up to a sample volume < 5 ml and filtered through a 0.45 µm filter. Gel filtration 
was performed as described above following the programmed methods provided in Table 47 
and Table 51, depending on the particular sample volume. Purity of the elution fractions was 
confirmed by SDS- gel electrophoresis and Bid construct-containing fractions were pooled, 
concentrated and subjected to further crystallization studies.  
 
Table 51: Programmed method for ÄKTA – Gel filtration (Bid constructs) 
                 (HiLoad 16/600 Superdex 75 pg column, 5 ml sample loop, ≤ 5 ml sample volume) 
Action Breakpoint 
Volume 
[ml] 
Conc 
Buffer B 
[%] 
Flow 
rate 
[ml/min] 
Fraction 
size [ml] 
Inject 
valve 
position 
Equilibration 1 0 0 1 0 Load 
Sample injection 2 10 0 1 0 Inject 
Buffer wash 3 16 0 1 5 Load 
Elution 4 20 0 1 2 Load 
Elution wash out 5 45 0 1 2 Load 
Re-equilibration 6 160 0 1 2 Load 
 
2.16 Thrombin cleavage of His6- and GST-fusion proteins 
Thrombin is a protease used to digest fusion proteins prepared from pGEX or pET15b 
vectors, which include the thrombin recognition sequence (LeuValProArg↓GlySer). By 
cleaving the peptide bond between Arg and Gly, thrombin enables site-specific cleavage of 
recombinant fusion proteins and the removal of the purification His6- and GST-tag.  
After purifying the recombinant proteins by affinity and ion exchange chromatography, 
protein concentration was determined by photometry to calculate the required volume of 
thrombin (GE Healthcare, Bio-Science AB, Uppsala, Sweden). According to the 
manufacturer´s protocol, the lyophilized thrombin was solved in 1 x PBS to final solutions of 1 
U/µl or 0.1 U/µl. In order to preserve thrombin activity, aliquots were stored at -80°C. 
Generally, one unit thrombin will cleave ≥ 90 % of 100 µg GST-protein and cleavage should 
be complete following overnight treatment at 22°C with ≤ 10 units/mg fusion protein. For 
cleavage of His6-tagged full-length Bid one unit thrombin was used to cleave 50 µg of His6- 
protein. After addition of thrombin, the mixture was incubated at 37°C for 16 h and the 
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digestion was stopped by adding 1 mM of the serine protease inhibitor phenylmethylsulfonyl 
fluoride (PMSF). The cutting efficiency was controlled by SDS- gel electrophoresis followed 
by coomassie staining. In addition, MALDI-TOF analyses were performed by Jörg Kahnt at 
the Max-Planck-Institute of Terrestrical Microbiology, Marburg, Germany to confirm the 
cutting efficiency and to exclude further cleavage within the Bid protein sequence. For 
MALDI-TOF analysis, a buffer exchange of protein samples was performed prior to thrombin 
cleavage. Protein desalting was performed using ZebaTM Spin Desalting columns (Thermo 
Scientific, Langenselbold, Germany) according to the manufacturer´s protocol.  
GST- tagged Bid constructs (Bid1-Bid4) were cleaved after affinity chromatography in GST-
elution buffer (Table 41). For effective removal of the GST-tag, a thrombin concentration of 
3.5 U/ml was used, and to enhance thrombin activity, the digestion was carried out in the 
presence of 10-12 mM calcium chloride for 16 h at 37°C. Afterwards, thrombin activity was 
inhibited by addition of 1 mM PMSF. Alternatively, removal of GST-tag from GST-fused Bid 
constructs was performed using the thrombin protease provided from Novagen®, with the unit 
definition of 1U/mg protein. Cleavage efficiency was controlled by SDS- electrophoresis.  
2.17 Dialysis of recombinant proteins 
Dialysis is a process used to separate molecules in solution by the differences in their rates 
of diffusion through a semi permeable membrane. Due to the pore size of the membrane 
large molecules in the sample, such as proteins, cannot pass through the membrane, 
thereby restricting their diffusion from the sample chamber. In contrast, small molecules, 
such as salt molecules, will freely diffuse across the membrane and obtain equilibrium across 
the entire solution volume. In this study dialysis was used to decrease the salt concentration 
and to remove the imidazole content of the protein samples after purification by Ni-affinity 
chromatography.  
For dialysis a flexible Spectra/Por® cellulose membrane tube with a molecular weight cut-off 
of 7kDa (Serva electrophoresis, Mannheim, Germany) was used. Prior to sample dialysis, 
the dialysis tube was cut to a size dependent on the respective sample volume. Afterwards 
the membrane was incubated in the dialysis buffer (20 mM Tris pH 8, 10 mM β-
Mercaptoethanol) for 1-2 hours prior to sample addition. The tubing was closed at the end by 
a locking clamp and loaded with the protein solution and closed with a second locking clamp. 
The sample-filled tubing was placed into a chamber containing 5 liter of dialysis buffer and 
incubated at 4°C overnight with gentle stirring of the buffer. The day after the sample was 
transferred to a new sample tube and protein concentration was determined by Bradford 
assay or UV photometry before concentration of the protein when indicated.  
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2.18 Cut-off concentration of recombinant proteins 
To achieve the final concentration of recombinant proteins required for the respective 
experiments and to reach high concentration of pure protein for crystallographic studies 3-
kDa cut-off ultra-filtration was used. Therefore the respective samples were filled into 3-kDa 
cut-off Amicon concentrators (Amicon® Ultra-4/ Amicon Ultra-15, Millipore, Schwalbach, 
Germany) for volumes up to 4 ml or up to 15 ml, respectively. Afterwards the samples were 
centrifuged at 4,000 rpm at 4°C until the required protein concentration was reached. In the 
meantime of centrifugation, protein concentration was determined by absorption at 280 nm 
with the NanoPhotometerTM (Implen, Munich, Germany). 
2.19 Cleavage of full length Bid with Caspase 8 
Cleavage of full-length Bid with recombinant caspase 8 was performed as previously 
described69. Therefore, 200 µl of pure recombinant Bid in 20 mM Tris (ph 7.4), 50 mM NaCL, 
was 1:1 diluted with 200 µl of caspase-cutting buffer (50 mM Hepes, 100 mM NaCL, 10 mM 
DTT, 1 mM EDTA, 10% sucrose, ph 7.5) and incubated with 1 µl of recombinant caspase 8 
(7.6 mg/ml) for 2-4 h at room temperature. The cutting efficiency was estimated to be over 
95% by SDS-polyacrylamide gel electrophoresis and coomassie staining and additionally by 
western blot. After 1h, Bid was cleaved providing the insoluble C- and N-terminal fragment. 
For functional analysis of tBid, the mixture was applied to fluorescence liposomes (2.22.1.2). 
For thermophoresis measurements and analyzing the effect of tBid on VDAC1 channels the 
cleaved Bid fractions were separated from excess of caspase 8. Therefore, the solution was 
diluted 1:1 with SEC-buffer (25 mM HEPES/NaOH pH 7.5, 300 mM NaCl, 0.2 mM DTT, 2% 
OG) to resolve tBid and applied onto a Superdex 200 (GE Healthcare Bio-Science AB, 
Uppsala, Sweden) column, yielding both fragments of cleaved Bid protein as shown by SDS-
PAGE. tBid was concentrated with a 3-kDa cut-off Amicon concentrator (Amicon Ultra-15, 
Millipore, Darmstadt, Deutschland). The protein concentration was measured by absorption 
at 280 nm with the NanoPhotometerTM (Implen, Munich, Germany). The samples were stored 
at 4 °C until use.  
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2.20 Determination of protein concentration 
The concentration of recombinant proteins was determined either by the Bradford assay or 
by UV spectroscopy using the NanoPhotometerTM (Implen, GE Healthcare Europe GmbH, 
Freiburg, Germany). 
2.20.1 Bradford assay 
Total protein concentrations of expressed recombinant full-length Bid and different Bid 
constructs, were determined by the Bradford assay according to the manufacturers protocol 
(AppliChem, Darmstadt, Germany). The Bradford method is a fast procedure for 
determination of protein concentrations in solutions that depends on quantifying the binding 
of a dye, Coomassie Brilliant Blue G-250, to an unknown protein. The Coomassie blue G250 
binds most readily to arginyl and lysyl residues of the respective proteins and the binding is 
proportional to the protein amount present. When binding to a protein occurs, the 
absorbance maximum for the acidic solution of Coomassie Brilliant Blue-G250 shifts from 
465 nm to 595 nm, causing a visible color change in a linear range of the assay from 5 to 
25 µg/ml protein amount. The protein concentration of a test sample was determined by 
comparison to that of a standard protein, bovine serum albumin (BSA). 
For standard, a serial dilution of a BSA stock (10 mg/ml) was prepared by diluting the stock 
with protein buffer (20 mM Tris base, pH 7.4, 50 mM NaCl) to final concentrations of 0, 2, 4, 
6, 8, 10 µg BSA. To each sample 1 ml of Bradford reagent (AppliChem, Darmstadt, 
Germany) was added and mixed gently by vortexing. The reagent blank (0 µg BSA) was 
used to zero the spectrophotometer (BioRad laboratories, Munich, Germany). After 
transferring the samples to disposable trUViewTM cuvets (BioRad laboratories, Munich, 
Germany) the absorbance of each sample was measured at 595 nm using the Lambda 
595 nm assay. For sample preparation, 10 µl of each sample was filled up with protein buffer 
to a final volume of 100 µl. After adding 1 ml of Bradford reagent, samples were mixed gently 
by vortexing and transferred to cuvets. Using the BSA standard curve, the protein 
concentration of each sample was determined. Since samples were diluted 1:10 before 
measuring, the calculated protein concentration was multiplied by 10 to get the amount of 
protein in 100 µl. 
2.20.2 Nanodrop photometry 
For determining the protein amount of recombinant protein samples after chromatography 
purification, the absorbance of protein samples was measured using the NanoPhotometerTM 
(Implen, GE Healthcare Europe GmbH, Freiburg, Germany). The protein concentration was 
determined at 280 nm due to absorption by tyrosine, tryptophan and phenylalanine amino 
acids. Since the Abs 280 varies greatly for different proteins due to their amino acid content, 
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the specific absorption value for a particular protein must be determined. Therefore, a 
specific A280 factor was determined for each protein, according to the Implen 
NanoPhotometerTM User manual. The A280 factor is based on the extinction coefficient of the 
respective protein [molecular weight/molar extinction coefficient]. The molar extinction 
coefficients for each protein were determined based on the amino acid sequence data as 
described by Gill at al.187. Molar extinction coefficients were calculated as provided in Table 
52. Before measuring the protein concentration of each sample, A260 Factor was set to zero 
for direct λ280 UV protein measurement and A280 factor was set to the value calculated for 
the respective protein construct (Table 52). Afterwards the system was blanked using protein 
buffer (20 mM Tris base, pH 7.4, 50 mM NaCl) and each sample was measured using a 
sample volume of 4 µl. The respective protein concentrations were calculated as mean of at 
least three measurements. 
 
Table 52: Molar extinction coefficients and A280 factors 
Protein Molecular weight  
Molar extinction 
coefficient 
A280 Factor 
Full-length His6-Bid 24,114.75 g/mol 8250 mol/l*cm-1 2,923 
Full-length Bid 22,232.04 g/mol 8250 mol/l*cm-1 2,695 
Bid construct 1 17,626.22 g/mol 2560 mol/l*cm-1 6,885 
Bid construct 2 18,127.72 g/mol 8250 mol/l*cm-1 2,197 
Bid construct 3 17,569.17 g/mol 2560 mol/l*cm-1 6,863 
Bid construct 4 18.070,67 g/mol 8250 mol/l*cm-1 2,190 
 
2.21 Acetone precipitation 
To increase the concentration of soluble protein fractions after bacterial expression and pull-
downed proteins from protein-protein interaction studies, the protein samples were acetone 
precipitated according to the pierce protocol for acetone precipitation (Thermo Fisher 
Scientific, Schwerte, Germany). Briefly, samples were gently mixed with the 4-fold amount of 
cold acetone (Roth, Karlsruhe, Germany), and incubated at -20°C for at least 120 min. or 
overnight. Afterwards, the solution was centrifuged at 15,300 rpm, 4°C for 15-30 minutes. 
After removing the supernatant the acetone was evaporated from the uncapped tube at room 
temperature for 30 minutes without over-drying the pellet. The pellet was then resuspended 
in the respective protein buffer and supplemented with 5 x SDS buffer to control the samples 
by gel electrophoresis followed by coomassie staining or western blot analysis. 
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2.22 Functional analysis of recombinant proteins 
In order to investigate the functional activity of recombinant proteins, recombinant full-length 
Bid and its truncated form tBid were applied to in vitro assays addressing the effect of the 
proteins on lipid membranes and to investigate protein-protein interactions.  
2.22.1 Models of membrane permeabilization 
To explore the effect of full-length Bid, tBid and Bax on artificial lipid bilayer structures, which 
mimic the mitochondrial membrane, two in vitro assays for membrane permeabilization were 
established in this thesis.  
All lipids used for liposome and planar lipid bilayer preparations were derived from Avanti 
Polar lipids (Avanti Polar lipids, Alabaster, AL, USA) and provided in Table 53.  
 
Table 53: Lipids (Avanti Polar lipids) 
Lipid Origin Concentration Physical state 
L-α-Phosphatidylcholine (PC) Egg, Chicken 25 mg/ml Chloroform 
L- α-Phosphatidylethanolamine 
(PE) 
Egg, Chicken 25 mg/ml Chloroform 
Cardiolipin (CL) 
Heart, Bovine-
Disodium Salt 
25 mg/ml Chloroform 
 
2.22.1.1 Preparation of liposomes 
5,6-carboxyfluorescein (CF) containing liposomes, with a lipid composition reflecting that of 
the mitochondrial outer membrane (MOM), were prepared by extrusion using the Avanti-Mini-
Extruder (Avanti Polar lipids, Alabaster, AL, USA). Lipids used for liposome preparation are 
provided in Table 53. For cardiolipin-containing liposomes (PC/PE/CL: 54/20/26), 66.67 µl 
phosphatidylcholin (PC), 23.82 µl phosphatidylethoanolamine (PE) and 62.16 µl cardiolipin in 
chloroform were mixed. For comparison, liposomes without cardiolipin (PC/PE: 80/20) were 
prepared using a mixture of 98.76 µl PC and 23.82 µl PE in chloroform. For purification 
purposes, both liposome mixtures were supplemented with 1 % of rhodamine DHPE 
(LissamineTM rhodamine B 1,2-Dihexadecanoyl-sn-Glycero-3-Phosphoethanolamine, 
Triethylammonium Salt, Invitrogen, Karlsruhe, Germany). After stirring the liposome mixtures, 
the organic solvent was removed by evaporation under a nitrogen stream for 15 min. at room 
temperature or for 5-10 min. at 30°C using the EVA-EC1-24 evaporator (VLM GmbH, 
Bielefeld, Germany). Subsequently, lipid samples were incubated in an exsiccator under 
vacuum for 1-2 h at room temperature for complete removal of the chloroform. To avoid 
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drying out of the lipid film, samples were consistently inspected in between. Dry lipid films 
were resuspended in 1 ml 1 x PBS, pH7.4 containing 20 mM 5,6-carboxyfluorescein (CF, 
Invitrogen), respectively. Large multi-lamellar vesicles (LMV), obtained by hydration, were 
further downsized by subjection to several freeze/thaw (F/T) cycles followed by extrusion. 
For preparation of large uni-lamellar vesicles (LUV), samples were frozen in liquid nitrogen 
for 1 min. and thawed at 37°C in a water bath. After 20 F/T cycles, liposomes were extruded 
15 times through two polycarbonate filters with pores of 200 nm diameters using the Avanti-
Mini-Extruder. Prior to sample application, the extruder was prepared according to the 
manufacturer’s protocol. After extrusion, samples were stored at 4°C until all liposome 
samples were prepared. Liposomes were isolated and untrapped CF was removed by gel 
filtration using a pre-packed Sephadex-G25 column (PD MidiTrap G-25, GE Healthcare 
Europe GmbH, Freiburg, Germany). According to the manufacturer’s gravity protocol, the 
columns were three-times equilibrated with 15 ml of 1 x PBS. Afterwards 1 ml liposome 
sample was applied to the column and finally eluted with 1.5 ml 1 x PBS. Untrapped CF 
appeared as yellow band whereas rhodamine-stained liposomes were visualized as pink-
colored band in the gel-packed bed. 
Since the phase transition temperature (Tm) of all required phospholipids was approximately 
2°C, the whole procedure could be performed at room temperature.  
2.22.1.2 Liposome channel activity assay 
The liposome channel activity assay was performed in black 96-well plates (Greiner, 
Frickenhausen, Germany) on a fluorescence plate reader (FluoStar OPTIMA, BMG Labtech, 
Offenburg, Germany). Fluorescence was recorded as a function of time with excitation at 485 
nm and emission at 520 nm and fluorescence values were given every 5 seconds. Twenty µl 
of purified 5,6-carboxyfluorescein-containing liposomes were diluted in 80 µl PBS to give a 
suitable fluorescence value. For baseline fluorescence, liposomes were initially measured at 
room temperature without addition of proteins every 5 seconds for at least 3 minutes. 
Afterwards, recombinant proteins were added and the change in fluorescence was monitored 
every 5 seconds for at least 20 min. up to 1 hour. If proteins were able to induce channel 
formation or disrupture of the liposome membrane, 5,6-carboxyfluorescein was released as 
indicated as an increase in fluorescence over time. In detail, caspase 8- cleaved Bid (tBid) 
was added at final concentrations of 10 nM up to 6 µM for dose-dependence studies. 
Recombinant Bax was used in final concentrations of 100 nM and 500 nM when applied to 
liposomes alone. For investigation of the pore-forming activities of both proteins in 
combination, 100-500 nM Bax was mixed with 50 nM-6 µM tBid and the protein mixture was 
incubated 3 min. prior to adding the mixture to the liposomes. Addition of the appropriate 
protein buffer to the liposomes was used as negative control.  
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For comparison of fluorescence release, 20 µl of aqua demin. was added to the liposomes 
and the recorded fluorescence was set to 0 % release of CF. To reach 100 % release of CF, 
liposomes were incubated with 3-4% of TritonX-100. 
To establish the liposome channel activity assay as an in vitro assay to screen novel small-
molecules for their ability to inhibit Bid-channel activity,  recombinant Bid/tBid, in presence or 
absence of recombinant Bax, was pre-incubated with different concentrations of the Bid 
inhibitor BI6c9 at room temperature for 1-3 min. The mixture was afterwards added to the 
CF-containing liposomes and change in fluorescence (excitation 485 nm and emission 
520 nm) was recorded every 5 seconds for at least 20 min. up to 1 h.  
 
2.22.2 Analysis of protein-protein interactions 
2.22.2.1 In vitro Bid/tBid – VDAC1 binding assay 
Binding of VDAC1 to purified His6-tagged Bid or tBid was assayed by His-tag pull-down using 
Ni-NTA resin (Quiagen, Hilden, Germany). Therefore, 50 µg of recombinant full-length His6-
Bid (His-rBid) and 50 µg of caspase 8-cleaved Bid (His-rtBid) were mixed separately with 
50 µg of recombinant mVDAC1 (rVDAC1) or with 50 µg of a VDAC1 deletion mutant 
(rVDAC1 Δ11). Afterwards protein mixture were incubated with 150 µl of nickel-nitrilotriacetic 
acid-agarose (Ni-NTA) in binding buffer (10 mM Tris HCl pH 8.0, 100 mM NaCl, 0.05 % 
LDAO) at 4 °C with gentle rotation for 1-2 h, respectively. His-rBid without incubation with 
mVDAC1 and sample containing only mVDAC1 or rVDAC1 Δ11 were used as negative 
controls. The protein-Ni-NTA suspensions were loaded on a Poly-Prep® Chromatography 
column (BioRad Laboratories, Munich, Germany) and washed 2-3 times with 2 ml wash 
buffer (10 mM Tris HCl pH 8.0, 100 mM NaCl, 0.05 % LDAO, 20 mM imidazole) to remove 
unbound protein amounts. His-rBid and His-rtBid together with their binding partners bound 
to Ni-NTA, were finally eluted with 0.5 ml elution buffer containing 200 mM imidazole (10 mM 
Tris HCl pH 8.0, 100 mM NaCl, 0.05 % LDAO, 200 mM imidazole). The washing fractions 
(W) and elution fractions (E) for each sample were collected and acetone precipitated 
following the pierce manufacturer´s protocol for acetone precipitation. To determine protein-
protein interactions, the protein samples were analyzed by SDS-PAGE followed by 
coomassie staining. Alternatively, the SDS-PAGE was followed by western blot and proteins 
detected using specific antibodies as described before. Samples containing only one protein 
served as controls for non-specific binding.  
 
 
Materials and methodes | 85 
 
 
 
2.22.2.2 Thermophoresis measurements 
Microscale thermophoresis is based on the direct movement of biomolecules in a 
microscopic temperature gradient and is used to determine binding affinities or surface 
modifications of molecules. The method enables the quantitative analysis of molecular 
interactions in solution at a microliter scale. Changes of the hydration shell of small 
molecules or proteins due to structural or conformational alterations result in a relative 
change of movement along the temperature gradient. To study protein-protein interaction 
one proteins is fluorescently labeled and used under constant concentration and buffer 
condition, while the binding partner is titrated in serial dilution experiments. Thermophoresis 
of the fluorescent labeled protein differs significantly from the protein-target complex due to 
changes in size, charge and salvation entropy.  Therefore protein-protein interactions can be 
measured and sigmoid binding curves are obtained using different concentrations of the  
dilution series, resulting in dissociation constants KD. 
Thermophoresis experiments were performed by Barbara Mertins from the group of Prof. 
Essen (Philipps-University Marburg, Department of Chemistry, Marburg, Germany).For 
thermophoresis measurements of mVDAC1 and Bid/tBid, mVDAC1 was labeled using Alexa 
Fluor® 532 C5-maleimide (Invitrogen). 1mM TCEP (AppliChem) were added to 100 µM 
protein solution and incubated for 30 min at 4°C. After incubation 1 mM label was added and 
incubated over night at 4°C and 350 rpm in a Thermomixer (Eppendorf). Excess label was 
removed by using a Sephadex G25 column (GE Healthcare Bio-Science AB, Uppsala, 
Schweden). Protein concentration and label efficiency were measured at 280 nm and 532 
nm with a Nanodrop ND-1000 (peqLab). Microscale thermophoresis (MST) measurements 
were performed using the Monolith NT.115 instrument (NANO TEMPER). mVDAC1 
concentration was kept constant at 50 nM and Bid / tBid were added to the solution ranging 
from 15 nM to 500 µM. Protein solution was incubated in the dark for 20 min at RT and 
centrifuged (25402 g, 5 min) to remove precipitated proteins. Standard capillaries (NANO 
TEMPER) were filled with 8-10 µL of the protein solution and MST curves were recorded. KD 
values were calculated using the NT-Analysis software.  Fluorescently labeled OmpG was 
used to rule out unspecific interactions of Bid/tBid with β-barrels.  
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2.22.2.3 Single channel conductance recordings of mVDAC1 ion channels 
Single channel conductance recordings were performed using the black lipid membrane 
(BLM) technique188. The planar lipid membranes were prepared by painting or rising the 
solution surface over a 200 μm hole in a two chamber apparatus (polystyrene cuvette: CP2A, 
bilayer chamber: BCH-22A, Warner Instruments) filled equally with BLM buffer (10 mM 
Tris/HCl, pH 7.4, 1 M KCl, 5 mM CaCl2). As membrane mixture a solution of 
diphytanoylphosphatidylcholin (Avanti Polar Lipids, No.341601) in n-decane (25 mg/mL) was 
used. The porin was added beside the BLM, the bilayer was reconstituted and a voltage-
gradient was imposed across the membrane while waiting for insertion of single channels. 
Once a stable single VDAC1 channel was inserted, recombinant Bid or tBid were added to 
the cis side, respectively. For current detection voltages from +40 mV to −40 mV were 
applied and current was detected using the Multipatch 700B patch-clamp amplifier combined 
with a Digidata 1440A A/D converter with pClamp 10.2 software (Axon Instruments). The 
data were collected at 5 kHz and sampled at 200 Hz for further analysis. For each 
measurement the differences from the baseline to the stable high conductance state (S0) 
and the low conductance states (S1, S2, S2´) were determined with the software. Each data 
point of the U/I-curve was taken in account to determine the conductivity via the slope 
derived by linear regression. The BLM measurements were performed by Philip Reiß 
(Philipps-University of Marburg, Department of Chemistry, Marburg, Germany). 
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2.23 Crystallographic methods 
2.23.1 Protein crystallization 
To provide a basis for the structural understanding of molecular functions of Bid in cell death 
signaling and to allow the determination of protein-ligand complexes, the purified 
recombinant Bid constructs were subjected to extensive crystallization screening. Crystal 
structure analysis was performed using X-ray diffraction, which is the most advanced method 
available for obtaining high-resolution structural information about biological 
macromolecules.  
Crystallographic studies were performed at the MarXtal crystallization lab (SYNMICRO, 
University of Marburg, Germany) with the support of Ralf Pöschke.  
The integrity of Bid constructs was verified by MALDI-TOF analysis, which was kindly 
performed by Jörg Kahnt at the Max-Planck-Institute of Terrestrical Microbiology, Marburg 
(MPI, Marburg, Germany). 
Beside various crystallization screens using purified full-length Bid, slightly modified 
truncated Bid constructs were subjected to the described crystallization procedures 
2.23.1.1 Protein sample preparation 
For X-ray crystallization, the protein sample should be as pure as practically possible (>95%) 
and free of amorphous and particulate material. Highly pure protein has to be obtained in 
concentrations of 5-25 mg/ml, commonly approximately 10 mg/ml. Such high protein 
concentrations enable a faster crystal growth than less concentrations of protein. 
Therefore, recombinant full-length Bid as well as recombinant Bid constructs (Bid1- Bid4) 
were purified as outlined above. After gel-filtration, purity of the proteins was confirmed by 
SDS-PAGE and estimated about 98%. Proteins were concentrated using 3-kDa cut-off 
Amicon concentrators (Amicon® Ultra-4/ Amicon Ultra-15, Millipore, Schwalbach, Germany) 
to concentrations as high as possible. Notably, a concentration of 10 mg/ml could not always 
be reached due to limitations in protein sample amount and protein absorption on filter 
membranes. Therefore, protein concentrations of 4.5 mg/ml up to 15 mg/ml were subjected 
to the following crystallographic methods. To avoid bacterial growth during crystallization all 
proteins samples were sterile-filtered using a 0.2 µm filter (Whatman PuradiscTM 4 mm 
Syringe filter, Whatman, Dassel, Germany). All proteins were subjected to crystallization 
screens in buffer containing 20 mM Tris, ph 7.4, 50 mM NaCl, and 0.03% Na-azide.  
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2.23.1.2 Crystal growth techniques 
In this study, crystallization screens were performed utilizing the vapor-diffusion technique, 
which is the most common used crystallization technique, due in part to the simplicity of the 
experiments and the diversity of variables that can be manipulated. Vapor-diffusion 
experiments undergo a dynamic equilibration process. At the beginning of the crystallization 
experiment a crystallization drop is sealed into an airtight chamber with a reservoir solution. 
The difference in concentration between the drop and the reservoir drives the system 
towards the equilibrium by diffusion through the vapor phase. Thereby the experiment drop 
dehydrates and reduces its volume, driving the protein toward a state of supernaturation 
where crystallization may occur189. 
Using this technique, a small droplet of the respective Bid protein (1µl using 24 well-plates, 
0.3 µl using 96-well plates), was mixed with an equal volume of the appropriate precipitating 
solution. For all initial crystallization screens the sitting-drop technique was performed 
(Figure 11A), thus sitting drops are more mechanically stable and more resistant to 
temperature changes than hanging drops. However, it can be hard to mount crystals from 
sitting drops. Therefore, some optimization screens were performed in 24-well plates using 
hanging-drop vapor-diffusion by placing a small droplet of sample mixed with crystallization 
reagent on a screw cap (EasyXtal tool, Qiagen, Hilden Germany) inverted over the reservoir 
in vapor equilibration with the reagent (Figure 11B). 
 
            
             Figure 11: Vapor-diffusion techniques: A) sitting-drop, B) hanging-drop. 
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2.23.1.3 Crystallization screens 
To obtain crystals for determination the three-dimensional structure of a protein, a wide array 
of crystallization conditions has to be screened. Since many factors, such as protein 
concentration, precipitant concentration, pH value, buffer composition, presence of salt 
anions and/or additives, influences the crystallization of a protein, initial screening was 
performed using the Quiagen NeXtal-screening suites (Qiagen, Hilden, Germany). These 
screening suites utilize the sparse matrix screening strategy that typically maps a wide sector 
of the chemical space using many different reagents selected from known and published 
crystallization conditions. Each screening suite consists of a set of 96 precisely defined 
chemical solutions and differs in pH, buffer material, salt and precipitant. Starting with 
different sets of initial screening conditions, the search for a suitable condition can be 
narrowed down by further developing conditions surrounding a promising “hit” condition that 
provides crystalline forms (see 2.23.2).  
All initial trials were performed by “automated sitting-drop crystallization in 96-well plates” 
using the MarXtal crystallization equipment. Prior to protein sample application, each of the 
96 screening suite solutions was transferred automatically into a 2.2 ml 96-deep-well plate 
(Abgene, Thermo Fischer Scientific, Schwerte, Germany) using the Lissy-system (Zinsser 
Analytic GmbH, Frankfurt, Germany). Afterwards 80 µl of each of the reservoir solutions was 
pipetted into the corresponding reservoir of a MRC2 2-drop-chamber 96-well crystallization 
plate (Jena Bioscience, Jena, Germany), which was then loaded on the Cartesian MicrosysTM 
SQ4000 crystallization robot (Genomic Solutions, Huntingdon, UK, USA). Using this robot, 
300 nl drops of the respective reservoir were transferred into each of the two corresponding 
wells on the plate. Afterwards, 300 nl of either protein or buffer solution were pipetted into the 
freshly prepared reservoir drops. Finally, the setup was isolated by sealing the plates with 
ViewSealTM (Greiner Bio-one, Frickenhausen, Germany) adhesive transparent plastic 
sheets.  
The procedure was repeated for each screening suite and the finished crystallization plates 
were stored at 18°C or 4°C in the Formulatrix Rock ImagerTM (MarXtal, Department of 
Chemistry, University of Marburg), which is a fully automated documentation system for 
crystallization experiments. Within this Rock Imager, each well of the respective screening 
plates was automatically monitored by microscopy and images were taken in continuous 
time-lags. Screening results were scored by analyzing the taken photomicrographs using the 
Rock Maker Web provided by MarXtal (Department of Chemistry, University of 
Marburg).Using this setup, the respective recombinant Bid constructs, expressed and 
purified in this thesis, were initially subjected to 13 different screenings suites, respectively. 
Since temperature does affect crystal growth most of the screens were duplicated at 4°C and 
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18°C. Table 54 predicts the initial standard setup for the different Bid constructs tested for 
crystallization during this work.  
 
Table 54: Initial screens and set ups tested for the different Bid constructs 
Parameter His6-Bid Bid-22 
Bid 1 
(12-47) 
Bid 2 
(12-51) 
Bid 4  
(13-51) 
Drop 1 Protein Protein Protein Protein Protein 
Drop 2 Buffer Buffer Buffer Buffer Buffer 
Protein 
concentration 
(mg/ml) 
4.5 mg/ml  9.9 mg/ml 9.5 mg/ml  8.5 mg/ml 10.0 mg/ml 
Protein buffer Tris 20 mM, 50 mM NaCl, pH 7.4 
Screening 
temperature 
18°C 18°C 18°C 18°C 4°C + 18°C 
Screening 
Suites tested 
1-13* 
1, 3, 5, 7-9, 
11, 13* 
1-13* 1-13* 1-13* 
* Screening 
Suites 
(Qiagen) 
1. AmSO4 Suite, 2. Anions Suite, 3. Classics Suite, 4. Classics Lite 
Suite, 5. Cryos Suite, 6. JSCG+ Suite, 7. JCSG Core Suite I, 8. JCSG 
Core Suite II, 9. JCSG Core Suite III, 10. JCSG Core Suite IV, 11. 
MBClass I Suite, 12. MBClass II Suite and 13. PACT Suite 
 
Following this strategy, Bid construct 4 was additionally applied to screening suites Classic, 
Cryos, JSCG+, JCSG Core suite I-IV and PACT suite in concentrations of 15.2 mg/ml at 
18°C.  Initial screens were repeated at 18°C and 4°C using the Bid construct 1 in 
concentrations of 10.5 mg/ml. In duplicate screens, Bid1-containing protein drops were 
supplemented with nanoparticles. Hit conditions found during initial screening were optimized 
as described below. Additionally, co-crystallization of Bid1 with the Bid inhibitor BI-6c9 was 
attempted using the screening suites JCSG Core I-IV, PACT and JCSG+. 
2.23.2 Optimizing and reproducing crystallization 
Optimization of crystallization aims to enlarge the crystal size and to enhance the occurrence 
of single crystals obtained in the initial crystallization screen. Conditions where initial 
crystallization was observed, referred to as “hit” conditions, were manually set up and 
adjusted in a grid screen. In contrast to the sparse matrix screen, in a grid screen the 
precipitant type of the “hit” condition is screened systematically in a separate tray, varying pH 
and precipitant concentration. Optimization of hit conditions was initially performed using the 
hanging-drop technique in 24-well plates with a screw cap (EasyXtal tool, Qiagen, Hilden 
Germany). Protein solution was added in volumes of 2 µl to an equal volume of the 
respective reservoir solution. Optimizations of Bid 22 crystals were performed in 24-VDX 
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plates by sitting-drop vapor diffusion. To initialize crystal growth some optimization grids 
were additionally supplemented by heterogeneous or homogeneous seeding (2.23.2.2). 
Since small differences in drop and reservoir volumes can affect crystal growth, optimizations 
performed in 24-well plates were additionally transferred to 96-well crystallization plates. 
Reservoir conditions in 24-well plates were prepared using customized buffers and reagents, 
while 96-well optimizations were mostly performed with the original NeXtal stock solutions 
(Quiagen, Hilden, Germany). Final buffer compositions were manually pipetted and 
transferred into 96-deep well plates. Pipetting of 0.3 µl protein solution and 0.3 µl reservoir 
solution was performed either manually or using the Cartesian MicrosysTM SQ4000 
crystallization robot. Table 55 et sqq. show the optimization steps of most promising hit 
conditions performed for the different Bid constructs, respectively.  
 
24-well plate optimization grids: 
Table 55: Optimization of Bid 22 crystals I, 4°C + 18°C 
                 (based on condition 21 from the Classic Suite) 
Composition Original Optimization steps 
0.1 M Tris (pH) 8.5 7.5/8.0/8.5 
2-Methyl-2,4 pentanediol (% in v/v) 50 50/55/60/65 
Ammonium di-hydrogenphosphat (M) 0.2 0.2 
 
Table 56: Optimization of Bid 22 crystals II, 4°C + 18°C 
                (based on condition 12 from JCSG Core I Suite) 
Composition Original Optimization steps 
Polyethyleneglycol (PEG) 3,350  
(% in v/v) 
20 20/23/26/29 
0.2 M Magnesiumacetat (pH) -- 7.5/8.0/8.5 
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Table 57: Optimization of Bid construct 1 I, 21°C 
                (based on condition 5 from Cryos Suite) 
Composition Original Optimization steps 
0.085 M Hepes sodium salt (pH) 7.5 7.0/7.25/7.5/8.0 
PEG 4,000 (% in v/v) 17 13/15/17/19/21/23 
Isopropanol (% in v/v) 8.5 8.5 
Glycerol (% in v/v) 15 15 
Heterogenous seeding 5% nanoparticles 
 
Table 58: Optimization of Bid construct 1 II, 21°C 
                (based on condition 79 from JCSG+ Suite ) 
Composition Original Optimization steps 
0.1 M succinic acid (pH) 7.0 6.5/7.0/7.5/8.0 
PEG 3,3500 (% in v/v) 15 11/13/15/17/19/21 
Homogenous micro-seeding -- After 3 days 
 
96-well plate optimization grids: 
Table 59: Opti-Grid 96 of Bid construct 1 I, 4°C + 18°C 
                (based on condition 5 from Cryos Suite) 
Composition Original Optimization steps 
0.085 M Hepes sodium salt (pH) 7.5 6.5/7.0/7.5/8.0 
PEG 4,000 (% in v/v) 17 9/11/13/15/17/19/21/23/25 
Isopropanol (% in v/v) 8.5 8.0/8.5/9.0/9.5/10 
Glycerol (% in v/v) 15 13/15/17/19/21 
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Table 60: Opti-Grid 96 of Bid construct 1 II, 4°C + 18°C 
                (based on condition 79 from JCSG+ Suite) 
Composition Original Optimization steps 
0.1 M succinic acid (pH) 7.0 6.5/7.0/7.5/8.0/8.5 
PEG 3,3500 (% in v/v) 15 11/13/15/17/19/21/23/25 
 
Screens with both opti-grids 96 were performed under three conditions: once without any 
addition, once with seeding of nanoparticles and once with seeding from old crystal stocks. 
Optimizations were performed with two batches of Bid1 protein (9.5 mg/ml and 10.5 mg/ml) 
and screens were always duplicated for crystal growth at 4°C and 18°C.  
2.23.2.1 Additive screen 
Another strategy for crystal fine-tuning used in during this work was the application of 
additives to the most promising screening conditions yielding crystals in the initial and 
optimization screens. A number of additives have been identified as useful for enhancing 
crystallization. According to their chemical properties, additives are divided into different 
classes. For example, salts, co-factors, multivalent cations, linker, amino acids, reducing 
agents, polymers, detergents and non-detergents as well as chelators and organics are 
common.  
To investigate a wide array of additives, the commercial Additive Screen HTTM (Hampton 
Research, Aliso Viejo, CA, USA) was used to fine-tune the hits based on condition 5 from 
cryos suite and condition 79 from the JSCG+ suite. The Additive Screen HTTM consists of 96 
unique additives pre-formulated in deionized water and sterile filtered. Additive screens were 
performed in 96-well sitting-drop crystallization plates. First, 90 µl of the respective hit 
condition was transferred into each of the 96 reservoir wells. Afterwards 10 µl of the 
appropriate additive was pipetted into the corresponding reservoir and mixed gently. For drop 
setup, 0.3 µl of Bid 1 protein (10.5 mg/ml) was mixed with 0.3 µl of crystallization 
reagent/additive mixture from the reservoir. The procedure was repeated for each of the 
remaining additives. After finishing for all 96 additives, the plates was sealed with ViewSealTM 
(Greiner Bio-one, Frickenhausen, Germany) and stored in the Rock Imager. In addition to the 
additive applications, the protein solution was supplemented with nanoparticles prior to 
pipetting. Additive screens for cryos condition 5 and JSCG+ condition 79 were duplicated 
and the crystallization plates stored and imaged at 18°C and 4°C, respectively.  
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2.23.2.2 Seeding  
Crystals obtained in initial screens that did not have the desired diffraction properties, 
because they were too small or grew together, were used as seeds in new experiments to 
optimize the original growth conditions or to explore other crystallization conditions. Two 
seeding procedures were performed, streak seeding and modified micro-seeding. For streak 
seeding, a 24-well crystallization plate was prepared with the respective reservoir conditions 
for reproducing crystal growth or optimization of hit conditions. Before seeding, the protein/ 
crystallization reagent drop was prepared as described above and the sealed plate was 
stored for at least 12 h to allow drop equilibration and first drop concentration. Afterwards, 
the plate was resealed for the seeding procedure. A cat whisker was used as a seeding tool 
to touch and stroke the surface of the parent crystal in the old mother liquor. Thereby small, 
not visible seeds of the old crystal adhered at the surface of the whisker. The whisker was 
then transferred into the fresh crystallization drops by drawing the tip along the surface of 
each drop in a straight line. Four to six drops were seeded sequentially without redipping the 
whisker on the old crystal. The procedure was repeated until all 24 drops were seeded. The 
plate was sealed again and stored at 21°C or 4°C.  Crystal growth was observed along the 
streak line within a few days.  
For seeding of 96-well crystallization plates, modified micro-seeding was performed. 
Therefore, a micro-seed stock was prepared by breaking a parent crystal with a thorn. A 
previously obtained crystal was transferred into a tube containing a small volume of mother 
liquor solution (respective reservoir solution) and broken as much as possible using the 
thorn. The generated microcrystal solution was then diluted 1:10 in reservoir solution. 1-2 µl 
of the seeding solution was mixed with 50 µl of fresh protein solution. The protein/seeding 
solution was used for preparation of 96-well crystallization plates using the Cartesian 
MicrosysTM SQ4000 crystallization robot as outlined above.  
 
2.23.3 Scoring and interpretation of crystallization drop results 
For scoring of crystallization conditions and crystal growth, the screening plates were 
monitored by microscopy. 96-well crystallization plates were automatically imaged in the 
Formulatrix Rock ImagerTM (MarXtal, Department of Chemistry, University of Marburg) and 
photomicrography analyzed using the Rock Maker Web. After initialization of the screening 
plates, pictures of every well were taken every day during the first week, then once every 
week and finally at exponentially increasing times after dispensing. 24-well crystallization 
plates were analyzed manually by microscopy.  
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For interpretation of drop results, a non-Q scoring system was used, as recommended by 
Bergfors T.M.189. Table 61 shows the scoring system used for interpretation of crystallization 
drop results. Pictures reveal examples of drop results that were obtained in the crystallization 
screens performed during this work. 
 
Table 61: Scoring system used for interpretation of crystallization drop results 
                 (Modified by Bergfors T.M.189, pictures were obtained from crystallization screens 
                  performed within this work)  
Score Phenomenon Drop example 
Protein is not precipitated 
0 clear drop 
 
1 artifacts (dust, fiber) 
 
Precipitate shows no birefringence and has no edges 
2 partial precipitation 
 
3 heavy precipitates, skin 
 
4 
Gelatinous and white 
precipitants 
 
5 phase separation 
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Precipitate shows birefringence and has edges 
6 spherulites, microcrystals 
 
Crystals 
7 needles 
 
8 plates (2D crystals) 
 
9 3D crystals 
 
 
2.23.4 Differentiation between of protein and salt crystals  
Observing a crystal in an initial or optimization screen does not necessarily indicate a protein 
crystal. Many of the typical components in the crystallization mother liquor, besides the 
protein, can crystallize, such as salts and detergents. Although, the only definitive test to 
distinguish between salt and protein is to put the crystal into the X-ray beam, it is not always 
possible, since crystals could be too small for mounting. During this thesis, three methods for 
distinguishing salt and protein crystals were performed prior to X-ray diffraction. In addition, 
all crystallization screens were controlled by comparing protein drops and buffer solution 
drops on the 2-drop chamber crystallization plate. 
2.23.4.1 Polarized light 
During storage of the crystallization plates in the Rock Imager, imaging was additionally 
performed using polarized light. Anisotropic protein crystals show a double refraction that 
causes color effects while viewed with polarized light. The obtained color of a crystal is 
different to that of the background and i.e. different from the color reflection from the plastic 
tray in phase separation. Notably, most crystals obtained from salt or detergent have also 
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strong optical properties and show extensive birefringence under a cross polarizer. In 
general, protein crystals have a weaker birefringence than salt and detergent crystals. 
2.23.4.2 Dye-test 
Protein crystals can be stained using different dyes, such as Izit (methylene blue) or 
coomassie blue dye. Protein, peptide and nucleic acid crystals typically have large solvent 
channels which will accommodate the small molecule dye, and thereby color the crystal. In 
contrast, inorganic crystals do not posses such solvent channels and will not absorb the dye 
thereby remaining uncolored. Notably, some screening conditions in a high relative 
supersaturation can precipitate or even crystallize the dye. Crystallized dyes typically appear 
as dark colored needles or whiskers within a few minutes after adding the dye.  
To differentiate between protein and salt crystal, methylene blue solution (Izit Crystal DyeTM, 
Hampton Research, Aliso Viejo, CA, USA) was used. Methylene blue is a cationic organic 
dye that binds to negative charges on the protein. The crystals were transferred into a 4-10 µl 
mother liquid drop on a cover slide. Afterwards 0.5-1 µl Izit was pipetted into the drop 
containing the crystals. For purposes of comparison, 0.5-1 µl Izit was pipetted into a 4-10 µl 
reservoir solution drop containing salt crystals. The uptake of the dye was observed with the 
microscope immediately, after few hours and then overnight. Protein crystals appeared blue, 
whereas salt crystals did not become blue. The blue color of the protein crystals was typically 
intensified within the crystal over time.  
2.23.4.3 Snap-test 
Physical manipulation of crystals can be used to differ between protein and salt crystals, 
since a biological crystal behaves more like an ordered gel than a hard crystal. Because of 
the high solvent content of protein crystals, they are soft, and powder, crumble or break 
easily when touched with a micro tool or a needle. In contrast, salt crystals are very hard and 
require more force to break apart. Typically one can hear a snap or crunching sound when 
inorganic crystals breaking apart under the force of a micro tool. For the Snap-test, crystals 
were transferred to a cover slide and crashed using a micro tool (Hampton Research, Aliso 
Viejo, CA, USA). The hardness of the crystals and the sound while breaking apart were 
analyzed subjectively. Once a crystal is broken, it cannot be used for X-ray diffraction 
anymore. Therefore, the snap-test was only performed with small crystals that were not 
mountable, or when many crystals were grown in the respective screening condition. 
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2.23.5 Mounting crystals and diffractometric measurements 
For collecting X-ray data on the obtained crystals, cryo-crystallography was performed. 
Protein crystals were measured at very low temperatures, such as that of liquid nitrogen 
(boiling point -196°C) to avoid radiation damage during the diffraction experiment. However, 
freezing crystals might result in damage of crystals due to formation of ice crystals. For cryo-
protection, the crystals were placed into mother liquor containing a cryo-protectant such as 
PEG 400, glycerol or MPD for 5-30 seconds. Crystals that were already grown in cryo-
conditions, as crystals obtained from the cryo suite or from optimization screens containing 
MPD or glycerol, were native frozen and mounted directly. For sample preparation, the 
crystals were picked out of the mother liquor using a Cryo-loop (Hampton Research, Aliso 
Viejo, CA, USA) with the required loop size. If necessarily, the loop containing the crystal 
was transferred into the cryo-solution for 10-15 seconds. Afterwards, the crystals were flash 
frozen by dipping the loop into liquid nitrogen. Crystals were stored in a dewar container filled 
with liquid nitrogen until X-ray data collection.  
2.23.6 Data collection and processing 
Data were collected by Synchrotron measurements of the respective protein crystals either at 
the Helmholtz-Zentrum Berlin using the MX Beamline 14.1, BESSY II (Berliner 
Elektronenspeicherring-Gesellschaft für Synchrotronstrahlung, Berlin, Germany)190 or at the 
DESY Hamburg, using the EMBL MX1 and MX2 beamline at the PETRA III ring (Deutsches 
Elektronen Synchrotron, Hamburg, Germany). Data processing was performed by Holger 
Steuber (Core Facility Structural Biology, LOEWE Center of Synthetic Microbiology 
(SYNMIKRO)) using XDS191 as implemented in XDSAPP192.  Molecular replacement (MR) 
trials were attempted using Phaser193 with search models from various sources (e.g. Bid 
NMR structures obtained from the PDB, poly-Ala models) 
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3 Results 
3.1 Targeting Bid for mitoprotection 
The first anti-apoptotic small molecules targeting Bid were developed by Becattini et al. and 
inhibited tBid-induced Smac/DIABLO release, caspase-3 activation and cell death99, 114, 
suggesting that pharmacological Bid inhibition could provide a protective benefit against 
several disorders, such as neurodegenerative diseases, mood disorders, liver inflammation 
and other pathologies, where Bid has been implicated as a major trigger of the underlying 
cell death63, 98, 99, 194-196.  
In order to confirm that pharmacological inhibition of Bid is sufficient to provide 
mitoprotection, the specific Bid inhibitor BI-6c9 (5) was used to validate the model of 
glutamate-induced cell death in the HT-22 cell-line as suitable model for the initial screening 
of novel Bid-targeting molecules. In line with previous studies97, 116, Bid inhibition by BI-6c9 
resulted not only in the preservation of cell morphology and cell viability of glutamate-treated 
HT-22 cells but also prevented several hallmarks of Bid-mediated mitochondrial dysfunction. 
Recent studies supposed Bid as an upstream mediator of mitochondrial impairments and the 
associated neuronal death signaling63, 197, 198, and further revealed a pivotal role of Bid in the 
balance of mitochondrial fission and fusion and a Bid-mediated permeabilization of the outer 
mitochondrial membrane24, 97, 199, 200. As shown previously, pharmacological Bid inhibition 
using BI-6c9 was sufficient to prevent the glutamate-induced Bid translocation to 
mitochondria97 as well as mitochondrial demise downstream of Bid activation. Further, Bid-
mediated mitochondrial fission, the associated accelerated production of highly detrimental 
ROS as well as the breakdown of Δψm  and impairments in mitochondrial ATP production and 
oxygen consumption were significantly prevented by BI-6c9, as shown below (see 3.1.3 et 
sqq.), confirming the pivotal role of the pro-apoptotic protein Bid in the regulation of 
mitochondrial integrity and function.  
 
3.1.1 Neuroprotective potency of BI-6c9 
In order to achieve a better classification of the neuroprotective potency of BI-6c9, the Bid 
inhibitor was titrated in HT-22 cells at concentration ranges from 0.1 µM up to 10 µM and cell 
viability was analyzed by MTT assay 14 h after exposure to glutamate (3 mM) (Figure 12 A). 
Notably, slightly protective effects against glutamate-induced cell death were already 
achieved by BI-6c9 at low concentrations of 1 µM, while cell viability was completely restored 
at concentrations of 2.5 µM and higher (Figure 12 A). To calculate the half maximal effective 
concentration (EC50) of BI-6c9 at the applied concentration ranges, cell viability data were 
normalized between 0 % for glutamate only treated cells (vehicle) to 100 % protection at 
10 µM and a concentration-response curve was fitted with a sigmoid function (dose response 
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fit). Revealing an EC50 of 2.5 µM, BI-6c9 emerges as a potential Bid-targeting molecule, 
suitable for further structure optimizations and investigations of Bid-dependent cell death 
features.  
 
 
Figure 12: Neuroprotective potency of BI-6c9 – half maximal effective concentration.  
A, Determination of cell viability 14 h after co-treatment with glutamate (3 mM) and BI-6c9 in a concentration-
range of 0.1 µM up to 10 µM. BI-6c9 prevents glutamate-induced toxicity in a concentration-dependent manner. 
Cell viability is completely preserved by BI-6c9 in concentrations of 2.5 µM and higher. The experiment was 
independently repeated three times with an n = 8 per treatment condition. Results are presented as mean ± SD 
(***p < 0.001 compared to glutamate treated vehicle controls, ANOVA, Scheffé’s test). B, Based on this data, a 
concentration-response curve and an EC50 value was calculated for BI-6c9. Cell viability data were normalized 
between un-treated control conditions (0%) and maximum amplitude at 10 µM (100%). Using OriginPro8.5 
Software, the resulting data were fitted with a sigmoid function following the equation y=A1+(A2-
A1)/(1+10^((LOGx0-x)*p)) and EC50 values were generated from three independent experiments.  
 
3.1.2 tBid-induced cell death in HT-22 cells  
The abovementioned data confirmed the important role of Bid in glutamate-induced cell 
death, indicating its apparent direct action at the level of mitochondria to regulate the control 
point of life and death. To further confirm, that the cleaved and active protein tBid is the main 
mediator downstream of glutathione depletion and the activation of lipoxygenases116 and 
sufficient to induce cell death in the present neuronal cell line, a model of tBid-induced cell 
death was validated in order to examine the specific Bid-targeting of novel small-molecules 
that were screened within this thesis. Therefore, HT-22 cells were transfected with a tBid-
expression vector (pIRES-tBid) and cell morphology as well as cell viability were addressed 
17-24 h after tBid-transfection. Over-expression of tBid resulted in excessive alterations in 
cell morphology, similar to the glutamate-induced phenotype of cell death. tBid transfected 
cells clearly appear shrunken, rounded up and detached from the bottom of the culture plate 
(Figure 13 A). To exclude that these cytotoxic effects were a result of the transfection 
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process itself, control cells were transfected with an empty control vector (pcDNA3.1+) or 
only treated with the transfection reagent attractene (vehicle), revealing the normal spindle-
like cell morphology (Figure 13 A). It is important to note, that the sensitivity of HT-22 to tBid-
induced toxicity is highly dependent on the cell density (Figure 13), even more than the 
sensitivity to glutamate toxicity. While cells seeded at a density of 40,000 to 50,000 cells per 
well (24-well plate) respond with severe damage to tBid over-expression, seeding densities 
of 60,000 to 70,000 cells per well results in a resistance of cells to tBid-induced cell death, 
indicating that confluent cell growth prohibits either the efficient transfection of the cells with 
the tBid-encoding plasmid or permits protective strategies via cell-cell contacts (Figure 13). 
Quantification of cell viability by MTT assay confirmed, that over-expression of tBid reduces 
cell viability by approximately 75 % depending on the respective cell density (Figure 13 B). It 
should be noted, that the mechanisms of Bid-mediated cell death signaling might only be 
partly reflected in the model of tBid over-expression as Bid truncation to tBid was not 
detectable in glutamate-exposed HT-22 cells by western blot analysis. However, in 
consideration of the fact that tBid is well accepted to be the active death promoting form of 
Bid, the model system is appropriate to mimic mechanisms that occur downstream of Bid 
activation and further provides a suitable screening model to examine the effect of novel 
compounds on tBid-mediated neurotoxicity.  
In order to confirm that tBid-induced toxicity is accompanied by detrimental effects on 
mitochondria, mitochondrial membrane potential of tBid over-expressing HT-22 cells was 
investigated. TMRE-FACS recordings revealed that tBid over-expression causes a 
remarkable drop in red fluorescence by approximately 40 % of control cells, indicating a tBid-
induced loss of mitochondrial membrane permeability, which was clearly prevented by 
pharmacological Bid inhibition (Figure 14 A). Notably, tBid-toxicity was similarly effective as 
CCCP treatment (Figure 14 B), while pre-treatment of cells with BI-6c9 significantly restored 
Δψm almost to control levels (Figure 14 B).  
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Figure 13: tBid-induced cell death in HT-22 cells. 
HT-22 cells were cultured in 24-well plates at densities of 40,000; 50,000; 60,000 and 70,000 cells per well and 
transfected with a tBid-encoding plasmid (pIRES-tBid) 24 h after seeding. Transfection of cells with an empty 
vector (pcDNA3.1+) was used as control. Vehicle cells were treated only with the transfection reagent attractene. 
20-24 h after plasmid transfection, tBid-induced toxicity was determined by microscopy (A) and measurements of 
cell viability using the MTT assay (B). A, tBid-induced cell death is detectable by typical alterations in cell 
morphology of HT-22 cells, indicated by rounded and shrunken cells detached from the bottom of the cell culture 
plate, as shown by photomicrographs (10 x 0.25 NA objective). Of note, sensitivity of HT-22 cells to tBid-induced 
toxicity depends on the cell density. Cells seeded at density of 40,000 cells per well are more sensitive against 
tBid-over-expression than cultures of ≥ 50,000 cells. Cells seeded at a density of 70,000 cells per well show 
almost complete confluent growth and are not responding to tBid-over-expression. B, MTT assay reveals, that 
tBid over-expression reduces cell viability of HT-22 cells up to 74 % compared to control cells depending on the 
cell density. The experiments were repeated three times with n = 4 per treatment condition and the results 
provided as mean ± SD, (***p < 0.001 compared to vehicle controls, ANOVA, Scheffé’s test). 
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Figure 14: tBid-induced loss of Δψm is prevented by BI-6c9 
Mitochondrial membrane potential was analyzed by FACS recordings of HT-cells stained with MitoPT
TM
 TMRE 
dye and transfected with a tBid-encoding plasmid. A, Eighteen hours after tBid over-expression a remarkable 
breakdown of mitochondrial membrane potential (Δψm) was detectable, indicated by a significant drop of red 
fluorescence up to 40 % of control cells. Pre-treatment (1 h before tBid transfection) of cells with BI-6c9 (10 µM) 
prevents tBid-induced loss of Δψm. Numbers are mean percentages ± SD with n = 4 per treatment group, 
indicating loss of Δψm (left side) or intact Δψm (right side). Pictures are representatives of at least three 
independent experiments. B, Quantification of TMRE fluorescence confirms, that tBid over-expression decreases 
mitochondrial membrane potential, which was restored by BI-6c9 (10 µM) pretreatment. tBid over-expression was 
almost as effective as the positive damage-control CCCP, which causes a fast breakdown of the mitochondrial 
membrane potential. The experiments were repeated at least three times with n = 4 and data presented as mean 
± SD (***p < 0.001 compared to tBid-transfected vehicle, ANOVA, Scheffé’s test). 
 
The presented data fortify the current model of glutamate- and tBid-induced cell death in the 
HT-22 cell line as suitable model systems to screen newly-synthesized compounds for their 
ability to prevent Bid-mediated cell death. Since BI-6c9 was shown to target and inhibit Bid 
and provided a sustained protection against several hallmarks of neuronal intrinsic cell death 
pathways, the Bid inhibitor was used as a positive control for neuroprotection throughout the 
following experiments and was always applied at a concentration of 10 µM as shown before 
to provide 100 % protection (Figure 12). 
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3.1.3 Synthesis strategy for development of novel small Bid inhibitors 
The data above point to the pivotal role of Bid in the regulation of intrinsic neuronal cell death 
pathways that are relevant also in brain injury caused by acute brain damage and 
neurodegenerative diseases63, 97, 114. Major roles of Bid-dependent mitochondrial cell death 
mechanisms were also substantiated in models of cerebral ischemia and traumatic brain 
injury in vivo, thereby encouraging to focus on Bid as a molecular drug target for the 
development of novel small molecule Bid inhibitors that are needed for treatment of 
pathologies associated with mitochondrial demise and neuronal dysfunction.  
As mentioned before, the Bid inhibitor BI-6c9 was discovered as one of the first small Bid-
targeting molecules. The structure of BI-6c9 (5) was derived by Becattini et al. through 
combinations of the Bid-binding fragments BI-2A7 (1) and BI-2A1 (3) and described as the 
compound with the most active binding to Bid (Figure 4)99, 114. Despite the promising 
neuroprotective properties of this available Bid inhibitor BI-6c9 in vitro, it failed, however, in 
model systems of neuronal degeneration in vivo. Possible reasons for the lack of efficacy in 
vivo are limited affinity to the target and/or a poor bioavailability. It should be noted, that a 
major disadvantage of BI-6c9 is based on the poor solubility limiting its application to cell 
culture models, as it is only soluble in serum-containing medium or in high DMSO 
concentrations. Therefore BI-6c9 was chosen as a template for further development of 
structurally novel small-molecules aiming to provide protection against neurotoxic insults by 
targeting the pro-apoptotic protein Bid. Key structural elements of BI-6c9 were identified by 
the chemical department using ligand-based virtual screening and are depicted in Figure 15 
(marked in red). Chemical modifications based on the structure of BI-6c9 resulted in three 
structurally diverse classes of small-molecule compounds, namely N-aryl substituted 
phenoxyanilines, N-phenyl substituted thiazolidine-2,4-diones and N-aryl substituted 
pyrazolopyrimidindiones (Figure 15). The former two chemical structure classes were 
synthetically optimized, yielding in approximately 120 small chemical compounds that were 
screened in this thesis for their ability to provide neuroprotection, with the aim to identify 
novel highly potent Bid inhibitors suitable for applications in model systems of brain damage 
in vivo.  
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Figure 15: Synthesis strategy for development of novel Bid inhibitors 
Key structural elements of the available Bid inhibitor BI-6c9, marked in red, were identified by ligand-based virtual 
screening, which was performed by S. Glinca (Pharmaceutical Chemistry, University of Marburg, Marburg, 
Germany). By replacement of pharmacophors and reduction of the molecular structure of BI-6c9, three 
structurally diverse classes of compounds were developed, one of which was synthetically optimized. Syntheses 
of novel compounds were performed by the group of Prof. Schlitzer (Pharmaceutical Chemistry, University of 
Marburg, Marburg, Germany). 
 
The following chapters reveal the development of the most promising compounds and focus 
on their protective properties in the respective screening assays. Depicted results of 
functional analysis of the compounds effects on cell viability, proliferation and mitochondrial 
function are only a few examples and represent the most potent compounds for the 
respective class.   
In general, all newly synthesized structures were initially screened for their protective effects 
in the model of glutamate-toxicity in HT-22 cells. Therefore, the compounds were applied to 
the cells in concentration ranges of 1 µM up to 100 µM and analyzed in the presence and 
absence of toxic glutamate levels (3-5 mM). After 14-16 h treatment, cell viability of HT-22 
cells was determined by the MTT assay. The neuroprotective properties of the most 
promising compounds were additionally confirmed by real-time analysis of cell impedance 
using the xCELLigence system (Roche). In order to investigate the intended interference of 
the synthesized compounds with the pro-apoptotic activities of Bid, the protective efficiency 
of the target molecules was further examined in the described model of Bid-induced toxicity 
in the present neuronal cell line. Most potent compounds were further analyzed for their 
ability to prevent glutamate-induced Bid-mediated impairments in mitochondrial integrity 
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and function. Results of the initial screening (MTT assay) of all synthesized and tested 
compounds as well as their chemical structures are provided in Table 67-Table 70 
(appendix).  
Chemical syntheses of all novel compounds were performed by the group of Prof. Schlitzer 
(Dept. Pharmaceutical Chemistry, University of Marburg, Marburg, Germany).  MTT assays 
of the first screening in the glutamate-toxicity model were kindly supported by Katharina 
Elsässer.  
 
3.1.4 N-acyl derivatives of 4-phenoxyaniline as neuroprotective agents 
The development of alternative Bid-inhibitors was based on the structure of BI-6c9 (5) 
identified above as the potential Bid-targeting compound. Since structural analogues of BI-
6c9 (5), having a similar molecular size, revealed no protective activities in the model of 
glutamate toxicity, further structure modifications were based on a fragment similar to BI-2A7 
(1). This fragment (1) was shown to reduce Bid-mediated Smac/DIABLO release and chosen 
by Becattini et al. as a scaffold for their inhibitors99, 114. The first synthetic modification of BI-
2A7 (1) was the replacement of the metabolically unstable 4-(4-aminophenyl)sulfanylaniline 
substructure by simple 4-phenoxyaniline (6) (Figure 16).  
 
 
 
Figure 16: Structures of fragment BI-2A7 and the replacement 4-phenoxyaniline. 
Based on the fragment BI-2A7
99
 (1), the metabolically unstable 4-(4-aminophenyl)sulfanylaniline substructure was 
replaced by simple 4-phenoxyaniline (6). Synthesis of compound 6 was performed by the group of Prof Schlitzer 
(Pharmaceutical Chemistry, University of Marburg, Marburg, Germany). 
 
Further modifications were aimed at avoiding structure toxicity. Therefore the second amino 
group of compound 6 was omitted since 4-(4-aminophenoxy)aniline is known to be highly 
toxic201. Thus, the subsequent development included the enlargement of compound 6 by 
acylation of the aromatic amino group of the 4-phenoxyaniline with small acyl residues 
addressing the remaining areas of the presumed inhibitor binding site. Following this 
synthesis strategy 32 N-acyl-4-phenoxyaniline derivatives were generated by the chemistry 
department (group of Prof Dr Schlitzer) and screened in this thesis to prevent Bid-mediated 
neuronal cell death.  
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Table 62 depicts the chemical structure and the neuroprotective activities of representative 
compounds obtained within this development. Further derivatives and their screening results 
are provided in appendix Table 67 and Table 68. 
 
        
Table 62: Neuroprotective properties of N-acyl phenoxyanilines. 
Chemical structures and neuroprotective activities of representative N-acyl 4-phenoxyanilines against glutamate-
induced toxicity as achieved by the first screening and determined by MTT assay. Results are representatives of 
3-8 independent experiments each with n = 8 (*p < 0.05; ** < p 0.01; *** p < 0.001 compared to glutamate treated 
controls, ANOVA Scheffé´s test; N/A
α
, not active: compound revealed no toxic effects in HT-22 cells at 
concentrations from 1 µM up to 100 µM). 
 
3.1.4.1 Neuroprotective activity of N-acyl phenoxyanilines in the model of 
glutamate-induced cell death 
The first screening of compound 6 in the model of glutamate-induced toxicity affirmed the 
hypothesis that the 4-phenoxyanilin is a potent scaffold for further structure optimizations. 
Photomicrographs of HT-22 cells treated with 20 µM of compound 6 in the presence and 
absence of toxic glutamate solution revealed its ability to prevent the phenotype of 
glutamate-induced cytotoxicity (Figure 17 A). MTT assay confirmed the considerable 
neuroprotective activity of compound 6 against glutamate-induced toxicity (Figure 17 B). Cell 
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viability of glutamate-treated HT-22 cells was significantly reduced up to 20% compared to 
un-treated control cells, whereas co-treatment of cells with compound 6 in concentration 
ranges of 10 µM up to 50 µM preserved cell viability 15 h after glutamate exposure (Figure 
17 B).  
 
Figure 17: Neuroprotective activity of compound 6 in HT-22 cells exposed to glutamate. 
HT-22 cells were co-treated with SCHL 28001 (6) in application ranges of 10 µM up to 50 µM and toxic glutamate 
solution (3 mM). BI-6C9 was applied at 10 µM and used as a positive control for neuroprotection. DMSO was 
applied to cells as a solvent control. A, Photomicrographs (10 x 0.25 NA objective) show protective effects of 
compound 6 (20 µM) against glutamate-induced morphological changes of HT-22 cells. B, 16 h after treatment, 
cell viability of HT-22 cells was determined by MTT assay. Compound 6 significantly prevents glutamate-induced 
cell death in concentrations of 20 µM to 50 µM. Data are normalized to untreated control (100% cell viability). The 
experiment was independently repeated at least three times with n = 8 per treatment condition. Data are predicted 
as mean ± SD (*p < 0.05, ***p < 0.001 compared to glutamate treated vehicle, ANOVA, Scheffé`s test).  
 
To investigate the compound`s ability to provide neuroprotection in low concentrations and 
additionally to examine if large doses cause toxic effects, all substances were further 
screened in concentration ranges from 1 µM up to 100 µM. Structure-activity relationships 
that were derived from the first screening results suggested that high structure flexibility, 
accompanied for example with long side chains (compound 7), might hamper the binding of 
the compounds to the target protein Bid. Therefore, more rigid 4-phenoxyanilines derivatives, 
with a terminal nitrogen incorporated in a cyclic system, were investigated in the following. 
The most potent compounds emerged from these developments were compound 8 and 9, 
which significantly prevented glutamate-induced toxicity of HT-22 cells. While compound 8 
revealed significant protective effects at concentrations as low as 1 µM, sufficient protection 
by compound 9 was achieved at concentrations of 10 µM and higher as determined by MTT 
assay (Figure 18 A, B). Of note, both compounds caused slightly toxic effects under control 
conditions, when applied at high concentrations of 100 µM, although a protection against 
glutamate-toxicity was still detectable (Figure 18 A, B). 
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Figure 18: Neuroprotective activities of compounds 8 and 9 against glutamate-induced cell 
death. 
MTT assay reveals neuroprotective properties of the SCHL 24519 (8) (A) and SCHL 24543 (9) (B) against 
glutamate-induced cell death in a concentration-dependent manner and predicts slightly toxic effect of 
compounds in applications of 100 µM. HT-22 cells were treated with compound 8 and 9 in concentrations of 1 µM 
up to 100 µM as indicated, or BI-6C9 (10 µM) in the presence or absence of glutamate (3 mM). A DMSO 
treatment was used as solvent control. Cell viability was analyzed by MTT assay 14.5 h after glutamate exposure. 
The presented data are normalized to untreated control. For statistical analysis, the experiments were repeated at 
least 6 times with n = 8 and results presented as mean ± SD (#p < 0.05 compared to untreated controls, 
***p < 0.001 compared to glutamate treated vehicle, ANOVA, Scheffé`s test). 
 
Based on these results, compound 8 was used for further investigations resulting in a series 
of 4-piperidin carboxylic acid derivatives and identifying an important role of the terminal 
amino moiety and the rigidity of the piperidin as critically involved in the positioning and 
interaction with the Bid protein (Table 67). In a last series, N-alkylated substances were 
synthesized, revealing the apparent trend that neuroprotective activity is increased by short 
hydrophilic chains, possibly due to specific interactions via hydrogen bonds with the terminal 
Asp195 of Bid. 
For example, compound 11, containing a terminal hydrophilic chain, significantly provided 
protection against glutamate-induced cell death at concentrations of 1 µM up to 100 µM, 
although slightly toxic effects were observed at concentrations of 100 µM (Figure 19). 
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Figure 19: Compound 11 provides neuroprotection against glutamate-induced cell death. 
SCHL 24521 (11) was screened for its ability to prevent glutamate-induced cell death in HT-22 cells. Cell viability 
of HT-22 cells was determined by MTT assay 14.5 h after treatment of cells with compound 11 in application 
ranges of 1 µM up to 100 µM as indicated. The Bid inhibitor BI-6C9 (10 µM) was used as positive control for 
neuroprotection. Compound 11 provides strongest protection against glutamate-induced cell death at 
concentrations of 25 µM. The experiment was independently repeated at least 4 times and data are provided as 
mean ± SD (###p < 0.001 compared to untreated controls, ***p < 0.001 compared to glutamate treated vehicle, 
ANOVA, Scheffé`s test). 
 
As compound 8, 9 and 11 were identified as the most potent structures obtained from the 
series of N-acyl-phenoxyanilines, they were subjected to further analyses in order to gain 
more insight into their neuroprotective effects and their ability to specifically target Bid.   
Therefore, molecular docking analyses of the compounds into the three-dimensional 
structure of Bid (PDB code 1DDB) were kindly performed by Dr Wegscheid-Gerlach 
(Pharmaceutical Chemistry, University of Marburg, Marburg, Germany). Virtual docking 
solutions of compound 8 (Figure 20 A) and compound 11 (Figure 20 C) into a deeply buried 
pocket of the Bid protein show that the inhibitors fit nicely into the presumed binding site 
(Figure 20) and reveal for both compounds a possible interaction between the C-terminal 
Asp195 of Bid and the terminal basic amino function of compound 8 and accordingly the 
terminal hydroxyl group of compound 11, possibly by forming a salt bridge (Figure 20 B, D).  
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Figure 20: Molecular docking of compounds 8 and 11 into the 3D-structure of Bid. 
A, C, Molecular docking of compound 8 (A) and compound 11 (C) into the three-dimensional structure of Bid 
(PDB code 1DDB). The compounds fit into the hydrophobic crevice on the surface of Bid. The solvent-accessible 
surface of Bid is represented with formal charges (red negative; blue positive). For the inhibitor compounds the 
carbon atoms are shown in grey, oxygen in red and nitrogen in blue. B, D, 2D-representation of the docking 
solutions of compound 8 (B) and compound 11 (D) and the suggested interactions with amino acids of Bid shown 
in green. Docking analyses were kindly performed by Dr. Wegscheid-Gerlach (Pharmaceutical Chemistry, 
University of Marburg, Marburg, Germany). 
 
For a better evaluation of the compounds’ potency to achieve neuroprotection and to 
distinguish between transient and persistent effects of the individual structures, the most 
potent compounds 8 and 11 were investigated by real-time analysis of cell impedance using 
the xCELLigence system. In accordance with our findings determined by MTT assay, 
treatment of cells with compound 8 or compound 11 restored cell proliferation and viability in 
a concentration-dependent manner, indicated by the prevention of the glutamate-induced 
decline of NCI (Figure 21 A, B). While both compounds provided only transient protective 
effects at concentrations of 1 µM and 10 µM, a sustained protection over approximately 10 h 
was achieved by adding compound 8 at concentrations of 50 µM (Figure 21 A). In 
comparison, compound 11 provided almost persistent protection even at lower 
concentrations of 25 µM, while higher concentrations of 50 µM decreased cell proliferation 
even though a complete breakdown of NCI was still prevented (Figure 21 B). These data 
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confirm that the glutamate-induced loss of NCI and cell death can be prevented by N-acyl-
phenoxyanilines derivatives in a concentration-dependent manner, and further accentuate 
real-time monitoring of the glutamate-induced cytotoxicity as a useful tool to generate 
compound-specific profiles allowing to modulate the effective time window of the 
neuroprotective compounds.  
 
 
Figure 21: Real-time detection of cellular impedance confirms neuroprotective properties of N-
acyl-phenoxyanilines. 
Cell proliferation of HT-22 cells was monitored for 24 h before treatment (0 h). Compound 8 (A) and 11 (B) were 
applied to cells at concentrations of 1 µM up to 50 µM, as indicated, in the presence and absence of 3 mM 
glutamate. BI-6C9 was applied at 10 µM and used as positive control for persistent protection. Cellular impedance 
was continuously monitored using the xCELLigence systeme (Roche) for another 16-18 h after treatment. Cell 
index was normalized at 0 h (treatment-time). NCI of HT-22 cells revealed reduction of cell viability around 4-6 h 
after glutamate treatment. Compounds 8 and 11 provided a dose-dependent transient protection against 
glutamate-induced toxicity. Results are predicted as mean ± SD with n = 8 per treatment group. The experiments 
were independently repeated at least three times. 
 
3.1.4.2 Specificity of 4-phenoxyaniline scaffolds against tBid-induced toxicity 
Although the glutamate-induced oxidative cell death has been linked to Bid transactivation to 
mitochondria, Bid-mediated breakdown of Δψm and subsequent release of AIF and 
Smac/DIABLO97, 99, 202 as described above, and the delayed neuronal cell death, occurring in 
a constant and small time window as shown by the xCELLigence measurements (Figure 21), 
is well correlated with time frames of glutamate-induced Bid translocation to mitochondria97, it 
is not mandatory, that the protective effects of compounds in this glutamate-toxicity model 
are mediated by the specific inhibition of the pro-apoptotic protein Bid. Even though the 
targeting of Bid was suggested by the docking analysis (Figure 20), the specificity of the 
N-acyl-phenoxyanilines to inhibit Bid, had to be confirmed in a further study.  
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Therefore, the molecules were further screened in HT-22 cells transfected with a tBid-
encoding plasmid (Figure 22). As shown above (Figure 13), over-expression of Bid resulted 
in characteristic alterations in cell morphology (Figure 22, pIRES-tBid). In contrast, 
application of compound 8 (10 µM), compound 9 (10 µM) or compound 11 (10 µM) 1 h 
before tBid-transfection clearly preserved the spindle shaped morphology of cells 
comparable to control conditions (Figure 22 A). In addition, MTT assay confirmed that cells 
pre-treated with the compounds 8, 9 or 11 at concentrations of 10 µM were significantly 
protected from tBid-induced cell death (Figure 22 B, C, D).  
Furthermore, the model of tBid-induced toxicity was used for cellular dose-response studies. 
Pre-treatment of cells with the compounds at concentrations as low as 1 µM attenuated tBid-
induced cell death to a slightly lesser extent as revealed for concentrations of 10 µM (Figure 
23), while at concentrations higher than 40 µM the compounds showed toxic effects in this 
cell death model. Figure 24 represents an example of the toxic effect of compound 8, 9 and 
11 obtained in application ranges of 50 µM. Applying high doses of the compounds under 
control conditions caused a severe cytotoxic damage of HT-22 cells as shown by 
photomicrographs (Figure 24 A) and thereby a reduction of cell viability as determined by 
MTT assay (Figure 24 B). Similar toxic results were detected for all three compounds applied 
in doses ranges from 40 µM up to 100 µM. Overall, the protective activities of the N-acyl-
phenoxyanilines against tBid-mediated toxicity at concentrations lower than 10 µM strongly 
indicate the compounds specific mode of action and confirm their ability to target and inhibit 
Bid 
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Figure 22: Neuroprotective activities of N-acyl-phenoxyanilines against tBid-induced neuronal 
cell death. 
HT-22 cells were pre-treated with novel compounds 1 h before transfection with a tBid-encoding plasmid (pIRES-
tBid). 20-22 h after tBid over-expression cell morphology (A) was analyzed by microscopy and cell viability (B, C, 
D) was determined by MTT assay. Novel compounds were applied at concentrations of 10 µM and BI-6C9 
(10 µM) was used as a positive control for prevention of tBid-induced toxicity. A, tBid over-expression induces 
typical changes in cell morphology, while compounds 8, 9, 11 preserved spindle shaped cell morphology as 
shown by photomicrographs (10 x 0.25 NA objective). B, C, D, Cell viability was quantified by MTT assay, 
confirming the compounds ability to prevent tBid-induced toxicity (B; SCHL 24519 (8), C; SCHL 24543 (9), D; 
SCHL 24521 (11)). The presented data are normalized to un-transfected controls (100% cell viability). The 
experiments were independently repeated at least three times with n = 3 per treatment condition. Results are 
predicted as mean ± SD (***p < 0.001 compared to tBid-transfected vehicle, ANOVA, Scheffé`s test). 
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Figure 23: N-acyl-phenoxyanilines provide slightly protective effects against tBid-induced 
toxicity in low concentrations as 1 µM. 
MTT assay was used to determine protective effects of compound 8, 9 and compound 11 at low concentrations of 
1 µM. HT-22 cells were pre-treated with 1 µM of each compounds 1 h prior to tBid transfection. Cell viability was 
analyzed 20-24 h after tBid over-expression. All compounds show moderate protection against tBid-induced cell 
death. The experiments are representatives of 3-6 experiments with n = 3 per treatment condition. Data are 
presented as mean ± SD (***p < 0.001 compared to tBid-transfected vehicle, ANOVA, Scheffé`s test). 
 
 
Figure 24: Concentration-dependent toxic effects of N-acyl-phenoxyanilines 
HT-22 cells were pre-treated with novel compounds 1 h before transfection with a tBid-encoding plasmid (pIRES-
tBid). 20-22 h after tBid over-expression cell morphology (A) was analyzed by microscopy and cell viability (B, C, 
D) was determined by MTT assay. For analysis of doses limitations, novel compounds were applied at 
concentrations of 50 µM. A, Photomicrographs (10 x 0.25 NA objective) reveal cytotoxic effects of the compounds 
8, 9, 11 when applied to HT-22 cells at concentrations of 50 µM compared to un-treated control cells. Cells 
treated with high doses of the compounds show already typical cell death features without tBid over-expression. 
B, C, D, Cell viability was quantified by MTT assay, which confirms the concentration-dependent toxicity, thereby 
doses limitations of the applied compounds (B; SCHL 24519 (8), C; SCHL 24543 (9), D; SCHL 24521 (11). 
Compound 9 was still slightly protective against tBid-induced toxicity, while compound 8 and compound 11 reveal 
no protective activity in concentrations of 50 µM. Similar results were obtained by compound treatment in 
concentrations of 40 µM and 100 µM. The presented data are representatives for compound-toxicity studies. The 
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experiments were independently repeated at least three times with n = 3 per treatment condition (*p < 0.05 
compared to tBid-transfected vehicle, ###p < 0.001 compared to un-transfected control, ANOVA, Scheffé`s test). 
 
In conclusion, these data predict a novel type of neuroprotective agents based on a 
4-phenoxyaniline scaffold, and displayed significant neuroprotective activities of the 
compounds at concentrations as low as 1 µM. The results, obtained from the docking of the 
molecules into the three-dimensional structure of Bid, and more considerable the findings 
emerged from the compound-screening in the model of tBid-induced toxicity indicated that 
these small-molecule agents indeed target the Bid protein and represent a significant step in 
the ongoing development of therapeutically useful neuroprotective agents.  
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3.1.5 N-phenyl substituted thiazolidindiones provide protection against tBid-
mediated cell death pathways 
Upon the basis of the promising neuroprotective effects achieved by the N-aryl substituted 
phenoxyanilines, presented above, structural optimizations were continued resulting in a 
series of N-phenyl substituted thiazolidinedions, which are presented in the following.  
These optimizations were again accorded to the lead compound BI-6c9 (5) and further 
advanced based on the N-propionyl-derivative of p-phenoxyaniline (12). In order to reduce 
the conformational flexibility and thereby to enhance the binding affinity to the target Bid, the 
acylamid partial structure of 12 was incorporated into a thiazolidine-2,4-dione (13) (Figure 
25), giving the core structure of about 36 novel compounds depicted in Table 69.  
 
Figure 25: Development of thiazolidine-2,4-dione structure 13 based on the structure of BI-6C9 
(5). 
Based on the structure of BI-6c9 (5), the N-propionyl-derivate of 4-phenoxyaniline (12) was synthesized. The 
acrylamide partial structure of compound 12 was incorporated into a thiazolidine-2,4-dione (13), concurrently 
reducing the conformational flexibility. Structure syntheses and estimation of structure-activity relationships were 
performed by the group of Prof Schlitzer (Pharmaceutical Chemistry, University of Marburg, Marburg, Germany). 
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3.1.5.1 N-phenyl substituted thiazolidinediones provide neuroprotection 
against glutamate-induced toxicity 
To investigate the protective and toxic properties of this compound class, the thiazolidine-
2,4-diones were subjected to the first screening approach using the present model of 
glutamate-induced toxicity. All substances were applied in concentration ranges of 0.1 µM up 
to 50 µM and cell viability of HT-22 cells was determined 14 h after co-treatment with 3 mM 
glutamate solution. Table 63 depicts the results of representative structures of the N-phenyl 
substituted thiazolidinediones (all provided in appendix Table 69), which will be characterized 
more in detail in this chapter. 
 
Table 63: Neuroprotective properties of N-phenyl substituted thiazolidinediones. 
Chemical structures of newly synthesized compounds are shown. Neuroprotective activity of the compounds 
against glutamate-toxicity in HT-22 cells was determined within the first screening approach by MTT assay. EC50 
are given as the mean drug concentration required for inhibiting cell death by 50 % compared to controls. Toxicity 
values indicate toxic drug concentrations found to induce cell death without co-treatment with glutamate. (***p < 
0.001 compared to glutamate treated control, ANOVA Scheffé´s test; N/A
α
, not active – substance revealed no 
toxic properties at concentrations of 0.1 µM up to 100 µM; N/D
β
, not determinable – EC50 values could not be 
Results | 119 
 
 
 
calculated due to lack of protective effects. The results presented are representatives of 4-6 independent 
experiments (MTT assay). 
 
Notably, the first screening set up, examining substance concentrations between 10 µM and 
50 µM, revealed maximal neuroprotection for most of the compounds at a concentration of 
20 µM, while concentrations higher than 30 µM and up to 50 µM could not further increase 
the protective properties (Figure 26) 
 
 
Figure 26: N- phenyl substituted thiazolidinediones provide maximal neuroprotection at 
concentrations of 20 µM and higher. 
Initially all thiazolidindiones were analyzed by their ability to prevent glutamate-induced cell death in 
concentrations of 10 µM up to 50 µM. HT-22 cells were cultured in 96-well plates with 10.000 cells per well and 
cell viability was determined 14 h after co-treatment with glutamate (3 mM) and novel compounds. BI-6C9 
(10 µM) was used as a positive control for neuroprotection. SCHL 24277 (14) (A), SCHL 24213 (15) (B) as well 
as SCHL 24292 (16) (C) reveal maximum protective effects against glutamate- induced toxicity at concentrations 
of 20 µM and higher. The presented data are normalized to un-treated controls. For statistical analysis, the 
experiments were independently repeated at least three times with an n = 8 per treatment condition. Results are 
presented as mean ± SD (***p < 0.001 compared to glutamate- treated control (vehicle), ANOVA, Scheffé´s test). 
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In order to examine the doses required to achieve maximal protection, thiazolidine-2,4-
diones were further tested in concentration ranges between 0.1 µM and up to 10 µM, and the 
concentration of 50 µM was set as steady state dose providing 100 % protection. Figure 27 
shows the protective effects of three representative 3-aryl substituted thiazolidinedione 
derivatives, which significantly preserved cell viability of glutamate-treated HT-22 neurons in 
a concentration-dependent manner between 5 µM up to 50 µM (Figure 27 A, C, E). 
Impressively, the compounds 14, 15 and 16 achieved full protection against glutamate-
induced toxicity at concentrations higher than 20 µM (Figure 27 A, C, E). This pronounced 
protective effect was comparable to the protective effect of the available Bid inhibitor BI-6C9 
(10 µM) that was always applied in the screening experiments as a reference for maximal 
protection in this cell death model. Importantly, treatment of cells with the newly synthesized 
substances alone revealed no toxic effects in concentrations up to 50 µM (Figure 26 A, B, C 
and Figure 27 A, C, E). Similar results were obtained for further synthesized thiazolodin-2,4-
diones depicted in appendix Table 69. 
To further compare the neuroprotective potency of all tested compounds, half maximal 
effective concentrations (EC50) were calculated from the cell viability data at the applied 
concentration ranges. Since the MTT data revealed full protective effects of the compounds 
at concentrations of 50 µM (positive control for highest protection), cell viability data were 
normalized between 0 % for glutamate only treated cells (vehicle) to 100 % protection at 
50 µM and concentration-response curves were fitted with a sigmoid function (Dose 
Response Fit). Concentration-response curves for compound 14, 15 and 16, which represent 
highest therapeutic potency within the series of thiazolidin-2,4-diones, are shown in Figure 
27 (Figure 27 B, D, F) and calculated EC50 values of all structures are provided in Table 63 
and Table 69. The EC50 values calculated for the newly synthesized thiazolidinediones were 
almost as good as the EC50 value obtained for BI-6c9 (Figure 12).  
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Figure 27: N-Phenyl substituted thiazolidinediones provide neuroprotection against glutamate-
induced toxicity. 
MTT assay was used to determine cell viability of HT-22 cells 14 h after co-treatment with glutamate (3 mM) and 
respective small molecules in different concentrations from 0.1 µM to 50 µM. BI-6C9 (10 µM) was used as a 
positive control for neuroprotection. SCHL24277 (14) (A), SCHL 24213 (15) (C) and SCHL 24292 (16) (E) 
attenuates glutamate-induced toxicity in a concentration-dependent manner. For statistical analyses, experiments 
were independently repeated at least three times with an n = 8 per treatment condition. Results are presented as 
mean ± SD (***p < 0.001 compared to glutamate-treated control (vehicle), ANOVA, Scheffé´s test). B, D, F, 
Based on this data concentration-response curves and EC50 values were calculated for each substance. Cell 
viability data were fitted from 0 for glutamate-treated control (vehicle) to 100 for highest protection at 50 µM and 
dose response fits for compound 14 (B), 15 (D) and 16 (F) are shown. 
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As described for the N-aryl substituted phenoxyanilines above, real time analysis of cell 
impedance (xCELLigence) were reapplied in order to substantiate the neuroprotective 
properties of the N-phenyl substituted thiazolidinediones that were determined by MTT assay 
(Figure 28). While cellular impedance significantly decreased in cell populations exposed to 
glutamate (3 mM) 5 h to 8 h after treatment, NCI was fully preserved to control levels by co-
treating the cells with glutamate (3 mM) and compounds 16, 14, or 15 at a concentration of 
50 µM, respectively (Figure 28 A-C). Compound 16 and 15 revealed transient 
neuroprotection at concentrations of 5 µM, 10 µM and 25 µM (15) while a sustained 
protection over time was revealed at concentrations of 50 µM (Figure 28 B, C). Similarly, 
compound (14) was only transiently protective at concentrations lower than 5 µM, but 
attenuated the complete decline of NCI already at concentrations of 10 µM, although not to 
levels of control cells. However, persistent neuroprotection against glutamate-induced toxicity 
was achieved at a concentration of 50 µM (Figure 28 A). Concluded, these RTCA-
measurements could not only confirm the findings detected by MTT assay, but further 
provided a better estimation of the protective potential of the novel small-molecules.  
 
 
Figure 28: Real time monitoring of cell impedance confirms concentration-dependent 
neuroprotection mediated by thiazolidindiones.  
The indicated cell groups were co-treated with glutamate (3 mM) and the novel compounds SCHL24277 (14) (A), 
SCHL 24213 (15) (B) and SCHL 24292 (16) (C) in concentrations of 1 µM to 50 µM. Cellular impedance was 
continuously monitored by the xCELLigence system (Roche) and cell index was normalized at 0 h (treatment 
time-point). Co-treatment with glutamate and BI-6C9 (10 µM) was used as a positive control for persistent 
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protection. Each compound revealed a dose-dependent transient protection at concentrations from 10 µM to 
25 µM yet a sustained protection over time at 50 µM. Results are provided as mean ± SD with n = 8 per treatment 
group. All experiments were independently repeated three times. 
 
3.1.5.2 Specificity of the thiazolidinediones 
3.1.5.2.1 N-phenyl substituted thiazolidinediones target Bid to prevent cell death in 
HT-22 cells 
To investigate the compound`s ability to target Bid, the role of the newly developed N-phenyl 
substituted thiazolidinediones was examined in the current tBid-mediated cell death model 
(see 3.3.5). 
Compound 14, compound 15 and compound 16, as representatives of the thiazolidinediones, 
clearly attenuated tBid-induced cell damage and morphologic shape changes already at low 
concentrations of 1 µM (Figure 29 A), and significantly prevented the tBid-induced reduction 
in cell viability of HT-22 cells assessed by the MTT assay (Figure 29 B, C, D). Similar results 
were observed pre-treating the cells with the indicated compounds at higher concentrations 
of 10 µM and 50 µM, while, in contrast to the N-aryl phenoxyanilines, no toxic effects of the 
thiazolidine-2,4-diones were detected when applied under control conditions (data not 
shown). These findings show that the new N-phenyl substituted thiazolidinedione compounds 
are able to rescue HT-22 cells after tBid-over-expression thereby providing strong evidence 
that the newly synthesized compounds indeed provided neuroprotection by targeting the pro-
apoptotic protein Bid. 
The compound´s ability to specifically inhibit Bid was further confirmed by virtual docking 
analysis into the three-dimensional structure of Bid, kindly performed by Dr Wegscheid-
Gerlach (Pharmaceutical Chemistry, University of Marburg, Marburg, Germany) (Figure 30). 
Thereby a possible binding mode of compound (14), which revealed the highest protective 
potency (EC50 = 6.78), was derived: the thiazolidinedione moiety points into a deeply buried 
pocket on the surface of Bid, like BI-6C9, and allows interactions with the amino acids VAL 
186 and ILE86 of Bid. Further, a hydrophobic interaction between the aromatic ring of 
compound 14 with the side chain of TYR 185 of Bid is suggested (Figure 30 B) and 
substantiate the intended specific targeting of the Bid protein.  
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Figure 29: N-Phenyl substituted thiazolidinediones attenuate tBid-induced neuronal cell death. 
tBid-induced toxicity was determined 21-23 h after transfection of HT-22 cells with a tBid-encoding plasmid 
(pIRES-tBid). Cell morphology was analyzed by microscopy (A) and cell viability was determined by MTT assay 
(B, C, D) Pre-treatment with the novel compounds SCHL 24277 (14), SCHL 24213 (15) and SCHL 24292 (16) 
(1 µM) was performed 1 h before tBid-transfection. A, Photomicrographs (10 x 0.25 NA objective) show typical 
alterations in cell morphology of HT-22 cells 20 h after tBid over-expression (pIRES-tBid, control). Compound 14, 
15 and 16 preserves cell morphology of HT-22 cells. B, C, D, Quantification of cell viability confirms significant 
protective effects against tBid-induced toxicity mediated by compound 14 (B), compound 15 (C) and 
compound 16 (D).The presented data are representatives of concentration-dependent studies. Similar protective 
effects were obtained when compounds were applied in concentrations of 10 µM and 50 µM. No toxic effects 
were observed. The presented data are normalized to un-transfected control (100% cell viability). For statistical 
analysis, experiments were independently repeated at least three times with n = 3 per treatment condition and 
results are reported as mean ± SD (***p < 0.001 compared to t-Bid treated control cells, ANOVA, Scheffé´s-test).  
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Figure 30: 2D and 3D-representation of the binding mode of compound 13 for inhibition of Bid.  
A, 3D-Docking of SCHL 24277 (14) in the hydrophobic groove of Bid. B, 2D-representation of the docking solution 
of A reveals interaction of compound 14 with VAL186 and ILE86 and TYR185 of Bid. A, B, For the inhibitor 
compound the carbon atoms are shown in gray, oxygen in red, nitrogen blue and sulphur in yellow. The solvent-
accessible surface of Bid is represented with formal charges (red- negative; blue positive). Docking analyses were 
kindly performed by Dr. Wegscheid-Gerlach (Pharmaceutical Chemistry, University of Marburg, Marburg, 
Germany). 
 
3.1.5.3 Thiazolidine-2,4-diones prevent glutamate-induced Bid-mediated 
mitochondrial impairments 
As the protective effects of the N-phenyl substituted thiazolidinediones in the models of 
glutamate- and tBid-induced toxicity were convincing, it should be further investigated 
whether these compounds are also able to prevent impairments in mitochondrial integrity and 
function that are shown to be Bid-dependent and precede the final execution of intrinsic 
caspase-independent cell death24, 58, 63, 97, 98. 
Therefore, the effect of compound 14, 15 and 16 on mitochondrial membrane potential (Δψm) 
was investigated. As described above, glutamate causes a significant drop in red TMRE 
fluorescence, indicating a glutamate-induced loss of Δψm (Figure 31 A, B). In contrast, the 
application of 20 µM of the compounds 14, 15 or 16 did not affect Δψm under control 
conditions, but almost completely attenuated the pronounced breakdown of Δψm after 
glutamate challenge (Figure 31 A, B). The protective effects mediated by the novel 
compounds were comparable to that of the available Bid inhibitor BI-6C9, suggesting that the 
thiazolidinediones preserve Bid translocation to mitochondria thereby maintaining Δψm. To 
further address whether the N-phenyl thiazolidinediones are also able to prevent the 
functional integrity of mitochondria, ATP levels of compound-treated HT-22 cells were 
examined in the presence and absence of glutamate (Figure 31 C). Indeed, the rapid 
depletion in cytoplasmic ATP caused by glutamate-induced cell injury, was completely 
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attenuated by compound 14, 16 and 15, whereas ATP levels of control cells were not altered 
(Figure 31 C). Therefore, these data confirmed at a functional level that the predicted N-
phenyl substituted thiazolidinedione derivatives preserve mitochondrial integrity and energy 
production of glutamate-treated HT-22 cells. 
 
 
Figure 31: N-Phenyl substituted thiazolidinediones preserve mitochondrial integrity and 
function. 
A, Mitochondrial membrane potential (Δψm) was determined by TMRE-FACS recordings. HT-22 cells were treated 
with glutamate (5 mM) alone or co-treated with glutamate (5 mM) and thiazolidinedione derivates (20 µM). Twenty 
hours after treatment, cells were stained with MitoTM
TM
 TMRE dye and red fluorescence of 10,000 cells per 
treatment condition was analyzed. Glutamate-treated cells (vehicle) show significant reduction of red fluorescence 
(loss of Δψm) compared to control vehicle, while SCHL 24277(14), SCHL 24292 (16) and SCHL 24213 (15) 
prevent breakdown of Δψm. Numbers are mean percentages ± SD of TMRE fluorescence of the indicated cell 
groups with n = 3. High red fluorescence indicates intact mitochondria (right side), drop of red fluorescence 
depicts loss of Δψm (left side). Pictures are representatives of three independent experiments. B, Quantification of 
TMRE fluorescence (A) confirms the breakdown of Δψm in glutamate exposed vehicle cells, which is significantly 
prevented by the compounds 14, 16 and 15. The uncoupler CCCP, which causes a fast breakdown of the 
mitochondrial membrane potential, was used as a positive damage-control. The experiment was independently 
repeated four times with n = 3 and data are presented as mean ± SD. C, ATP-levels of HT-22 cells, treated with 
20 µM of the compounds 14, 16 or 15 as indicated, were analyzed in the presence or absence of glutamate 
(5 mM, 20 h) by ATP-luminescence measurements. Compound treatment does not affect basal ATP levels, but 
significantly prevents ATP depletion after glutamate exposure. Experiment was repeated three times with n = 8 
per treatment condition and results are provided as mean ± SD (***p < 0.001 compared to glutamate-treated 
vehicle, ANOVA, Scheffé test (B, C)). 
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Broader insights into the compounds ability to rescue metabolic functions were derived from 
from measurements of oxygen consumption rate (OCR) of intact HT-22 cells, enabling the 
evaluation of mitochondrial bioenergetics and metabolism under conditions that are more 
physiologically realistic compared to isolated mitochondria203. O2-consumption of HT-22 cells 
was analyzed in the presence and absence of glutamate using the Extracellular Flux 
Analyzer (Seahorse Bioscience) designed for the exposure of mitochondria to defined 
substrates and inhibitors to modulate mitochondrial respiration in adherent cells204. In 
accordance with previous studies reporting that glutamate-induced mitochondrial dysfunction 
involves changes in mitochondrial acidification and oxygen consumption205, glutamate 
exposure of HT-22 cells decreased oxygen consumption rate (OCR) indicating a glutamate-
induced reduction in mitochondrial respiration (Figure 32). After recording the basal 
mitochondrial respiration, the ATP synthase inhibitor oligomycin was added to uncouple 
mitochondrial respiration from ATP production. While OCR of control cells was decreased 
after oligomycin injection, glutamate-treated cells responded less to oligomycin, (Figure 32). 
This indicates a glutamate-induced decrease in ATP production, which is in line with the ATP 
luminescence measurements described above. In comparison, OCR measurements similarly 
confirmed the preservation of ATP-generation by the compound 14, 16 and 15 at 
concentrations of 20 µM, respectively and BI-6c9 at concentrations of 10 µM (Figure 32 A till 
B).The further application of the protonophor FCCP increased OCR to a maximum extent 
allowing the examination of the maximum oxygen flux (MOF) and mitochondrial respiratory 
capacity (MRC) of cells. After glutamate treatment both, MOF and MRC were significantly 
decreased, but notably restored by co-treatment of cells with compound 14, 16 and 15 or BI-
6c9 (Figure 32). Finally, the mitochondrial respiratory chain was inhibited by the application 
of the complexes I and III inhibitors, rotenone and antimycin A. While rotenone/antimycin A-
sensitive OCR specifically indicates respiration in mitochondria, rotenone/antimycin A-none-
resistant rate identifies non-mitochondrial respiration203 and allows for calculation of 
mitochondrial maximum respiration. The remarkable reduction in mitochondrial maximum 
respiration in glutamate-treated HT-22 cells was significantly prevented by the compounds 
14, 16 and 15 and the Bid inhibitor BI-6c9 (Figure xx A, B). The ability of BI-6c9 and the 
newly synthesized compounds to prevent the glutamate-induced reduction in mitochondrial 
respiratory capacity and maximum respiration provides additional evidence that inhibition of 
Bid emerges as potential strategy for maintaining mitochondrial metabolic functions. 
In conclusion, the N-phenyl substituted thiazolidinediones rescued metabolic functions and 
maintained energy metabolism in mitochondria of HT-22 cells challenged with glutamate. Of 
note, the fact that the compounds do not affect mitochondrial maximum respiration, providing 
a full protection against respiratory dysfunctions, presumes that all three molecules 
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(compound 14, 15 and 16) act upstream of mitochondria, thereby supporting the hypothesis 
that the protective effects are mediated by inhibiting Bid. 
 
 
Figure 32: N-Phenyl substituted thiazolidinediones preserve mitochondrial respiration 
A-C, Time course of oxygen consumption rate (OCR) in HT-22 cells in the presence and absence of glutamate. 
HT-22 cells were seeded in XF96-well micro plates (Seahorse Bioscience) at a density of 10,000 cells per well 
and treated with glutamate (5 mM) and/ or the indicated thiazolidindiones SCHL 24277 (14) (A), SCHL 24213 
(15) (B), SCHL 24292 (16) (C), or the Bid inhibitor BI-6c9 (D), respectively. Twenty hours after treatment, 
mitochondrial respiration was analyzed using the XF Mito Stress kit and recorded as the rate of OCR by the 
Extracellular Flux Analyzer (Seahorse Bioscience). As controls, Oligomycin (3 µM) was used to inhibit ATP-linked 
OCR, FCCP (0.4 µM) to measure uncoupled respiration and Rotenone/Antimycin (1 µM) to inhibit complex I/III-
dependent respiration. Glutamate exposure of HT-22 cells decreases oxygen consumption rate and thereby 
mitochondrial respiration. Co-treatment of cells with the indicated thiazolidindiones in concentrations of 20 µM 
respectively, restores mitochondrial maximum respiration as well as respiratory capacity. Data were depicted as 
normalized OCR (% baseline rate) for each individual populations of cells and representative of four independent 
experiments, each with n = 8 for all treatment groups, respectively.  
 
In summary, these data demonstrate, that the screened N-phenyl substituted 
thiazolidindiones, showed a pronounced potency against glutamate toxicity and indicate the 
specific inhibition of Bid as the underlying key mechanism of their protective properties. 
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3.1.6 N-aryl substituted pyrazolopyrimidinones promise a novel class of 
neuroprotectants 
Several other small-molecules differing in their chemical structure, size and solubility were 
screened within this thesis revealing variable efficiency in protecting the cells against 
glutamate- and tBid-induced toxicity (appendix Table 70). 
 
 
Table 64: Neuroprotective properties of N-aryl substituted pyrazolopyrimidinone (19) 
Chemical structure of the 1-(4-Aminophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-on is shown. The 
pyrazolopyrimidinone provided significant protection against glutamate-toxicity in HT-22 cells at concentrations of 
25 µM up to 100 µM and revealed no toxic effects as determined by MTT assay  (***p < 0.001 compared to 
glutamate treated control, ANOVA Scheffé´s test; N/A
α
, not active – substance revealed no toxic properties at 
concentrations of 1 µM up to 100 µM). The result presented is a representative of 5 experiments (MTT assay). 
 
It is noteworthy that one compound (19) (Table 64) representing the chemical class of N-aryl 
substituted pyrazolopyrimidindiones emerged as potent neuroprotectant and indicates this 
structure type as promising scaffold for the ongoing development of neuroprotective 
compounds..  
This compound 19 attenuated glutamate-induced cell death of HT-22 cells in a 
concentration-dependent manner from 25 µM up to 100 µM as revealed by MTT assay 
(Figure 33 A) and further confirmed by the RTCA-measurements, showing a transient 
protective effect of compound 19 in concentrations of 30 µM up to 100 µM (Figure 33 B).  
Interestingly, despite this moderate protection against glutamate-toxicity, the compound 19 
was highly potent against tBid-mediated cell injury and provided significant protection already 
at low concentrations of 1 µM (Figure 34). Noteworthy, compound 19 did not reveal toxic 
effects in any of the applied model systems at concentrations up to 100 µM, which is an 
advance of this structure type compared to the N-aryl phenoxyanilines described above.  
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Figure 33: N-aryl substituted pyrazolopyrimidinone protects against glutamate-induced toxicity 
in a concentration dependent manner. 
SCHL 24394 (19) reveals protective effects against glutamate-induced toxicity in a concentration dependent in 
from 1 µM up to 100 µM. A, Cell viability of HT-22 cells was determined by MTT assay 16 h after co-treatment 
with glutamate (3 mM) and compound 19. BI-6C9 (10 µM) was used as a positive control for neuroprotection. 
Substance treatment alone shows no toxic effects and attenuates against glutamate toxicity at concentration of 
25 µM and higher. Results are presented as mean ± SD (***p < 0.001 compared to glutamate- treated control, 
ANOVA, Scheffé´s test). B, Real-time analysis of cellular impedance with the xCELLigence system (Roche) 
confirms the concentration-dependent protective effect of compound 19. While concentrations of 30 µM and 
50 µM obtained only slightly protection, a more pronounced protection is revealed at concentrations of 100 µM. 
Cell index was normalized at 0 h (treatment time-point). Results are provided as mean ± SD with n = 8 per 
treatment group. All experiments were independently repeated three times. 
 
As this compound represents the first structure of the class of N-aryl substituted 
pyrazolopyrimidindiones, further chemical modifications are warranted in order to further 
explore structure-activity relationships of this structure for developing highly potent and 
specific Bid inhibitors that may provide neuroprotection in a low and in vivo applicable 
concentration range.  
In summary, these studies revealed the development and screening of a series of novel 
small-molecules designed to inhibit the pro-apoptotic molecule Bid in neurons. Based on the 
structure of the available Bid inhibitor BI-6c9, three diverse compound classes were 
developed and structurally optimized by the chemistry department (group of Prof Dr 
Schlitzer) in order to explore the structure-activity relationships of the small-molecules 
targeting Bid. Seven compounds, belonging to the class of N-acyl substituted 4-
phenoxyanilines, N-phenyl substituted thiazolidindiones and accordingly N-aryl substituted 
pyrazolopyrimidindiones, were identified as novel small-molecules with promising potential 
for neuroprotection in a range of cellular model systems, including glutamate- as well as tBid-
induced cell injury. Therefore, the compounds presented in this work are not only potent 
scaffolds for future structure optimization resulting in compounds with favorable 
pharmaceutical properties, but might indicate already promising drug candidates for first trials 
in model systems of brain damage in vivo. 
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Figure 34: Compound 19 prevents tBid-induced neuronal cell death. 
tBid-induced toxicity was determined 18-20 h after transfection of HT-22 cells with a tBid-encoding plasmid 
(pIRES-tBid). Compound 19 was applied to cells 1 h before pIRES-tBid-transfection. A, Photomicrographs 
(10 x 0.25 NA objective) reveal the preservation of the spindle-like morphology of HT-22 cells after tBid over-
expression by the application of compound 19 at concentrations of 1 µM up to 100 µM. B, Quantification of cell 
viability by the MTT assay confirms significant protective effects of SCHL 24394 (19) against tBid-induced toxicity, 
while no toxic effects of the compound 19 was observed. For statistical analysis, experiments were independently 
repeated at least three times with n = 3 per treatment condition and results are reported as mean ± SD 
(***p < 0.001 compared to t-Bid treated control cells, ANOVA, Scheffé´s-test). 
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3.2 Expression, purification and crystallization of recombinant Bid 
constructs 
The molecular mechanism by which the pro-apoptotic protein Bid regulates mitochondrial cell 
death pathways, and in particular how Bid mediates impairments in mitochondrial membrane 
integrity and function is still far from being explained. Structural and functional studies are 
required for a more thorough understanding of Bid action, and thereby for the development of 
target-directed perspectives of therapies for neuronal diseases. 
While the first part of this work could already demonstrate promising Bid-targeting 
compounds that provide protection in various approaches of cell death models, the exact 
mechanism of their inhibitory activity remains to be clarified, and further structural 
optimization is required to improve their binding affinities to low nanomolar concentrations. 
The determination of protein-ligand structures and the facilitation of a rational and structure-
guided design of novel compounds that selectively target the protein of interest, Bid, is a 
challenge. The three-dimensional structures of biological macromolecules are not only often 
the key to gaining a deep understanding in the proteins function, but, beyond doubt, they are 
the necessary tool for target-specific drug development. While crystal structures of other Bcl-
2 family proteins, such as Bcl-xl, Mcl-1 or Bax68, 105, 109, 121, 122, provided the basis for the 
design of selective inhibitors, up to now there is no report on a crystal structure determination 
of Bid from any species. In an effort to gain more insights in the structural properties of Bid 
and to explore the binding affinities of novel compounds, the further part of this work includes 
the establishment of a suitable pipeline from construct design and cloning to expression and 
purification of recombinant Bid required for the first Bid crystallization set up.  
The approach of recombinant proteins further aimed at the development and validation of in 
vitro assay systems suitable to address the physical action of Bid on artificial membranes 
(3.3) and to generate a basis for primary screening of small-molecule Bid inhibitors. Lastly, 
purified Bid protein should be used for determining its functional interactions with other 
proteins involved in the mechanisms of intrinsic cell death. 
 
3.2.1 Expression of recombinant full-length Bid and its active form tBid 
The first step towards crystallization is the high-yield expression and purification of the target 
protein. Therefore, full-length mouse Bid as well as its truncated, active form tBid were 
cloned as fusion proteins with a hexa-histidin-tag into the pET15b vector and tested for 
effective expression in Escherichia coli Rosetta2 (DE3).  
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3.2.1.1 High-yield expression of full-length Bid 
To investigate the expression efficiency and solubility of His6-tag full-length Bid, Rosetta2 
(DE3) singles were transformed with the pET15b-Bid 22 vector and grown at 37°C in LB 
medium. When bacterial growth reached an optical density (OD600) of 0.6 AU, protein 
expression was induced by addition of 1 M IPTG solution. Gel-electrophoresis and western 
blot analysis confirmed the effective expression of full-length Bid in E.coli and its recovery in 
the soluble protein fraction (Figure 35 A, B). An increasing 22 kDa Bid-band was detected 
2 h to 6 h after IPTG induction, while no Bid protein appeared at time point 0 and in the 
bacterial overnight culture (control) (Figure 35 B). Notably, large amounts of Bid were already 
produced 2 h after IPTG induction, indicating the protein is suitable for large-scale 
production. In addition, full-length Bid was also found in the membrane-bound protein 
fractions 2 h after expression induction, but in a less amount compared to the soluble 
fractions (Figure 35 C).  
 
 
Figure 35: Effective expression of full length Bid. 
Expression efficiency and solubility of His6-tag full length Bid was analyzed by expression tests in Rosetta2 (DE3). 
A, Coomassie stained SDS-PAGE predicts soluble protein fractions after expression of His6-tag full length Bid in 
Rosetta2 (DE3). Full length Bid is efficiently expressed and recovered in a high amount in the soluble fraction 2 h 
after IPTG expression.  B, Western blot analysis confirms the successful expression of full length Bid recovered in 
the soluble fraction after cell lysis. C, Coomassie stained SDS-PAGE of the membrane-bound proteins after 
expression of His6-tag full length Bid in Rosetta2 (DE3). Bid is predicted after 2 h IPTG induction. Note that the 
amount of Bid protein in the soluble protein fractions is much more pronounced than in the membrane-protein 
fractions.  
As Bid is described as a soluble and cytosolic protein in healthy cells61, the detection of Bid in 
the bacterial membrane fractions (Figure 35 C) might be due to adsorbance of the soluble 
protein to bacterial membranes. Notably, in contrast to the highly effective expression of full-
length Bid, no expression could be detected for the truncated and active form tBid, indicating 
that E. coli. strains avoid the expression of the toxic construct. 
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3.2.2 Purification of full length Bid yields reasonable protein amounts 
For large-scale production and purification of full-length Bid, the His6-tagged protein was 
expressed in E. coli. Rosetta2 (DE3) as described above. The determination of an 
exponential growth curve for E. coli. indicated that the bacterial culture reached an OD600 of 
0.6 AU 4-5 h after growth induction. Therefore, Bid expression was mostly induced 4.5 h 
after inoculating the bacterial overnight culture to fresh LB medium for large-scale protein 
production.  
His6-tagged full-length Bid could be readily purified from raw cell lysates following expression 
and three chromatography steps. The initial purification step was performed manually by 
nickel-affinity chromatograph yielding a protein recovery from the initial purification set of 
7.2 mg per liter bacterial culture, or by Ni-affinity chromatography using the Äkta prime plus 
system, allowing for large-scale purification of volumes up to 25 ml bacterial lysate within one 
purification run (Figure 36). His6-tagged Bid was sufficiently eluted between 200 mM and 250 
mM imidazole (Figure 36 A). Gel-electrophoresis of the elution fractions revealed the highest 
amount of Bid in fraction E10 and E11 (Figure 36 B). Of note, the elution profile was almost 
constant for all further affinity purifications of novel protein batches. The Bid-containing 
fractions were subjected to the second purification step performed by ion exchange 
chromatography (Figure 36 C, B). Within a continuous NaCl gradient, the elution of Bid was 
observed at approximately 250 mM NaCl, as shown in the ion exchange chromatogram 
(Figure 36 C). Gel-electrophoresis confirmed the purity of the eluted protein in the fractions 
E42-E48 (Figure 36 D). Although the chromatogram revealed two peaks, SDS-PAGE 
confirmed that both peaks (E40-44 and E48) belong to the full-length Bid protein and no 
degradation products were detected (Figure 36 D). Notably, protein-containing fractions 
could be stored at 4°C over several weeks until further use.  
SDS-PAGE followed by western blot (Figure 37 A, B) confirmed the identity of the purified 
Bid protein. Even though high amounts of Bid achieved by affinity chromatography were 
decreased after ion exchange, probably due to exceeding the column binding affinity, the 
highly pure Bid was finally recovered in amounts of about 15-20 mg per liter bacterial culture. 
Since the purity of the His6-tagged Bid was already approximately 90-95 % after ion 
exchange chromatography (Figure 37 A), protein samples were suitable for functional 
analysis as described below. 
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Figure 36: Purification of full length Bid by Äkta-chromatography. 
Successful purification of one of full length Bid by chromatography using the Äkta prime plus. A, Elution profil of 
Nickel-affinity chromatography is shown. B, The elution-fractions within the peak area were analyzed by SDS-
PAGE followed by coomassie staining. Fraktions E8 – E12 were pooled for further purification by ion exchange 
(TL=cellular lysate, FT= Flow through). C, Second step purification: Ion exchange chromatography. The protein 
was eluted at 250 mM NaCl. D, Confirmation of high purified Bid protein by gel electrophoresis and coomassie 
staining.  M = protein size ladder, FT = Flow through, E13-E48 = elution fractions within the peak area of C.  
 
 
Figure 37: Purified His6-Bid. 
A, Coomassie-stained SDS-PAGE reveals purity of recombinant His6-Bid after Affinity chromatography (Affinity) 
and ion exchange. TL = Total lysate, soluble protein fractions; FT = Flow through; M = protein size ladder. B, 
Western blot analysis confirms the identity of Bid. Final recovery of Bid was 15-20 mg/ml bacterial culture.  
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Since X-ray crystallization requires the highest purity and homogeneity of the protein as 
practically possible (≥ 95-98%)189, the final purification step of all recombinant proteins was 
performed by gel filtration. Highly pure Bid was eluted in 20 mM Tris (ph 7.4), 50 mM NaCl as 
confirmed by the gel filtration chromatogram (Figure 38 A). The second peak was confirmed 
as the Bid absorbance peak as gel-electrophoresis revealed high yields of Bid protein in the 
elution fractions E17 and E18 (Figure 38 B), revealing a purity of about 98 %.  
 
 
Figure 38: Gel filtration of full length His6-Bid. 
A, Gel filtration chromatogram of full-length His6-Bid. Bid was eluted in 20 mM Tris (pH 7.4), 50 mM NaCl in the 
fractions E17-E19. B, Coomassie-stained SDS-PAGE confirms the purity of Bid  ( > 98 %). 
 
Crystallization requires to bring the macromolecule to supersaturation189, 206. Therefore, pure 
protein batches were concentrated to the highest possible concentration without causing 
aggregation or precipitation of the macromolecule206. Concentrations between 5-25 mg/ml, 
sometimes even up to 100 mg/ml are recommended with the commonly used concentration 
of 10 mg/ml. Notably, the required concentration for obtaining crystals that diffract to high 
resolution always depends on the behavior of each individual protein and has to be 
established during the initial crystallization screens.  
Even though high yields of protein were obtained after gel filtration (~10-15 mg protein per 
liter culture), concentration of His6-tagged full-length Bid was limited to a concentration of 
4.5-5 mg/ml. In an effort to improve the concentration of full-length Bid and due to the fact, 
that purification-tags might interfere with the crystallization of proteins, an alternative 
purification set up for full-length Bid was scaled up, including the proteolytic cleavage of the 
His-tag. Initial purification was performed by Nickel-affinity chromatography followed by ion 
exchange as described above. Separation of the thrombin-cleaved His-tag and full-length Bid 
was finally achieved using gel filtration. 
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The high recovery and purity of full-length Bid was confirmed by determining the respective 
yields of protein after the particular purification runs within one SDS-PAGE (Figure 39 A). 
Notably, affinity chromatography provided yields of 65 % compared to the total lysate (TL), 
which was retained by ion exchange without loss of protein. The final gel filtration step 
achieved the highest purity of the Bid protein, up to 99%, but in fewer yields (50 % compared 
to affinity chromatography, Figure 39 A). The successful cleavage of the His-tag and integrity 
of full-length Bid was finally confirmed by MALDI-TOF analysis, which was kindly performed 
by Jörg Kahnt at the Max-Planck-Institute of Terrestrial Microbiology, Marburg, Germany 
(Figure 39 B).  
 
 
Figure 39: Recovery of full-length Bid during chromatography purification and MALDI-TOF 
analysis.  
A, 12.5 % coomassie stained SDS-Page predicts the results from each purification step. Pooled fractions which 
contained the purified Bid protein after Ni-affinity chromatography (affinity), Ion exchange and gel filtration, 
respectively were analyzed to estimate the protein recovery and purity. Cleavage of the His6-tag was performed 
after ion exchange and separation of the purification tag and full-length Bid was achieved by gel filtration. The 
final yield was 10-15 mg protein per liter bacterial culture. M = protein size ladder, TL = Total lysat before 
purification, FT = Flow through during affinity chromatography, FT2 = Flow through during ion exchange. B, Maldi 
analysis of the produced recombinant full length Bid after Thrombin- cleavage of the His-tag, confirms the 
production of Bid with a molecular weight of 22.256 kDa. 
 
Notably, cleavage of the His6-tag benefitted the final concentration step of full-length Bid 
resulting in concentrations of up to 9.5-10.0 mg/ml compared to 4.5-5 mg/ml for full-length 
Bid containing the His6-tag.  
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3.2.3 Crystallization of full-length Bid 
Crystal structure determination is regarded as the preferred method to obtain insights into the 
structural understanding of the molecular function of proteins as well as into the interaction 
geometry of protein-ligand complexes. To date, 86 % of the Protein Data bank (rcsb-PDB) 
entries are macromolecular structures that were determined using X-ray crystallography. The 
successful determination of the crystal structure of a protein requires the preparation of 
crystals suitable for X-ray analysis, usually single crystals characterized by a high degree of 
homogeneity, long-range order and suitable size with an optimum between 10-4 and 10-3 mm3 
189, 206-209, causing the process of obtaining crystals as cumbersome and not trivial.  
As the purity, homogeneity and monodispersity of the respective Bid protein sample was 
evaluated at the purification stage, the protein was introduced to precipitating agents that can 
promote the nucleation of protein crystals in the solution. All crystallization screens 
throughout this thesis were performed using the vapor-diffusion technique as the main 
commonly used method for obtaining crystals. Initial crystallization screenings for the 
respective Bid protein constructs were performed using typical protein crystallization screens 
purchased from Qiagen (see Table 54) thereby testing about 1300 different conditions at two 
different temperatures (4°C and 18°C) respectively, as temperature can influence protein 
solubility and thereby crystallization. The crystallization screens were carried out at the Core 
Facility Structural Biology, LOEWE Center of Synthetic Microbiology (SYNMICRO), 
University of Marburg, using a HoneyBee crystallization robot and 96-well plates with 600 nL 
mother liquor and protein (1:1) and 80 µl reservoir volume incubated, and continuously 
imaged using a Formulatrix RockImager (see methods for detail). For scoring and 
interpretation of crystallization drop results, a non-Q scoring system was used189, which is 
shown in Table 61 (2.23.3). 
3.2.3.1 Highly flexible regions eliminate crystallization of full-length Bid 
Purified His6-tagged full-length Bid was subjected to crystallization screening at a 
concentration of 4.5 mg/ml. Despite of 1300 crystallization conditions, the first crystallization 
screens failed to yield Bid crystals, although some tendencies for initial crystal nucleation and 
micro-crystallization could be observed. The formation of heavy precipitates (score 2-3) was 
often observed in the presence of cadmium, nickel or zinc ions, while microcrystals and 
needles (score 6-7) could be obtained in the presence of cryoprotectants, such as 2-Methyl-
2,4 pentanedion (50% MPD) or different polyethyleneglycols (PEG 3350, PEG 4000). 
However, reproduction and optimization failed to identify a clear “hit”-condition for the 
crystallization of His6-tagged full-length Bid. 
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Full-length Bid lacking the His6-tag was subjected to a selection of 8 screening suites (Table 
54) at higher concentrations of 9.9 mg/ml and monitored at 18°C which was found to be the 
more promising temperature. Two conditions are worth mentioning, condition 21 from the 
classic suite and condition 12 form JCSG Core I suite, revealing small micro-crystals (score 
6) approximately 25-30 days upon drop incubation. Both conditions were optimized as 
presented in Table 55 and Table 56. Although, crystal growth could be slightly improved, the 
obtained microcrystals were still too small for mounting and appeared to be overlapping each 
other, forming small and amorphous crystal clusters. 
As these observations demonstrated that crystallization screening of full-length Bid failed to 
yield crystals suitable for diffraction measurements, further work included the design of novel 
Bid constructs which should facilitate the crystallization procedure.  
 
3.2.4 Design of modified truncated Bid constructs promise successful 
crystallization 
Structures of mouse and human Bid proteins generated so far by nuclear magnetic 
resonance (NMR) techniques provide insights into the structural mobility of Bid: consisting of 
20 NMR solutions differing in their energy (PDB entry, 1DDB)65, the three-dimensional 
solution structure of Bid predicts the arrangement of the eight α helices, building the core of 
Bid,  and two strongly disordered regions with a high conformational mobility (Figure 40, 
marked in red). The conformation of the unstructured N-terminal region and the highly 
flexible loop located between α2 and α3 predicted in Figure 40 A are only two of many that 
satify the NMR-derived restraints. Thus, the presence of these highly mobile regions might 
explain the failure of obtaining crystals using full-length Bid as a conformational mobility 
interfere with the generation of severe ordered crystal packages. As shown in Figure 40 B 
revealing an overlay of the NMR structure of mouse Bid (1DDB)65 and the X-ray structure of 
mouse Bcl-xl (1MAZ)68, the overall tertiary fold derived for Bid is similar as that observed for 
the Bcl-xl structure68, 113. Therefore, further strategies for Bid crystallization were based on 
previous experiences collected for the construct design and crystallization of Bcl-xl and other 
related proteins such as Bcl-2 and Mcl-168, 122, 210, indicating that crystallization of Bid could 
be facilitated by removing the mobile N-terminus and loop. 
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Figure 40: Highly flexible regions of full-length Bid 
A, Overlay of two NMR structure of full-length mouse Bid (PDB entry, 1DDB)
65
. Ribbon depiction reveals, that the 
protein Bid consists of a eight-helix core shown in grew and turquoise, respectively and two strongly disordered 
regions located at the N-terminus and between helices α2 and α3 (both marked in red). The schematic drawing 
illustrates the size and two possible conformations of the flexible N-terminus and the loop. As the 1DDB structure 
solution of full-length mouse Bid consist of 20 NMR solutions 
65
, the predicted orientations of the loop are only two 
of many that satisfy the NMR-derived restraints. In contrast, the core conformation is almost consistent. B, 
Overlay of one NMR structure solution of mouse full-length Bid in grey (PDB entry, 1DDB) and x-Ray structure of 
mouse Bcl-xl (PDB entry, 1MAZ)
68
 in yellow. The Bcl-xl protein consists of two central hydrophobic α-helices 
surrounded by amphipathic helices and a highly flexible 60-residue loop connecting helices α1 and α2. Since the 
removal of this loop was essential for obtaining crystals, it is not predicted in the yellow Bcl-xl structure.  
 
Based on these considerations211, four different Bid constructs lacking the highly flexible 
regions of mouse Bid were designed as GST-fusion proteins following the strategy predicted 
in Figure 41 A, namely pGEX Δ12-Y47 (Bid 1), pGEX Δ12-D51 (Bid 2), pGEX Δ13-Y47 
(Bid 3) and pGEX Δ13-D51 (Bid 4). 
 
        
Figure 41: Strategy for design of novel truncated Bid constructs. 
A, Schematic drawing of the NMR solution structure of mouse full-length Bid (PDB entry, 1DDB)
65
, revealing the 
structure core of Bid in grey and unstructured regions in red. Highlighted amino acids (black) predict the cleavage 
points for generation of four Bid construct. First cleavage was performed at the N-terminus at either Glycin 12 
(G12) or Alanin 13 (A13). Secondly, the loop was cleaved from either Thyrosin 47 (Y47) or Aspartat 51 (D51) up 
to Glutamate 77 (E77). The combination of both cleavages resulted in four truncated Bid constructs. B, PCR 
analysis confirms successful cloning of the truncated Bid constructs: pGEX Δ12-Y41 (Bid 1), pGEX Δ12-D51 (Bid 
2), pGEX Δ13-Y47 (Bid 3) and pGEX Δ13-D51 (Bid 4).  
A B
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The successful cloning of the N-terminal truncated Bid constructs starting with Glycin 12 or 
Alanin 13 (designated Δ12 and Δ13, respectively) into the pGEX1λT vector and the removal 
of the unstructured loop from either Thyrosin Y47 or Aspartat D51 to glutamate 77, was 
analyzed by PCR (Figure 41 B) and finally confirmed by multiple alignment of the four 
generated Bid constructs and mouse full-length Bid (Table 65).  
 
Table 65: Gene alignment of novel Bid constructs and mouse full-length Bid 
 
Multiple Alignment of Bid constructs 
 
12          GAEHITDLLVFGFLQSSGCTRQELEVLGRELPVQAYWEADLEDELQTDGSQAS  64 
„12-47“   GSGAEHITDLLVFGFLQSSGCTRQELEVLGRELPVQAY----------------- 
„12-51“   GSGAEHITDLLVFGFLQSSGCTRQELEVLGRELPVQAYWEAD------------- 
„13-47“   GS-AEHITDLLVFGFLQSSGCTRQELEVLGRELPVQAY----------------- 
„13-51“   GS-AEHITDLLVFGFLQSSGCTRQELEVLGRELPVQAYWEAD------------- 
 
65      RSFNQGRIEPDSESQEEIIHNIARHLAQIGDEMDHNIQPTLVRQLAAQFMNGSLSEEDKR  124 
„12-47“ -------------SQEEIIHNIARHLAQIGDEMDHNIQPTLVRQLAAQFMNGSLSEEDKR 
„12-51“ -------------SQEEIIHNIARHLAQIGDEMDHNIQPTLVRQLAAQFMNGSLSEEDKR 
„13-47“ -------------SQEEIIHNIARHLAQIGDEMDHNIQPTLVRQLAAQFMNGSLSEEDKR 
„13-51“ -------------SQEEIIHNIARHLAQIGDEMDHNIQPTLVRQLAAQFMNGSLSEEDKR 
 
125     NCLAKALDEVKTAFPRDMENDKAMLIMTMLLAKKVASHAPSLLRDVFHTTVNFINQNLFS  184 
„12-47“ NCLAKALDEVKTAFPRDMENDKAMLIMTMLLAKKVASHAPSLLRDVFHTTVNFINQNLFS 
„12-51“ NCLAKALDEVKTAFPRDMENDKAMLIMTMLLAKKVASHAPSLLRDVFHTTVNFINQNLFS 
„13-47“ NCLAKALDEVKTAFPRDMENDKAMLIMTMLLAKKVASHAPSLLRDVFHTTVNFINQNLFS   
„13-51“ NCLAKALDEVKTAFPRDMENDKAMLIMTMLLAKKVASHAPSLLRDVFHTTVNFINQNLFS   
 
185     YVRNLVRNEMD  195 
„12-47“ YVRNLVRNEMD 
„12-51“ YVRNLVRNEMD 
„13-47“ YVRNLVRNEMD   
„13-51“ YVRNLVRNEMD 
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3.2.5 Effective expression of GST-tagged Bid constructs 
As GST-tags positively influence protein solubility and expression efficiency of small proteins, 
the designed Bid constructs were expressed in E. coli. as GST-fusion proteins. For 
evaluation of gene expression, Rosetta2 (DE3) singles were transformed with the respective 
designed plasmids and protein expression was succeeded 5 h to 19 h after IPTG induction 
(Figure 42 A, B). Expression tests revealed an increased protein expression from 2 h up to 
5 h, while the amount of protein decreased again 19 h after expression induction (Figure 
42 A, B). Notably, all four Bid constructs were easily expressed in high amounts, as 
confirmed by gel-electrophoresis revealing just soluble extracts without purification (Figure 
42 A, B). To ensure the maximal yield of protein expression, protocols for expression of the 
respective Bid constructs were scaled up and bacteria were harvested 4.5-6 h after IPTG 
induction to avoid deficiencies due to protein degradation.   
 
 
 
Figure 42: Effective expression of truncated Bid constructs. 
Effective expression of the truncated Bid constructs was analyzed by expression tests in Rosetta 2 (DE3). E. coli 
were transformed with the respective pGEX-1λT vectore encoding the truncated Bid construct as GST-fusion 
protein. Samples were taken after 0 h – 19 h after induction of protein expression by 1 M IPTG. Soluble protein 
fractions were analyzed by gel-electrophoresis followed by coomassie staining. Protein expression of all four Bid 
constructs was significantly increased from 2 h up to 5 h, while slightly less protein was detected after 19 h 
bacterial growth. The molecular weight of the GST- tagged constructs is about 40 kDa. Note that the gels show 
just soluble extracts without purification. 
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3.2.6 Purification of the Bid construct pGEX Δ12-Y47 (Bid 1) 
The GST-fusion protein pGEX Δ12-Y47 (Bid 1) was highly expressed in Rosetta2 (DE3) and 
recovered in the soluble protein fraction (TL) 4.5-6 h after IPTG induction, as confirmed by 
gel-electrophoresis followed by coomassie staining (Figure 43 B (TL)). Purification of 
pGEX Δ12-Y47 was performed by two chromatography steps using the Äkta prime plus 
system. GSH-affinity chromatography yielded high amounts of GST-Bid 1, eluted with 10 mM 
glutathione in the fractions E7-E9 (Figure 43 A, B). Notably, the chromatogram revealed only 
one clear absorbance peak for Bid 1, already indicating a high purity of the recovered protein 
(Figure 43 A), which was confirmed by the related SDS-PAGE which estimated a purity of 
90-95% (Figure 43 B). Due to this high purity after affinity chromatography the Bid construct 
was directly subjected to further gel filtration without ion exchange in between. To avoid 
interference of the relatively large GST-tag (24 kDa) during crystallization, the GST-tag was 
effectively cleaved using thrombin (3.5 U/ml) as confirmed by gel-electrophoresis revealing 
the GST-tag at 24 kDa and the pure Bid 1 below (Figure 43 C). The following gel filtration 
successfully separated the purification-tag from the cleaved Bid 1, as shown by the diverse 
peaks in the purification run profile (Figure 43 D). Notably, compared to high absorbance up 
to 500-800 AU for the GST-tagged protein, the Bid 1 absorbance peak shown in the 
chromatogram (second peak) is relatively small as only a few aromatic amino acids are 
present in the Bid 1 sequence (Table 65). The related coomassie stained SDS-PAGE 
confirmed a purity of >98%, enabling the subjection of the batch to crystallization screenings. 
A final yield of 15-20 mg Bid 1 per liter culture could be obtained (Figure 43 E).  
Based on the sequence of the pGEX Δ12-Y47 (Bid 1) construct a molecular mass of 18 kDa 
(17.626 kDa) was calculated. However, purification SDS-PAGEs revealed the eluted protein 
between 11 and 15 kDa (Figure 43 C, E). In order to investigate the identity of the construct, 
the final purification batch was subjected to MALDI-TOF analysis (Figure 44), confirming the 
actual mass of ≈ 18 kDa (17.645 kDa). Markedly, the sample subjected to MALDI-TOF had 
been stored for a couple of weeks, explaining the appearance of additional peaks that might 
be due to protein aggregations or reagent adsorptions during purification.  
For crystallization studies, the purified Bid 1 construct was concentrated up to concentrations 
of 9.5-10.5 mg/ml. In particular, the removal of the flexible N-terminus and loop benefitted the 
concentration procedure, which was more effective compared to the concentrations 
performed for full-length Bid. 
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Figure 43: Purification of Bid 1 (pGEX-Δ12-Y47). 
Bid 1 was expressed as a GST-fusion protein in E. coli (Rosetta 2 (DE3)) and recovered in the soluble protein 
fraction. A, GSH-affinity chromatography using the Äkta prime plus system connected to a GSTrap FF column 
(GE Healthcare). Protein elution was performed with buffer containing 10 mM glutathione. B, Coomassie stained 
12.5 % SDS-PAGE revealing the analyzed elution fractions within the peak area shown in A (TL = total lysate 
before purification, FT = flow through, E7-E10 = elution fractions). Fractions E7 to E19 were pooled and subjected 
to the following thrombin cleavage. C, The GST-tagged Bid 1 construct was digested with thrombin (3.5 U/ml) for 
16 h at 37°C. The successful removal of the GST-tag was confirmed by 12.5 % gel-electrophoresis and 
coomassie staining. D, Separation of GST-tag and Bid1 by gel filtration. The chromatogram shows 5 peaks, 
predicting GST-Bid1 fusion protein at 40-50 min. and cleaved GST-tag at 60 min. The cleaved Bid 1 was eluted 
between 70 min. and 80 min. Other peaks indicate thrombin and PMSF. E, Highly pure Bid 1 protein was 
recovered in elution fractions E32-E34 (second chromatogram peak) as confirmed by 12.5 % coomassie stained 
SDS-PAGE. Fractions E20-E26 were recovered from the first chromatogram peak predicting GST-Bid1, fractions 
E26 and E27 show the GST-tag. 
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Figure 44: MALDI-TOF analysis of Bid1 (pGEX-Δ12-Y47). 
A, Purified Bid 1 was subjected to MALDI-TOF analysis, performed by Jörg Kahnt at the Max-Planck-Institute of 
Terrestrical Microbiology, Marburg, Germany. The molecular mass of Bid 1 represents 17645 Da in the predicted 
MALDI-TOF spectrum and fits to the theoretically calculated mass of 17626 Da.  Additional peaks in the mass 
spectrum might be due to storage or glutathione adsorption during purification.  
 
3.2.7 Crystallization screening of pGEX Δ12-Y47 (Bid 1) 
The purified Bid 1 construct was subjected to an extensive crystallization screening at 
concentrations of 9.5 mg/ml as well as at concentrations of 10.5 mg/ml. Initial crystallization 
screens were performed as described above (0). As crystallization from solution generally 
occurs via the sequential steps of nucleation of the phase, destined by the compositions of 
the solution, followed by growth of the nuclei to larger sizes by incorporation of the solution 
material189, 209, a common method for promoting nucleation is to supplement the protein-
reservoir drops with nanoparticles. Therefore, duplicate crystallization screens of Bid 1 were 
performed in the presence of 2 % nanoparticles. The first crystals of pGEX Δ12-Y47 (Bid 1) 
were finally obtained upon drop incubation at 277 K after mixing 300 nL protein solution with 
300 nL reservoir solution of two different conditions: (a) Cryo suite condition 5, containing 90 
mM HEPES pH 7.5, 15 % (V/V) glycerol, 8.5 % (V/V) 2-propanol and 17 % (V/V) PEG 4000 
(Figure 45 A), and (b) JCSG+ suite condition 79, consisting of 0.1 M di-sodium succinat 
pH 7.0 and 15 % (V/V) PEG 3350. (Figure 45 B). While first crystals obtained from condition 
(a) were observed 20 days after drop incubation showing an increasing growth up to day 35, 
crystals yielded from condition (b) were debuted on day 9 with an increasing growth up to 
day 23.  Figure 45 shows the continuous growth of crystals obtained from the respective 
conditions.  
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Figure 45: Successful result of Bid 1 crystallization. 
Highly pure Bid 1 protein (construct Δ12-Y47) was subjected to extensive crystallization screening using the 
Quiagen NeXtal screening suites. A, Successful crystallization was obtained using the cryo suite condition 5, 
containing. First crystal growth was obtained 90 mM HEPES (pH 7.5), 15 % Glycerol, 8.5 % 2-propanol and 17 % 
PEG 400020 days after screening start and mounted after 38 days. Cross polarized light was used on day 35 to 
confirm that the crystal is a protein crystal. B, Successful crystallization was obtained using the JCSG+ condition 
79, containing 0.1 M di-Sodium succinat (pH 7.5), 15 % PEG 3350. First crystal growth was obtained at day 9 
after initial screening set up and a continuous growth was observed up to day 23. Crystals were frozen at day 26. 
 
The relatively slow growth of the crystals as well as their three-dimensional shape strongly 
indicated protein crystals rather than salt crystals. This was further suggested as the buffer 
control, always performed in drop 2 (Table 54), obtained no crystal growth. However, as 
many compounds, not just the protein, can crystallize in the crystallization drop189, further 
tests to distinguish between protein and salt crystals were performed. Both crystals were 
stainable with methylene blue and physical manipulation using a micro tool indicated a soft 
and easy breaking behavior of both crystals. These results strongly indicated the presence of 
a protein crystal as a salt crystal would not be stainable with dyes and would break apart with 
a snap or crunching sound under the force of a micro tool (2.23.4.3). Additional evidence for 
the presence of protein crystals was derived from viewing the crystals with polarized light 
which revealed color effects due to a double refraction of the anisotropic protein crystal as 
shown for crystal_11 of the cryo suite condition 5 (Figure 45 A, cross polarizer). However, 
the only definitive test to confirm the identity as a protein crystal is the X-ray diffraction 
pattern, which was finally obtained by synchrotron measurements described below for 
crystals obtained from both conditions (a) and (b). 
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3.2.8 Optimization strategies of Bid 1 crystals 
Several optimizations rounds were performed in order to optimize the respective 
crystallization hit conditions (a) and (b) as described in Table 57 et sqq.. It is worth 
mentioning that in protein crystal growth, the formation of crystals is often hard to reproduce 
even by scrupulously following the original conditions207. Therefore, optimization experiments 
were also used to improve the reproducibility of crystal growth in the abovementioned hit 
conditions. Notably, reproduction and optimization of condition (a) was even more 
cumbersome than optimizations of condition (b). Figure 46 A predicts a representative result 
obtained from the cryo suite condition 5 opti-grids, revealing crystals which are larger in 
length compared to the original hit crystals (Figure 46 A), but with a shape of  thin needles 
(score 7) rather than 3D crystals (score 9).  In contrast, optimizations of hit condition (b) 
succeeded in producing several crystals that were grown in conditions consisting of 0.1 M di-
sodium succinat and different concentrations of PEG 3350 in a range of 11 % up to 21 % 
(V/V), respectively. Although crystal growth was observed in conditions with low pH of 6.5 
(Figure 46 B), the preferred pH for crystal growth within these conditions was obviously pH 
8.0 revealing the most crystals during optimization (Table 56 et sqq.). In addition to seeding 
strategies, the abovementioned hit conditions were supplemented with additives using the 
commercial Additive Screen HTTM (Hampton Research) performed in the 96-well format at 
both temperatures of 4°C and 18°C. Using this approach, crystals were obtained from 
condition (b) supplemented with 5 % (W/V) n-dodecyl-β-D-maltoside (Additive screen 
condition 72 (F12)), 40 % (V/V) 2,5-hexanediol (mixture of isomers, Additive screen condition 
78 (G6)) and 40 % (V/V) formamide (Additive screen condition 89 (H5)).  
 
 
 
Figure 46: Bid 1 crystals obtained form opti grid conditions. 
Bid 1 (10.5 mg/ml) was subjected to optimization grids of condition cryo A5 and condition JCSG+ G7. To 
examples of the obtained crystals are shown. A, Bid 1 crystal obtained from cryo opti-grid condition A9 consisting 
of 90 mM HEPES (ph 7.5), 30 % Glycerol, 21 % 2-propanol and 17 % PEG 4000 at 18°C. B, Bid 1 crystal 
obtained from JCSG+ opti-grid condition A3, consisting of 0.1 M di-Sodium succinat (ph 6.5), 15 % PEG 3350 at 
4°C. Of note, further crystals were obtained during optimization of the JCSG+ G7 condition at ph 8 and a range of 
11 % to 21 % PEG 3350. 
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3.2.9 Data collection and processing  
Crystals obtained for the indicated hit conditions, as well as crystals obtained from the 
respective optimization grids and additive screens were harvested from mother liquor, frozen 
in liquid nitrogen in the presence of a cryoprotectant if necessary, and transferred to the 
synchrotron. Data were collected at 100 K at BESSY II (Helmholtz-Zentrum Berlin, 
Germany), Beamline 14.1190 or at PETRA III (DESY, Hamburg, Germany) and processed 
using XDS191 as implemented in XDSAPP192. From all crystals measured, the best results 
were recorded for crystals obtained from the original hit conditions (a) and (b). Figure 47 
reveals the typical diffraction pattern obtained throughout data collection on the respective 
Bid 1 crystals shown above and recorded at BESSY II under cryoconditions. Although 
crystals obtained from condition (a) were the larger and better-looking crystals, best data 
were produced from the smaller and ´uglier´ crystals of condition (b) as in line with plenty of 
reports mentioning that the best data are often derived from the most unimpressive crystal 
shapes189, 207, 209. Table 66 depicts the results of data processing for the most promising data 
collection that was obtained for Bid 1 crystal_11 derived from the abovementioned condition 
(b). Indexing of the initial diffraction data revealed unit cell constants as expected for crystals 
of this protein size. Data processing suggests a crystal form in space group C2221 with two 
monomers per asymmetric unit, as indicated by the Matthews coefficient of 2.2 Å³/Da and an 
estimated solvent content of 44.1%.  
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Figure 47: Bid 1 crystals used for data collection and typical diffraction pattern 
The Bid 1 crystals, obtained by initial crystal screening for Bid 1 (10 mg/ml) and grown in condition 5 from cryo 
suite (A) an appropriate 79  from JCSG+ suite (B) were frozen in liquid nitrogen and transferred to the 
synchrotron. B, D, Typical diffraction pattern obtained throughout data collection on the respective Bid 1 crystals 
shown above and recorded at BESSY II. Crystal A: 3.63 Ǻ, Crystal B: 3.28Ǻ. 
 
Despite extensive molecular replacement (MR) trials using Phaser193 with search models 
from various sources, such as Bid NMR structures obtained from the PDB (PDB entry, 
1DDB, 2BID), homology models and poly-Ala models with different domain boundaries, no 
unique MR solution could be identified so far, implying a preliminary status to the space 
group assignments given in Table 66. Data indexing and molecular replacement trials were 
performed by Holger Steuber (LOEWE Center of Synthetic Microbiology (SYNMICRO), 
University of Marburg). 
 
Table 66: Statistics for data collection and processing for Bid 1. 
Crystal Bid_11 was obtained from JCSG+ suite, condition 79 
Data collection and processing Crystal Bid_11 
Radiation Source    Bessy MX 14.1 
No. of crystals used 1 
Wavelength [Å] 0.91841 
possible Space group C222/C222(1) 
Unit cell parameters  
    a, b, c [Å] 
63.4; 128.2; 78.0 
     ,  
90 ; 90 ; 90 
Matthews coefficient [Å³/Da] 2.2 
Solvent content [%] 44.1 
Diffraction data  
Resolution range [Å] 22.0 – 3.75 (3.95-3.75) 
Unique reflections 3 442 (487) 
R(I)sym [%] 15.9 (61.3) 
Completeness [%] 99.4 (100.0) 
Redundancy 6.3 (6.5) 
   I/(I) 
12.7 (3.5) 
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3.2.10 Purification and crystallization of pGEX Δ12-D51 (Bid 2) and pGEX Δ13-
D51 (Bid 4) 
The Bid constructs pGEX Δ12-D51 (Bid 2) and pGEX Δ13-D51 (Bid 4) were analogously 
expressed as GST-fusion proteins in Rosetta2 (DE3) and purified using the optimized and 
scaled up expression and purification protocol for construct pGEX Δ12-Y41 (Bid 1), with 
minor changes. Figure 48 reveals the purification profiles and related SDS-PAGEs for 
purification of the Bid 2 construct. Gel-electrophoresis of the bacterial total lysate (TL, Figure 
48 B) confirmed the recovery of Bid 2 in the soluble protein fraction and the high purity of the 
construct achieved by elution during GSH-affinity purification (Figure 48 B (E)). The 
subsequent cleavage of the GST-tag was further improved by the use of 1 U thrombin 
(Novagen) per mg protein succeeding in a complete removal of the purification-tag (Figure 
48 B, (+thrombin)). The final gel filtration yielded large quantities of Bid 2 (20 mg protein per 
liter culture) with a high purity of > 98 % (Figure 48 C, D). Bid 2 containing fractions were 
pooled, concentration and subjection to the crystallization approach.  
 
 
Figure 48: Purification of Bid 2 (pGEX-Δ12-D51). 
The fusion protein GST-Bid 2 was successful expressed in E. coli (Rosetta 2 (DE3) after IPTG induction for 4.5 h. 
A, GSH-Affinity chromatography of Bid 2 was performed using a glutathione HiCap Cartridge. 20 ml of Bid 2 
protein lysate was injected four times via a 5 ml sample loop. Elution of the protein was performed with buffer 
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containing 10 mM glutathione. B, The purity of the elution fraction (peak area) was confirmed by 12.5 % gel- 
electrophoresis and coomassie staining. Note that the elution fraction reveals already pure protein compared to 
the total lysate (TL) before purification and flow through (FT). For removal of the GST-tag, the recovered elution 
fraction, containing 22 mg protein, was supplemented with 22 U thrombin (+ Thrombin) and incubated for 16 h at 
37°C. Notably, the cleavage of the GST-tag was almost completely. C, To separate the cleaved GST and to yield 
highly pure protein, gel filtration was performed and the pure protein eluted in 20 mM Tris, 50 mM NaCl buffer (pH 
7.4). D, The elution fractions within the peak area predicted in the gel filtration chromatogram (C) were analyzed 
by 12.5 % SDS-PAGE. While elution fraction 26 (E26) contains the GST-tag, pure Bid 2 protein was recovered in 
the fractions E32-E35. 
 
The high purity and integrity of pGEX Δ12-D51 (Bid 2) indicated by the clear and improved 
chromatography profile (Figure 48), was further confirmed by MALDI-TOF analysis, revealing 
only one peak at the expected molecular mass of 18 kDa (Figure 49). 
 
 
Figure 49: MALDI-TOF analysis of purified Bid 2 (pGEX-Δ12-D51). 
Purified Bid 2 was subjected to MALDI-TOF analysis, performed by Jörg Kahnt at the Max-Planck-Institute of 
Terrestrical Microbiology, Marburg, Germany. The molecular mass of Bid 2 represents 18130 Da in the predicted 
MALDI-TOF spectrum as expected by theoretically calculated mass of 18127 Da.  Note, that the well defined 
peak, indicating highly pure and intact Bid 2 protein. 
 
 
Finally, the pGEX Δ13-D51 (Bid 4) construct was subjected to the described purification 
procedure, as shown in Figure 50. Notably, gel electrophoresis after GSH-affinity 
chromatography revealed a relatively high amount of Bid 4 in the flow through fractions (FT, 
FT2, Figure 50 B), indicating an even more pronounced high-yield expression of this 
construct compared to construct Bid 2. This was confirmed by determining the protein 
amount after the first purification step, predicting a mentionable yield of 86 mg protein per 1.2 
liter bacterial culture. Admittedly, cleavage of the GST-tag was probably not completely due 
to undercharged amounts of thrombin (Figure 50 C). Nevertheless, the fractions that 
revealed Bid 4 completely separated from the GST-tag (E31-E35, Figure 50 D) contained 
high amounts of pure Bid 4 protein (> 98%), that could be concentrated up to values of 
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15.2 mg/ml.  The following MALDI-TOF analysis confirmed the molecular mass of 18 kDa for 
Bid 4, although additional peaks at higher values (18.381 kDa and 18.689 kDa) were 
observed and might indicate a contamination with remains of GST-Bid 4 fusion protein 
(Figure 51).  
 
 
Figure 50: Purification of highly pure Bid 4 protein (pGEX-Δ13-D51). 
Bid 4 was expressed as a GST-fusion protein in E. coli (Rosetta 2 (DE3)) and recovered in the soluble protein 
fraction. A, GSH-affinity chromatography. 25 ml of protein solution was loaded and protein elution was performed 
with buffer containing 10 mM glutathione. B, Coomassie stained 12.5 % SDS-PAGE (TL = total lysate before 
purification, FT = flow through, flow through end method, E34-E39 = elution fractions). The fractions E34-E39 
were pooled, containing 7.2 mg/ml pure protein (total amount 86 mg). Note that FT2 contains high amounts of Bid 
4, indicating that the binding capacity of the column was exceeded. C, The GST-tagged Bid 2 construct was 
digested with thrombin (Novagen) for 16 h at 37°C. Separation of GST-tag and Bid 4 was achieved by gel 
filtration. The chromatogram shows 3 peaks, predicting GST-Bid 4 fusion protein at 50-60 min. and cleaved GST-
tag at 60 min. The cleaved Bid 4 was recovered in the elution fractions E31-E36. D, Gel-electrophoresis confirms 
the purity of Bid 4 in elution fractions E31-E36. Fractions E22 and E26 were recovered from the first 
chromatogram peak predicting the GST-tag. 
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Figure 51: MALDI-TOF analysis of purified Bid 4 (pGEX-Δ13-D51). 
Purified Bid 4 was subjected to MALDI-TOF analysis, performed by Jörg Kahnt at the Max-Planck-Institute of 
Terrestrical Microbiology, Marburg, Germany. The molecular mass of Bid 4 represents 18071 Da in the predicted 
MALDI-TOF spectrum as expected by theoretically calculated mass of 18070 Da. The protein sample might 
contain remains of GST-Bid 4 fusion protein as indicated by the peak with the mass 18381 Da. 
 
Constructs pGEX Δ12-D51 (Bid 2) and pGEX Δ13-D51 (Bid 4) were analogously subjected 
to the abovementioned crystallization screenings at a concentration of 8.5 mg/ml for Bid 2 
and at concentrations of 10.0 mg/ml and 15.5 mg/ml for Bid 4. The tested screening suites 
are quoted in Table 54. So far no crystals suitable for X-ray diffraction were obtained for any 
of the construct Bid 2 and Bid 4. As crystallization screenings are still ongoing only some 
tendencies can be mentioned up to date. Both constructs immediately precipitate if ions such 
as cadmium or zinc are present in the crystallization screening conditions, as it was similarly 
observed for full-length Bid and construct Bid 1. Promising conditions observed for Bid 2 
were conditions 14, 38 and 58 from the JCSG+ suite and conditions 38, 39 and 61 from the 
JSCG core I suite. Crystallization screens performed for Bid 4 obtained similar results, but 
with a more pronounced tendency for precipitations and phase separations. In general, more 
promising results were observed when crystallization screening was performed at 18°C 
compared to the drop results obtained at 4°C. Further screenings and optimizations have to 
be conducted to improve the crystallization of both constructs.  
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3.2.11 Functional analysis of Bid constructs in HT-22 cells 
It is well accepted, that the pro-apoptotic activity of Bid is mainly mediated by its truncated 
active form tBid61, 66, 173, rapidly accumulating at the mitochondrial membrane and initiating 
cytochrome c release and cell death. As described above, beside the caspase-8 mediated 
cleavage of full-length Bid, cleavage can also be mediated by granzyme B, calpains or 
cathepsins that all cleave Bid in the unstructured loop region between helices α1 and α260, 61, 
74, 76, 212. Since the Bid constructs Bid 1-Bid 4 lack the flexible loop region, a cleavage 
mediated by any of the abovementioned proteases is unlikely and thereby a pro-apoptotic 
function of the novel Bid constructs is not expected. However, a death-promoting nature of 
full-length Bid was also reported by previous studies, showing that apoptosis could be 
induced by over-expression of full-length Bid55 or a Bid mutant lacking the caspase-8 
cleavage site213. Furthermore, it has been described that the N-terminal sequence of Bid 
ensures its cytoplasmic localization and negatively regulates the binding of Bid to 
membranes thereby inhibiting the exposure of the BH3 region and its apoptotic function61. To 
investigate, if the designed Bid constructs, that lack the first 12 and accordingly 13 amino 
acids of the N-terminus, procure a pro-apoptotic activity in cellular systems, over-expression 
of the respective constructs was examined in the present HT-22 cell line. To this aim, the 
constructs were cloned into the pcDNA3.1 vector suitable for expression in eukaryotic cells 
(2.14.4.1). In accordance to the tBid-toxicity assay, HT-22 cells were transfected with the 
plasmids encoding the sequence of the truncated Bid construct 3 and 4, respectively, and 
cell viability was analyzed 24 h to 48 h after over-expression. To compare the toxic or non-
toxic activity of Bid 3 and Bid 4 with the tBid-induced cell death features, controls were 
transfected with the tBid-encoding plasmid as outlined above. Photomicrographs revealed 
that any of the truncated Bid constructs induced alterations in cell morphology, as they were 
observed in tBid-over-expressing HT-22 cells (Figure 52 A). Cells over-expressing Δ13-Y47 
and Δ13-D51, respectively, retained the normal spindle-shaped morphology comparable to 
pcDNA3.1 transfected cells (Figure 52 A). Quantification of cell viability determined by MTT 
assay, confirmed that none of the both constructs induced cell death in HT-22 cells, 
indicating a “full-length Bid like behavior” of Δ13-Y47 and Δ13-D51 rather than a tBid-like 
function when over-expressed in HT-22 cells. 
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Figure 52: Functional analysis of Bid constructs. 
HT-22 cells were transfected with a plasmid containing either Bid 3 sequence (pc-Δ13-Y47) or the Bid 4 sequence 
(pc-Δ13-D51). Controls were treated with attractene only (vehicle) or transfected with an empty control vector 
(pcDNA3.1). Transfection of cells with the tBid-encoding plasmid (pIRES-tBid) was used as positive control for 
tBid-induced toxicity. A, Cell morphology was analyzed by microscopy. Photomicrographs show the typical 
phenotype of tBid-induced cell death in cells transfected with the pIRES-tBid vector, but no alterations in cells 
transfected with the truncated Bid concstructs, comparable to control pc-DNA3.1. B, Cell viability was analyzed by 
MTT assay 48 h after over-expression of the respective Bid constructs. Note that cell viability is not affected by 
any of the novel truncated Bid constructs (Bid 3 and Bid 4), yet significantly decreased by over-expression of tBid.  
 
To summarize, the work above provides the basis for a suitable pipeline form Bid construct 
design, cloning, expression up to protein purification and first Bid crystallization approaches. 
Protocols for recombinant expression and purification were optimized and scaled up not only 
for full-length Bid, but also for diverse truncated Bid constructs, yielding high amounts of 15-
50 mg Bid variant per liter culture, depending on the respective Bid variant. The pure protein 
batches were subjected to extensive crystallization screenings, including initial screens using 
1300 different crystallization conditions at two temperatures respectively, as well as several 
optimization strategies such as opti-grids, seeding or additive screenings. The construct Δ12-
Y47 (Bid 1) was successfully crystallized and yielded diffraction data of 3.75 to 3.95 Ǻ 
resolution under X-ray exposure at the BESSY II synchrotron. In addition, constructs Δ12-
D51 (Bid 2) and Δ13-D51 (Bid 4) also promise successful crystallization, although further 
optimizations have to be performed with both Bid variants. Lastly, the constructs were over-
expressed in the HT-22 cell line confirming the non-apoptotic function of the truncated 
variants as expected from the structural modifications. Further optimizations of crystallization 
and diffraction properties of the Bid crystals, which were obtained during this work, promise a 
successful structure determination of Bid as an indispensable tool for a deeper 
understanding of the molecular mechanisms of Bid and the further structure-guided 
development of Bid-targeting compounds. 
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3.3 Functional analysis of recombinant Bid and Bax – a model system 
for membrane permeabilization 
Although previous studies demonstrated that Bid mediates apoptotic cell death via 
detrimental effects at the mitochondrial membranes24, 63, 97, the precise mechanism by which 
Bid or tBid trigger MOMP is still not fully understood. Several studies point to the caspase 8 
cleaved C-terminal fragment tcBid as the pro-apoptotic form with activity for membrane 
binding and permeabilization69, 214 and suggest a tBid-mediated Bax activation and 
subsequent MOMP69, 71, 77, 82, 215-219. A well accepted tool for investigating the pore-forming 
abilities of diverse proteins is the use of artificial lipid bilayer structures which mimic the 
mitochondrial membrane69, 72, 77, 82, 218, 219. To investigate the effect of the newly synthesized 
recombinant Bid and caspase-8 cleaved cBid on lipid membranes, in the presence and 
absence of recombinant Bax, continuing work included the validation of a model systems for 
membrane permeabilization, namely the liposome channel activity assay (3.3.1). The system 
was further used to examine the role of cardiolipin (CL) in Bid-mediated membrane 
permeabilization as many previous reports suggest CL as mitochondrial receptor for Bid77, 220-
225.   
3.3.1 Liposome channel activity demonstrates cBid- and Bax-mediated 
membrane permeabilization to be dependent on the presence of 
cardiolipin  
To investigate the effect of Bid and Bax on artificial membranes, 5,6-carboxyfluorescence-
containing liposomes were prepared using phosphatidylcholin (PC) and 
phosphatidylethanolamine (PE) as the most abundant lipids of the mitochondrial outer 
membrane (MOM). For investigation of the role of cardiolipin, PC/PE liposomes were 
compared to liposomes containing CL in addition. For baseline fluorescence, liposomes were 
initially measured at RT without the addition of proteins for 3-5 min. To rule out unspecific 
destabilization effects caused by protein buffer compositions, buffer containing 20 mM Tris 
(ph 7.4), 50 mM NaCl was added to act as a 0 % CF-release control (Figure 53 A), while the 
addition of Triton X-100 was used to induce 100 % CF release (Figure 53 B). Liposome 
stability as well as permeabilization ability was further investigated over a period of 60 min. 
(Figure 53 C), revealing that no CF was released in the absence of Triton X or when 
liposomes were just measured in PBS without compound addition, indicating that the system 
is suitable for investigating the pore-forming abilities of the recombinant proteins Bid and 
Bax. 
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Figure 53: Liposome channel activity assay as model system for membrane permeabilization. 
Liposomes with a lipid composition of phosphatidylcholin (PC), phosphatidylethanolamin (PE) and cardiolipin (CL) 
(PC/PE/CL: 54/20/26) stained with 1 % rhodamine DHPE and containing 20 mM 5,6 carboxyfluorescein (CF) 
were incubated in PBS and measured at RT without proteins. A, B, Change in fluorescence was measured over 
time after addition of H20 as negative control (A) or addition of 4% Triton-X as positive control for 100 % CF-
release (B). C, Stability of liposomes was determined over 60 min and 4 % Triton-X was added 12 min and 40 
min after initial measurement, respectively, revealing 100 % CF-release in both cases. Note the stability of 
liposomes after addition of H20 (A) and without any addition of Triton-X (C). Experiments show a measurement 
with n=3 (blue, green, red line, respectively) as a representative series of five independent measurements.  
 
As mentioned above, cleavage of full-length Bid is necessary for induction of its apoptotic 
function. In order to simulate the activation of Bid by caspase 8 and thereby to compare the 
pore-forming or membrane destabilizing abilities of full-length Bid and cleaved Bid, purified 
full-length Bid was modified through proteolysis by recombinant caspase 8 (Figure 53 A-C). 
Full-length Bid was already efficiently cleaved 0.5 h after caspase 8 incubation, as confirmed 
by gel-electrophoresis followed by coomassie staining (Figure 53 A) and western blot 
analysis (Figure 53 B), revealing the C-terminal fragment (tc Bid) and the 6.5 kDa N-terminal 
fragment (tnBid). As both, cBid and tBid are described to be pro-apoptotic and have been 
used in recently published mechanistic studies72, 77, 221, the following experiments were 
performed using cBid, without octylglucoside-mediated dissociation of the tcBid and tnBid 
fragment. The purity and integrity of the cleaved Bid samples S1 and S2 used for these 
studies was confirmed by gel-electrophoresis as shown in Figure 53 C.  
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Figure 54: Cleavage of full-length Bid with caspase 8. 
Purified recombinant full-length was cleaved with recombinant caspase 8 to obtain cleaved Bid (cBid). A, 
Recombinant Bid in 20 mM TRis (ph 7.4), 50 mM NaCl was diluted 1:1 with caspase-cutting buffer (50 mM 
HEPES (ph 7.5), 100 mM NaCl, 1 mM EDTA, 10 mM DTT, 10 % sucrose) and incubated with caspase 8 (7.6 
mg/ml) at RT. To determine the cutting efficiency, samples were taken at the indicated time points between 0 h 
and 2 h after caspase 8 incubation and analyzed by 12.5 % SDS-PAGE followed by coomassie staining. 
Complete cleavage was obtained already after 0.5 h. Control predicts full-length Bid without caspase 8 addition. 
B, western blot analysis confirms the successful production of tBid. C, Coomassie stained 12.5 % SDS-PAGE 
confirms the complete cleavage of full-length Bid 1.5 h after caspase 8 incubation. S1 and S2 indicate two 
different samples of cleaved Bid (cBid) that were used for membrane permeabilization assays.  
 
As cleaved Bid has been described as the protein with the more pronounced permeabilizing 
properties especially in the presence of CL, the effect of cBid was initially analyzed by adding 
increasing concentrations of cBid to cardiolipin-containing liposomes filled with 20 mM of CF. 
Upon protein addition, a clear concentratrion dependence of permeabilization rates for cBId 
could be detected (Figure 55 A). While no release of CF was observed using 10 nM of cBid, 
high concentrations of 6 µM increased the fluorescence values even though in slow kinetics 
(Figure 55 A). Of note, the cBid mediated fluorescence release did not reach 100 % 
compared to the Triton X release (Figure 55 B), resulting in an undervaluation of the 
liposome permeabilization. Experiments performed in parallel revealed a further increase in 
CF-release due to post-treatment of liposomes with Triton X. This is in line with recent 
reports observing similar results, when comparing the tBid- and cBid-induced fluorescence 
release to detergent-solubilization of liposomes72. As these results revealed the dose-
dependent membrane permeabilization mediated by cBid, the next step was to examine if 
the pore-forming ability of cBid is dependent on the presence of cardiolipin. In contrast to the 
reproducible CF-releasing effect of cBid on liposomes containing cardiolipin (Figure 55 C), no 
change in fluorescence was recorded when cBid was added to CF-incorporated liposomes 
lacking cardiolipin (Figure 55 B), confirming the previous reported importance of the 
phospholipid for Bid-mediated liposome permeabilization77, 91, 219. While these results 
revealed that cleaved Bid itself was able to induce CF release of liposomes at a 
concentration above 100 nM, full-length Bid showed no membrane destabilizing properties 
Results | 159 
 
 
 
as no change in fluorescence could be recorded after subjection of full-length Bid to the 
liposome channel activity assay (Figure 55 D, E). Notably, the absence of CF-release after 
Bid addition was independent of the presence or absence of cardiolipin (Figure 55 D, E).  
 
Figure 55: Permeabilization of cardiolipin-containing liposomes is induced by Bid in a 
concentration dependent manner, but not by full-length Bid. 
CF-containing liposomes with a lipid composition of PC/PE/CL: 54/20/26 were compared to liposomes lacking 
cardiolipin (CL) with a composition of PC/PE of 80/20. Both liposomes were stained with 1 % rhodamine DHPE, 
diluted in PBS and measured at RT for 3-5 min prior to protein addition. A, After addition of caspase 8 cleaved 
cBid in concentrations of 10 nM, 100 nM and 6 µM, change in fluorescence was measured over time. While 10 
nM of cBid was not sufficient to release CF and 100 nM showed slight increases in fluorescence, high 
concentrations of 6 µM increased fluorescence up to 600 RFU. B, cBid (6µM) was added to PC/PE liposomes 
lacking cardiolipin and fluorescence was measured at RT for further 25 min. No release of CF was detected. C, 
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Addition of cBid (6µM) to cardiolipin-containing induced the release of CF as indicated by increase in 
fluorescence. D, E, Addition of full-length Bid (6µM) to CF-liposomes containing PC and PE (D) and CF-liposomes 
containing cardiolipin in addition (E) did not induce release of CF as indicated by stable values of fluorescence. All 
experiments were performed with n=3 independent prepared liposome (green, blue, red line, respectively) 
samples and present a representative series of measurements from three independent experiments. cBid, 
caspase 8 cleaved Bid without dissociation of the t
c
Bid and t
n
Bid fragment. 
 
Since several previous reports described a Bax-induced lipidic pore formation that is 
accelerated by tBid71, 72, 77, 82, 91, 217-219, 225, the effect of recombinant Bax was examined on 
both, PC/PE- and PC/PE/CL-liposomes. In line with the abovementioned reports, no CF 
release was observed when Bax (100-500 nM) was added alone to the liposomes (Figure 
56 A, B). Intriguingly, post-addition of cBid to the Bax-liposome mixture had no effect on the 
liposome stability (Figure 56 A, B), while fluorescence release was clearly increased when 
both proteins, Bax and cBid, were pre-incubated prior to co-addition to the liposomes (Figure 
56 C).  These results indicate that either both proteins have to interact before recruitment to 
membranes, or that the sequential arrangement of cBid- and Bax- membrane association is 
essential for the subsequent permeabilization. The effects of the recombinant proteins Bid, 
cBid and Bax on lipid membranes obtained by the fluorescent liposome preparations were 
could be confirmed by preliminary data revealing the pore forming properties of cBid and Bax 
on CL-containing black lipid membranes (BLMs) produced by the Ionovation Compact 
system and measured by the Ionovation GmbH, Osnabrück, Germany. 
In order to examine, if the established liposome channel activity assay is a suitable system 
for testing the direct inhibitory effects of the Bid inhibitors, preliminary experiments were 
performed using the available Bid inhibitor BI-6c9 (Figure 56 D). As the cBid/Bax mixture 
induced the most prominent CF release of cardiolipin-containing liposomes, this set up was 
chosen to test the effect of BI-6c9 (10 µM).  Although BI-6c9 is well established to sufficiently 
inhibit Bid, addition of this inhibitor to the cBid/Bax mixture prior to co-addition to the CF-
containing liposomes resulted in only one of three measurements in a decrease of the 
cBid/Bax-induced fluorescence release (Figure 56 D). However, it should be noted, that the 
addition of BI-6c9 to the protein buffer immediately caused the partial precipitation of the 
compound, so that its effective concentration in solution cannot be estimated. Therefore, the 
failure of BI-6c9 to completely inhibit the cBid/Bax-induced fluorescence release might be 
due to undercharged concentration rather than to its failure to inhibit. Nevertheless, the 
results indicate that the CF-liposome channel activity assay is a well validated model system 
for mitochondrial membrane permeabilization and in general suitable as a primary in vitro 
screen for examining the effects of novel Bid inhibitors.  
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Figure 56: cBid-mediated permeabilization of cardiolipin-containing liposomes is increased by  
pre-incubation with Bax, and slightly reduced by the Bid inhibitor BI6c9.  
A, B, CF release of PC/PE- and PC/PE/C-containing liposomes was measured prior and after addition of Bax 
(100 nM) and cBid (10 nM), respectively. Bax alone was not able to permeabilize both types of liposomes and 
post-incubation with cBid did not increase the fluorescence values. C, Bax (500 nM) and cBid (6 µM) were pre-
incubated 5 min. prior to addition to cardiolipin- containing CF-liposomes. Changes in fluorescence were 
measured for 60 min after protein incubation. cBid-mediated permeabilization was increased in presence of Bax 
up to 1000 RFU. D, Cardiolipin-containing CF-liposomes were incubated with the cBid/Bax mixture in presence of 
the Bid inhibitor BI6c9 (10 µM). Only one of three samples revealed a decrease in fluorescence release 
(green line). Experiments reveal representative series of 2-3 measurements with n=3 (green, blue, red 
line). cBid, caspase 8 cleaved Bid without dissociation of the t
c
Bid and t
n
Bid fragment. 
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3.4 Role of VDAC1 in Bid-mediated mitochondrial demise and cell death 
In conditions of lethal stress increasing evidence points to a crucial role of mitochondrial 
dynamics and integrity for the decision between cellular life and death20, 24. The widely 
accepted role of the pro-apoptotic protein Bid in mediating mitochondrial injury and 
subsequent cell death24, 116, was elaborately substantiated in the abovementioned part of this 
thesis. While the sequences of Bid transactivation to mitochondria and the subsequent Bid-
dependent cell death pathways are well established, the precise mechanism by which Bid 
mediates MOMP and mitochondrial dysfunction is unknown. An alternative model to the Bcl-
2 family involvement in MOMP, is the opening of the mitochondrial permeability transition 
pore (mPTP) consisting of the voltage-dependent anion channel (VDAC), the adenine 
nucleotide transporter (ANT) and the matrix protein cyclophilin D, among other proteins23, 40. 
VDAC1 is proposed as the main channel-forming protein of the mPTP and it is reported to be 
involved in the regulation of mitochondrial apoptosis participating in the release of death 
promoting factors and interacting with anti-apoptotic proteins21, 125, 126, 131, 132, 157, 161. However, 
how these different mechanisms lead to MOMP and in particular whether Bcl-2 family 
proteins and VDAC are related to each other is widely discussed126, 130, 131, 151.  
Therefore, the next part of the present thesis addressed the question, whether the voltage-
dependent anion channel VDAC1 might serve as a rational target for Bid or its active form 
tBid to mediate MOMP and mitochondrial impairments in in vitro and in vivo paradigms of 
intrinsic cell death.  
 
3.4.1 Expression of VDAC1 and VDAC2 in HT-22 cells 
In mammals, three homologues genes encode three VDAC isoforms, namely VDAC1, 
VDAC2 and VDAC3132. The three proteins have similar molecular weights (30-35 kDa), each 
shares approximately 70 % identity, and all are highly conserved across species and can be 
found in most tissues125, 132, albeit in different amounts. VDAC1 is reported as the most 
abundant isoform in most cells, being ten times more prevalent than VDAC2 and 100 times 
more abundant than VDAC3 in HeLa cells226. Since a pore-forming activity and thereby a 
possible involvement in apoptosis has been discussed for VDAC1 and VDAC2, but not for 
VDAC3, further work focused on these two isoforms. To confirm, that both proteins are 
expressed in the neuronal HT-22 cell line, and to further determine the more prominent 
isoform, mRNA levels of VDAC1 and VDAC2 were verified by RT-PCR (Figure 57). 
Compared to the high and equable expression levels of VDAC1 in control and glutamate 
exposed HT-22 cells, VDAC2 is expressed in a less amount, confirming VDAC1 as the most 
abundant sub-type in this cell line (Figure 57). Notably, mRNA levels of VDAC2 apparently 
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decreased after glutamate exposure of HT-22 cells as determined by RT-PCR (Figure 57). 
However, this decrease could not be confirmed on the protein level by western blot. 
 
Figure 57: Expression levels of VDAC1 and VDAC2 in HT-22 cells. 
Expression levels of VDAC1 and VDAC2 in HT-22 cells in the absence and presence of glutamate exposure were 
examined by RT-PCR using specific primers for VDAC1 and VDAC2, respectively. RT-PCR with primers specific 
for glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was used as control. Note, that the isoform VDAC1 is 
much more higher expressed than VDAC2, indicating VDAC1 as the most abundant isoform in HT-22 cells. 
VDAC1 levels in HT-22 control cells are not altered after glutamate-induced cell death of cells.  
 
Since these data confirmed the expression of VDACs in HT-22 neurons, revealing VDAC1 as 
the most prominent voltage-dependent anion channel, further study addressed the role of 
VDACs in glutamate- and Bid-mediated neuronal cell death pathways. 
 
3.4.2 The anion channel blocker DIDS provides neuroprotection in HT-22 cells 
The anion channel blocker DIDS was used in order to gain an initial insight to the question of 
whether VDAC1 plays a relevant role in Bid-dependent mechanisms of neuronal cell death. 
Due to the lack of specific inhibitors for the subunit VDAC1, the existence of several side 
effects of the abused VDAC inhibitor König´s polyanion227-229, and the apoptosis-inducing 
ability of the VDAC targeting phosphorothioate (PS) oligonucleotide G3139230, the anion 
channel blocker and well accepted VDAC inhibitor 4,4´-diisothio-cyanatostilbene-2,2´-
disulfonic acid (DIDS)148, 158, 231 was subjected to the following experiments. 
3.4.2.1 DIDS protects against glutamate-induced toxicity 
According to other studies reporting a protective role of DIDS against neuronal injury, 
particularly preventing penumbral cell death232 and accordingly delayed neuronal death in 
hippocampal neurons after transient forebrain ischemia233, a significant neuroprotective effect 
of DIDS could be revealed in the model of glutamate-induced toxicity in HT-22 cells. 
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The morphological phenotype of glutamate-induced injury was clearly prevented by DIDS in 
applications of 500 µM up to 1 mM, respectively, preventing the retraction of cellular 
processes and shrinking of glutamate-exposed HT-22 cells (Figure 58 A). In addition, DIDS 
was able to enhance cell viability in glutamate-treated cells (3 mM, 17 h) in a concentration-
dependent manner as detected by the MTT assay (Figure 58 B, C). Real-time impedance 
measurements (Figure 58 D) confirmed a transient protective effect of DIDS in concentration 
ranges from 250 µM up to 750 µM, yet a persistent protection at 1 mM (Figure 58 C, D). 
Notably, low micromolar concentrations of DIDS revealed no protective properties against 
glutamate-induced reduction in cell viability and proliferation (Figure 58 B, C). This is in line 
with other studies, using DIDS mostly in the upper micromolar range231, 232, 234, presumably 
due to the high polar structure of DIDS possibly hampering its passage through hydrophobic 
cell membranes. Therefore, further examinations were mostly performed using 500 µM and 
1 mM of DIDS in parallel. 
Although increasing evidence has suggested that DIDS provides protection in a variety of 
experimental preparations, including the inhibition of neuronal cell death induced by several 
apoptotic factors235-238, it was reported in contrast that DIDS acts as an apoptotic inducer in 
hippocampal HT-22 neurons234. To address this confounding finding, FACS analysis of 
apoptotic cells after annexin-V/propidium iodide-staining of HT-22 neurons were performed. 
Therefore, HT-22 cells were treated with DIDS at concentrations of 500 µM and 1 mM in the 
absence and presence of glutamate (3 mM) and cell death was detected 16-18 h after 
treatment. In contrast to the reports of Pamenter et al.234, a DIDS-induced apoptosis was not 
detectable in any concentration (Figure 59 A, B). DIDS treatment of HT-22 neurons neither 
increased annexin V binding to cells, which would indicate apoptosis induction, nor induced 
the uptake of propidium iodide in necrotic cells. In fact, both concentrations of DIDS were 
sufficient to significantly abolish the glutamate-induced cell death (63 ± 3 %) up to control 
levels (6 ± 1 %) (Figure 59 A, B). Thus, these data confirm the neuroprotective effects of 
DIDS in HT-22 cells and might indicate a critical involvement of VDACs in the mechanisms of 
glutamate-induced intrinsic cell death. 
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Figure 58: DIDS protects against glutamate-induced toxicity. 
A, Photomicrographs (10 x 0.25 NA objective) of HT-22 cells. The anion channel blocker DIDS (500, 1000 µM) 
preserves the spindle-like cell morphology of HT-22 cells after glutamate treatment (3 mM, 17 h). B, C, Cell 
viability of HT-22 cells was analyzed by MTT assay 17 h after glutamate exposure (3 mM). DIDS provides 
significant protection against glutamate-induced cell death in a concentration-dependent manner. D, Real-time 
analysis of cell impedance for 22 h after glutamate treatment (3 mM) confirmed the transient protection of DIDS 
against glutamate toxicity. While concentrations of 250 µM reveal only slightly protective effects, high 
concentrations of 1 mM prohibit cell injury about 10 h after glutamate challenge. The Bid inhibitor BI-6c9 (10 µM) 
is used as positive control for protection against glutamate- induced toxicity. All experiments were independently 
repeated at least three times with n = 8 per treatment condition. Data are predicted as mean ± SD (*p < 0.05, 
***p < 0.001 compared to glutamate treated vehicle, ANOVA Scheffé´s test). 
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Figure 59: DIDS attenuates apoptotic and necrotic cell death. 
A, B, HT-22 cells were co-treated with DIDS and 3 mM toxic glutamate solution. A, FACS analysis of annexin-
V/propidium iodide-stained HT-22 cells depicts dead cells in the upper right corner and healthy cells in the lower 
left corner. Note that glutamate- induced cell death (61±3 %) is completely prevented by DIDS in a concentration 
of 500 µM and 1000 µM. Numbers are mean percentages ± SD for three cell groups treated as indicated in the 
corresponding quadrants. Glut, Glutamate, 3 mM. B, Quantification of AV
+
/PI
+
- cells (A), indicated as percentage 
of dead cells. The Bid inhibitor BI-6c9 (10 µM) is used as positive control for neuroprotection. All Experiments 
were independently repeated at least three times. (***p < 0.001 compared to glutamate treated vehicle and 
control, #p<0.05 compared to control, n=8, ANOVA, Scheffe´test). 
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3.4.2.2 DIDS preserves mitochondrial integrity and function 
In order to investigate the potential mechanisms behind the protection mediated by DIDS, 
mitochondrial integrity and function was assessed. 
3.4.2.2.1 Mitochondrial energy metabolism and respiratory activity is maintained by 
the anion channel blocker DIDS 
Mitochondrial dysfunction, with the resulting compromise of cellular ATP supply and 
impairments in the respiratory chain, is an essential event described to ultimately trigger cell 
death6. As an important role of VDAC1 in the exchange of ATP/ADP and other metabolites 
into and out of the mitochondria as well as its involvement in oxidative phosphorylation has 
been described previously39, 138, 141, the effect DIDS on mitochondrial energy metabolism and 
respiratory activity was investigated to determine if DIDS might act on mitochondrial VDAC1. 
Notably, high doses of DIDS (750 µM and 1 mM) decreased basal cellular ATP levels of HT-
22 cells, but significantly restored the further rapid ATP decline after the onset of glutamate 
exposure (Figure 60 A), indicating that VDAC inhibition by DIDS is sufficient to rescue 
metabolic functions in mitochondria. These findings were further substantiated by 
measurements of oxygen consumption rate (OCR). In accordance to previous experiments 
using this method, glutamate induced a remarkable reduction in mitochondrial maximum 
respiration and respiratory capacity (Figure 60 B, C). Concentrations of 500 µM DIDS 
preserved both impairments (Figure 60 B), though high concentrations of 1 mM DIDS 
affected mitochondrial respiration already under control conditions (Figure 60 C).  
These data accentuate VDAC inhibition as a suitable tool for further investigations of 
mechanisms that trigger mitochondrial demise and point to VDAC as a possible target for 
neuroprotection against glutamate-induced cell injury.  
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Figure 60: The anion channel blocker DIDS maintains mitochondrial energy metabolism and 
respiratory activity.  
HT-22 cells were co-treated with glutamate (4-5 mM) and DIDS (500 µM or 1000 µM) or BI-6c9 (10 µM). 
Seventeen to twenty hours after the onset of glutamate mitochondrial integrity was analyzed. A, ATP-
luminescence measurements of HT-22 cells. High concentrations of DIDS (750 µM and 1000 µM) reduced basal 
ATP level, but prevented glutamate-induced ATP-depletion. The Bid inhibitor BI-6c9 was used as a positive 
control for restored ATP level after glutamate challenge( ### p < 0.001 compared to control, *** p < 0.001 
compared to glutamate treated vehicle (ANOVA, Scheffé´s test). Experiments were independently repeated 3 to 5 
times. B, Oxygen consumption rate (OCR) of HT-22 cells, treated as indicated, was measured by using the 
Seahorse Bioscience system. Glutamate-induced reduction in mitochondrial maximum respiration and respiratory 
capacity was prevented by co-treatment with DIDS (500 µM). Treatment of cells with high concentrations of 1 mM 
DIDS were less protective against impairments in mitochondrial respiration. The results are representatives of 3-4 
experiments. 
 
3.4.2.2.2 DIDS is sufficient to prevent lipid peroxidation, mitochondrial fission and 
permeabilization of the mitochondrial outer membrane of HT-22 cells 
The suspicion that plays a crucial role in the mechanisms of glutamate-induced Bid-mediated 
mitochondrial demise was substantiated as a pronounced protection against increases in 
detrimental ROS formation was achieved by DIDS (Figure 61 A, B). BODIPY-FACS analysis 
revealed a significant production of lipid peroxides in HT-22 cells 18 h after glutamate 
exposure, indicated by increases in green fluorescence (Figure 61 A). This late and 
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secondary boost in lipid peroxides, previously shown to be caused by Bid-mediated 
mitochondrial dysfunction116, was not affected by DIDS in concentrations of 500 µM, but 
completely blocked when applied at concentrations of 1 mM (Figure 61 A, B).  
 
 
Figure 61: DIDS prevents glutamate-induced ROS formation. 
A,B, BODIPY-FACS analysis of lipid peroxides. HT-22 cells were treated with DIDS (500 µM or 1000 µM) or BI-
6c9 (10 µM) 24 h after seeding. Lipid peroxide formation was determined 17 h after the onset of glutamate 
(4 mM). A, Values in the corresponding quadrants predict mean percentages ± SD for three indicated treatment 
groups. Note, that formation of lipid peroxides is completely preserved by DIDS (1000 µM) and comparable to the 
preservation of ROS by Bid inhibition (BI-6c9). B, Quantification of lipid peroxides in HT-22 cells after glutamate 
and DIDS co-treatment. The experiment was repeated four times with n = 3-4 and results provided as mean ± SD 
(*** p < 0.001 compared to glutamate treated vehicle, ANOVA, Scheffé test).  
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Analyses of mitochondrial morphology confirmed the protective potential of DIDS in the 
model of glutamate-induced toxicity. Application of DIDS (500 µM and 1 mM) preserved the 
tubular mitochondrial morphology and completely rescued HT-22 cells from glutamate-
induced mitochondrial fission (Figure 62 A, B). Quantification of mitochondrial morphology 
substantiated the potent effect of DIDS, revealing that the anion channel blocker increased 
the overall mitochondrial length thereby shifting the majority of mitochondria into category I in 
glutamate-treated HT-22 cells (Figure 62 B).   
Previous reports described a VDAC1 mediated breakdown of the mitochondrial membrane 
barrier and the subsequent cell death through mitochondrial dysfunction143, 144. Since the loss 
of mitochondrial membrane potential (Δψm) is a major feature of glutamate-induced cell death 
that is associated with mitochondrial fragmentation24, 97, the further experiments addressed 
the impact of DIDS, as a tool for VDAC inhibition, on the functional integrity of mitochondrial 
membranes. TMRE-FACS staining of HT-22 neurons revealed a glutamate- induced 
reduction in red fluorescence in glutamate-treated cells (Figure 62 C) indicating a decrease 
in Δψm 17 h after glutamate challenge. In contrast, DIDS prevented the pronounced 
depolarization of the mitochondrial membrane and showed significantly higher Δψm than 
glutamate exposed control cells (Figure 62 C, D).  
Notably, the pronounced protection against various hallmarks of glutamate-induced toxicity 
achieved by DIDS was similar to the protective effects of the Bid inhibitor BI-6c9, which was 
always applied in the experiments as a positive control for neuroprotection (Figure 58 - 
Figure 62). This finding strongly assumes a close relationship between the mechanisms 
behind both protective effects, mediated by Bid inhibition or DIDS, and might indicate a close 
interrelationship among mitochondrial anion channels and the BH3-only protein Bid. 
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Figure 62: DIDS prevents mitochondrial fission and loss of Δψm. 
A, HT-22 cells were stained with Mitotracker red and co-treated with glutamate (4 mM) and DIDS (500 µM) or 
BI6c9 (10 µM). Confocal fluorescence photomicrographs reveal mitochondrial fission 17 h after glutamate 
challenge, which is preserved by DIDS and BI-6c9. B, Quantification of mitochondrial morphology: Category I: 
elongated, category II: intermediate, category III: fragmented mitochondria. Data represent the mean ± SD of 
three independent experiments, each with 500 cells per treatment condition (###p < 0.001 compared to category 
I, ***p < 0.001 compared to category III in glutamate treated vehicle, ANOVA, Scheffé test). C, Mitochondrial 
membrane potential (Δψm) of HT-22 cells treated with DIDS (500 µM and 1000 µM) was analyzed by TMRE-
FACS recordings 17 h after glutamate treatment (4 mM). Numbers are mean percentages ± SD of TMRE 
fluorescence for n = 3 indicated treatment groups. Glutamate treated HT-22 cells showed significantly reduced 
red fluorescence compared to controls, whereas DIDS treatment prevented the breakdown of the mitochondrial 
membrane potential as indicated by preservation of the red TMRE-fluorescence. D, Quantification of TMRE 
fluorescence of HT-22 cells co-treated with DIDS (500 µM or 1000 µM) in the presence and absence of 
glutamate. The experiment was independently repeated three times with n = 3 per treatment group, data are 
provided as mean ± SD (*** p < 0.001 compared to glutamate treated vehicle, ANOVA, Scheffé test). 
 
3.4.2.3 DIDS prevents tBid-induced mitochondrial depolarization and cell death 
To further clarify whether DIDS provides protection downstream of Bid activation, the anion 
channel blocker was applied to the model of tBid-induced toxicity (3.1.2). As described 
above, over-expression of tBid induced characteristic alterations in cell morphology indicating 
cytotoxicity, such as retraction of cell processes, rounding up and detaching from the culture 
dish (Figure 63 A). These morphological changes were clearly preserved in cells pre-treated 
with DIDS (500 µM and 1 mM). The tBid-induced toxicity in HT-22 cells was further detected 
by FACS analysis of tBid-expressing cells after annexin V/propidium iodide staining (Figure 
63 B, C) and cell viability measurements by MTT assay (Figure 63 D). DIDS was sufficient to 
prevent both, the tBid-induced increases in AV/PI positive cells (ptBid, Figure 63 B, C) as 
well as tBid-induced reduction in cell viability (Figure 63 D). Notably, application of DIDS was 
as effective against tBid toxicity as Bid inhibition by the Bid inhibitor BI-6c9 (Figure 
63 A, C, D), confirming DIDS´action downstream of tBid activation. The fact, that DIDS 
achieved an even more pronounced protection than BI-6c9 might be allegeable through 
additional unspecific effects of DIDS on the level of mitochondria (Figure 63 B-D). 
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Figure 63: tBid-induced toxicity in HT-22 cells is prevented by DIDS. 
HT-22 cells were pre-treated with the anion channel blocker DIDS (500 µM and 1000 µM) or the Bid inhibitor 
BI6c9 (10 µM, positive control for protection) 1 h before transfection with a tBid-encoding plasmid (ptBid/pIRES-
tBid). A, Photomicrographs (10 x 0.25 NA objective) show morphological changes of HT-22 cells 18 h after tBid 
over-expression. B, C, Annexin-V/propidium iodide-FACS analysis of tBid-over-expressing cells. Numbers are 
mean percentages ± SD for three cell groups treated as indicated in the corresponding quadrants. C, 
Quantification of AV
+
/PI
+
- cells (b), indicated as percentage of dead cells. D, tBid-induced reduction in cell viability 
was significantly prevented by DIDS (500 µM) as determined by MTT assay. (***p < 0.001 compared to tBid over-
expressing vehicle) Experiments were independently repeated 3 to 5 times with n = 4 per treatment group. 
Results are predicted as mean ± SD. 
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Final evidence that DIDS attenuates tBid-mediated mitochondrial dysfunction was achieved 
from TMRE-FACS measurements (Figure 64 A, B). tBid over-expression induced a reduction 
in red TMRE fluorescence up to approximately 50 % of control cells, which was fully restored 
by pre-treatment of cells with DIDS (500 µM and 1 mM, Figure 64 A, B).  As these data 
reveal that tBid-induced loss of Δψm and cell death was significantly attenuated by DIDS-
mediated VDAC inhibition, they do not only substantiate the hypothesis that VDACs are 
involved in glutamate- and tBid-induced cell death pathways, but also leads to the 
assumption that VDAC- and Bid-associated MOMP mechanisms are related to each other. 
 
Figure 64: DIDS prevents tBid-induced loss of Δψm. 
HT-22 cells were pre-treated with the anion channel blocker DIDS in concentrations of 500 µM and 1000 µM 1 h 
before tBid-transfection. A, TMRE-FACS analyses reveal a tBid-induced loss of Δψm, which is prevented by DIDS. 
Drop in red TMRE fluorescence indicates loss of Δψm (left side), high red fluorescences indicate intact 
mitochondria (right side). Numbers are mean percentages ± SD of TMRE fluorescence of three indicated 
treatment groups. B, Quantification of TMRE fluorescence confirmed the protective effects of DIDS against tBid- 
induced breakdown of Δψm. (*** p < 0.001 compared to tBid over-expressing vehicle) Experiments were 
independently repeated five times and data presented as mean ± SD. 
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3.4.3 Direct and functional interaction between Bid/tBid and VDAC1  
Based on the data above, a close interplay between Bid and mitochondrial anion channels, 
likely VDACs, relating to intrinsic mitochondrial cell death pathways was suggested. This 
implication was supported by previous reports suggesting that Bid reduces metabolic 
exchanges between mitochondria and the cytosol through interactions with VDACs thereby 
leading to impaired mitochondrial function161. Although a close interplay of VDAC with Bcl-2 
family proteins such as Bcl-xl, Bax or Bid has been proposed157, 159, 161, 162, a direct interaction 
of VDAC1 with any of these Bcl-2 family members had not yet been demonstrated on the 
cellular level. Therefore, the further effort of this thesis was to prove the assumed interaction 
between both proteins and to scrutinize whether a disturbance of the Bid-VDAC interplay 
might be the underlying mechanism of the protective effects achieved by VDAC inhibition.   
Since determining protein-protein interactions within living cells is challenging as the 
detection might depend on several circumstances, including cell type, cell death stimuli as 
well as buffer and reagents used for the different binding studies, a possible interplay 
between Bid and VDAC1 was first examined in vitro using recombinant proteins.  
 
3.4.3.1 In vitro Bid-VDAC1 binding assays confirm the direct interaction of 
both proteins   
The first evidence of a direct interaction of Bid and its active form tBid with VDAC1 was 
derived from in vitro Bid- VDAC pull down assays. (Figure 65 A, B) Purified recombinant 
VDAC1 (mVDAC1) bound to recombinant His6-tagged Bid (His-rBid) as well as to 
recombinant truncated Bid ((His)-rtBid) as shown by SDS-PAGE and western blot analysis 
(Figure 65 A, B).  
 
Figure 65: Direct interaction between recombinant Bid/tBid and VDAC1. 
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Direct interaction between rVDAC1 and rBid was confirmed by in vitro Bid/tBid-VDAC1 binding assays. A, Purified 
recombinant His-rBid and rVDAC1 were incubated for 2 h before incubation with NTA- Agarose (2 h) on a poly-
prep
®
 chromatography column. Elution fractions (E) and wash fractions (W) were aceton precipitated and 
analyzed by SDS-Page and coomassie staining. Recombinant rBid and rVDAC1 were used as protein size 
controls. E: Elution fractions, W: wash fractions. B, The direct interaction between purified rBid and rVDAC1 was 
confirmed by western blot analysis. For generation of tBid, recombinant full-length Bid was incubated with 
recombinant caspase 8 for 2 h at RT. Pull down of His-rBid and His-rtBid was done as described in A. Elution-
fractions (E) and wash-fractions (W) were analyzed by SDS-PAGE followed by western blot. Anti-Bid antibody 
was used to detect full-length Bid as well as tBid (upper panel).  Direct binding of VDAC1 to full-length Bid and 
tBid was indicated by clear VDAC1 bands in His-rBid and His-rtBid elution-fractions. For comparison, deletion of 
the N-terminal helix of VDAC1 (rVDAC1 Δ11) did not affect co-IP with Bid. 
 
3.4.3.2 Thermophoresis analysis results in different binding affinity 
coefficients (KD) for tBid and Bid binding to VDAC1 
Although a crucial role of tBid for VDAC1 activity was proposed previously161,  a convincing 
characterization of the direct interaction between these proteins was missing. To address this 
problem, thermophoresis measurements of AlexaFluor 532 C5 maleimide-labeled 
recombinant mVDAC1 with purified Bid and tBid were performed and revealed apparent 
dissociation constants (KD) of 37.1 ± 1.12 µM for tBid- and 1420 ± 3.04 µM for Bid binding to 
VDAC1, respectively (Figure 66 C). These KD values indicated a 38-fold stronger binding of 
tBid to VDAC1 compared to the binding of full length Bid. Nonspecific binding of Bid/tBid to β-
barrels or detergent micelles was ruled out since no tBid/Bid binding was detected in 
experiments using either the Escherichia coli outer membrane protein G (OmpG) or empty 
detergent micelles. In consequence these in vitro observations suggested a highly specific 
mode of interaction between VDAC1 and tBid (Figure 66 A). 
 
Figure 66: Thermophoresis measurements revealed KD values for Bid/tBid binding to VDAC1. 
Thermophoresis measurements confirmed the specific and direct interaction between Bid/tBid and VDAC1 and 
revealed KD values of 37.1 µM for tBid- (dots, blue line) and 1420 µM for Bid- (squares, red line) binding to 
fluorescently labeled mVDAC1. The concentration of Bid/tBid was varied from 15 nM to 500 µM, whereas a 
constant concentration of 50 nM for mVDAC1 and OmpG was used. After 20 min incubation at RT in the dark the 
mixtures were loaded to MST-grade capillaries and thermophoresis studies were performed using the Monolith 
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NT-115. Fluorescently labeled OmpG was used as a negative control to exclude unspecific interaction between 
tBid and β-barrels: Addition of Bid to OmpG leads to no significant change in the thermophoretic signal (triangle, 
green line). Bars represent SD of three independent measurements. Thermophoresis measurements were kindly 
performed by Barbara Mertins (Group of Prof Essen, Department of Chemistry, University of Marburg, Marburg, 
Germany). 
 
3.4.3.3 tBid facilitates a reduction in the VDAC1 channel´s conductance, while 
DIDS addition promotes a VDAC1 channel closure 
Based on this data, showing that tBid and Bid both bind to VDAC1, the impact of this 
interaction on VDAC1 channel activity was further examined. It was previously described that 
addition of tBid to membrane reconstituted VDAC1 leads to a reduced conductivity state of 
VDAC1 in black lipid membrane (BLM) measurements and a Bid-induced VDAC closure was 
hypothesized even though a physical interaction of VDAC with tBid had not been 
demonstrated161.  
Indeed, the addition of tBid to mVDAC1-containing planar lipid bilayers (BLM), facilitated a 
reduction in the channel´s conductance but did not promote formation of the expected 
VDAC1 sub-conducting closed states. Native mVDAC1 exhibited the expected gating 
behavior, responding linearly to the application of both positive and negative potentials, and 
alternating between high and low conducting states128, 129, 154. In line with previous findings188,  
in voltage ranges of -40 to +40 mV native-like mVDAC1 occupied the fully open S0 state with 
a conductance of 3.94±0.04 nS  and the closed S1 and S2 states with conductances of 
2.61±0.01 nS and 1.90±0.06 nS respectively (Figure 67 A). Following the addition of 
recombinant tBid, the channel´s conductance suffered a 23% reduction (3.05±0.24 nS, 
N=131) with respect to that of the S0 state (unpaired T-test: P=10-4) (Figure 67 A, blue 
squares, B). Furthermore, tBid induced minor yet atypical fast channel switching transitions 
(Figure 67 C). Since the tBid-lowered conductance differed significantly from the closed-state 
S1 and S2 conductances (unpaired T-test: P=10-4) it seems highly likely that the tBid-VDAC1 
interaction promotes a conformational change of the VDAC1 channel rather than its full 
closure. The effect of tBid addition on VDAC1 channels was further compared with the 
VDAC1 channel behavior after addition of the VDAC inhibitor DIDS. Notably, addition of 
DIDS to reconstituted mVDAC1 resulted in a 1.6-fold reduction of VDAC1 conductance 
(2.47± 0.03 nS, N = 50) (Figure 67 D), and no switching transitions were recorded for up to 
one hour. Since the lowered conductance mediated by DIDS is between the closed S1 and 
S2 states of VDAC1, it suggests that DIDS directly alters VDAC1 gating and affects channel 
closure. Based on this observation, it is highly likely that DIDS occupies the same biniding 
side as tBid albeit with higher affinity, since tBid assumedly fails to interact with mVDAC1 in 
DIDS presence. 
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In conclusion, these data clearly demonstrated not only a highly specific interaction between 
recombinant Bid/tBid and VDAC1 but also indicate the impact of this interaction on the 
VDAC1 channel´s behavior in vitro. 
 
 
Figure 67: tBid promotes a reduction in the VDAC1 channel´s conductances, while DIDS 
triggers VDAC1 closure 
A, The conductance values of the corresponding VDAC1 channel states were determined by using Ohm-plots 
Reconstituted native mVDAC1 responded linearly to application of both positive and negative potentials, 
alternating between an open (S0; grey) and two major (S1; red and S2; green) closed states. After tBid addition to 
the cis-side of the BLM chamber, the overall conductance of the channel drops to 77% compared to S0 (blue). 
Determined conductances: S0; 3.9±0.0 nS, S1; 2.6±0.0 nS; S2; 1.9±0.1 nS and after tBid addition; 3.0±0.2 nS. 
Bars represent standard errors of a minimum of 10 replicates per measurement. B, Representative traces of 
mVDAC1 (black), mVDAC1 after tBid (red) and DIDS (green) addition at +10 mV. Addition of tBid resulted in a 
reduced VDAC1 channel conductivity by approximately 23% compared to the open state of mVDAC1 (S0). C, A: 
representative trace of the mVDAC1 gating activity at +40 mV. The observed S0, S1 and S2 states, in the + 
40 mV trace, are indicated by blue, red and green lines respectively. B: representative trace of mVDAC1 after 
addition of tBid at +40 mV. The channel shows minor yet atypical fast channel switching events. D, Ohm-plots 
were used for determining the VDAC1 channel conductance before and after addition of the VDAC inhibitor DIDS. 
Reconstituted native mVDAC1 responded linearly to application of both positive and negative potentials and 
revealed the expected gating behavior as described in A. DIDS addition to the cis-side exhibited a 1.6-fold 
reduction in its conductance (2.47±0.03 nS, N=50 , blue). BLM measurements were kindly performed by the 
group of Prof Essen (Department of Chemistry, University of Marburg, Marburg, Germany). 
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3.4.4 Direct interaction of Bid and VDAC1 in cultured neurons  
Encouraged by the findings above, a further aim was to examine if the Bid-VDAC1 
interaction measured in vitro can be transferred to cell culture and in vivo models. Initially this 
goal was probed in the hippocampal HT-22 neurons subjected to the toxic effects of 
glutamate thereby analyzing the proposed interplay between Bid and VDAC1 in relationship 
to intrinsic cell death mechanisms. Indeed, immunoprecipitation studies using protein 
extracts from this neuronal cell line provided the first evidence of the interaction of Bid and 
VDAC1 in living cells, as western blot analysis revealed an increased binding of VDAC1 to 
Bid after glutamate challenge (Figure 68 A). Notably, 12 h after glutamate exposure, a 70 
kDa protein bound to Bid was detected by the applied anti-VDAC1 antibody (Figure 68 A), 
indicating that activated Bid binds to VDAC1 dimers that may form upon glutamate treatment. 
This finding is consistent with previous studies showing that VDAC1 dimerization and 
oligomerization increase substantially upon apoptosis induction239, 240. As VDAC1 is 
discussed as a component of the permeability transition pore (PTP), which is a multi-protein 
complex consisting of VDAC, the adenine nucleotide transporter (ANT), the matrix protein 
cyclophilin D, and likely other proteins23, 40, 241, 242, co-immunoprecipitations of Bid with VDAC1 
from HT-22 cells did not necessarily indicate the direct association of these two proteins as 
other proteins may also be involved in a higher complex. The proposed direct interaction of 
Bid and VDAC1 was finally confirmed by co-immunoprecipitations of endogenous VDAC1 
and FLAG-VDAC1 expressed in the HT-22 cells (Figure 68 B, C). Both, VDAC1- and FLAG-
VDAC1 immune complexes revealed an increasing binding of Bid between 6-15 h after 
glutamate exposure (Figure 68 B, C). The fact that a direct binding of Bid and VDAC1 only 
occurred after glutamate exposure indicates that this interaction is an essential step in 
mitochondrial death pathways. 
As immortalized HT-22 hippocampal neurons, lack ionotropic NMDA and AMPA/kainate 
receptors, cell death is initiated through glutathione depletion after glutamate-induced 
inhibition of the glutamate-cystine antiporter243. Consequently, the HT-22 model of glutamate-
induced oxidative stress only partly reflects the mechanisms of neuronal death after acute 
brain injury. In primary cortical neurons, glutamate-induced excitotoxicity involves an 
immediate increase in the intracellular Ca2+-concentration through activation of NMDA 
receptors. However, this initial calcium overload triggers the increase of reactive oxygen 
species and the subsequent mitochondrial damage as it occurs likewise in the HT-22 cells. 
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Figure 68: Direct interaction of Bid and VDAC1 after the onset of glutamate exposure in HT-22 
cells. 
Immunoprecipitation analyses of Bid and VDAC1 protein revealed a direct interaction between Bid and VDAC1 6-
15 h after glutamate exposure of HT-22 cells. A, Immunoprecipitation of Bid protein was prepared from 2.5 mg 
total protein lysate of HT-22 cells exposed to 3 mM glutamate at the indicated time points of 8-12 h. Western blot 
panels on the left side show results from the Bid pull down and on the right side total protein lysates with 30 µg 
protein. Eight hours after the onset of glutamate a pronounced binding of VDAC1 to Bid is detected.  12 h after 
glutamate exposure a 70 kDa protein was detected by the applied VDAC1 antibody (Santa Cruz, VDAC1-N18), 
indicating VDAC1 dimerization. B, Immunoprecipitation of endogenous VDAC1 protein confirmed the direct 
interaction between VDAC1 and Bid in glutamate-treated HT-22 cells. Western blot panels on the left side reveal 
an increasing Bid binding to pull downed VDAC1 between 6 h to 15 h after the glutamate challenge. Total protein 
lysates, depicted on the right side, were used as controls. C, HT-22 cells were transfected with a FLAG-VDAC1 
encoding plasmid and treated with glutamate 24 h after transfection. Western blot analysis of Flag-
immnoprecipitations of FLAG-VDAC1 protein from HT-22 cells exposed to 5 mM glutamate at the indicated time 
points of 0 h-15 h confirm the increasing Bid binding to VDAC1 during cell damage. To rule out unspecific binding 
of Bid to the FLAG-tag, a negative control containing only a FLAG-plasmid without VDAC1 sequence was used as 
control. Western blot panels on the right side show total protein lysates, confirming an equal expression of FLAG-
VDAC1 in the indicated protein samples. All western blots are representatives of at least 3-4 independent 
experiments. 
 
To confirm, the relevance of the described Bid-VDAC1 interplay as an essential key in the 
mechanisms of neuronal death after brain injury and to exclude a cell type specific 
appearance, the proposed interaction was confirmed in the model of glutamate-induced 
excitotoxicity in primary cortical neurons (PCN) (Figure 69). Therefore, primary mouse 
cortical neurons were exposed to 25 µM glutamate solution after 7-9 days in culture, when 
ionotropic glutamate receptors were expressed and the neurons are highly sensitive to 
glutamate. Immunoprecipitations were performed 4 h to 22 h after excitotoxicity and 
confirmed the direct interaction between Bid and VDAC1 (Figure 69). In line with our findings 
in HT-22 cells, the Bid-VDAC1 interaction was also clearly detected at later time points after 
glutamate-induced excitotoxicity in PCNs, while no binding was detected under control 
conditions (Figure 69). 
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Figure 69: Direct interaction between Bid and VDAC1 in primary cortical neurons. 
Immunoprecipitations of endogenous Bid and VDAC1 protein (left side) and total protein lysates (right side) from 
primary cortical neurons exposed to 25 µM glutamate at the indicated time points. Bid and VDAC1 
immunoprecipitations were prepared from 1 mg to 1.5 mg total protein lysat from PCNs 0 h, 4 h and 22 h after the 
induction of glutamate-induced excitotoxicity. PCNs were treated on day 7-9 after culturing to ensure NMDA 
receptor expression. While no interaction was detected in controls and after 4 h excitotoxicity, a direct interaction 
was revealed 22-24 h after treatment. Total lysates confirm the equal expression of both proteins in all samples. 
The data are representative western blots from 4 independent experiments. 
3.4.5 Direct interaction of Bid and VDAC1 during ischemic brain damage in 
vivo 
The described cell culture findings on both a neuronal cell line and primary neurons led to 
further examinations in whole organisms, in a model of cerebral ischemia (Figure 70 A, B, C). 
The model of transient middle cerebral artery occlusion (MCAo) was conducted by Uta 
Mamrak and the following immunoprecipitations were performed together with Lilja Meissner 
at the Ludwig-Maximilians-University in Munich, Germany. 
The C57BL/6 mice were subjected to 60 min of transient focal ischemia by introducing a 
silicon-coated nylon filament into the internal carotid artery to occlude the middle cerebral 
artery (MCA), followed by reperfusion. Co-immunoprecipitation studies were performed from 
tissue homogenates of the cortical penumbra 2 h, 6 h and 24 h after the onset of ischemia, 
respectively. In these homogenates, Bid–VDAC1 interaction became detectable at 6 h and 
24 h after ischemia in all mice subjected to transient MCAo. While the interaction significantly 
increased over 6-24 h in the ischemic brain tissue, no interaction was found at early time-
points, i.e. 2 h after ischemia or in the contralateral controls (Figure 70 A, B, C).  
Consequently, these data confirmed the importance of the Bid-VDAC1 association in 
glutamate-induced cell death in HT-22 cells and primary neurons, further highlighting the 
relevance of this interaction in an in vivo model for human disease. 
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Figure 70: Direct interaction of Bid and VDAC1 during ischemic brain damage in vivo. 
A, Western blot analyses reveal results from immunoprecipitation studies of Bid (left panel) and VDAC1 protein 
(middle panel) and total protein lysates (right panel) from control (ctr) and ischemic (MCAo) brain tissue of mice 
2 h, 6 h, and 24 h after transient middle cerebral artery occlusion (MCAo). 6 h and 24 h after transient ischemia a 
direct interaction of Bid and VDAC1 was detected, while no interaction was observed at early time points (2 h) 
after MCAo. Contralateral controls showed no interaction at all, confirming the relevance of the Bid-VDAC1 
binding during neuronal injury. B, C, Box-blots reveal significant VDAC1-Bid binding (B) and Bid-VDAC1 binding 
(C) in brain tissue of mice 6 h and 24 h after ischemia (MCAo). Data were collected from 6 mice per time-point. 
(Bottom and top of the box represent first and third quartile (25-75%), band inside the box predicts median and 
whiskers are shown from minimum to maximum, *** p < 0.001, ANOVA, Kruskal-Wallis test). 
 
3.4.6 Interaction of Bid and VDAC1 determines mitochondrial demise and cell 
death in HT-22 cells 
Combining the data above, a specific and direct interaction between tBid and VDAC1 is 
clearly demonstrated, with the protective effects of the VDAC inhibitor DIDS in the present 
cell death models (3.4.2), it is highly likely that both proteins, Bid and VDAC1, interfere 
together in the mechanisms of intrinsic cell death triggered by oxidative stress and indeed 
point to VDAC1 as a possible target for Bid and its active form tBid to regulate mitochondrial 
integrity and function. Although DIDS is well accepted as a VDAC inhibitor158, 231, which may 
also inhibit VDAC2 and VDAC3, as well as other anion channels244, it cannot achieve 
sufficient specificity for inhibition of the isoform of interest, i.e. VDAC1.  
To gain further insight in the signaling events downstream of the Bid-VDAC1 interplay, the 
impact of VDAC1 in Bid-mediated hallmarks of cell death in HT-22 cells was analyzed by 
using siRNA-mediated VDAC1 silencing. 
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3.4.6.1 VDAC1 gene silencing attenuates glutamate-induced cell death in HT-22 
cells 
Specific down regulation of VDAC1 was achieved by two different sequences of VDAC1- 
targeting siRNA (VDAC1 siRNA1 and VDAC1 siRNA2). Both siRNA sequences significantly 
reduced the expression of VDAC1 whereas control scrambled siRNA (scr siRNA) did not 
alter VDAC1 levels in HT-22 cells as assessed by RT-PCR and Western blot analysis (Figure 
71 A). In contrast, expression levels of VDAC2 were not altered by VDAC1 gene silencing 
(Figure 71 B), confirming the specific targeting of the isoform VDAC1. To investigate the 
effect of reduced VDAC1 protein levels, cell morphology as well as cell viability of glutamate 
exposed cells were analyzed. Unlike control cells, VDAC1- depleted cells sustained their 
normal spindle-shaped morphology (Figure 71 C) and were rescued from glutamate-induced 
toxicity as revealed by MTT assay (Figure 71 D,E) and fluorescence-activated cell sorting 
(FACS) analysis of annexinV/propidium iodide-stained HT-22 cells (Figure 72 A, B). 
Moreover, real-time cell analysis (RTCA) of cellular impedance, depicted as normalized cell 
index (NCI) over at least 22 h, indicated a significant reduction in cell viability within a small 
time window of 2-4 h for glutamate-exposed control and non-functional scrambled 
(scr) siRNA-treated cells, yet a sustained protection over time in cells pre-treated with 20 nM 
of VDAC1 siRNA (Figure 72 C, D). Notably, RTCA-recordings revealed, that siRNA cells 
proliferate slower than un-transfected control cells, which is in line with siRNA mediated 
reduction in cell viability detected by the MTT assay (Figure 72 C, D and Figure 71D, E)   
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Figure 71: VDAC1 knockdown by different VDAC1 sequences attenuates glutamate-induced 
toxicity in HT-22 cells. 
A, VDAC1 knockdown by two different VDAC1 siRNA sequences was verified by RT-PCR analysis of VDAC1 
mRNA (upper panels) and western blot analysis of VDAC1 protein (lower panels) 48 h after application of 20 nM 
VDAC1 siRNA 1 or siRNA 2. B, RT-PCR analysis of VDAC2 mRNA levels ruled out unspecific knockdown by 
VDAC1 siRNA1 and siRNA2 in concentrations of 20 nM to 80 nM. C, Morphological phenotype from glutamate-
induced apoptosis is preserved by VDAC1 silencing. Photomicrographs (10 x 0.25 NA objective) reveal 
morphological chances of non-transfected HT-22 cells (vehicle) and cells transfected with scr siRNA (20 nM) 16 h 
after the glutamate (3 mM) challenge. D, E, Cell viability was determined by MTT assay 16 h after glutamate 
treatment (3 mM) of HT-22 cells transfected with the respective VDAC1 siRNA sequences (VDAC1 siRNA 1, 
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20 nM, D and VDAC1 siRNA 2, 20 nM, E). D, MTT assay confirmed the protective effect of VDAC1 siRNA 1 
against glutamate toxicity. E, Likewise siRNA 1, VDAC1 siRNA 2 provided significant protection against glutamate 
toxicity. All experiments were repeated at least three times and data are provided as mean ± SD (**p < 0.01, 
***p < 0.001 compared to glutamate treated vehicle and scr siRNA, ANOVA, Scheffé´s test). 
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Figure 72: VDAC1 depletion prevents glutamate-induced cell death 
VDAC1-depleted HT-22 cells are resistant to cell death induced by glutamate. A, HT-22 cells were transfected 
with either VDAC1 siRNA 1 or VDAC1 siRNA 2 (both 20 nM) and exposed to toxic glutamate solution (5 mM, 
17.5 h) 24 h after transfection. FACS-analysis of annexin-V/propidium iodide-stained HT-22 cells depicts dead 
cells (AV+/PI+)  in the upper right corner and healthy cells (AV-/PI-) in the lower left corner. Percentages of cells 
are provided as mean values ± SD for three cell groups treated as indicated in the corresponding quadrants. Glut, 
glutamate 5 mM, 17.5 h. VDAC1 depleted cells show significantly lower percentages of AV+/PI+ cells compared 
to vehicle control and scrambled (scr) siRNA treated cells. B, Quantification of AV/PI-FACS analyses (A) 
confirmed significant prevention of cell death by both VDAC siRNAs. C, D, VDAC1 siRNA transfected HT-22 cells 
were seeded in 96-well E-plates at a density of 8,000-10,000 cells per well and cell proliferation and cell death 
was monitored by the real-time cell analyzer (RTCA, xCELLigence) over 23 h after exposure of cells to 4 mM 
glutamate. C, Note the persistent protective effect of VDAC1 siRNA 1 transfected cells (dark blue circle) against 
glutamate- induced cell death (Glut, 4 mM) compared to control (Ctrl) or scr siRNA treated cells. D, VDAC1 
siRNA 2 transfected cells (dark green circle) are similarly protected against glutamate- induced cell death (Glut, 4 
mM) as VDAC1 siRNA 1-treated cells. For statistical analysis all experiments were independently repeated three 
to five times with n=3-4 (A, B) or n=8 (C, D) per treatment condition. Data are provided as mean ± SD (***p < 
0.001 compared to glutamate treated vehicle and scr siRNA, ANOVA, Scheffe´test). 
 
3.4.6.2 Preservation of mitochondrial integrity and function by VDAC1 gene 
silencing 
3.4.6.2.1 VDAC1 deficiency maintains mitochondrial energy metabolism and 
respiration and prevents glutamate-induced ROS formation  
Further investigations on the impact of VDAC1 in pathways of intrinsic death included 
measurements of ATP-levels, mitochondrial oxygen consumption rate (OCR) and ROS 
formation. Consistent with recent studies, revealing that down-regulation of VDAC1 
decreases ATP production and cell growth39, 141, and in line with the results obtained by 
DIDS-mediated VDAC inhibition (Figure 60), VDAC1 depleted cells revealed reduced ATP 
levels under control conditions compared to vehicle or scr siRNA-treated cells (Figure 
73 A, B). This reduction in basal ATP generation observed upon silencing of VDAC1 
confirms the major role of VDAC1 for nucleotide transport and might be attributed to limited 
transport of ADP into the mitochondria followed by impaired ATP synthesis141. However, the 
further accelerated ATP depletion after glutamate-induced cell injury was significantly 
prevented by both VDAC1 siRNAs (Figure 73 A, B), confirming preserved mitochondrial 
integrity and active energy metabolism in VDAC1 deficient cells. Additional evidence for 
rescued metabolic functions in mitochondria by VDAC1 silencing was derived from OCR 
measurements (Figure 73 C-F). Glutamate exposure significantly reduced mitochondrial 
maximum respiration as well as mitochondrial respiratory capacity in control cells (non-
treated and scr siRNA treated cells), whereas mitochondrial respiration remained unaffected 
in VDAC1-depleted cells (Figure 73 C-F). Notably, the preservation of mitochondrial energy 
production and respiration achieved by both VDAC1 siRNA sequences was much more 
pronounced than the effects obtained by DIDS (Figure 60). This might indicate that inhibition 
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of VDAC by DIDS is reversible and causes a transient protection, while VDAC1 gene 
silencing is sufficient to provide a sustained protection over time (Figure 71). 
 
Figure 73: VDAC1 deficiency maintains mitochondrial energy metabolism and respiration. 
HT-22 cells were transfected with scr siRNA (20 nM) or either VDAC1 siRNA 1 or VDAC1 siRNA 2 (20 nM) and 
treated with glutamate (4-5 mM, 17-20 h). A, B, Alteration of ATP levels by VDAC1 gene silencing were 
determined by ATP-luminescence measurements. ATP-levels from VDAC1 siRNA 1 (A) and VDAC1 siRNA 2 (B) 
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transfected HT-22 cells were analyzed in the presence or absence of glutamate (5 mM, 20 h). VDAC1 knockdown 
decreased ATP levels under control conditions, but restores ATP production after glutamate exposure. The 
experiment was repeated three times with n = 8 and results are predicted mean ± SD (###p < 0.001 compared to 
vehicle and scr siRNA controls, ***p < 0.001 compared to glutamate treated vehicle and scr siRNA treated cells, 
ANOVA, Scheffé´s test). C-F, VDAC1 siRNA preserves mitochondrial maximum respiration and respiratory 
capacity. Mitochondrial respiration, indicated as oxygen consumption rate (OCR) was analyzed by the Seahorse 
Bioscience system using the XF Mito Stress kit. D, E, Quantification of OCR revealed percentages of 
mitochondrial maximum respiration and respiratory capacity in VDAC1 depleted HT-22 cells compared to un-
transfected controls and scrambled (scr) siRNA transfected cells. VDAC depletion does not affect mitochondrial 
respiration under control conditions and preserves mitochondrial respiratory function after the onset of glutamate 
exposure. Experiment was independently repeated 5 times with n = 6 and data are provided as mean ± SD (***p 
< 0.001 compared to scr siRNA treated cells, ANOVA, Scheffé´s test). 
 
Furthermore, VDAC1 deficiency protected against increases in ROS as shown by the 
determination of lipid peroxides 18 h after the onset of glutamate (Figure 74 A, B), 
suggesting a strong impact of VDAC1 on Bid-dependent irreversible mitochondrial damage 
and the subsequently accelerated ROS formation116. Overall, these data indicate a clear 
involvement of VDAC1 in intrinsic death pathways established at the level of mitochondria in 
the applied model of glutamate toxicity. It appeared that a disturbed interaction between 
VDAC1 and Bid was the underlying mechanism of the protective effects mediated by VDAC1 
silencing. 
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Figure 74: Glutamate-induced ROS production is prevented by VDAC1 silencing. 
A, B BODIPY-FACS analysis of lipid peroxidation in HT-22 cells transfected with VDAC1 siRNA 1 or VDAC1 
siRNA 2 (both 20 nM) in comparison to control and scrambled (scr) siRNA transfected cells. The pronounced 
formation of lipid peroxides 18 h after the onset of glutamate exposure (4 mM) was significant prevented by 
VDAC1 silencing as fluorescence detection of ROS revealed a significant reduction in green fluorescence in 
VDAC1 depleted cells compared to vehicle and scr siRNA transfected cells. Values are averages (%) ± SD for 
three indicated treatment groups, each with 10,000 cells per flow measurement. Low green fluorescence 
represents healthy cells without lipid peroxidation (upper left corner) whereas high values of green fluorescence 
indicate increased formation of lipid peroxides in apoptotic cells (upper right corner). B, Quantification of lipid 
peroxides in in VDAC1-depleted HT-22 cells confirms that VDAC1 deficiency completely prevents the formation of 
ROS 18 h after the onset of glutamate (4 mM).The experiments were repeated three times and the results 
presented as mean ± SD (***p < 0.001 compared to scr siRNA treated cells, ANOVA, Scheffé´s test). 
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3.4.6.2.2 VDAC1 is required for Bid-mediated mitochondrial injury 
Recent studies revealed a pivotal role of Bid in the balance of mitochondrial fission and 
fusion, and a Bid-mediated permeabilization of the outer mitochondrial membrane24, 97, 200 
The channel porin VDAC1 is also thought to participate in mitochondrial-membrane 
permeabilization, loss of Δψm, and the release of pro-apoptotic mitochondrial proteins, such 
as cytochrome c, AIF and Smac/DIABLO143, 144, 159, 160, 245. The precise mechanism of VDAC1 
activation towards mitochondrial impairment, however, is not yet clarified and remains highly 
controversial144, 151. To further investigate whether the direct interaction between Bid and 
VDAC1 provides a convergence point in the aforementioned mechanisms, it should be 
examined whether the protective effect of pharmacological VDAC inhibition and VDAC1 
depletion in the model of glutamate-induced toxicity was associated with preserved 
mitochondrial morphology and membrane potential. 
In agreement with previous findings and the results presented above, glutamate exposure 
triggered detrimental mitochondrial fission (Figure 75 A)24, 200 in HT-22 cells, whereas VDAC1 
gene silencing sustained the native-like mitochondrial morphology (category I) and prevented 
the peri-nuclear accumulation of the fragmented organelles (category III) (Figure 75 A). 
Quantification of changes in mitochondrial morphology confirmed the glutamate-induced shift 
from cells containing long elongated mitochondria (category I) to damaged cells containing 
highly fragmented organelles (category III) that was significantly prevented by both VDAC1 
siRNAs (Figure 75 B, C). 
These findings are in line with further effects of VDAC1 siRNA towards the integrity of 
mitochondrial membranes. FACS analysis of TMRE-stained HT-22 cells revealed that both 
VDAC1 siRNAs prevented the loss of Δψm (Figure 76 A, B), a key event of glutamate- and 
tBid-induced cell injury24, 246. 
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Figure 75: VDAC1 depletion prevents glutamate-induced mitochondrial fission. 
A, Confocal fluorescence photomicrographs reveal protection against glutamate-induced mitochondrial 
fragmentation in VDAC1 siRNA 1 and VDAC1 siRNA 2 (both 20 nM) transfected HT-22 neurons. Cells were 
stained with MitoTracker red 30 min before glutamate treatment (5 mM, 17 h). Glutamate induced mitochondrial 
fission in control vehicle and scr siRNA transfected cells, which is prevented by VDAC1 gene depletion. B, C, 
Quantification of mitochondrial morphology: Category 1: elongated, fused mitochondria distributed throughout the 
whole cytosol, category II: intermediate, slightly fragmented mitochondria and category III strongly fragmented 
mitochondria and peri-nuclear accumulation of the organelles. Data represent the mean ± SD of three 
independent experiments (
###
p < 0.001 compared to category I glutamate treated control and scr siRNA ; ***p < 
0.001 compared to category III glutamate treated control and scr siRNA, ANOVA, Scheffè´s test). 
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Figure 76: Preservation of mitochondrial membrane potential by VDAC1 gene silencing. 
HT-22 cells were cultured in 24-well plates at a density of 33,000 cells per well and transfected with either VDAC1 
siRNA 1 or VDAC1 siRNA 2 (both 20 nM). A, TMRE-FACS recordings of mitochondrial membrane potential (Δψm) 
were performed 17 h after glutamate treatment (4 mM) and staining of HT-22 cells with MitoPT
TM
 TMRE dye. 
Glutamate exposed vehicle and scr siRNA transfected HT-22 cells showed significant reduction of red 
fluorescence, indicating loss of Δψm, while both VDAC1 siRNAs prevented breakdown of Δψm as indicated by 
preservation of red fluorescence comparable to control cells. Numbers are mean percentages ± SD of TMRE 
fluorescence for n=3 indicated treatment groups. High red fluorescences indicate intact mitochondria (right side), 
drop of red fluorescence depict loss of Δψm (left side). B, Quantification of TMRE fluorescence (A) confirms the 
preservation of Δψm in VDAC1 depleted HT-22 cells. CCCP was used as the positive damage-control for a fast 
depolarization of the mitochondrial membrane. The experiment was independently repeated four times and values 
are given as mean ± SD (***p < 0.001 compared to glutamate-treated vehicle and scr siRNA treated cells, 
ANOVA, Scheffé´s test). 
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3.4.6.3 tBid is not able to induce loss of Δψm  and cell death without functional 
VDAC1 
The observation that the pronounced protection against various hallmarks of glutamate 
toxicity achieved by DIDS (3.4.2) as well as by VDAC1 gene silencing was similar to the 
protective effects of the Bid inhibitor BI-6c9 (3.1)24, 116, 200 and comparable to the sustained 
protective effects of Bid gene silencing as shown in previous studies63, 97, strongly 
strengthened the hypothesis that the direct interaction between both proteins represents the 
mechanism behind Bid-mediated impairments of mitochondrial integrity and function. To 
confirm that both Bid and VDAC1, are indeed equally involved in the mechanisms of intrinsic 
cell death, HT-22 cells were transfected with a tBid-encoding plasmid (ptBid), and various 
endpoints of cell death were investigated in the presence or absence of VDAC1 protein 
expression. Over-expression of tBid induced the described characteristic alteration in the 
morphology (vehicle, scr siRNA, see also 3.1.2), contrary to VDAC1-silenced cells whose 
morphology remained unaffected (Figure 77 A). FACS analysis after annexin-V/propidium 
iodide-staining confirmed the protective effect of VDAC1 deficiency against tBid-induced 
toxicity (Figure 77 B, C).  
VDAC1 could finally be confirmed as a required target for tBid-mediated loss of Δψm (Figure 
78 A, B). TMRE staining of tBid-over-expressing HT-22 cells (ptBid, scr siRNA + ptBid) 
revealed a tBid-induced decline in Δψm by approximately 40 % of control cells, which was 
completely prevented by VDAC1 gene silencing (Figure 78 A, B). The fact that tBid caused 
neither breakdown of Δψm nor cell death at all in VDAC1 depleted cells confirmed that a 
direct interplay between tBid and VDAC1 is required to induce toxicity. 
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Figure 77: VDAC1 siRNA 1 and siRNA 2 prevent tBid-induced toxicity. 
HT-22 cells transfected with VDAC1 siRNA 1 or VDAC1 siRNA 2 (both 20 nM) were post-transfected (24 h) with a 
tBid encoding plasmid (ptBid). Cells treated only with attractene (vehicle) or scr siRNA transfected cells were 
used as controls. Seventeen to eighteen hours after tBid over-expression cell morphology (A) and cell death (B, 
C) were analyzed. A, Photomicroscopy (10 x 0.25 NA objective) reveals, that VDAC1-depletion preserves the 
spindle-shape morphology of HT-22 cells 17 h after tBid over-expression (ptBid) compared to vehicle and scr 
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siRNA treated cells which show extensive morphological alterations: cells appear shrunken, rounded up and 
detach from the bottom of the culture dishes. B, FACS-recordings of annexin-V/propidium iodide stained HT-22 
cells show resistance of VDAC1-depleted cells to tBid-induced cell death. HT-22 cells were stained with AV/PI 
and 10,000 cells per treatment condition were analyzed for cell death by flow cytometry (AV
+
/PI
+ 
: dead cells, 
upper right corner, AV
-
/PI
- 
: healthy cells, lower left corner) Numbers are mean values (%) ± SD for three indicated 
treatment groups in the corresponding quadrants. C, Quantification of AV
+
/PI
+
 cells confirmed that VDAC1 
depleted cells (VDAC siRNA 1 and 2) are protected against tBid- induced cell death. All experiments were 
independently repeated three to five times and results are reported as mean ± SD (***p < 0.001 compared to 
pIRES-tBid transfected vehicle and scr siRNA treated cells, ANOVA, Scheffé´s test). 
 
 
Figure 78: VDAC1 silencing prevents tBid-induced loss of Δψm. 
TMRE-FACS measurements of mitochondrial membrane potential 18 hours after tBid over-expression. A, HT-22 
cells were transfected with VDAC1 siRNA 1 or VDAC1 siRNA 2. Cells transfected with an empty pcDNA3.1+ 
vector were used as control (vehicle). After tBid-induced cell death was morphological detectable, all treatments 
groups were stained with MitoPT
TM
 TMRE dye and fluorescence was detected by FACS measurements. Numbers 
are mean percentages ± SD of n = 3 per treatment group, indicating loss of Δψm (left side) or intact Δψm (right 
side). The tBid-induced drop in red fluorescence was prevented in VDAC1-depleted cells compared to cells 
transfected with scramble (scr) siRNA. B, Quantification of TMRE fluorescence revealed significant loss of Δψm in 
cells over-expressing tBid which was restored by both VDAC1 siRNA sequences. The experiment was 
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independently repeated five times and data are reported as mean ± SD (***p < 0.001 compared to pIRES-tBid 
transfected vehicle and scr siRNA, n=3, ANOVA, Scheffé test). 
 
3.4.6.4 VDAC1 induced cytotoxicity requires Bid 
Vice versa, it was previously reported that VDAC1 over-expression induces depolarization of 
the inner membrane147 and thereby apoptotic cell death characterized by enhanced nuclear 
fragmentation141, 149. Such VDAC1 induced toxicity could be blocked by different agents 
shown to inhibit VDAC channel activity, e.g. DIDS148, ruthenium red (RuR) or hexokinase 
(HK)149, substantiating that VDAC1 expression levels appear to be critical for mitochondria 
mediated apoptosis. Nevertheless, it was still questioned how the enhanced VDAC1 
expression causes cell death. To further investigate whether the proposed interaction 
between Bid and VDAC1 is important for VDAC1 induced cytotoxicity, HT-22 cells were 
transfected with FLAG-tagged VDAC1 and analyzed by fluorescent confocal microscopy 
(Figure 79 A, B, Figure 80 A, B). Although VDAC1 is present in high abundance in the 
mitochondrial outer membrane (OMM), various studies have revealed that VDAC is also 
localized at low abundance to cell compartments other than mitochondria247-249. To confirm 
the mitochondrial localization of the over-expressed FLAG-VDAC1, mitochondria of HT-22 
cells were visualized by co-transfection of cells with mito-GFP or by staining with MitoTracker 
red. Confocal microscopy pictures revealed the co-localization of FLAG-VDAC1 and mito-
GFP as well as the VDAC1 co-localization with MitoTracker red stained mitochondria, both 
confirming the localization of FLAG-VDAC1 in the OMM (Figure 79 A, B, merge, Figure 
80 A, B). Of note, co-localization was not completely observed, indicating the partial 
exposure of VDAC1 to the cytoplasm as also expected by previous studies137, 250.  
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Figure 79: Mitochondrial localization of FLAG-VDAC1  
Localization of FLAG-VDAC1 in the mitochondrial outer membrane was confirmed by confocal fluorescence 
microscopy. A, HT-22 cells were co-transfected with plasmids encoding FLAG-VDAC1 and mito-GFP. 24 h- 48 h 
after transfection, FLAG-VDAC1 was immunostained using the primary anti-FLAG antibody and the secondary 
Dylight 648 antibody. Confocal fluorescence microscopy revealed the co-localization of FLAG-VDAC1 and mito-
GFP (merge), indicating the mitochondrial localization of over-expressed VDAC1. B, Co-localization of VDAC1 
and mitochondria was confirmed by immunostaining of FLAG-VDAC1 with the Alexa Fluor 488 antibody (green) 
and visualization of mitochondria by MitoTracker red. Note, that co-localization appears not completely, indicating 
the localization of VDAC1 in the outer mitochondrial membrane with the C-terminus outside of mitochondria.  
 
Twenty four to forty eight hours after plasmid transfection, VDAC1 over-expression resulted 
in cell death, as characterized by fragmented mitochondria and rounded cells (Figure 80 A, 
upper panel, Figure 80 B, lower panel), indicating that mitochondrial injury and cell death was 
triggered by VDAC1 expression levels. In contrast, control cells only transfected with mito-
GFP showed elongated mitochondria and spindle-like cell morphology (Figure 80 B, upper 
panel). In continuation, it was examined, if the VDAC1-induced cytotoxicity is linked to the 
pro-apoptotic effects of Bid. Interestingly, pre-incubation of cells with 10 µM of the Bid 
inhibitor BI6c9 preserved cell morphology and prevented death of VDAC1 transfected cells 
(Figure 80 A, lower panel). Since mitochondria of FLAG-VDAC1 over-expressing cells 
appeared highly fragmented, whereas mitochondria in mito-GFP transfected cells remained 
elongated, it is likely that VDAC1 over-expression causes toxicity via detrimental effects at 
the level of mitochondria. The results substantiated the required association of both proteins 
and suggested that the Bid inhibitor BI6c9 interfered with VDAC1-Bid interactions thereby 
protecting the cells against cell death induced by VDAC1 over-expression.  
In conclusion, these data demonstrate a direct interaction of tBid and Bid with the 
mitochondrial porin VDAC1, which is obviously highly relevant for determining mitochondrial 
demise and intrinsic cell death in cultivated cells and in vivo. The results predict that neither 
tBid nor VDAC1 alone are able to trigger mitochondrial injury and cell death without their 
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respective binding partner. This finding strongly indicates that the proposed Bid-VDAC1 
interaction provides a converging point for the mechanisms of MOMP that were previously 
considered separately, as they were either contributed solely to the Bcl-2 family proteins or to 
VDACs. 
 
 
Figure 80: VDAC1 induced cytotoxicity is inhibited by the Bid inhibitor BI6c9. 
HT-22 cells were co-transfected with FLAG-VDAC1 and mito-GFP in the presence and absence of the Bid 
inhibitor BI6c9 (10µM). Localization of VDAC1 and cell morphology was analyzed by confocal fluorescence 
microscopy 24-48 h after plasmid transfection and immunostaining of FLAG-VDAC1 using the anti-FLAG antibody 
followed by incubation with Dylight 648. Pictures were taken immediately after immunostaining. A, Localization of 
VDAC1 in the mitochondrial outer membrane was confirmed by co-localization of VDAC1 with mito-GFP. Note, 
that over-expression of FLAG-VDAC1 resulted in highly fragmented mitochondria, the perinuclear accumulation of 
the organelles and rounded cells (A, upper panel, B, lower panel). Pre-incubation of HT-22 cells with the Bid 
inhibitor BI-6c9 (10 µM) prevented the VDAC1-induced cytotoxicity (A, lower panel).  B, Confocal fluorescence 
microscopy of control cells transfected only with mito-GFP (upper panel) or FLAG-VDAC1 (lower panel), 
respectively. Note, that mito-GFP-transfected control cells show elongated mitochondria distributed through the 
whole cytosol (B, upper panel), whereas cells transfected with FLAG-VDAC1 revealed category II to category III 
mitochondria (B, lower panel).  
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3.5 VDAC2 plays a minor role in neuronal intrinsic cell death pathways 
Besides the involvement of VDAC1 in the regulation of mitochondrial membrane 
depolarization and the following apoptotic pathways, the mitochondrial outer membrane 
protein VDAC2, a VDAC isoform present in low abundance251, has been recently described 
as a crucial component in mitochondrial cell death signaling93, 251, 252, recruiting pro-apoptotic 
Bcl-2 family proteins to the outer mitochondrial membrane (OMM)93. Interestingly, in non-
neuronal mouse embryonic fibroblasts (MEFs) a regulatory function of VDAC2 in the Bak-
mediated cell death cascade has been described by linking the isoform to tBid-mediated loss 
of Δψm and cell death
93. These studies suggested that a direct association between VDAC2 
and Bak inhibits Bak activation and apoptosis and further reported a tBid-mediated Bak 
displacement from the VDAC2-Bak complex and thereby a tBid-induced recruitment of Bak 
to the mitochondria93. While these studies revealed a specific involvement of VDAC2 in non-
neuronal apoptosis, the role of VDAC2 in neuronal cell death is unknown so far. Therefore, 
the further work addressed the question, if a regulatory role of VDAC2 can be also 
determined in the neuronal Bid-mediated death signaling, or if the described Bid-VDAC1 
interaction might be the neuronal mirror of the emerging non-neuronal tBid-VDAC2-Bak 
concepts of apoptosis. 
 
3.5.1 VDAC2 gene silencing provides only transient protective effects against 
glutamate-induced toxicity 
To investigate the role of VDAC2 in neuronal cell death, the impact of VDAC2 gene depletion 
was analyzed in the model of glutamate-induced toxicity in HT-22 cells. 
Specific down-regulation of VDAC2 in HT-22 neurons was achieved by transfection of cells 
with two different sequences of VDAC2-targeting siRNA (VDAC2 siRNA a and VDAC2 
siRNA b) at concentrations of 20 nM, 40 nM and 80 nM (Figure 81 A-D). Both sequences of 
VDAC2 siRNA were sufficient to reduce cellular VDAC2 mRNA- as well as VDAC2 protein-
levels as verified by RT-PCR (Figure 81 A, C) and western blot analysis (Figure 81 B, D). Of 
note, concentrations of 20 nM siRNA reduced VDAC2 mRNA-levels by approximately 40% 
compared to vehicle and scramble siRNA-treated cells, whereas a complete deficiency of 
VDAC2 mRNA was obtained at siRNA-concentrations of 40 nM and 80 nM (Figure 81 A). 
Therefore, further functional analyses were performed using 40 to 80 nM of siRNA approach. 
Determination of VDAC1 mRNA expression levels confirmed a specific targeting of VDAC2 
by both VDAC2 siRNAs at concentrations of 40-80 nM (Figure 81 E).  
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Figure 81: VDAC2 gene silencing by two different VDAC2 siRNA sequences. 
HT-22 cells were transfected with two different sequences of VDAC2 siRNA (siRNA a and siRNA b) at 
concentrations of 20 ng, 40 ng and 80 ng. Specific knockdown of VDAC2 was verified by RT-PCR (A) and 
western blot analysis (B) 48 h after transfection of HT-22 cells. VDAC2 expression of VDAC2 siRNA transfected 
cells was compared to non-transfected cells (control), cells treated with the transfection reagent Lipofectamin 
RNAiMax (vehicle) and cells transfected with non-functional scrambled siRNA (scr siRNA). C, Quantification of 
VDAC2 mRNA amount 48 h after transfection of  HT-22 with 20 nM VDAC2 siRNA a and VDAC2 siRNA b. D, 
Quantification of VDAC2 protein amount 48 h after transfection of  HT-22 with 20 nM VDAC2 siRNA a and 
VDAC 2 siRNA b. E, Unspecific knockdown of VDAC1 by VDAC2 siRNA was ruled out by PCR analysis. Data are 
representatives of 3-5 independent transfection experiments. 
 
The effect of VDAC2 deficiency upon apoptosis was investigated by analyses of cell 
morphology and cell viability of HT-22 cells 16-18 h after the onset of glutamate exposure. In 
contrast to the reported results in VDAC2-depleted MEF cells93, revealing a resistance of 
VDAC2-/- cells to tBid-mediated apoptosis, VDAC2 deficiency was only slightly protective in 
HT-22 neurons. After glutamate exposure, HT-22 cells showed their typical morphological 
phenotype, which was only partly protected by VDAC2 silencing using VDAC2 siRNA a. 
However, a more pronounced protection against glutamate cytotoxicity was achieved by 
transfection of cells with VDAC2 siRNA b, preserving the spindle shape cell morphology 
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(Figure 82 A). This observation could be confirmed by FACS-analysis of annexin-
V/propidium iodide-stained HT-22 neurons (Figure 82 B, C), depicting no significant 
protection of cells treated with VDAC2 siRNA a. In contrast, VDAC2-depletion by VDAC2 
siRNA b attenuated glutamate-toxicity by approximately 40% compared to glutamate-treated 
control cells (Figure 82 B, C). Quantification of cell viability determined by MTT assay finally 
substantiated the lack of protection by VDAC2 siRNA a, yet a concentration-dependent 
enhancement of cell viability in cells transfected with VDAC2 siRNA b (Figure 82 D). Since 
control scrambled siRNA could not attenuate cell viability after glutamate-induced damage in 
HT-22 cells, un-specific effects of the siRNA approach were ruled out (Figure 82 A-D).  
Since potency and time of protection varies in different experiments depending on the cell 
passage, density and thereby glutamate-sensitivity of HT-22 cells, the protective potential of 
VDAC2 silencing was further analyzed by real-time detection of cell death using the 
xCELLigence system (Figure 83 A, B). Therefore, cell impedance of HT-22 neurons, 
transfected as indicated, was monitored over at least 18 h after glutamate-treatment, 
revealing a delayed cell death in VDAC2 siRNA b transfected cells (Figure 83 B) up to a 
persistent protection at a siRNA concentration of 80 nM. In line with the cell viability data 
obtained by FACS and MTT analysis, transfection of cells with VDAC2 siRNA a achieved 
only a short and transient protective effect with a delay of cell death of 1-3 hours compared 
to controls exposed to glutamate (Figure 83 A).   
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Figure 82: VDAC2 knockdown by different VDAC2 siRNA sequences provides slight protection 
against glutamate toxicity. 
HT-22 cells were transfected with VDAC2 siRNA a and VDAC2 siRNA b (40 nM and 80 nM) and challenged with 
glutamate (4 mM) 48 h after transfection. A, Photomicrographs (10 x 0.25 NA objective) reveal the phenotype of 
glutamate-induced cell death, which is slightly prevented by VDAC2 siRNA a and VDAC2 siRNA b (both 40 nM). 
B, FACS analysis of annexin-V/propidium iodide-stained HT-22 cells depicts dead cells in the upper right corner 
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and healthy cells in the lower left corner. Glutamate induced cell death of about 47-48% in vehicle and scr siRNA 
treated cells, which is only prevented by knockdown of VDAC2 using VDAC2 siRNA b. Numbers are mean 
percentages ± SD for three cell groups treated as indicated in the corresponding quadrants. Glut, Glutamate, 4 
mM. C, Quantification of AV
+
/PI
-
-stained HT-22 cells 48 h after transfection with 40 nM of either VDAC2 siRNA a 
or VDAC2 siRNA b and the onset of glutamate exposure (4 mM, 16-18 h) confirms slightly protective effects of 
VDAC2 siRNA a, that are achieved more pronounced by VDAC2 siRNA b (*p < 0.05; ***p < 0.001; n=4, compared 
to glutamate-treated vehicle and scrambled (scr) siRNA). D, MTT assay 65 h after transfection with both VDAC2 
siRNA sequences at concentrations of 40 nM and 80 nM confirms a concentration-dependent protection of 
VDAC2 siRNA b, while no significant protection was obtained by VDAC2 siRNA a (**p < 0.01; ***p < 0.001; n=8, 
compared to glutamate-treated vehicle and scrambled (scr) siRNA). All experiments were repeated at least three 
times and data are provided as mean ± SD with n=4-8. All statistics were obtained using ANOVA, Scheffé´s test. 
 
 
 
Figure 83: VDAC2 siRNA attenuates glutamate-induced cell death in a concentration-dependent 
manner. 
A, B, HT-22 cells were cultured in 96-well E-plates at densities of 8,000- 10,000 cells per well and transfected 
with VDAC2 siRNA a and VDAC2 siRNA b 48 h prior to glutamate exposure (Glut, 4 mM). A, VDAC2 siRNA a 
revealed only short and transient protection against glutamate-induced cell death compared to cells transfected 
with scrambled (scr) siRNA (n=8). B, VDAC2 siRNA b predicts stronger protection at concentrations of 40 nM and 
a persistent protection over time at concentrations of 80 nM (n=8).  
 
Interestingly, although a more pronounced and complete depletion of VDAC2 protein 
expression levels was achieved by specific VDAC2 knockdown using the VDAC2 siRNA a 
sequence, almost no protective effects could be observed in any of the endpoint or real-time 
analyses of cell viability. Transfection of HT-22 neurons with the siRNA sequence b exerted 
less reduction in the VDAC2 protein expression levels (Figure 81 B), yet a significant, even 
though slight protection against glutamate-induced cell death. Notably, the protection 
achieved with relative high concentrations of VDAC2 siRNA b (40 nM and 80 nM) was still 
not as pronounced as the protective effects achieved by knockdown of the isoform VDAC1 
using less siRNA concentration of 20 nM. In addition, preliminary data obtained from VDAC2 
knockdown experiments using 20 nM of VDAC2 siRNA revealed no protection at all in the 
model of glutamate-induced toxicity, suggesting a minor role of VDAC2 in neuronal cell death 
compared to the crucial and essential role of VDAC1. 
204 | Results 
 
 
 
3.5.2 Mitochondrial membrane potential is not affected by VDAC2 silencing 
To gain broader insight into the question if Bid-mediated mitochondrial demise and cell death 
could be regulated by VDAC2, as proposed by previous studies93, the impact of VDAC2 
deficiency on mitochondrial membrane potential (Δψm) was investigated, since the previous 
experiments clearly confirmed a Bid/tBid-mediated breakdown of Δψm in the present HT-22 
cell line.  
Again in contrast to the findings of Roy et al.93, a VDAC2 dependence of Bid/tBid-induced 
MOMP could not be revealed in HT-22 neurons. TMRE-FACS analysis predicted that 
glutamate-induced toxicity in non-silenced control and scr siRNA treated cells is 
accompanied with a pronounced loss of Δψm, which could be only slightly prevented by 
transfection of cells with VDAC2 siRNA b (Figure 84 A, B). In line with the findings above, 
VDAC2 siRNA a was not sufficient to preserve the breakdown of Δψm and did not exert 
protection against glutamate induced mitochondrial injury (Figure 84 A, B), demonstrating 
that Bid-mediated glutamate-induced MOMP is not dependent on VDAC2 expression levels. 
These data strongly indicate that VDAC2 does not play a major role in Bid-mediated 
mitochondrial demise and cell death signaling in neurons, although VDAC2 might be 
important for non-neuronal apoptotic pathways that are triggered by the Bak/Bax assembly. 
This hypothesis is substantiated by several previous studies, reporting the absence of 
functional Bak in neurons, indicating separate pathways for non-neuronal and neuronal 
apoptosis253-255. However, further analyses are required to investigate whether neuronal 
VDAC2 is dispensable for mitochondrial injury and cell death at all or if there might be a 
regulatory function of VDAC2 in the neuronal death signaling that hasn´t been investigated 
so far.  
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Figure 84: Mitochondrial membrane potential is only slightly affected by VDAC2 silencing. 
Mitochondrial membrane potential (Δψm) of HT-22 cells was analyzed 72 h after transfection with VDAC2 siRNA a 
and b (40 nM) and glutamate treatment (6 mM, 17 h). A, TMRE-FACS recordings reveal loss of Δψm 17 h after 
the onset of glutamate exposure. Numbers are mean percentages ± SD of TMRE fluorescence for n = 3 indicated 
treatment groups. High red fluorescence indicates intact mitochondria (right side), drop of red fluorescence 
depicts loss of Δψm (left side). Glutamate-induced reduction in red fluorescence was detected in vehicle and 
scrambled (scr) siRNA treated cells as well after transfection with VDAC2 siRNA a. VDAC2 siRNA b was only 
slightly protective against this breakdown of the mitochondrial membrane potential. B, Quantification of TMRE 
fluorescence of VDAC2 depleted HT-22 cells in the presence and absence of glutamate. CCCP was used as a 
positive damage-control which causes a fast breakdown of the mitochondrial membrane potential. Glutamate-
induced loss of Δψm was only prevented by VDAC2 siRNA b (40 nM), while VDAC2 siRNA a showed no 
protective effects. The experiment was independently repeated three times with n = 3 per treatment group, data 
are provided as mean ± SD (**p < 0.01 compared to glutamate treated vehicle, ANOVA, Scheffé test). 
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4 Discussion 
The present thesis highlights the pro-apoptotic protein Bid as a druggable target for 
mitoprotection and suitable for crystal structure analysis. Furthermore, the data of this study 
provided new insights in the underlying mechanisms of Bid-dependent mitochondrial injury 
that is a convergence point for different proposed mechanisms of MOMP which were 
previously attributed either to the activity of apoptogenic Bcl-2 family proteins or to protein 
complexes containing the voltage-dependent anion channel VDAC. 
Key decision points in the sequence of glutamate-induced impairments in mitochondrial 
integrity and function, such as MOMP, disturbed mitochondrial energy production and 
respiration, the accelerated production of ROS as well as imbalance in mitochondrial fission 
and fusion occur in a Bid-dependent manner. As inhibition of Bid protects against such 
mitochondrial demise, the present thesis focused on Bid as a target for mitoprotection. To 
this aim, the first part of the study addressed the identification of small-molecule ligands 
targeting Bid. Seven compounds obtained from three structural diverse chemical classes 
were identified as highly protective against glutamate- and tBid-induced toxicity in the 
present HT-22 neurons. The results provide strong evidence that inhibition of Bid was the 
underlying mechanism of the observed protective effects. The most promising compounds 
prevented not only cell death, but also restored Δψm, ATP levels as well as mitochondrial 
respiration after induction of oxidative stress and over-expression of tBid in HT-22 cells. 
Overall, this part of the study indicated these compounds as potent scaffolds for future 
optimizations and further applications in model systems of brain damage in vivo. 
The second part of the work provides important requisites for the use of recombinant Bid 
proteins for the first Bid crystallization trials and further structure-guided drug design. 
Protocols for effective expression and purification of different recombinant Bid constructs 
were optimized and scaled up, yielding 15-50 mg Bid variant per liter culture thereby 
providing sufficient amounts for crystallization screening. One of the designed Bid constructs 
was successfully crystallized and X-ray diffraction data of 3.75 to 3.95 Ǻ resolution could be 
obtained, confirming that the appropriate constructs of Bid are suitable for crystal structure 
analysis. Optimizations in construct design and crystallization approach were explored in 
order to improve the diffraction properties of the Bid crystals obtained in this thesis. Over-
expression of the diverse Bid constructs in HT-22 cells revealed their non-apoptotic function, 
indicating their behavior as a ´full-length Bid like protein´, in contrast to the detrimental 
effects of tBid over-expression.  
In addition, the work here included the validation of a model system for membrane 
permeabilization in order to analyze the effect of recombinant Bid proteins and Bid inhibitors 
on artificial lipid membranes that mimic the mitochondrial outer membrane. A particular focus 
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here was on the role of cardiolipin in Bid-mediated MOMP. The data demonstrated that only 
cleaved Bid, but not full-length Bid was able to induce pore formation and membrane 
destabilization of CF-containing liposomes and planar lipid bilayers and that membrane 
targeting of Bid was dependent on the presence of CL. The combination of cBid and Bax was 
sufficient to increase fluorescence release and pore-opening, whereas Bax alone showed no 
effect. These results indicate an ordered series of events that occur on mitochondrial 
membranes to induce MOMP and the release of death promoting proteins.  
Lastly, the present thesis demonstrates for the first time a direct interaction of Bid with the 
voltage-dependent anion channel VDAC1 as an essential key for mitochondrial damage in 
cultured neurons and in vivo. Co-immunoprecipitation experiments, thermophoresis, and lipid 
bilayer measurements revealed VDAC1 as a binding partner for Bid. Most intriguingly, Bid-
VDAC1 interaction significantly increased over 6-24 h in ischemic brain tissue of mice 
subjected to transient focal cerebral ischemia, indicating the relevance of this interaction in 
neuronal cell death. To investigate the role of VDAC1, the anion channel blocker DIDS as 
well as siRNA-mediated VDAC1 gene silencing was applied in the present models of 
glutamate- and tBid-induced toxicity. Both, DIDS and VDAC1 siRNA, significantly attenuated 
Bid-mediated impairments in mitochondrial oxygen consumption and ATP production, as well 
as hallmarks of intrinsic death pathways, such as mitochondrial fission, increased 
mitochondrial ROS production and breakdown of the mitochondrial membrane potential. 
These data highlight a critical role for VDAC1 as a mitochondrial receptor for activated Bid 
and indicate the Bid-VDAC interaction as a major control point of life and death at the level of 
mitochondria in vitro and in vivo. In contrast, only a minor role in neuronal cell death was 
suggest for the isoform VDAC2, as VDAC2 gene silencing provided only transient protective 
effects against glutamate-induced toxicity and could not restore Δψm. Therefore, the data 
implicate the observed Bid-VDAC1 interaction as a new mechanism in neuronal cells that 
might mirror the emerging concepts of the Bid-VDAC2-Bak interplay in cell death pathways 
of non-neuronal cells.  
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4.1 Targeting Bid for protection against mitochondrial injury and 
neuronal cell death  
The present thesis confirmed the pro-apoptotic protein Bid as a key player in mitochondrial 
pathways of neuronal cell death triggered by oxidative stress and thereby substantiated the 
detrimental involvement of Bid in neurological diseases associated with impairments in 
mitochondrial integrity and function. The involvement of Bid in the neuronal cell death 
cascade was mainly characterized in immortalized mouse hippocampal HT-22 neurons 
exposed to toxic glutamate concentrations. As these neuronal cells lack ionotropic glutamate 
receptors, glutamate-induced cell death is mediated by inhibition of the cellular cystine 
import, subsequent glutathione depletion, enhanced formation of reactive oxygen 
species (ROS) through increased lipid peroxidation and Bid-dependent mitochondrial 
damage165, 166. Furthermore, it was shown that glutamate-induced Bid transactivation to 
mitochondria triggers the release of AIF, which in turn translocates to the nucleus and 
induces a nuclear condensation and DNA fragmentation97. The crucial role for Bid in the 
model of glutamate-induced oxidative stress was confirmed by the approach of siRNA-
mediated Bid gene silencing and pharmacological Bid inhibition24, 97, 116. The fact that 
inhibition of Bid as well as Bid depletion were sufficient to protect against various features of 
mitochondrial injury, including the breakdown of the Δψm, mitochondrial fission, impaired 
energy supply and mitochondrial ROS formation, indicates Bid as a target for mitoprotection. 
Previous studies demonstrated an involvement of Bid in neuronal injury revealing that 
reduced Bid expression prevented cell death in a model of oxygen glucose deprivation 
(OGD) in primary cultured neurons, and genetic depletion of Bid also reduced brain damage 
in models of cerebral ischemia and brain trauma in vivo98, 202. Moreover, recent reports 
showed that both proteins, full-length Bid as well as its truncated form tBid, are sufficient to 
induce mitochondrial dysfunction and cell death in neurons and only differ in kinetics and cell 
death pathways58. While tBid is suggested to induce rapid mitochondrial damage in a 
caspase-dependent manner, full-length Bid is thought to be involved in caspase-independent 
apoptosis with slower kinetics59. In the currently applied model system of glutamate toxicity in 
HT-22 cells, activated full-length Bid as well as tBid may both contribute to neuronal cell 
death pathways. Pharmacological Bid inhibition was sufficient to prevent the glutamate-
induced translocation of full-length Bid to mitochondria and the subsequent accumulation of 
the fragmented organelles and additionally attenuated mitochondrial injury and cell death 
after over-expression of tBid. It should be noted, that the p15 tBid fragment was hardly 
detectable in cytosolic or mitochondrial fractions of glutamate-exposed HT-22 cells. 
However, this does not necessarily indicate the absence of tBid in the model of glutamate-
induced cell death, but suggests that upon glutamate exposure the caspase-8 cleaved Bid 
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(cBid) translocates to the mitochondria where the separation of the p7 and p15 Bid (tBid) 
fragment could occur rapidly and in a small time window after membrane targeting72.   
Overall, these findings in model systems of neuronal death in vitro and in vivo strongly 
suggested that targeting Bid is a promising approach to develop pharmaceutical drugs for 
mitoprotection with high relevance for novel therapeutic strategies in neurological diseases 
where mitochondrial demise is prominent. Indeed, it was recently demonstrated, that 
pharmacological inhibition of Bid with the available inhibitor BI-6C9, which was used as 
positive control for protection in the present study, strongly reduced tBid-induced release of 
Smac/DIABLO from isolated mitochondria at concentrations as low as 20 µM in vitro and 
prevented effectively tBid-mediated cell death in mitochondria- and cell-based assays of 
caspase-dependent cell death99. In particular, the available Bid-inhibitors developed by 
Becattini et al. reduced caspase-3 activity in tBid-transfected HeLa cells at 50 µM and 
persistently blocked caspase activity at 100 µM99. This thesis revealed that the key events of 
glutamate-induced caspase-independent cell death, such as MOMP, mitochondrial fission 
and ATP depletion as well as impairments in mitochondrial respiration were apparently Bid-
dependent and could be prevented by BI-6c9 at concentrations of 10 µM. However, despite 
the pronounced neuroprotective potency of BI-6c9 in vitro, it failed so far to protect brain 
tissue in vivo. Since the solubility of BI-6c9 is dependent on the serum-content of the culture 
media, BI-6c9 is not applicable to serum free conditions in cell culture models. A further 
aspect is the relatively high molecular weight of BI-6c9 that might hamper the penetration of 
the blood-brain barrier, and metabolically unstable substructures, such as the 4-(4-
aminophenyl)sulfanylaniline structure, might cause a fast peripheral metabolism resulting in 
molecules with less activity.  
The small-molecule compounds that were developed in this thesis based on the structure of 
BI-6c9, provided protective effects against glutamate-induced cell death at concentrations of 
5 µM up to 50 µM, and attenuated tBid-induced toxicity even at concentrations as low as 
1 µM. The observed protective effect in the model of oxidative stress is promising, since the 
screened compounds may provide a protective benefit against pathological pathways 
occurring in neurodegenerative diseases where oxidative stress triggers the onset of 
neuronal cell death. The finding that the newly synthesized structures preserved cell viability 
in HT-22 cells after tBid over-expression strongly support the specificity of the small-
molecules to provide mitoprotection by targeting the pro-apoptotic protein Bid. Key features 
of mitochondrial dysfunction, such as impairments in energy metabolism and loss of 
mitochondrial membrane potential described as ´point of no return´ in the cells` commitment 
to die19 were effectively prevented by the most promising thiazolidin-2,4-diones. Further, the 
data demonstrated the compounds` ability to preserve oxygen consumption rate of HT-22 
cells and thereby mitochondrial respiration and bioenergetics, described to be defective in 
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neurodegenerative disorders204. The fact that the compounds provided almost full protection 
against mitochondrial dysfunction indicated that the molecules acted upstream of 
mitochondria. This supports even more the hypothesis that the protective effects are 
mediated by inhibiting Bid. The specific targeting of Bid was further substantiated by virtual 
docking analysis revealing that the compounds fitted nicely into the hydrophobic grove on the 
surface of the Bid protein. Indeed, the Bid-ligand binding could be confirmed very recently by 
fluorescence based assays and label-free EnSpire analysis (data not shown)256. 
Furthermore, latest investigations revealed that these compounds are able to inhibit the 
translocation of Bid to mitochondria and were also protective against glutamate-induced 
excitotoxicity in cultured primary cortical neurons (data not shown). Therefore, the data 
obtained from this thesis indicate that Bid is a druggable target that promises novel strategies 
for future therapeutic perspectives for treatment of diseases associated with mechanisms of 
Bid-dependent mitochondrial cell death. The relevance of targeting Bid in the brain has been 
further confirmed by recent studies, reporting that chemical inhibition of Bid exerted 
antidepressant-like effects in behavioral models in vivo, such as the forced swim test, 
the tail suspension test and learned helplessness paradigms, indicating that Bid might 
be also a target of a new class of antidepressants257-259. However, it remains to be 
validated whether Bid inhibitors are suitable for long-term systemic use and whether Bid-
antagonists can alleviate neurodegenerative or depressive symptoms in human patients. 
It is further an open question whether these compounds cause side effects due to 
inhibition of apoptosis pathways, albeit Bid-deficient mice are viable and develop 
normally260, 261. In addition, side effects caused by the chemical structure of the 
thiazolidindiones comparable to that observed by the thiazolidinediones (TZDs) used for 
treatment of type II diabetes is unlikely. Those anti-diabetic compounds, also known as 
glitazones (e.q. Rosiglitazone) act through activation of peroxisome proliferator-activated 
receptors (PPARγ). The PPARγ-binding was responsible for several side effects, such as 
increased risk of cardiovascular events, hepatitis and potential liver failure causing the 
withdrawn of some glitazones. In contrast to those thiazolidinedione-based PPAR ligands 
that need to possess a free N-H, all of the Bid-targeting thiazolidinediones screened here are 
N-substituted, and thus a binding to PPAR’s and the resulting side effects are not expected. 
However, one should keep in mind that the data obtained in this thesis are preclinical and 
have to be transferred to in vivo studies. Further optimizations should be performed in order 
to improve the protective potency of the compounds to nanomolar concentrations required 
for first PK studies and observations in vivo.  
In conclusion, this part of the thesis identified seven small-molecules as potent inhibitors 
against neuronal cell death and indicates the inhibition of Bid as the key mechanism of their 
protective properties. In particular, the compounds provided significant protection against 
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glutamate toxicity and tBid-over-expression in hippocampal HT-22 cells, and further 
prevented detrimental impairments of mitochondrial integrity and function, thereby inhibiting 
the final execution of intrinsic cell death. Future optimization of the structures should result in 
compounds with favorable pharmaceutical properties that are applicable in model systems of 
cell death in vivo and furthermore in pharmaceutical drugs that are suitable for therapeutic 
strategies not only in the treatment of neurodegenerative diseases, such as Alzheimer´s 
disease and Parkinson´s disease, but also for therapeutic interventions in ischemic stroke, 
mood disorders e.g. major depression, liver inflammation, or other diseases where a role of 
Bid has been implicated. 
 
4.2 Bid protein crystallization – a pipeline for structural knowledge and 
structure-guided drug design 
The atomic resolution structures of a protein provides not only a deep and unique 
understanding of the molecular protein function and sheds light on chemical interactions and 
the inner working of the cells206, but is also an indispensable tool for the development of 
highly selective inhibitors of a target protein. Since X-ray crystal structures can account for 
geometric properties of ligand-protein complexes, they enable a rational and structure-guided 
drug design that facilitates the further improvement of physico-chemistry and affinity 
properties of small-molecule compounds. Thus, crystal structures serve as the basis for 
developing pharmaceuticals against diseases where the target protein plays a major role in 
the underlying pathology262, 263. While several previous studies, reported the advantage of 
crystal structures for the development of selective inhibitors of other Bcl-2 family proteins, 
such as Bax, Bcl-xl, or Mcl-168, 105, 109, 121, 122, to date similar drug discovery campaigns for the 
pro-apoptotic protein Bid were hampered by the absence of appropriate crystal structures of 
isolated Bid. So far only small Bid BH3-peptides were co-crystallized in combination with the 
pro-apoptotic protein Bax and used to explore the activation of Bax121. However, an atomic 
resolution structure of full-length Bid is not available. Figure 85 depicts the general workflow 
which has been pursued within this thesis for obtaining a basis for Bid protein crystallization.  
Since every protein has its own distinctive chemical properties and there is no 
comprehensive theory to guide a successful crystallization, macromolecular crystal growth is 
largely empirical in nature, demanding patience, perseverance and intuition189, 207, 209, starting 
not at the stage of the obtaining crystals, but much earlier at the selection of the protein. It 
has been described, that full-length protein constructs versus truncations, chemical 
modifications and mutations can dramatically influence the crystal formation207, a 
phenomenon that was also observed in the present thesis. Although purification of full-length 
Bid allowed for harvesting reasonable amounts of the protein, several crystallization screens 
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failed to yield Bid crystals. Based on previous experiences collected for the construct design 
and crystallization of the related proteins, Bcl-2, Bcl-xl and Mcl-168, 121, 122 it was suggested 
that flexible regions in the structure of the Bid protein interfere with the crystallization 
process. Indeed, the present study revealed that truncation of the disordered N-terminus and 
loop region of full-length Bid enhanced the ability to reach high protein concentration as well 
as the tendency for obtaining crystals within the first screens. Therefore, the truncation of full-
length Bid is an important advance, absolutely essential for obtaining the first diffracting Bid 
crystals. Notably, the choice of an appropriate protein construct may already cause 
differences in the expression efficiency, as it was observed in case of the tBid plasmid. While 
the expression of the active and pro-apoptotic truncated Bid in E. coli. was completely 
refused, bacterial expression of the newly designed Bid constructs (Bid 1-Bid 4) succeeded 
in high protein amounts (Step1).  
 
Figure 85: Workflow from construct design to protein crystallography. 
Pipeline from Bid construct design, cloning, expression and protein purification to Bid protein crystallography. 
Step 1: The pro-apoptotic protein Bid was selected for purification and crystallization studies. Different Bid 
constructs were designed and respective plasmids were cloned suitable for protein expression in E. coli. Large 
scale production yielded in high protein amount suitable for step 2. Step 2: Protein purification: Depending on the 
protein construct and the respective purification tag, protein purification was performed by 2-3 chromatography 
steps as indicated. The purity of the protein was estimated by SDS-PAGE followed by coomassie staining and 
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western blot analysis. To guarantee the identity of the protein Maldi-Tof analysis were performed. The proteins 
were concentrated to approximately 10 mg/ml. Step 3: Protein crystallization was performed by the vapor-
diffusion technique and initial screening was conducted using the Quiagen NeXtal-screening suites containing a 
wide sector of different crystallization conditions differing in ph, precipitants, buffer and salts. Hit conditions, 
yielding the first protein crystals were further optimized by additive screening, seeding or grid screens. Hit 
conditions were further reproduced. Step 4: Obtained protein crystals were analyzed by X-ray diffraction. 
Synchrotron measurements of protein crystals took place either at the Helmholtz-Zentrum Berlin using the MX 
Beamline 14.1, BESSY II or at the DESY Hamburg using the EMBL MX1 and MX2 beamline at the PETRA III 
ring.  Step 5: First molecular replacement trials were performed using Phaser with search models from various 
sources (Bid NMR structures (PDB), homology models and poly-Ala models). So far no MR solution could be 
identified.  Of note, if protein purification, crystallization screens or data processing was not satisfying, all steps 
were repeated beginning at step 1. Pictures predict protein expression and protein analysis (step 1), the first Bid 
crystal obtained during this work, and the NMR solution structure of Bid (1DDB) used for molecular replacement.  
 
The second step in the crystallization pipeline included the preparation of a pure 
homogenous protein sample, which is often a key factor in obtaining crystals that diffract to 
high resolution189, 264. As recommended for the initial crystallization screening, highly pure 
protein (> 98%) could be achieved for all of the designed and purified Bid constructs and 
concentration efficiency could be clearly increased by cutting the His-tag of full-length Bid 
and further by removal of the flexible loop and N-terminal region, confirming the protein itself 
as an important variable during the crystallization approach. The most important parameters 
that affect protein solubility and thereby crystallization are reported to be protein 
concentration, precipitant type and concentration, pH and temperature189, 265-268. Notably, it is 
essential to carefully review the screening outcomes within the first crystallization process, 
bearing in mind that even negative results provide precious information207, 264. Initial 
crystallization screens revealed that all Bid constructs tended to heavy precipitates in the 
presence of cadmium, zinc or nickel ions, while most promising conditions often consisted 
cryoprotectans such as PEGs (PEG 3350, PEG 4000) or higher concentrations of MPD (20-
50 % (V/V)).  
Regardless of the screening condition, temperature was an important variable to evaluate. 
As Bid is temperature stable protein, crystallization screens could be performed at 4°C and 
18°C, revealing even the most promising results at the higher temperature.  
Beside these chemical and physical parameters, the choice of the crystallization method can 
affect the crystallization result189, 269, 270. In accordance to the PDB, the present thesis utilized 
the vapor diffusion technique as the most popular method used in obtaining the majority of 
the X-ray structures for which the crystallization method was reported189. A couple of 
promising conditions with crystalline material as well as 3D crystals were observed within the 
initial Bid crystallization trials, but unfortunately they were often not suitable for X-ray 
diffraction analysis or diffracted only at low resolution. This was not surprising, as it has been 
estimated, that only 10 %-20 % of the crystals produced in the first level of screening are 
diffracting crystals, while the majority requires further refinement189. Optimizations performed 
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for Bid crystallization included not only the variation of parameters such as buffer and 
precipitant concentration as well as pH, but also contained the approach of crystal seeding 
and addition of diverse additives. Compared to the initial screening, which is generally 
fraught with the greater risk, as many proteins refuse to form crystals, the systematic 
alteration of the initial conditions proves the more demanding and more time consuming 
step120, 267. Crystallization screens performed with full-length Bid succeeded only in 
microcrystals and could not be optimized to 3D-crystals. So far, crystallization trials for Bid2 
and Bid4 yielded only microcrystals and further optimizations have to be performed for those 
constructs. In contrast, diffracting crystals of Bid construct 1 were already observed within 
the initial crystallizations screenings, indicating two promising conditions which were used for 
further optimization trials.  
However, despite all performed optimization trials, the best diffracting pattern (step 4 data 
collection) were observed from the initial “hit” crystals obtained from JSCG+ condition 79 and 
cryo condition 5. While those initial crystals yielded resolution ranges between 3.75 Ǻ–
3.95 Ǻ, several other crystals obtained from optimization trials were recorded with lower 
resolutions between 3.8 Ǻ and 6 Ǻ and indexing of diffraction data was not always possible. 
Data collection of the both “hit” crystals, obtained from the abovementioned conditions, 
reached a high redundancy (6.3) and completeness (99.4 %) and the X-ray diffraction signal-
to-noise ratio (I/σI) was > 2, which is in general required for good-quality structures119. 
However, no unique X-ray structure solution for Bid could be obtained so far. It should be 
noted, that many protein crystals do not diffract to atomic resolution as a result of inherent 
mobility and solvent content surrounding the protein molecule. Additionally, significant 
amounts of solvents, which were ~44 % for the present Bid crystals, cause the susceptibility 
of crystals to damage by X-rays, although such radiation damage was reduced by collecting 
the data at 100 K. Of note, successful structure elucidation for related proteins has been 
achieved from crystals obtained from similar conditions as those for the Bid crystals. As 
recently reported, Bax crystals were grown from conditions consisting of 10 % PEG3350, 
20 % MPD, 0.5 % CHAPS and 0.1 M Tris (pH 8.0)121 and the first diffracting Bcl-xl crystals 
were obtained from 28-31 % PEG 4000, 0.2 M ammonium acetate, 0.1 sodium citrate (pH 
7.5)68. In consideration of the fact, that the truncated Bid constructs share a high structural 
similarity to the crystallized Bcl-xl- and Bax protein and considering that the most promising 
Bid crystals were as well obtained in similar conditions containing either PEG3350/PEG4000 
or MPD and at pH values of 7.5 to 8.0, it might be likely that further optimizations of the 
presented conditions yield high resolution crystals of Bid.  
Beside further structure elucidation trials using the here obtained Bid diffraction data via 
molecular replacement, further optimization trials could include the following ideas: In 
addition to variations of temperature, pH and concentration of precipitants, the concentration 
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of the respective Bid constructs is a significant variable. It has been described that the 
protein concentration can differ from as low as 2 mg/ml to as much as 100 mg/ml for 
successful crystallization outcomes120, 264, 266, 268. Moreover, the presence or absence of 
ligands, inhibitors, metal ions or coenzymes are relevant considerations, even though the 
influence of those has to be empirically defined for the particular Bid construct209. As 
substrates and inhibitors are reported to maintain a protein in a more compact and stable 
form209, it might be possible to achieve a greater degree of structural homogeneity by 
complexing the protein with a ligand before attempting its crystallization189. Thus, it is 
worthwhile to explore complexes of the Bid protein with the newly synthesized Bid inhibitors 
or the addition of cofactors271 at these early stages of Bid crystallization, as such complexes 
could be inherently even more interesting as the apo-Bid protein. However, co-crystallization 
of the Bid 1 protein with the available BI-6c9 failed to yield crystals so far, probably reasoned 
by the poor solubility of the inhibitory compound rather than by the general impossibility of 
protein-ligand crystal growth. Furthermore, ligand binding could be associated with more or 
less severe changes in the arrangement of the helical organization of Bid as well as in the 
Bid crystal form as it was also suggested by similar approaches crystallizing the Bcl-xl 
protein in complex with inhibitors (PDB entries 1MAZ versus 2YXJ)68, 272. However, previous 
reports substantiate the advantage of such crystallization approaches for the identification 
and improvement of selective protein-binding compounds272-274, and are thereby 
indispensable for further optimization of the here presented Bid inhibitors. Therefore, it would 
be worthwhile to address the crystallization of diverse protein-ligand complexes, even if 
those might require additional screening campaigns to find suitable conditions in dependence 
on the ligand chemotype to be analyzed. Beside these considerations, further Bid protein 
engineering approaches are desirable, since length and type of the truncation or further 
mutations may significantly influence the crystallization and diffraction ability of the Bid 
protein.  
Although, further crystallization studies have to be performed to finally elucidate the crystal 
structure of Bid allowing for a campaign of structure-based development of Bid inhibitors, the 
present thesis provided already a suitable pipeline from Bid construct design to Bid 
crystallization. The presented work gained insights in the chemical behavior of the Bid 
protein by identifying the removal of disordered and flexible regions of the Bid structure as 
essential for protein solubility and crystal growth. Indicating the crucial importance of 
construct design, the performed crystallization screenings succeeded in the first diffracting 
Bid crystals reported so far. Overall, these results reveal the Bid crystallization approach as a 
powerful tool for a better understanding of Bid activation and function as well as a promising 
set up for further Bid-inhibiting drug discovery and pharmaceutical research.  
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4.3 Mechanisms of Bid-mediated MOMP and mitochondrial impairments 
The present thesis substantiates the crucial involvement of Bid in the regulation of MOMP 
and mitochondrial injury. Several previous studies reported that upon its activation and 
translocation to mitochondria, Bid provokes impaired mitochondrial integrity and disturbed 
mitochondrial dynamics and function24, 63, 97, 116, but the precise mechanism how Bid triggers 
mitochondrial dysfunction is not fully understood. Mitochondrial outer membrane 
permeabilization (MOMP) is considered as the most critical event and ´point of no return´ in 
the mitochondrial apoptotic pathway5, 18, 19 promoting apoptosis by releasing IMS pro-
apoptotic proteins such as cytochrome c and AIF to the cytosol. However, so far, the 
mechanisms of MOMP are still elusive and several models have been proposed. Recently, it 
has been suggested that MOMP might be closely linked to the molecular machinery involved 
in mitochondrial fission24, 275, 276, reporting that mitochondrial fragmentation occurs 
concomitantly with cytochrome c release276. 
Alternatively, MOMP has been proposed to be initiated at the inner mitochondrial membrane 
(IMM) by an increase in permeability to small molecules, a subsequent osmotic swelling and 
distension of the IMM followed by rupture of the MOM. This phenomenon is promoted by 
increases in cytosolic Ca2+ and/or ROS23, 277.  
A further model of MOMP refers to the mitochondrial permeability transition pore (mPTP). 
The permeability transition pore complex (PTPC) is described as a large multi-protein 
complex constituted of several components. Major components of the PTPC are the voltage-
dependent anion channel (VDAC), the adenine nucleotide translocator (ANT) and cyclophilin 
D (CypD), although their precise involvement in MOMP is not yet clear23. Both, opening and 
closing of the mPTP are discussed to trigger MOMP. On the one hand closure of the mPTP 
is thought to result in osmotic swelling, mitochondrial membrane rupture and the non-specific 
release of intermembrane space proteins. On the other hand opening of the mPTP or 
oligomerization of VDAC is reported to be important for cytochrome c release19, 130.  
Last but not least, MOMP has been related to the members of the Bcl-2 family proteins5, 44. 
The pro-apoptotic multi-domain proteins Bax and Bak are thought to be directly responsible 
for MOMP by creating protein-permeable pores in the outer mitochondrial membrane. Pro-
apoptotic BH3-only proteins, such as activated Bid or Bim can directly induce conformational 
changes in Bax/Bak, which triggers their oligomerization and pore-formation. Furthermore, a 
pivotal role for the mitochondrial lipid cardiolipin (CL) has been shown for Bcl-2 family-
mediated MOMP80, 82, 91, 278.  
CL is described to act as an anchor for cytochrome c at the inner mitochondrial membrane 
(IMM) and CL peroxidation is thought to be required for weakening of this interaction and full 
release of cytochrome c279. Thus, CL seems to play an active role in MOMP as substantiated 
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by the finding that inhibition of CL peroxidation prevents Smac/DIABLO release279. CL is 
prominently found in the IMM within cristae, but has been also described to be located at the 
contact sites between MOM and IMM80. Notably, also tBid and Bcl-2 have been reported to 
cluster at the same contact points81 and further studies showed that the mPTP spans the 
IMM and MOM in close proximity to the IMM/MOM contact sites23. In particular, a CL affinity 
for VDAC has been reported suggesting that the specific lipid composition of the 
mitochondrial membrane and/or contact sites influence MOM permeability by regulating 
VDAC and mPTP gating131. However, it is discussed whether MOMP is mainly mediated by 
the PTPC, conformation changes of the Bcl-2 family proteins and pore-formations and/or 
protein-protein and protein-membrane-interactions.  
Although it might depend on the cellular model, the apoptotic stimulus and the experimental 
conditions85, 277, it seems to be likely that the abovementioned mechanisms underlying 
MOMP might work in a coordinated manner. The present thesis reveals that Bid-mediated 
MOMP and mitochondrial demise seem to require both the mitochondrial lipid CL as well as 
a component of the PTPC, namely VDAC1. In vitro studies revealed the essential role of CL 
for cBid-mediated membrane destabilization and cell culture and in vivo studies highlighted 
the direct interaction between Bid and VDAC1 as essential for mitochondrial demise. Thus 
this thesis connects the proposed mechanisms of MOMP, as discussed below. 
 
4.3.1 Role of cardiolipin in cBid/Bax mediated pore formation – a model 
system of membrane permeabilization 
It was an aim of the present study to address the function of recombinant Bid and Bax on 
artificial lipid membranes and to explore the participation of Bid in MOMP. While attempting 
to establish the use of liposomes as model system for Bid-mediated membrane 
permeabilization and the screening of Bid-targeting compounds, the lipid constitution of the 
mitochondrial outer membrane was recreated. As a particular focus of the applied membrane 
assay was on the specific role of cardiolipin (CL) in Bid-mediated membrane integration and 
membrane permeabilization, the studies were performed in the presence and the absence of 
CL. It was previously reported that Bid and its truncated form tBid preferentially associate 
with liposomes containing CL levels comparable to those found in mitochondrial 
membranes81, 91, and the absolute requirement of CL for tBid binding was reported by studies 
involving CL-deficient yeast strains280, 281. Previous reports revealed that liposomes require 
the presence of at least 7 mol % CL in their membranes to undergo optimal permeabilization 
induced by cleaved Bid and Bax 91, 219, 282, and other groups reported even the requirement of 
20 mol % CL for tBid binding to liposomes80. However the physiological relevance of CL and 
the nature of tBid/Bax-mediated permeabilization remained controversial. While several 
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studies reported that CL facilitates Bax insertion, oligomerization and permeabilization of the 
membranes in liposomes82, 91, 219, 283, the physiological role of CL in Bax-mediated cell death 
was questioned by reports concluding that the apoptotic function of Bax occurs independent 
of CL, revealing the ability of Bax to trigger MOMP in mutants lacking CL synthase280, 284, 285. 
In contrast to the controversial requirement of CL for Bax, several studies suggest CL as a 
direct mitochondrial receptor for activated Bid77, 80, 219, 220, 286. It has been shown that CL 
increases the binding of both cBid and tBid to pure lipid vesicles as well as to MOM and 
thereby suggested the direct involvement of CL for Bid mediated apoptosis80, 281, 286. The work 
here reveals the role of cardiolipin for the specific targeting of activated Bid to lipid 
membranes by comparing the pore-forming ability of Bid, cBid and Bax in liposomes 
containing PE and PC to the protein-induced permeabilization of liposomes consisting 26 mol 
% CL in addition. Noteworthy, in accordance to several other studies using artificial 
mitochondrial membranes69, 91 the relatively high CL concentration was related to the 
enhanced content of CL at the IMM/MOM contact sites reported to be approximately 20 %221, 
and might not necessarily reflect the physiological conditions 4-6 % CL of in the IMM. tBid is 
thought to bind to the outer mitochondrial membrane at both contact and non-contact sites81, 
88, but also reported to preferentially insert into the negative lipids of the mitochondrial 
contact sites between IMM and MOM287. Previous studies reported that the tBid-CL binding 
occurs at the mitochondrial contact sites and is accompanied with a remodeling of the 
mitochondrial crystae, permeability transition and cytochrome c release85, 220.  
In line with the abovementioned findings, a cBid-induced permeabilization of CF-containing 
liposomes was only obtained in the presence of CL, while liposomes lacking CL were not 
disturbed. The cBid mediated CF-release was observed at relatively high concentrations up 
to micromolar ranges compared to the required concentrations for truncated tBid used in 
previous studies generating tBid by OG-induced separation of the p7 and p15 fragment of 
caspase-8 cleaved Bid (cBid)215, 219. This suggests that both cBid and tBid differ in their 
catalytical efficiency dependent on the exposed hydrophobicity which is increased in the 
case of tBid61. Furthermore, a membrane-destabilizing ability for full-length Bid could not be 
detected in any liposomes containing and lacking CL. Although this is in opposite to previous 
studies reporting a CL-binding and pro-apoptotic activity for full-length Bid86, 87, 89, the 
observed failure of full-length Bid for membrane permeabilization substantiates the 
hypothesis that the hydrophobic structures of Bid have to be exposed for Bid recruitment to 
membrane. The important role of CL for cBid activity on artificial lipid membranes could be 
further confirmed by preliminary studies using planar lipid bilayers, revealing a pore-forming 
ability of cBid dependent on the CL-content.  
In contrast to the necessity of CL for the recruitment of activated Bid to lipid membranes, CL 
seems not to be required for the pro-apoptotic protein Bax. Bax alone was not able to induce 
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pore-formation of BLMs or destabilization of liposomes independent on the presence or 
absence of CL. In contrast, the data clearly revealed the important presence of activated Bid 
on lipid membranes prior to Bax addition. A cBid/Bax-mediated increase in fluorescence 
release was observed when both proteins were incubated before co-addition to liposomes 
and conductance of BLMs was enhanced after addition of both proteins to the cis chamber. 
These results are in line with several other studies reporting the necessity of activated Bid for 
Bax induced liposome permeabilization71, 215, 218, 288. Intriguingly, a cBid/Bax-induced CF-
release could not be detected when Bax was the first protein in the assay.  
These results indicate that the described events, resulting in efficient pore formation, occur in 
an ordered sequence, requiring the initial binding of activated Bid to lipid membranes, 
particularly to CL, and the subsequent activation of Bax. That both, Bid-lipid binding and 
protein-interaction can occur in parallel is substantiated by previous observations, revealing 
that activated Bid targets mitochondrial membranes independent of the BH3-domain which is 
required for its interactions with Bax or Bak220. These studies revealed that the helix αH6 of 
Bid was responsible for targeting Bid to mitochondrial CL and for the subsequent 
reorganization of mitochondrial cristae. A key property of CL could be the ability to alter the 
membrane curvature and to promote the formation of non-bilayer structures. tBid was found 
to induce negative membrane curvature289 and structural distortion of the lipid bilayer 
following its interaction with CL290. Cristae reorganization and disruption of mitochondrial 
membrane organization might facilitate either Bax oligomerization or pore formation, or both, 
as an enrichment of Bax oligomers has been found at the mitochondrial fission sites, where 
CL may also be enriched225. Further reports additionally described the relevance of Bid-CL 
binding for disruption of mitochondrial bioenergetics220, 286, thereby supporting the importance 
of the Bid-CL interaction for both, mitochondrial targeting and pro-apoptotic activity of Bid. 
The suggested specificity of CL for Bid binding has been further substantiated by studies 
using proteo-liposomes revealing that the CL dependence was only seen when Bax was 
activated by cleaved Bid, but not by other activator BH3-only proteins such as Bim77. 
Interestingly, these studies further suggested the importance of at least one factor other than 
CL that facilitated the Bid/Bax-induced membrane permeabilization77, and assumed that 
other mitochondrial proteins are required. The idea that CL might not be the only receptor for 
targeting of activated Bid to mitochondria was in line with previous studies revealing that tBid 
binds only to CL in presences of membranes but not to free CL80. Further reports suggested 
that under physiological conditions the formation of protein-channels by tBid or Bax 
molecules might occur together with and/or in dependence of MOM-resident membrane 
proteins, such as VDACs or Mtch272, 94, 95, 142, 159. Therefore, CL may be a physiological 
receptor for tBid although its function may overlap or synergize with Mtch2 or other 
mitochondrial proteins that target Bid to membranes.  
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However, it remains to be shown whether CL is absolutely required for Bid-mediated 
apoptosis. It has to be determined if a tBid/cBid-CL interaction functions by changing 
membrane structure and curvature thereby promoting Bax oligomerization and release of 
proteins from the IMS, or if CL is just a membrane receptor for cBid/tBid to promote further 
protein-protein interaction that trigger MOMP. Either way, it is likely that tBid might act as a 
bi-functional molecule, first binding to mitochondrial membranes through interaction with the 
mitochondrial lipid cardiolipin, destabilizing mitochondrial membrane structure and interacting 
with other proteins such as Mitch2, VDAC and/or Bax to trigger AIF and cytochrome c 
release as the final execution of intrinsic apoptotic cell death.  
Although these considerations remain to be determined at the cellular level, the presented 
liposome channel assay is an appropriate model system to investigate Bid-mediated 
mitochondrial membrane permeabilization. Further studies should address the effect of 
activated Bid on liposomes and BLM with reconstituted Mitch2 or VDACs in the presence 
and absence of CL to investigate if the suggested mechanisms occur in parallel or depend 
on each other. Furthermore, the assay is a suitable model system for analyzing the inhibitory 
effects of small-molecules targeting activated Bid, as for example shown for the Bid inhibitor 
BI-6c9 which decreased the cBid/Bax-induced CF-release. Therefore the system allows the 
screening of novel compounds that selectively target Bid and inhibit membrane integration 
and pore formation of activated Bid and/or Bax in a cell free system. Thus, the liposome 
assay is a useful method to identify compounds which should block mitochondrial membrane 
depolarization and related intrinsic pathways of cell death.  
 
4.4 The role of the voltage-dependent anion channel VDAC1 in Bid-
mediated mitochondrial demise and cell death 
The present study demonstrated a pivotal role for the voltage-dependent anion channel 1 
(VDAC1) in Bid-mediated mitochondrial apoptotic pathways. The data revealed that Bid-
mediated mitochondrial fission, loss of mitochondrial membrane integrity, accumulation of 
detrimental ROS as well as impairments in mitochondrial energy metabolism and respiration 
depend on VDAC1 activity. Thus it is indicated that both proteins Bid and VDAC1 are equally 
involved in the mechanisms of mitochondrial intrinsic cell death signaling. VDACs have been 
proposed as important regulators of the intrinsic apoptotic pathway and increasing evidence 
indicates that both anti- and pro-apoptotic proteins, such as Bcl-2, Bcl-xl, Bax and Bid 
interact with VDAC to regulate mitochondrial pathways of apoptosis157, 159, 160, 162. However, 
published reports about whether and how Bcl-2 family proteins interact with VDAC and how 
they might alter VDAC channel activity, towards closure or opening, are highly 
controversial157, 161-163, 291, 292. For instance, Bcl-xl has been reported to facilitate the open 
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configuration of VDAC channels thereby maintaining the permeability of the mitochondrial 
outer membrane to ATP and ADP153, but Bcl-xl has also been shown to induce VDAC 
channel closure and thus to prevent apoptosis154, 157. Moreover, Bax has been discussed to 
interact with VDAC1 to induce channel opening159 and is further reported to form a 
heteromeric complex with VDAC1 to promote cytochrome c release142, 159, 293. In contrast, 
others showed that Bid but not Bax modulates VDAC channel conductance161, yet it is further 
discussed that tBid/Bax-mediated cytochrome c release occurs independently of VDAC163. 
The presented thesis now highlights new insights into the mechanisms of Bid-dependent cell 
death and the involvement of VDAC1 in mitochondrial apoptosis. VDAC1 function can be 
modulated by various physiological ligands, such as adenine nucleotides or NADH as well as 
non-physiological compounds, such as Koenig´s polyanion227, ruthenium red (RuR), 4,4´-
diisothiocyanatostilbene-2,2´-disulfonic acid (DIDS)135 or the PS oligonucleotide G3139230.  
However, specific inhibitors for the subunit VDAC1 are missing. In the present thesis, the 
commonly-used non-specific anion channel blocker DIDS232, 294 was used in order to gain an 
initial insight to the question whether VDACs might play a role in Bid-mediated intrinsic cell 
death pathways. Previous studies reported protective effects of DIDS against various 
pathologies, including for example STS-induced apoptosis in leukemia cells, neuronal 
volume-dependent apoptosis and delayed neuronal death in hippocampal neurons233, 234. The 
protective effects achieved by DIDS are usually attributed to inhibition of anion channels or 
anion exchangers and associated reductions of Cl- or ROS flux that regulate cell volume and 
diverse downstream cell death pathways234 mediated by toll-like receptors, protein kinase C 
and matrix metalloproteinases among others232, 234, 295. Furthermore, DIDS has been used as 
a well accepted VDAC inhibitor in several in vitro and cell-based assays, revealing that DIDS 
blocks VDAC channel conductance and VDAC-induced apoptosis158, 231. In contrast to the 
protective effects mediated by DIDS, it has been also reported that DIDS inhibits cellular 
proliferation in some cell types and induces apoptosis in tumor cells as well as in 
hippocampal neurons234. However, the effects of DIDS and their underlying mechanisms 
might depend on the cell type and the nature of the cell death stimuli.  
The present thesis demonstrated that DIDS exerted significant protective effects in the 
currently used model systems of glutamate- and tBid-induced toxicity in hippocampal HT-22 
cells and indicated that these effects might be mainly mediated through pathways 
downstream of Bid activation. This suggestion is based on the findings showing that that 
DIDS preserved not only cell viability but also mitochondrial morphology, Δψm, ATP levels 
and mitochondrial respiration after induction of oxidative stress in HT-22 cells, and further 
prevented the secondary increase in lipid peroxidation, which was associated with 
mitochondrial damage. All of these cellular features, indicating intact mitochondria, were 
shown to be defective in Bid-induced toxicity and were further reported to be affected by 
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VDACs143, 144. In addition, the data revealed that DIDS was also sufficient to prevent tBid-
induced loss of Δψm and cell death, substantiating that DIDS acts at the level of mitochondria 
and provides protection through inhibition of anion channels localized in the MOM, likely 
VDACs. The fact that the protective effect of DIDS against several hallmarks of glutamate-
induced Bid-mediated toxicity was comparable to the protective effects achieved by the Bid 
inhibitor BI-6c9 further suggested that the respective mechanisms behind both substances 
are correlated to each other, although DIDS might exert additional unspecific effects. 
Therefore it was assumed that DIDS acts via inhibition of mitochondrial VDACs and that 
there might be a close relationship between the involvement of Bid and VDAC in apoptosis. 
This hypothesis was finally substantiated by the finding that VDAC1 gene silencing exerted 
pronounced protection against glutamate- and tBid-induced cell death comparable to the 
effects achieved by DIDS. 
4.4.1 Direct interaction of Bid and VDAC1 determines mitochondrial demise 
Based on the abovementioned considerations, the present thesis addressed the suggested 
interplay between Bid and VDAC and demonstrated, for the first time, a direct interaction of 
tBid and Bid with VDAC1, a process with high relevance for mitochondrial integrity and 
intrinsic cell death signaling. The proposed interaction was not only observed at the physical 
and functional level using recombinant proteins, but also occurs in cell-based death models 
of glutamate-induced toxicity in HT-22 cells and primary neurons, and in vivo. Therefore, the 
data suggested that the proposed Bid/tBid-VDAC1 interaction is essential for mitochondrial 
demise and cell death in cultivated cells as well as during pathological conditions in whole 
organisms. This conclusion was substantiated by the observation that pronounced 
VDAC1/Bid interaction occurs only after glutamate exposure of HT-22 cells and primary 
neurons and significantly increased over 6-24 h in ischemic brain tissue of mice subjected to 
transient focal cerebral ischemia. Therefore, the data suggested that both proteins, Bid and 
VDAC1, interfere together in neuronal cell death signaling, and pointed to VDAC1 as a 
mitochondrial receptor for activated Bid to regulate mitochondrial integrity and function. This 
hypothesis was confirmed by the findings that VDAC1 gene silencing was sufficient to 
prevent Bid-mediated impairments in mitochondrial morphology and Δψm as well as disturbed 
mitochondrial bioenergetics and attenuated glutamate toxicity in neuronal cells. Indicating a 
clear involvement of VDAC1 in the applied cell death models, the data suggested that a 
disturbed interaction between Bid and VDAC1 is the underlying mechanisms of the protective 
effects mediated by DIDS and VDAC1 gene silencing. This was affirmed by the data 
demonstrating that neither glutamate nor tBid were able to trigger mitochondrial dysfunction, 
MOMP and cell toxicity without functional VDAC1, and, vice versa VDAC1 over-expression 
did not induce mitochondrial fragmentation and cytotoxicity without Bid. Thus, the present 
thesis indicated that the association of both proteins is a key decision point for promoting 
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mitochondrial dysfunction and cell death thereby combining the abovementioned and long-
standing debate whether MOMP is regulated by the Bcl-2 family members or by the PTPC. 
However, what is the precise mechanism of this interaction and how does it affect the 
downstream signaling cascades? 
In agreement with previous studies reporting the oligomeric assembly of VDAC1 coupled to 
cell death stimuli with increasing conformational changes upon apoptotic signaling239, 240, the 
data revealed dimeric VDAC1 around 12 h of glutamate treatment, i.e. when mitochondrial 
demise marks the final execution phase of intrinsic cell death. Interestingly, this dimeric 
assembly still interacted with Bid, indicating that the Bid-VDAC1 interaction might trigger the 
formation of VDAC1 oligomers. Furthermore, the presented in vitro data revealed that the 
binding affinity of tBid to VDAC1 is 38-fold higher than for the binding of full length Bid to 
VDAC1 and suggested that tBid is the more effective partner for a direct interaction with 
VDAC1. In cells exposed to toxic glutamate levels, cleavage of full-length Bid to its active 
form tBid, or dissociation of the cleaved Bid fragments likely takes place at the mitochondrial 
membrane nearby the VDAC channel.  In fact, earlier observations suggested that tBid most 
likely affects VDAC following its association with lipid membranes161 and recent reports 
showed that separation of the N- and C-terminal tBid fragments occurs rapidly upon initial 
binding of tBid to the mitochondrial outer membrane72. Thus after dissociation of the N-
terminal p7 tBid fragment, tBid could bind to VDAC1 with high affinity to regulate its gating 
behavior. While it has been described that tBid induces VDAC1 channel closure161,  the 
mechanism by which Bid alters channel gating, either directly or indirectly, was not reported. 
The data here revealed that the VDAC1 channel can adopt two major closed states at 40% 
and 60% of its original conductance188. Following tBid/Bid binding a reduction of the overall 
current was observed in BLM measurements, indicating that Bid-VDAC1 interaction induces 
a conformational change of the VDAC1 channel, rather than its full closure.  In line with 
previous studies suggesting the importance of the N-terminus of VDAC for its channel gating 
and protein-interactions188, 242, deformations of the VDAC channel may squeeze the N-
terminal α-helix out of the hydrophilic cavity and therefore enable helix-mediated interactions 
with certain substrates and protein effectors. In accordance, a simplified model for the 
Bid/tBid-VDAC1 interaction can be suggested: upon cell death stimuli full-length Bid targets 
VDAC1 to induce a first conformational change of the channel. Cleavage of Bid and the 
dissociation of the cleaved p7 Bid fragment, which occurs rapidly upon initial binding of cBid 
to the mitochondrial outer membrane72, may promote a tighter binding of tBid to VDAC1. The 
tBid-VDAC1 complex with a reduced channel current further enables the exposure of the N-
terminal α-helix of VDAC1 to the inner mitochondrial space (IMS). Since tBid binding reduces 
the overall pore diameter of VDAC1, the tBid-VDAC1 complex might reflect a transitional 
state that further catalyzes the formation of VDAC1 homo-oligomers or hetero-oligomers with 
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other pro-apoptotic proteins, e.g. Bax, to sequester a pore formation enabling the release of 
death promoting factors into the cytosol and the subsequent cell death (Figure 86). 
Interestingly, the addition of DIDS to reconstituted VDAC1 in BLMs resulted in a completely 
dysfunctional VDAC1 channel and no opening or closing events could be detected once 
DIDS was added. The fact that in the presence of DIDS, tBid fails to interact with BLM 
reconstituted mVDAC1, and additionally was not able to induce loss of Δψm  and cell death at 
all in HT-22 cells, indicates that DIDS induces the closed state of the VDAC channel thereby 
prohibits channel deformation by tBid. As DIDS facilitates a channel state that is likewise a 
nonfunctional VDAC1 channel, it is not surprising that in cells VDAC1 gene depletion and 
DIDS promote similar protective effects against various features of Bid-dependent cell death 
pathways.  
 
Figure 86: Proposed model of the direct interaction of Bid and VDAC1. 
Upon apoptotic stimuli, Bid and VDAC1 interact in a direct manner. The association of full length Bid with VDAC1 
induces a first conformational change of VDAC1 resulting in a reduction of the pore diameter. The initial binding of 
Bid with membrane integrated VDAC1 facilitates Bid cleavage and the separation of the p7 tBid fragment, which 
benefits the tighter binding of the cleaved p15 tBid fragment to VDAC1. The tBid-VDAC1 complex might reflect a 
transitional state with a reduced overall current that enables the exposure of the VDAC1 α-helix to the inner 
mitochondrial space (IMS). The exposure of the α-helix to the IMS allows for further associations with several 
substrates including Ca
2+
, ATP/ADP or even other proteins present in the IMS. The partially closed state of 
VDAC1 together with the exposed α-helix catalyzes the further formation of VDAC1 oligomers or hetero-oligomers 
to sequester a pore diameter that enables the release of death promoting factors, such as apoptosis inducing 
factor (AIF), cytochrome c (c) and Smac/DIABLO (Sm), into the cytosol and the subsequent cell death. 
 
If other proteins are involved in the interplay between Bid/tBid and VDAC1 remains to be 
determined, although the nature of the more complex interactions may be dictated by cell 
type and the nature of the apoptotic stimulus. Although Bax and Bak are discussed to 
physically interact with VDACs, they might not necessarily be involved in the tBid-VDAC1 
complex. Since neurons do not express full-length Bak and in non-neuronal cells an 
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interaction of Bak and VDAC has been only demonstrated for the VDAC2 isoform296, it is 
likely that the proposed tBid-VDAC1 complex occurs independently of Bak. In contrast, Bax 
is widely expressed in neurons and discussed to interact with VDAC1, but so far no direct 
interaction between Bax and VDAC1 could be detected on the cellular level155. Although 
further studies are required to investigate whether the here proposed interaction might 
involve or even depends on Bax, a prerequisite role of Bax in the current cell death models is 
not expected, since previous studies revealed that Bax inhibitory peptides were not 
protective and Bax siRNA exerted only slightly protective effects in the model of glutamate-
toxicity in HT-22 cells297. In vitro and in vivo studies using Bax-/- knockout cells and mice 
would be required to gain a deeper insight if Bax might be involved in the Bid-VDAC1 
interplay. In any case, the direct interaction between tBid and VDAC1 seems to be essential 
for the subsequent impaired mitochondrial function and cell death, since deficiency of either 
Bid or VDAC1 is sufficient to provide protection, even if Bax is involved in the complex. Co-
crystallization of recombinant Bid and VDAC1 is subject of the current studies to provide a 
more detailed understanding of the proposed Bid-VDAC1 interaction and to determine 
structural sequences of both proteins that mediate their association and the subsequent 
conformational changes of the VDAC1 channel. Determining the respective residues of Bid 
that are required for VDAC1 binding is further worthwhile to examine if a Bid-Bax interaction 
could take place in parallel or if a Bid-Bax interplay would be competitive to the Bid-VDAC1 
interaction. Structural insights into the Bid-VDAC1 complex would further enabling for 
structure-guided drug campaigns and suggest a rationale for discovering antagonists that 
hinder the association of both proteins thereby inhibiting the subsequent mitochondrial 
demise.  
In conclusion, the presented data highlight VDAC1 as a mitochondrial receptor for Bid and its 
cleaved form tBid following introduction of apoptotic stimuli in neuronal cells (Figure 87). This 
interaction provides a convergence point for the proposed mechanisms of MOMP which were 
previously attributed solely to either the activity of apoptogenic BH3-only proteins or to 
VDACs. Targeting the tBid-VDAC1 interaction has high impact for therapeutic perspectives 
for neurological diseases, where mitochondrial demise is a major feature. 
 
4.5 Bid-mediated mitochondrial demise in neurons is independent on 
VDAC2 
In addition to the crucial involvement of VDAC1 in Bid-mediated neuronal cell death 
pathways, the present thesis addressed the role of the isoform VDAC2 in the current model 
of glutamate-induced toxicity. Similar to VDAC1, VDAC2 is a mitochondrial outer membrane 
protein with channel forming ability but present in low abundance251. Previous studies 
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indicated a specific the role of VDAC2 in mitochondrial cell death signaling describing the 
association of VDAC2 with pro-apoptotic Bak251 and providing evidence for VDAC2 
dependence of Bak targeting to the mitochondria252. Those studies revealed that VDAC2 
binds to Bak in un-stimulated mouse embryonic fibroblasts (MEFs) and that this 
sequestration is disrupted upon apoptotic signals, releasing Bak to carry out its pro-apoptotic 
function251. In line with these reports, Roy and colleagues linked the isoform VDAC2 to the 
apoptotic activity of tBid revealing that VDAC2-/- MEFs are insensitive to tBid-induced loss of 
Δψm, cytochrome c release and apoptosis
298. These studies suggested that VDAC2 is 
needed for tBid-mediated cell death by recruiting Bak to mitochondria and suggested that the 
Bak-VDAC2-tBid axis is more efficient at initiating apoptosis than the Bax-tBid pathway93. 
Further reports demonstrated a direct interaction between VDAC2 and Bak in un-stimulated 
HCT116 cells which was reduced after Fas- and STS-stimulation296, although the specific 
response to tBid was not addressed. Thus, in non-neuronal cells, VDAC2 seems to have a 
specific role in tBid-mediated cell death. However, in neuronal cells, the apoptotic 
mechanism might differ from that in non-neuronal cells, since a neuroprotective function for 
Bak and a specific role of VDAC2 in neuronal cell death has not been reported so far. The 
present thesis revealed that in contrast to the essential role of VDAC1, VDAC2 might be 
dispensable for Bid-mediated mitochondrial demise in neurons. This conclusion was drawn 
based on the findings that VDAC2 gene silencing achieved only minor protective effects in 
the model of glutamate-induced toxicity. Furthermore, the data demonstrated that in neurons 
Bid-mediated MOMP was not dependent on VDAC2, revealing that glutamate-induced loss 
of Δψm was not prevented by VDAC2 depletion. Although VDAC2 might be important for non-
neuronal cell death mediated by the tBid/Bak/Bax assembly, the data suggest a minor role of 
VDAC2 in neuronal cells. In regard to the reported absence of full-length Bak in neurons, 
indicating different non-neuronal and neuronal cell death mechanisms, the present thesis 
suggest that the proposed Bid-VDAC1 interaction in neurons mirrors the emerging non-
neuronal tBid-VDAC2-Bak pathway of apoptosis.  
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Figure 87: Proposed role of VDAC1 and Bid in neuronal apoptosis based on the findings in the 
glutamate-toxicity model in HT-22 cells. 
The model of glutamate-induced toxicity in HT-22 cells was demonstrated as a suitable model to investigate 
neuronal apoptosis. In this model system, oxidative stress, as it is induced by different neurodegenerative 
diseases, cerebral ischemia and others, leads to a detrimental increase of reactive oxygen species that trigger the 
following cleavage and activation of the pro-apoptotic protein Bid. Upon transactivation Bid initiates the point of no 
return in the mitochondrial cell death pathway: the depolarization of mitochondrial outer membrane (MOMP). The 
present thesis revealed an essential role for the voltage-dependent anion channel VDAC1 in the model of 
glutamate-induced toxicity and points to VDAC1 as a mitochondrial receptor for Bid to trigger mitochondrial 
demise and cell death. Both, over-expression of tBid as well as over-expression of VDAC1 induced mitochondrial 
fragmentation, loss of Δψm and cell death in HT-22 neurons. Upon the Bid/tBid–VDAC1 interaction, breakdown of 
the mitochondrial membrane potential, ATP depletion, impairments in mitochondrial respiration and finally the 
release of AIF and Cyt C trigger the final execution of mitochondrial apoptosis. Inhibition of either factor, VDAC1 
and Bid, is sufficient to block the other’s detrimental effect on mitochondria and execution of neuronal cell death. 
The Bid inhibitor BI-6c9 and Bid siRNA prevented the translocation of both, full-length Bid and tBid, to the 
mitochondria. Down-regulation of VDAC1 by siRNA as well as the anion channel blocker DIDS significantly 
preserved mitochondrial integrity and function, MOMP and reduced glutamate toxicity in neuronal cells.In contrast 
to VDAC1, VDAC2 down-regulation was not sufficient to provide protection against glutamate-induced Bid-
mediated apoptosis. Therefore, inhibition of the Bid/VDAC1 interaction is a promising therapeutic target to prevent 
mitochondrial demise, a crucial hallmark of neuronal cell death in acute and chronic neurodegenerative diseases, 
where glutamate toxicity and oxidative stress are prominent. 
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5 Summary 
Mitochondrial demise is a key feature of the progressive neuronal death in age-related 
neurodegenerative diseases such as Alzheimer’s disease or Parkinson’s disease and after 
acute brain injury. Oxidative stress or impaired calcium homeostasis converge at 
mitochondria where the permeabilization of the mitochondrial outer membrane (MOMP) are 
considered as ´point of no return´ in the cell’s commitment to die. The pro-apoptotic Bcl-2 
family protein Bid has been identified as a key regulator of mitochondrial injury and 
mitochondrial pathways of neuronal cell death. Upon its transactivation to mitochondria, Bid 
induces mitochondrial fragmentation and MOMP thereby accelerating the production of 
reactive oxygen species (ROS) and the release of death promoting factors into the cytosol 
that trigger the final steps of intrinsic cell death. The pivotal role of Bid in neuronal cell death 
has been further shown in models of cerebral ischemia and traumatic brain injury in vivo. 
Since it has been shown that inhibition of Bid maintains mitochondrial integrity and function 
thereby preventing mitochondrial cell death, Bid serves as a target for mitoprotection and 
neuronal cell survival. However, the precise mechanisms how Bid triggers mitochondrial 
impairment and disruption are still unknown and have to be explored to achieve efficient 
strategies for inhibition of Bid-mediated cell death pathways. 
Therefore, the present study was aimed to elucidate the mechanisms of Bid-dependent 
mitochondrial demise and addressed the associated Bid-protein interactions. Furthermore, 
the thesis focused on Bid crystallization campaigns and the development of Bid-inhibiting 
compounds with high impact for novel therapeutic perspectives in neurological diseases. Bid-
mediated cell death pathways were mainly addressed in immortalized mouse hippocampal 
HT-22 neurons exposed to toxic glutamate concentrations that induce oxidative stress 
through glutathione depletion. The findings were additionally confirmed in a model of tBid-
induced toxicity by over-expressing tBid in the HT-22 cell line and in vitro studies using 
recombinant proteins.  
The first part of the present study focused on the development of small-molecule ligands that 
target Bid for mitoprotection and neuronal cell survival. Seven compounds, obtained from 
three diverse chemical structure classes, were identified as effective inhibitors against 
glutamate- and tBid-induced cell injury. Most promising compounds were obtained from the 
class of thiazolidin-2,4-diones, revealing EC50 values in the lower micromolar range between 
6.78 µM and 13.27 µM. The compounds prevented not only cell death, but also preserved 
mitochondrial membrane potential, ATP levels as well as mitochondrial respiration after 
induction of oxidative stress in HT-22 neurons. The data further indicated the inhibition of Bid 
as the key mechanism behind their neuroprotective properties as substantiated by docking 
analysis and the compound´s protective effect against tBid-induced toxicity. Thus, the 
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identified compounds indicate potent scaffolds for future structure optimization which should 
result in small-molecules with favorable pharmaceutical properties, applicable also in model 
systems of cell death in vivo and further promise pharmaceutical perspectives for various 
neuronal and non-neuronal pathologies where Bid-mediated mitochondrial injury has been 
implicated.  
The second part of the thesis provided a basis for the use of recombinant Bid constructs 
suitable for Bid crystallization campaigns and further structure-guided drug design. Protocols 
for the design, expression and purification of different Bid constructs were scaled up, yielding 
reasonable amounts of Bid protein sufficient for crystallization screening. One of the 
designed Bid constructs was successfully crystallized obtaining diffraction data of 3.75 to 
3.95 Ǻ resolution under synchrotron-X-ray exposure. This observation indicates the 
appropriate Bid constructs as suitable for Bid crystal structure analysis. In addition, the 
activity of the novel Bid constructs was verified in the HT-22 cell line. Over-expression of 
those proteins revealed their non-apoptotic function and indicated their behavior as a ´full-
length Bid- like protein´, in contrast to toxic effects of tBid-over-expression. The further work 
investigated the effect of recombinant full-length Bid, caspase-8 cleaved Bid (cBid) and Bax 
on fluorescence-containing liposomes which mimic the mitochondrial membrane and focused 
on the role of cardiolipin (CL) in Bid-mediated membrane integration and permeabilization. 
The results indicated an ordered series of events that occur at mitochondrial membranes to 
induce MOMP and the release of death promoting proteins, revealing the requirement of CL 
for the recruitment of cBid to membranes and the role for Bax to enhance cBid-induced 
fluorescence release.  
The last part of the thesis demonstrated for the first time a direct interaction of Bid and 
VDAC1 with high relevance for Bid-mediated mitochondrial demise and neuronal cell death. 
The Bid-VDAC1 interaction significantly increased after glutamate-exposure of HT-22 cells 
and primary cortical neurons in vitro and after transient focal cerebral ischemia in vivo. The 
role of VDAC1 in Bid-dependent cell death signaling was verified by the protective effects of 
the anion channel blocker DIDS and VDAC1 siRNA in the present models of glutamate- and 
tBid-induced toxicity. Functional analysis revealed that both, Bid and VDAC1, cooperate 
during neuronal apoptosis to mediate impairments in mitochondrial oxygen consumption and 
ATP production, as well as mitochondrial fission, increased mitochondrial ROS production 
and the breakdown of the mitochondrial membrane potential. Inhibition of either factor, Bid or 
VDAC1, was sufficient to block the other’s detrimental effect on mitochondria and the 
execution of intrinsic cell death. These findings strongly indicated the proposed Bid-VDAC1 
interaction as a converging point for the mechanisms of MOMP that were previously 
contributed solely to either Bcl-2 family proteins or to VDACs. In contrast, only a minor role in 
Bid-mediated cell death signaling was suggested for the mitochondrial porin VDAC2, as 
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VDAC2 gene silencing could not protect against glutamate-induced injury. Therefore the data 
implicate a specific role for VDAC1 as mitochondrial receptor for activated Bid at the control 
point of life and death at the level of mitochondria in vitro and in vivo.  
Overall, the present thesis highlights the pro-apoptotic protein Bid as a promising druggable 
target for mitoprotection and neuronal survival and indicates recombinant Bid constructs as 
suitable for Bid crystal structure analysis. Furthermore, the data gained new insights in the 
mechanisms of Bid-dependent mitochondrial injury and the involvement of VDAC1 in 
mitochondrial apoptosis, connecting the controversial hypothesis of MOMP initiated by Bid 
and Bcl-2 family proteins or VDAC-mediated mPTP, respectively. Targeting the Bid-VDAC1 
interaction serves as a promising therapeutic approach aiming at preserved mitochondrial 
function and neuronal survival with high relevance for the treatment of neurological disorders, 
where oxidative stress and mitochondrial demise are prominent. 
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6 Zusammenfassung  
Mitochondriale Prozesse des Zelltods spielen eine entscheidende Rolle für den progressiven 
Verlust von Neuronen bei neurodegenerativen Erkrankungen (M. Alzheimer, M. Parkinson) 
und nach akuter Hirnschädigung durch Schädel-Hirn-Trauma oder zerebraler Ischämie. Eine 
Schlüsselfunktion nimmt hierbei das pro-apoptotische Bcl-2 Protein Bid ein. Durch die 
Aktivierung und mitochondriale Translokation von Bid kommt es zur Schädigung und 
Fragmentierung von Mitochondrien und letztlich zur Freisetzung von weiteren pro-
apoptotischen Faktoren (AIF, Cytochrom C, Smac/DIABLO), die den Untergang der Neurone 
steuern. Um in Zukunft Bid als potentielles Target für die Therapie von akuten und 
chronischen neurologischen sowie nicht neurologischen Erkrankungen nutzen zu können, 
müssen die bisher ungeklärten Mechanismen der Bid-induzierten mitochondrialen 
Schädigung, sowie die Interaktionen von aktiviertem Bid mit weiteren am Zelltod beteiligten 
Proteine aufgeklärt werden.  
Ziel dieser Arbeit war daher die Untersuchung Bid-abhängiger, mitochondrialer Zelltod 
Mechanismen und beteiligter Protein-Wechselwirkungen. Darüber hinaus stand die 
Entwicklung neuer Leitstrukturen für protektive Bid-Inhibitoren sowie die Etablierung erster 
Kristallisationsansätze verschiedener Bid Konstrukte im Fokus dieser Arbeit. Als 
Modellsyteme mitochondrialer Prozesse des Zelltods dienten vor allem immortalisierte 
hippokampale Neurone (HT-22 Zellen), in denen eine Behandlung mit Glutamat den durch 
oxidativen Stress gekennzeichneten Zelltod induziert. Als weiteres Schädigungsmodell 
wurde die Überexpression von aktiviertem Bid (tBid) eingesetzt. Zum Nachweis von 
Proteininteraktionen wurden weiterhin eine primäre neuronale Zellkultur und ein in vivo-
Modell der zerebralen Ischämie verwendet, sowie verschiedene Untersuchung mit 
rekombinanten Proteinen durchgeführt.  
Im ersten Teil der vorliegenden Arbeit wurden neue niedermolekulare Bid-Inhibitoren aus 
drei strukturell verschiedenen Substanzklassen mittels Zellviabilitätsmessungen auf 
neuroprotektive Effekte geprüft. Sieben Substanzen zeigten nicht nur deutliche Protektion 
gegenüber dem Glutamat- und tBid-induzierten Zelltod, sondern konnten ebenso die Bid-
abhängige mitochondriale Schädigung verhindern. Durch die Applikation dieser Substanzen 
konnten HT-22 Zellen vor dem Verlust des mitochondrialen Membranpotentials, dem Abfall 
intrazellulärer ATP Level sowie vor Störungen der mitochondrialen Atmung nach oxidativem 
Stress geschützt werden. Die hier gezeigten Verbindungen stellen daher wichtige 
Leitstrukturen für die Weiterentwicklung potenzieller Bid-Inhibitoren als Neuroprotektiva dar. 
Der zweite Teil dieser Arbeit beschäftigte sich mit der Kristallisation von rekombinantem Bid 
Protein, welche als Basis für ein grundlegendes Verständnis der molekularen Proteinfunktion 
sowie der Struktur-basierten Wirkstoffentwicklung dient. Hier wurde die Expression und 
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Reinigung verschiedener rekombinanter Bid Konstrukte etabliert und hoch gereinigtes Bid 
Protein für erste Kristallisationsätze verwendet. Durch Verfolgung wichtiger Strategien im 
Konstruktdesign konnte eines der verwendeten Bid Konstrukte erfolgreich kristallisiert 
werden und lieferte eine Strukturauflösung von 3.75 bis 3.95 Ǻ unter Synchrotronstrahlung. 
Die Arbeit konnte somit eine grundlegende Basis für die weitere Optimierung der hier 
erhaltenden Kristalle legen und sollte eine zukünftige Aufklärung der Kristallstruktur von Bid 
ermöglichen. Eine Überprüfung der verschiedenen Bid-Konstrukte im Zellsystem zeigte ein 
nicht-apoptotisches Verhalten im Gegensatz zur Überexpression von toxischem tBid. Im 
weiteren Rahmen dieser Promotionsarbeit wurde der Effekt der rekombinanten Proteine Bid, 
cBid und Bax auf Fluoreszenz-Liposomen getestet, um die Mechanismen der Bid-
abhängigen mitochondrialen Membranpermeabilisierung zu untersuchen. Es konnte hier eine 
Schlüsselrolle für das mitochondriale Lipid Cardiolipin gezeigt werden, in dessen 
Abhängigkeit Caspase-8 aktiviertes Bid (cBid) eine Membrandestabilisierung vermittelte, 
welche durch die Koexistenz von Bax gesteigert werden konnte.  
Der letzte Teil der Arbeit konnte erstmals eine direkte Interaktion zwischen Bid und dem 
mitochondrialen Porin VDAC1 in kultivierten Neuronen sowie in einem in vivo Modell der 
zerebralen Ischämie nachweisen. Die Inhibition von VDAC1 mittels Einsatz des Anionen-
Kanal-Blockers DIDS sowie der Verwendung von VDAC1 siRNA konnte sowohl die Funktion 
als auch die Integrität der Mitochondrien nach Glutamat- und tBid-induzierter Schädigung 
schützen und bestätigte somit die essentielle Rolle von VDAC1 im Bid-abhängigen Zelltod. 
Weitere Untersuchungen zeigten erstmalig, dass beide Proteine, Bid und VDAC1, 
gleichermaßen im neuronalen Zelltod involviert sind und offensichtlich zusammen eine 
Schädigung der mitochondrialen Membran induzieren. Die Hemmung eines der beiden 
Proteine war ausreichend, um die toxischen Effekte des Partnerproteins zu hemmen und so 
den Funktionsverlust der Neurone zu verhindern. Im Gegensatz dazu konnte gezeigt 
werden, dass die Isoform VDAC2 nur eine untergeordnete Rolle im Bid-induzierten Zelltod in 
Neuronen spielt.  
Die nachgewiesene Bid-VDAC1 Wechselwirkung besitzt hohe Relevanz für die 
mitochondrialen Prozesse des Zelltods. Damit verbindet die vorliegende Arbeit die bisher 
kontrovers betrachten Mechanismen der mitochodrialen Membranschädigung, die zuvor 
entweder auf die alleinige Aktivität der Bcl-2 Proteine oder auf VDACs zurückgeführt wurde. 
Mit der Identifizierung neuer potentieller Bid-Inhibitoren sowie durch Etablierung wichtiger 
Grundlagen für die Aufklärung der Kristallstruktur von Bid, stellt die Arbeit einen wesentlichen 
Beitrat für die strukturbasierte Wirkstoffentwicklung und Therapie verschiedener 
neurologischer und nicht neurologischer Erkrankungen dar, in welchen Bid-abhängige 
mitochondriale Prozesse des Zelltods eine wesentliche Rolle spielen. 
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7 Abbreviations 
A1 Bcl-2 related gene A1 
AD Alzheimer’s disease 
AIF Apoptosis inducing factor 
ALS Amyotrophic lateral sclerosis 
AMP Adenosine monophosphate 
ANOVA Analysis of variance 
APAF-1 Apoptosis protease-activating factor-1 
ATP Adenosinetriphosphate 
Bad Bcl-2 antagonist of cell death  
Bak Bcl-2 antagonist/killer 1  
Bax Bcl-2 associated protein X  
BCA  Bicinchonic acid 
Bcl-2 B-cell lymphoma-2 
Bcl-xl Bcl-2-releated gene, long isoform 
BH Bcl-2 homology  
BI Bid inhibitor 
Bid Bcl-2 interacting domain death antagonist  
Bim Bcl-2-interacting mediator of cell death 
BLM Black lipid bilayers 
BSA Bovine serum albumin 
BODIPY 
4,4-Difluoro-5-(4- phenyl-1,3-butadienyl)-4-
bora 3a,4a-diaza-sindacene-3-undecanoic 
acid 
Bp Base pairs 
°C Grad Celcius 
Ca2+ Calcium 
CAD Caspase-activated deoxyribonuclease 
cBid Caspase-8 cleaved Bid 
CCCP Carbonyl cyanide 3-chlorophenylhydrazone 
CL Cardiolipin 
Cl- Chlorid 
CNS Central nervous system 
CO2 Carbon dioxide  
Cu1+ Copper 
Cyp D Cyclophilin D 
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Cyt C Cytochrome C 
DAPI 4',6-Diamidino-2-phenylindole 
DED Death effector domain  
DIDS 
4,4-diisothio-cyanatostilbene-2,2´-disulfonic 
acid 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DTT D,L-Dithiotreitol 
EDTA Ethylenediamine-tetra-acetic acid 
EGTA 
Ethylene glycol-bis(2-aminoethylether)-
N,N,N’,N’- tetraacetic acid 
FACS Fluorescence-activated cell sorting 
FasL Fas-ligand 
FCS Fetal calf serum 
GAPDH 
Glyceraldehyde-3-phosphate-
dehydrogenase  
GFP Green fluorescence protein  
GSH Gluthatione  
Glut Glutamate 
Gpx 4 Glutathione peroxidase 4 
GSH Glutathione 
h hour 
HCL Hydrochloric acid  
HEPES 
4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid  
HD Huntington’s disease 
HRP Horseradish peroxidase 
IAP Inhibitors of apoptosis  
ICAD 
Inactive caspase-activated 
desoxyribonuclease  
IMM Inner mitochondrial membrane 
IPTG Isopropyl-β-D-thiogalactopyranosid 
kDa Kilo Dalton 
12/15 LOX 12/15 Lipoxygenase 
MCA Middle carotid artery  
MCAO  Middle carotid artery occlusion  
Mcl-1 Myeloid cell leukemia 1 
MEF Mouse embryonic fibroblast 
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MEM+  Eagle’s minimum essential medium  
mGFP 
Mitochondrial targeting green fluorescent 
protein  
mM Millimolar 
MOM Mitochondrial outer membrane 
MOMP 
Mitochondrial outer membrane 
permeabilization 
mPTP Mitochondrial permeability transition pore  
mtDNA Mitochondrial DNA  
MTT 
3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide 
NADH Nicotinamide adenine dinucleotide 
NaHCO3  Sodium hydrogen carbonate  
NaOH Sodium hydroxide 
nM Nanomolar 
NMDA  N-methyl-D-aspartic acid  
OG Octylglucosid 
OGD Oxygen-glucose deprivation 
Omi/HtrA2 High temperature requirement protein A2 
PBS Phosphate buffered saline  
PC Phosphatidylcholin 
PCR Polymerase chain reaction 
PCD Programmed cell death 
PD Parkinson’s disease 
PDB Protein data bank 
pDsRed2-Bid 
Plasmid encoding for a fusion protein of red 
fluorescent protein and Bid under control of 
the CMV promoter/enhancer 
PE Phosphatidylethanolamin 
PEG Polyethyleneglycole 
PEI Polyethylenimine  
PFA Paraformaldehyde 
PH Potentia hydrogenii  
PI Propidium iodide  
PS Phosphorothioate 
PTP  Permeability transition pore 
PTPC Permeability transition pore complex 
PVDF Polyvinylidenfluorid  
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ROS Reactive oxygen species 
RT Room temperature  
RuR Ruthenium red 
Scr Scrambled 
SD Standard deviation  
SDS Sodium dodecyl sulfate 
SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
siRNA Small interfering ribonucleic acid 
Smac/DIABLO 
Second mitochondria – derived activator of 
caspase/direct IAP binding protein with low 
pI 
STS Staurosporin 
TBE Tris/borate/EDTA 
TBI Traumatic brain injury 
tBid truncated Bid 
TBS Tris-buffered solution  
TBST Tris-buffered solution with Tween 20 
TE Trypsin-EDTA 
TEMED Tetramethylenethylendiamin 
TMRE Tetramethylrhodamin ethal ester 
TNF Tumor necrosis factor 
U Unit(s) 
V Volt 
VDAC Voltage-dependent anion channel 
xCT glutamine-cystine antiporter 
XIAP X-chromosomal linked inhibitor of apoptosis 
µ Micro 
µM Micromolar 
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8 Appendix 
Table 67: Neuroprotective properties of 4-phenoxyanilines 
Chemical structures and neuroprotective activities of representative N-acyl 4-phenoxyanilines against glutamate-
induced toxicity as achieved by the first screening and determined by MTT assay. Results are representatives of 
3-8 independent experiments each with n = 8 (*p < 0.05; ** < p 0.01; *** p < 0.001 compared to glutamate treated 
controls, ANOVA Scheffé´s test; N/A
α
, not active: compound revealed no toxic effects in HT-22 cells at 
concentrations from 1 µM up to 100 µM). 
Compound 
name 
Structure 
 
Neuroprotective 
activity 
compound concentration (µM) 
Cytotoxicity 
(µM, p < 0.001) 
  1. 10 25 50 100  
SCHL 24366 
 
--- --- --- --- --- N/Aα 
SCHL 24370 
 
--- --- *** *** *** ≥ 100 
SCHL 28131 
 
--- --- --- --- --- N/Aα 
SCHL 28132 
 
--- --- --- --- *** N/Aα 
SCHL 24388 
 
--- --- --- *** *** ≥ 100 
SCHL 24395 
 
--- --- --- --- *** ≥ 100 
SCHL 24396 
 
--- --- --- --- --- N/Aα 
SCHL 24382 
 
--- --- --- --- --- ≥ 100 
SCHL 28073 
 
--- --- * ** *** N/Aα 
SCHL 28074 
 
--- --- --- --- *** ≥ 100 
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SCHL 24365 
 
--- --- --- --- --- N/Aα 
SCHL 24375 
 
--- *** *** *** *** N/Aα 
SCHL 24390 
 
--- --- --- ** *** N/Aα 
SCHL 24368 
 
--- --- --- --- --- ≥ 10 
SCHL 28138 
 
--- *** *** *** *** N/Aα 
SCHL 28153 
 
--- --- --- --- --- N/Aα 
SCHL 28076 
 
--- --- *** *** *** ≥ 100 
SCHL 28127 
 
--- --- --- --- --- ≥ 100 
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Table 68: Neuroprotective properties of isonipecotic acid derivatives 
Chemical structures and neuroprotective activities of representative isonipecotic acid derivatives against 
glutamate-induced toxicity as achieved by the first screening and determined by MTT assay. Results are 
representatives of 3-8 independent experiments each with n = 8 (*p < 0.05; ** < p 0.01; *** p < 0.001 compared to 
glutamate treated controls, ANOVA Scheffé´s test; N/A
α
, not active: compound revealed no toxic effects in HT-22 
cells at concentrations from 1 µM up to 100 µM). 
 
Compound 
name 
Structure 
 
Neuroprotective 
activity 
compound concentration (µM) 
Cytotoxicity 
(µM, p < 0.001) 
  1. 10 25 50 100  
SCHL 28001 
 
--- *** *** *** *** ≥ 50 
SCHL 28002 
 
* *** *** *** *** N/Aα 
SCHL 24519 
 
*** *** *** *** *** N/Aα 
SCHL 24017 
 
--- --- --- *** *** ≥ 100 
SCHL 28025 
 
--- --- *** *** --- ≥ 100 
SCHL 28049 
 
--- *** *** *** --- ≥ 100 
SCHL 28069 
 
--- --- *** --- --- ≥ 100 
SCHL 28038 
 
--- *** *** *** *** ≥ 100 
SCHL 28052 
 
--- *** *** *** *** N/Aα 
SCHL 28146 
 
--- --- --- *** *** ≥ 100 
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SCHL 24543 
 
--- *** *** *** --- ≥ 100 
SCHL 24537 
 
--- *** *** *** --- ≥ 100 
SCHL 24062 
 
--- --- *** * --- ≥ 100 
SCHL 24545 
 
--- --- *** *** *** N/Aα 
SCHL 24546 
 
--- ** *** *** --- ≥ 100 
SCHL 24553 
 
--- * *** *** *** N/Aα 
SCHL 24518 
 
--- ** *** *** *** ≥ 100 
SCHL 24551 
 
--- --- * *** *** ≥ 100 
SCHL 24555 
 
--- --- --- *** *** N/Aα 
SCHL 28086 
 
--- *** *** --- --- ≥ 100 
SCHL 28119 
 
--- *** *** *** *** N/Aα 
SCHL 24520 
 
--- --- * * *** ≥ 100 
SCHL 24524 
 
--- *** *** *** *** ≥ 100 
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SCHL 24522 
 
** *** *** --- --- ≥ 100 
SCHL 28129 
 
--- --- --- --- --- ≥ 10 
SCHL 24379 
 
--- --- --- --- --- N/Aα 
SCHL 24380 
 
--- --- --- --- --- N/Aα 
SCHL 24381 
 
--- --- --- --- *** N/Aα 
SCHL 28037 
 
--- --- --- --- --- N/Aα 
SCHL 28045 
 
--- --- * * * N/Aα 
SCHL 28053 
 
--- *** *** *** *** ≥ 100 
SCHL 28047 
 
--- *** *** *** *** ≥ 100 
SCHL 24540 
 
--- --- --- --- --- ≥ 100 
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SCHL 28120 
 
--- --- --- --- --- N/Aα 
SCHL 28121 
 
--- --- --- --- --- ≥ 100 
SCHL 28117 
 
--- *** *** --- --- ≥ 100 
SCHL 24538 
 
--- --- *** *** *** ≥ 100 
SCHL 28048 
 
--- --- *** *** --- ≥ 100 
SCHL 24521 
 
*** *** *** *** *** N/Aα 
SCHL 28041 
 
--- --- --- *** *** ≥ 100 
SCHL 28050 
 
--- *** *** *** *** ≥ 100 
SCHL 28028 
 
--- --- *** *** --- ≥ 100 
SCHL 28031 
 
--- --- --- --- --- ≥ 100 
SCHL 28032 
 
--- --- --- --- --- ≥ 100 
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SCHL 28023 
 
--- 
*** *** *** --- ≥ 100 
SCHL 24535 
 
--- --- *** *** --- ≥ 100 
SCHL 28115 
 
*** *** *** --- --- ≥ 100 
SCHL 28155 
 
--- --- --- --- *** N/Aα 
SCHL 28152 
 
--- --- *** *** *** ≥ 50 
SCHL 24542 
 
--- 
*** *** *** *** ≥ 100 
SCHL 24526 
 
--- --- --- *** * ≥ 100 
SCHL 24523 
 
*** *** *** *** --- ≥ 100 
SCHL 28118 
 
--- --- --- --- --- ≥ 100 
SCHL 28116 
 
--- --- --- --- --- N/Aα 
SCHL 24527 
 
--- --- --- --- --- ≥ 100 
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Table 69: Neuroprotective properties of N-phenyl substituted thiazolidindiones. 
Neuroprotective activity of the compounds against glutamate-toxicity in HT-22 cells was determined within the first 
screening approach by MTT assay. EC50 are given as the mean drug concentration required for inhibiting cell 
death by 50 % compared to controls. Toxicity values indicate toxic drug concentrations found to induce cell death 
without co-treatment with glutamate. (***p < 0.001 compared to glutamate treated control, ANOVA Scheffé´s test; 
N/A
α
, not active – substance revealed no toxic properties at concentrations of 0.1 µM up to 100 µM; N/D
β
, not 
determinable – EC50 values could not be calculated due to lack of protective effects. The results presented are 
representatives of 4-6 independent experiments (MTT assay). 
 
Compound 
name 
 
Structure 
 
EC50 
(µM) 
Neuroprotective 
activity 
compound concentration (µM) 
Cytotoxicity 
(µM, p < 0.001) 
    0.1 1 5 10 50  
SCHL 30049 
 
 
N/Dβ --- --- --- --- --- N/Aα 
SCHL 24292 
 
 
9.87 --- --- *** *** *** N/Aα 
SCHL 30042 
 
 
18.10 --- --- --- *** *** N/Aα 
SCHL 24277 
 
 
6.78 --- --- *** *** *** N/Aα 
SCHL 30026 
 
 
19.30 --- --- --- --- *** N/Aα 
SCHL 24262 
 
 
11.87 --- --- ** *** *** N/Aα 
SCHL 24258 
 
 
18.10 --- --- --- *** *** N/Aα 
SCHL 24310 
 
 
9.59 --- --- *** *** *** N/Aα 
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SCHL 24324 
 
 
20.85 --- --- --- * ** N/Aα 
SCHL 24309 
 
 
9.60 --- --- --- *** *** N/Aα 
SCHL 24338 
 
 
9.28 --- --- * *** *** N/Aα 
SCHL 30024 
 
 
19.98 --- --- --- * *** N/Aα 
SCHL 30037 
 
 
19.73 --- --- --- --- *** N/Aα 
SCHL 24293 
 
 
13.20 --- --- *** *** *** N/Aα 
SCHL 24305 
 
 
15.71 --- --- *** *** *** N/Aα 
SCHL 30021 
 
 
19.50 --- --- --- --- *** N/Aα 
SCHL 30025 
 
 
19.46 --- --- --- * *** N/Aα 
SCHL 24386 
 
 
13.68 --- --- * *** *** N/Aα 
SCHL 24213 
 
 
9.39 --- --- *** *** *** N/Aα 
SCHL 24239 
 
 
14.94 --- --- --- *** *** ≥ 50 
246 | Appendix 
 
 
 
SCHL 24320 
 
 
14.14 --- --- --- *** *** N/Aα 
SCHL 24317 
 
 
13.5 --- --- --- *** *** N/Aα 
SCHL 24279 
 
 
N/Dβ NSγ NSγ NSγ NSγ NSγ N/Dβ 
SCHL 24387 
 
 
13.42 --- --- * *** *** N/Aα 
SCHL 24270 
 
 
13.27 --- --- * *** *** N/Aα 
SCHL 24385 
 
 
N/Dβ --- --- --- --- --- ≥ 10 
SCHL 24363 
 
 
14.5 --- --- --- *** *** N/Aα 
SCHL 30005 
 
 
N/Dβ --- --- --- --- --- ≥ 50 
SCHL 30004 
 
 
N/Dβ --- --- --- --- --- ≥ 50 
SCHL 30001 
 
 
N/Dβ --- --- --- --- --- ≥ 50 
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SCHL 24296 
 
 
N/Dβ --- --- *** *** *** ≥ 50 
SCHL 24298 
 
 
N/Dβ --- --- --- --- --- ≥ 50 
SCHL 24291 
 
 
N/Dβ --- --- *** *** *** ≥ 50 
SCHL 24216 
 
 
N/Dβ --- --- *** *** *** ≥ 50 
SCHL 30013 
 
 
N/Dβ --- --- --- --- --- ≥ 50 
SCHL 30014 
 
 
N/Dβ --- --- --- --- --- ≥ 50 
SCHL 30006 
 
 
N/Dβ --- --- --- --- --- ≥ 50 
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SCHL 30011 
 
 
N/Dβ --- --- --- --- --- N/Aα 
SCHL 30010 
 
 
N/Dβ --- --- --- --- --- ≥ 100 
SCHL 30008 
 
 
N/Dβ --- --- --- * * ≥ 50 
SCHL 24100    
 
 
N/Dβ --- --- --- --- --- N/Aα 
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Table 70: Neuroproctive properties of miscellaneous chemical compounds. 
Structures and neuroprotective activities of novel chemical compounds against glutamate-induced toxicity as 
achieved by the first screening and determined by MTT assay. Results are representatives of 3-8 independent 
experiments each with n = 8 (*p < 0.05; ** < p 0.01; *** p < 0.001 compared to glutamate treated controls, ANOVA 
Scheffé´s test; N/A
α
, not active: compound revealed no toxic effects in HT-22 cells at concentrations from 1 µM up 
to 100 µM). 
Compound 
name 
Structure 
 
Neuroprotective 
activity 
compound concentration (µM) 
Cytotoxicity 
(µM, p < 0.001) 
  1. 10 25 50 100  
SCHL 30032 
 
--- --- --- --- --- N/Aα 
SCHL 30040 
 
--- --- --- --- --- N/Aα 
SCHL 30002 
 
--- --- --- --- --- N/Aα 
SCHL 30027 
 
--- --- --- --- *** N/Aα 
SCHL 24398 
 
--- --- --- --- --- N/Aα 
SCHL 24401 
 
--- --- --- --- --- N/Aα 
SCHL 24394 
 
--- --- *** *** *** N/Aα 
SCHL 24552 
 
--- --- --- --- --- N/Aα 
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SCHL 24554 
 
--- --- --- --- --- N/Aα 
SCHL 24549 
 
--- --- --- --- --- N/Aα 
 
 
      
  
 
References | 251 
 
 
 
9 References 
 1.  Franklin, J. L. Redox regulation of the intrinsic pathway in neuronal apoptosis. 
Antioxid. Redox. Signal. 14, 1437-1448 (2011). 
 2.  Mattson, M. P. Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 1, 
120-129 (2000). 
 3.  Gorman, A. M. Neuronal cell death in neurodegenerative diseases: recurring themes 
around protein handling. J. Cell Mol. Med. 12, 2263-2280 (2008). 
 4.  Yuan, J. Neuroprotective strategies targeting apoptotic and necrotic cell death for 
stroke. Apoptosis. 14, 469-477 (2009). 
 5.  Galluzzi, L. et al. Molecular definitions of cell death subroutines: recommendations of 
the Nomenclature Committee on Cell Death 2012. Cell Death. Differ. 19, 107-120 
(2012). 
 6.  Majno, G. & Joris, I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am. 
J. Pathol. 146, 3-15 (1995). 
 7.  Vanden Berghe, T., Linkermann, A., Jouan-Lanhouet, S., Walczak, H. & 
Vandenabeele, P. Regulated necrosis: the expanding network of non-apoptotic cell 
death pathways. Nat. Rev. Mol. Cell Biol. 15, 135-147 (2014). 
 8.  Liu, Q. et al. Akt and mTOR mediate programmed necrosis in neurons. Cell Death. 
Dis. 5, e1084 (2014). 
 9.  Rosenbaum, D. M. et al. Necroptosis, a novel form of caspase-independent cell 
death, contributes to neuronal damage in a retinal ischemia-reperfusion injury model. 
J. Neurosci. Res. 88, 1569-1576 (2010). 
 10.  Yuan, J., Lipinski, M. & Degterev, A. Diversity in the mechanisms of neuronal cell 
death. Neuron 40, 401-413 (2003). 
 11.  Zong, W. X. & Thompson, C. B. Necrotic death as a cell fate. Genes Dev. 20, 1-15 
(2006). 
 12.  Kerr, J. F., Wyllie, A. H. & Currie, A. R. Apoptosis: a basic biological phenomenon 
with wide-ranging implications in tissue kinetics. Br. J. Cancer 26, 239-257 (1972). 
 13.  Oppenheim, R. W. Cell death during development of the nervous system. Annu. Rev. 
Neurosci. 14, 453-501 (1991). 
 14.  Graham, S. H. & Chen, J. Programmed cell death in cerebral ischemia. J. Cereb. 
Blood Flow Metab 21, 99-109 (2001). 
 15.  Kroemer, G., Petit, P., Zamzami, N., Vayssiere, J. L. & Mignotte, B. The biochemistry 
of programmed cell death. FASEB J. 9, 1277-1287 (1995). 
 16.  Mattson, M. P., Duan, W., Pedersen, W. A. & Culmsee, C. Neurodegenerative 
disorders and ischemic brain diseases. Apoptosis. 6, 69-81 (2001). 
 17.  Darwish, R. S. Regulatory mechanisms of apoptosis in regularly dividing cells. Cell 
Health and Cytoskeleton 2010,2, 59-68 (2010). 
252 | References 
 
 
 
 18.  Galluzzi, L., Blomgren, K. & Kroemer, G. Mitochondrial membrane permeabilization in 
neuronal injury. Nat. Rev. Neurosci. 10, 481-494 (2009). 
 19.  Kroemer, G., Galluzzi, L. & Brenner, C. Mitochondrial membrane permeabilization in 
cell death. Physiol Rev. 87, 99-163 (2007). 
 20.  Chan, D. C. Mitochondria: dynamic organelles in disease, aging, and development. 
Cell 125, 1241-1252 (2006). 
 21.  Chipuk, J. E., Bouchier-Hayes, L. & Green, D. R. Mitochondrial outer membrane 
permeabilization during apoptosis: the innocent bystander scenario. Cell Death. 
Differ. 13, 1396-1402 (2006). 
 22.  Culmsee, C. & Landshamer, S. Molecular insights into mechanisms of the cell death 
program: role in the progression of neurodegenerative disorders. Curr. Alzheimer 
Res. 3, 269-283 (2006). 
 23.  Green, D. R. & Kroemer, G. The pathophysiology of mitochondrial cell death. Science 
305, 626-629 (2004). 
 24.  Grohm, J., Plesnila, N. & Culmsee, C. Bid mediates fission, membrane 
permeabilization and peri-nuclear accumulation of mitochondria as a prerequisite for 
oxidative neuronal cell death. Brain Behav. Immun. 24, 831-838 (2010). 
 25.  Susin, S. A. et al. Molecular characterization of mitochondrial apoptosis-inducing 
factor. Nature 397, 441-446 (1999). 
 26.  Droge, W. Free radicals in the physiological control of cell function. Physiol Rev. 82, 
47-95 (2002). 
 27.  Phillis, J. W., Horrocks, L. A. & Farooqui, A. A. Cyclooxygenases, lipoxygenases, and 
epoxygenases in CNS: their role and involvement in neurological disorders. Brain 
Res. Rev. 52, 201-243 (2006). 
 28.  Ott, M., Gogvadze, V., Orrenius, S. & Zhivotovsky, B. Mitochondria, oxidative stress 
and cell death. Apoptosis. 12, 913-922 (2007). 
 29.  Coyle, J. T. & Puttfarcken, P. Oxidative stress, glutamate, and neurodegenerative 
disorders. Science 262, 689-695 (1993). 
 30.  Culmsee, C. & Krieglstein, J. Ischaemic brain damage after stroke: new insights into 
efficient therapeutic strategies. International Symposium on Neurodegeneration and 
Neuroprotection. EMBO Rep. 8, 129-133 (2007). 
 31.  Greenlund, L. J., Deckwerth, T. L. & Johnson, E. M., Jr. Superoxide dismutase delays 
neuronal apoptosis: a role for reactive oxygen species in programmed neuronal 
death. Neuron 14, 303-315 (1995). 
 32.  Lin, M. T. & Beal, M. F. Mitochondrial dysfunction and oxidative stress in 
neurodegenerative diseases. Nature 443, 787-795 (2006). 
 33.  Simon, H. U., Haj-Yehia, A. & Levi-Schaffer, F. Role of reactive oxygen species 
(ROS) in apoptosis induction. Apoptosis. 5, 415-418 (2000). 
References | 253 
 
 
 
 34.  Tan, S., Sagara, Y., Liu, Y., Maher, P. & Schubert, D. The regulation of reactive 
oxygen species production during programmed cell death. J. Cell Biol. 141, 1423-
1432 (1998). 
 35.  Landes, T. & Martinou, J. C. Mitochondrial outer membrane permeabilization during 
apoptosis: the role of mitochondrial fission. Biochim. Biophys. Acta 1813, 540-545 
(2011). 
 36.  Martinou, J. C. & Youle, R. J. Mitochondria in apoptosis: Bcl-2 family members and 
mitochondrial dynamics. Dev. Cell 21, 92-101 (2011). 
 37.  Giacomello, M., Drago, I., Pizzo, P. & Pozzan, T. Mitochondrial Ca2+ as a key 
regulator of cell life and death. Cell Death. Differ. 14, 1267-1274 (2007). 
 38.  Bolanos, J. P., Moro, M. A., Lizasoain, I. & Almeida, A. Mitochondria and reactive 
oxygen and nitrogen species in neurological disorders and stroke: Therapeutic 
implications. Adv. Drug Deliv. Rev. 61, 1299-1315 (2009). 
 39.  Desagher, S. & Martinou, J. C. Mitochondria as the central control point of apoptosis. 
Trends Cell Biol. 10, 369-377 (2000). 
 40.  Kroemer, G., Zamzami, N. & Susin, S. A. Mitochondrial control of apoptosis. Immunol. 
Today 18, 44-51 (1997). 
 41.  Halestrap, A. P., McStay, G. P. & Clarke, S. J. The permeability transition pore 
complex: another view. Biochimie 84, 153-166 (2002). 
 42.  Rao, V. K., Carlson, E. A. & Yan, S. S. Mitochondrial permeability transition pore is a 
potential drug target for neurodegeneration. Biochim. Biophys. Acta(2013). 
 43.  Garcia-Saez, A. J. The secrets of the Bcl-2 family. Cell Death. Differ. 19, 1733-1740 
(2012). 
 44.  Youle, R. J. & Strasser, A. The BCL-2 protein family: opposing activities that mediate 
cell death. Nat. Rev. Mol. Cell Biol. 9, 47-59 (2008). 
 45.  Chipuk, J. E. et al. Mechanism of apoptosis induction by inhibition of the anti-
apoptotic BCL-2 proteins. Proc. Natl. Acad. Sci. U. S. A 105, 20327-20332 (2008). 
 46.  Hardwick, J. M. & Youle, R. J. SnapShot: BCL-2 proteins. Cell 138, 404, 404 (2009). 
 47.  Kuwana, T. et al. BH3 domains of BH3-only proteins differentially regulate Bax-
mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. 
Cell 17, 525-535 (2005). 
 48.  Krajewska, M. et al. Expression of Bcl-2 family member Bid in normal and malignant 
tissues. Neoplasia. 4, 129-140 (2002). 
 49.  Krajewska, M. et al. Dynamics of expression of apoptosis-regulatory proteins Bid, Bcl-
2, Bcl-X, Bax and Bak during development of murine nervous system. Cell Death. 
Differ. 9, 145-157 (2002). 
 50.  Krajewski, S. et al. Immunohistochemical analysis of Mcl-1 protein in human tissues. 
Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for 
Mcl-1 in control of programmed cell death in vivo. Am. J. Pathol. 146, 1309-1319 
(1995). 
254 | References 
 
 
 
 51.  Krajewski, S. et al. Upregulation of bax protein levels in neurons following cerebral 
ischemia. J. Neurosci. 15, 6364-6376 (1995). 
 52.  Sun, Y. F., Yu, L. Y., Saarma, M., Timmusk, T. & Arumae, U. Neuron-specific Bcl-2 
homology 3 domain-only splice variant of Bak is anti-apoptotic in neurons, but pro-
apoptotic in non-neuronal cells. J. Biol. Chem. 276, 16240-16247 (2001). 
 53.  Chipuk, J. E., Moldoveanu, T., Llambi, F., Parsons, M. J. & Green, D. R. The BCL-2 
family reunion. Mol. Cell 37, 299-310 (2010). 
 54.  Shamas-Din, A., Kale, J., Leber, B. & Andrews, D. W. Mechanisms of action of Bcl-2 
family proteins. Cold Spring Harb. Perspect. Biol. 5, a008714 (2013). 
 55.  Wang, K., Yin, X. M., Chao, D. T., Milliman, C. L. & Korsmeyer, S. J. BID: a novel 
BH3 domain-only death agonist. Genes Dev. 10, 2859-2869 (1996). 
 56.  Kamer, I. et al. Proapoptotic BID is an ATM effector in the DNA-damage response. 
Cell 122, 593-603 (2005). 
 57.  Zinkel, S. S. et al. A role for proapoptotic BID in the DNA-damage response. Cell 122, 
579-591 (2005). 
 58.  Konig, H. G. et al. Full length Bid is sufficient to induce apoptosis of cultured rat 
hippocampal neurons. BMC. Cell Biol. 8, 7 (2007). 
 59.  Ward, M. W. et al. Real time single cell analysis of Bid cleavage and Bid translocation 
during caspase-dependent and neuronal caspase-independent apoptosis. J. Biol. 
Chem. 281, 5837-5844 (2006). 
 60.  Li, H., Zhu, H., Xu, C. J. & Yuan, J. Cleavage of BID by caspase 8 mediates the 
mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501 (1998). 
 61.  Billen, L. P., Shamas-Din, A. & Andrews, D. W. Bid: a Bax-like BH3 protein. 
Oncogene 27 Suppl 1, S93-104 (2008). 
 62.  Brustovetsky, N., Dubinsky, J. M., Antonsson, B. & Jemmerson, R. Two pathways for 
tBID-induced cytochrome c release from rat brain mitochondria: BAK- versus BAX-
dependence. J. Neurochem. 84, 196-207 (2003). 
 63.  Culmsee, C. & Plesnila, N. Targeting Bid to prevent programmed cell death in 
neurons. Biochem. Soc. Trans. 34, 1334-1340 (2006). 
 64.  Chou, J. J., Li, H., Salvesen, G. S., Yuan, J. & Wagner, G. Solution structure of BID, 
an intracellular amplifier of apoptotic signaling. Cell 96, 615-624 (1999). 
 65.  McDonnell, J. M., Fushman, D., Milliman, C. L., Korsmeyer, S. J. & Cowburn, D. 
Solution structure of the proapoptotic molecule BID: a structural basis for apoptotic 
agonists and antagonists. Cell 96, 625-634 (1999). 
 66.  Yin, X. M. Bid, a BH3-only multi-functional molecule, is at the cross road of life and 
death. Gene 369, 7-19 (2006). 
 67.  Suzuki, M., Youle, R. J. & Tjandra, N. Structure of Bax: coregulation of dimer 
formation and intracellular localization. Cell 103, 645-654 (2000). 
References | 255 
 
 
 
 68.  Muchmore, S. W. et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of 
programmed cell death. Nature 381, 335-341 (1996). 
 69.  Kudla, G. et al. The destabilization of lipid membranes induced by the C-terminal 
fragment of caspase 8-cleaved bid is inhibited by the N-terminal fragment. J. Biol. 
Chem. 275, 22713-22718 (2000). 
 70.  Zha, J., Weiler, S., Oh, K. J., Wei, M. C. & Korsmeyer, S. J. Posttranslational N-
myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. 
Science 290, 1761-1765 (2000). 
 71.  Lovell, J. F. et al. Membrane binding by tBid initiates an ordered series of events 
culminating in membrane permeabilization by Bax. Cell 135, 1074-1084 (2008). 
 72.  Shamas-Din, A. et al. tBid undergoes multiple conformational changes at the 
membrane required for Bax activation. J. Biol. Chem. 288, 22111-22127 (2013). 
 73.  Sutton, V. R., Wowk, M. E., Cancilla, M. & Trapani, J. A. Caspase activation by 
granzyme B is indirect, and caspase autoprocessing requires the release of 
proapoptotic mitochondrial factors. Immunity. 18, 319-329 (2003). 
 74.  Chen, M. et al. Bid is cleaved by calpain to an active fragment in vitro and during 
myocardial ischemia/reperfusion. J. Biol. Chem. 276, 30724-30728 (2001). 
 75.  Polster, B. M., Basanez, G., Etxebarria, A., Hardwick, J. M. & Nicholls, D. G. Calpain I 
induces cleavage and release of apoptosis-inducing factor from isolated 
mitochondria. J. Biol. Chem. 280, 6447-6454 (2005). 
 76.  Cirman, T. et al. Selective disruption of lysosomes in HeLa cells triggers apoptosis 
mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J. Biol. 
Chem. 279, 3578-3587 (2004). 
 77.  Schafer, B. et al. Mitochondrial outer membrane proteins assist Bid in Bax-mediated 
lipidic pore formation. Mol. Biol. Cell 20, 2276-2285 (2009). 
 78.  Grinberg, M. et al. tBID Homooligomerizes in the mitochondrial membrane to induce 
apoptosis. J. Biol. Chem. 277, 12237-12245 (2002). 
 79.  Crimi, M. & Esposti, M. D. Apoptosis-induced changes in mitochondrial lipids. 
Biochim. Biophys. Acta 1813, 551-557 (2011). 
 80.  Lutter, M. et al. Cardiolipin provides specificity for targeting of tBid to mitochondria. 
Nat. Cell Biol. 2, 754-761 (2000). 
 81.  Kim, T. H. et al. Bid-cardiolipin interaction at mitochondrial contact site contributes to 
mitochondrial cristae reorganization and cytochrome C release. Mol. Biol. Cell 15, 
3061-3072 (2004). 
 82.  Lucken-Ardjomande, S., Montessuit, S. & Martinou, J. C. Contributions to Bax 
insertion and oligomerization of lipids of the mitochondrial outer membrane. Cell 
Death. Differ. 15, 929-937 (2008). 
 83.  Lutter, M., Perkins, G. A. & Wang, X. The pro-apoptotic Bcl-2 family member tBid 
localizes to mitochondrial contact sites. BMC. Cell Biol. 2, 22 (2001). 
256 | References 
 
 
 
 84.  Ott, M., Zhivotovsky, B. & Orrenius, S. Role of cardiolipin in cytochrome c release 
from mitochondria. Cell Death. Differ. 14, 1243-1247 (2007). 
 85.  Scorrano, L. et al. A distinct pathway remodels mitochondrial cristae and mobilizes 
cytochrome c during apoptosis. Dev. Cell 2, 55-67 (2002). 
 86.  Eskes, R., Desagher, S., Antonsson, B. & Martinou, J. C. Bid induces the 
oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol. Cell 
Biol. 20, 929-935 (2000). 
 87.  Esposti, M. D., Erler, J. T., Hickman, J. A. & Dive, C. Bid, a widely expressed 
proapoptotic protein of the Bcl-2 family, displays lipid transfer activity. Mol. Cell Biol. 
21, 7268-7276 (2001). 
 88.  Esposti, M. D., Cristea, I. M., Gaskell, S. J., Nakao, Y. & Dive, C. Proapoptotic Bid 
binds to monolysocardiolipin, a new molecular connection between mitochondrial 
membranes and cell death. Cell Death. Differ. 10, 1300-1309 (2003). 
 89.  Sorice, M. et al. Cardiolipin and its metabolites move from mitochondria to other 
cellular membranes during death receptor-mediated apoptosis. Cell Death. Differ. 11, 
1133-1145 (2004). 
 90.  Cristea, I. M. & Degli, E. M. Membrane lipids and cell death: an overview. Chem. 
Phys. Lipids 129, 133-160 (2004). 
 91.  Kuwana, T. et al. Bid, Bax, and lipids cooperate to form supramolecular openings in 
the outer mitochondrial membrane. Cell 111, 331-342 (2002). 
 92.  Korsmeyer, S. J. et al. Pro-apoptotic cascade activates BID, which oligomerizes BAK 
or BAX into pores that result in the release of cytochrome c. Cell Death. Differ. 7, 
1166-1173 (2000). 
 93.  Roy, S. S., Ehrlich, A. M., Craigen, W. J. & Hajnoczky, G. VDAC2 is required for 
truncated BID-induced mitochondrial apoptosis by recruiting BAK to the mitochondria. 
EMBO Rep. 10, 1341-1347 (2009). 
 94.  Robinson, A. J., Kunji, E. R. & Gross, A. Mitochondrial carrier homolog 2 (MTCH2): 
the recruitment and evolution of a mitochondrial carrier protein to a critical player in 
apoptosis. Exp. Cell Res. 318, 1316-1323 (2012). 
 95.  Zaltsman, Y. et al. MTCH2/MIMP is a major facilitator of tBID recruitment to 
mitochondria. Nat. Cell Biol. 12, 553-562 (2010). 
 96.  Kook, S. et al. Caspase-cleaved arrestin-2 and BID cooperatively facilitate 
cytochrome C release and cell death. Cell Death. Differ. 21, 172-184 (2014). 
 97.  Landshamer, S. et al. Bid-induced release of AIF from mitochondria causes 
immediate neuronal cell death. Cell Death. Differ. 15, 1553-1563 (2008). 
 98.  Plesnila, N. et al. BID mediates neuronal cell death after oxygen/ glucose deprivation 
and focal cerebral ischemia. Proc. Natl. Acad. Sci. U. S. A 98, 15318-15323 (2001). 
 99.  Becattini, B. et al. Targeting apoptosis via chemical design: inhibition of bid-induced 
cell death by small organic molecules. Chem. Biol. 11, 1107-1117 (2004). 
References | 257 
 
 
 
 100.  Bermpohl, D., You, Z., Korsmeyer, S. J., Moskowitz, M. A. & Whalen, M. J. Traumatic 
brain injury in mice deficient in Bid: effects on histopathology and functional outcome. 
J. Cereb. Blood Flow Metab 26, 625-633 (2006). 
 101.  Yin, X. M. et al. Bid-mediated mitochondrial pathway is critical to ischemic neuronal 
apoptosis and focal cerebral ischemia. J. Biol. Chem. 277, 42074-42081 (2002). 
 102.  Henshall, D. C. et al. Cleavage of bid may amplify caspase-8-induced neuronal death 
following focally evoked limbic seizures. Neurobiol. Dis. 8, 568-580 (2001). 
 103.  Yamamoto, A. et al. Endoplasmic reticulum stress and apoptosis signaling in human 
temporal lobe epilepsy. J. Neuropathol. Exp. Neurol. 65, 217-225 (2006). 
 104.  Becattini, B. et al. Rational design and real time, in-cell detection of the proapoptotic 
activity of a novel compound targeting Bcl-X(L). Chem. Biol. 11, 389-395 (2004). 
 105.  Czabotar, P. E. & Lessene, G. Bcl-2 family proteins as therapeutic targets. Curr. 
Pharm. Des 16, 3132-3148 (2010). 
 106.  Degterev, A. et al. Identification of small-molecule inhibitors of interaction between 
the BH3 domain and Bcl-xL. Nat. Cell Biol. 3, 173-182 (2001). 
 107.  Kitada, S. et al. Discovery, characterization, and structure-activity relationships 
studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. 
J. Med. Chem. 46, 4259-4264 (2003). 
 108.  Leone, M. et al. Cancer prevention by tea polyphenols is linked to their direct 
inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res. 63, 8118-8121 (2003). 
 109.  Lessene, G. et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat. 
Chem. Biol. 9, 390-397 (2013). 
 110.  Manion, M. K. & Hockenbery, D. M. Targeting BCL-2-related proteins in cancer 
therapy. Cancer Biol. Ther. 2, S105-S114 (2003). 
 111.  O'Neill, J. W. & Hockenbery, D. M. Bcl-2-related proteins as drug targets. Curr. Med. 
Chem. 10, 1553-1562 (2003). 
 112.  Osford, S. M., Dallman, C. L., Johnson, P. W., Ganesan, A. & Packham, G. Current 
strategies to target the anti-apoptotic Bcl-2 protein in cancer cells. Curr. Med. Chem. 
11, 1031-1039 (2004). 
 113.  Sattler, M. et al. Structure of Bcl-xL-Bak peptide complex: recognition between 
regulators of apoptosis. Science 275, 983-986 (1997). 
 114.  Becattini, B. et al. Structure-activity relationships by interligand NOE-based design 
and synthesis of antiapoptotic compounds targeting Bid. Proc. Natl. Acad. Sci. U. S. 
A 103, 12602-12606 (2006). 
 115.  Tzung, S. P. et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 
3. Nat. Cell Biol. 3, 183-191 (2001). 
 116.  Tobaben, S. et al. Bid-mediated mitochondrial damage is a key mechanism in 
glutamate-induced oxidative stress and AIF-dependent cell death in immortalized HT-
22 hippocampal neurons. Cell Death. Differ. 18, 282-292 (2011). 
258 | References 
 
 
 
 117.  Anguissola, S. et al. Bid and calpains cooperate to trigger oxaliplatin-induced 
apoptosis of cervical carcinoma HeLa cells. Mol. Pharmacol. 76, 998-1010 (2009). 
 118.  Kohler, B. et al. Bid participates in genotoxic drug-induced apoptosis of HeLa cells 
and is essential for death receptor ligands' apoptotic and synergistic effects. PLoS. 
One. 3, e2844 (2008). 
 119.  Acharya, K. R. & Lloyd, M. D. The advantages and limitations of protein crystal 
structures. Trends Pharmacol. Sci. 26, 10-14 (2005). 
 120.  McPherson, A. & Gavira, J. A. Introduction to protein crystallization. Acta Crystallogr. 
F. Struct. Biol. Commun. 70, 2-20 (2014). 
 121.  Czabotar, P. E. et al. Bax crystal structures reveal how BH3 domains activate Bax 
and nucleate its oligomerization to induce apoptosis. Cell 152, 519-531 (2013). 
 122.  Stewart, M. L., Fire, E., Keating, A. E. & Walensky, L. D. The MCL-1 BH3 helix is an 
exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat. Chem. Biol. 6, 595-601 
(2010). 
 123.  Thomas, S. et al. Targeting the Bcl-2 family for cancer therapy. Expert. Opin. Ther. 
Targets. 17, 61-75 (2013). 
 124.  Weyhenmeyer, B., Murphy, A. C., Prehn, J. H. & Murphy, B. M. Targeting the anti-
apoptotic Bcl-2 family members for the treatment of cancer. Exp. Oncol. 34, 192-199 
(2012). 
 125.  Shoshan-Barmatz, V. & Mizrachi, D. VDAC1: from structure to cancer therapy. Front 
Oncol. 2, 164 (2012). 
 126.  Shoshan-Barmatz, V. & Golan, M. Mitochondrial VDAC1: function in cell life and 
death and a target for cancer therapy. Curr. Med. Chem. 19, 714-735 (2012). 
 127.  Bayrhuber, M. et al. Structure of the human voltage-dependent anion channel. Proc. 
Natl. Acad. Sci. U. S. A 105, 15370-15375 (2008). 
 128.  Hiller, S. et al. Solution structure of the integral human membrane protein VDAC-1 in 
detergent micelles. Science 321, 1206-1210 (2008). 
 129.  Ujwal, R. et al. The crystal structure of mouse VDAC1 at 2.3 A resolution reveals 
mechanistic insights into metabolite gating. Proc. Natl. Acad. Sci. U. S. A 105, 17742-
17747 (2008). 
 130.  Rostovtseva, T. K., Tan, W. & Colombini, M. On the role of VDAC in apoptosis: fact 
and fiction. J. Bioenerg. Biomembr. 37, 129-142 (2005). 
 131.  Rostovtseva, T. K. & Bezrukov, S. M. VDAC regulation: role of cytosolic proteins and 
mitochondrial lipids. J. Bioenerg. Biomembr. 40, 163-170 (2008). 
 132.  Shoshan-Barmatz, V. & Ben-Hail, D. VDAC, a multi-functional mitochondrial protein 
as a pharmacological target. Mitochondrion. 12, 24-34 (2012). 
 133.  De, S. D. et al. VDAC1 selectively transfers apoptotic Ca2+ signals to mitochondria. 
Cell Death. Differ. 19, 267-273 (2012). 
References | 259 
 
 
 
 134.  Keinan, N., Pahima, H., Ben-Hail, D. & Shoshan-Barmatz, V. The role of calcium in 
VDAC1 oligomerization and mitochondria-mediated apoptosis. Biochim. Biophys. 
Acta 1833, 1745-1754 (2013). 
 135.  Shoshan-Barmatz, V., Israelson, A., Brdiczka, D. & Sheu, S. S. The voltage-
dependent anion channel (VDAC): function in intracellular signalling, cell life and cell 
death. Curr. Pharm. Des 12, 2249-2270 (2006). 
 136.  Shoshan-Barmatz, V. et al. VDAC, a multi-functional mitochondrial protein regulating 
cell life and death. Mol. Aspects Med. 31, 227-285 (2010). 
 137.  Colombini, M. VDAC: the channel at the interface between mitochondria and the 
cytosol. Mol. Cell Biochem. 256-257, 107-115 (2004). 
 138.  Lemasters, J. J. & Holmuhamedov, E. Voltage-dependent anion channel (VDAC) as 
mitochondrial governator--thinking outside the box. Biochim. Biophys. Acta 1762, 
181-190 (2006). 
 139.  Rostovtseva, T. & Colombini, M. VDAC channels mediate and gate the flow of ATP: 
implications for the regulation of mitochondrial function. Biophys. J. 72, 1954-1962 
(1997). 
 140.  Rostovtseva, T. K. & Bezrukov, S. M. ATP transport through a single mitochondrial 
channel, VDAC, studied by current fluctuation analysis. Biophys. J. 74, 2365-2373 
(1998). 
 141.  Abu-Hamad, S., Sivan, S. & Shoshan-Barmatz, V. The expression level of the 
voltage-dependent anion channel controls life and death of the cell. Proc. Natl. Acad. 
Sci. U. S. A 103, 5787-5792 (2006). 
 142.  Shimizu, S., Ide, T., Yanagida, T. & Tsujimoto, Y. Electrophysiological study of a 
novel large pore formed by Bax and the voltage-dependent anion channel that is 
permeable to cytochrome c. J. Biol. Chem. 275, 12321-12325 (2000). 
 143.  Shimizu, S., Matsuoka, Y., Shinohara, Y., Yoneda, Y. & Tsujimoto, Y. Essential role 
of voltage-dependent anion channel in various forms of apoptosis in mammalian 
cells. J. Cell Biol. 152, 237-250 (2001). 
 144.  Tsujimoto, Y. & Shimizu, S. The voltage-dependent anion channel: an essential 
player in apoptosis. Biochimie 84, 187-193 (2002). 
 145.  Tajeddine, N. et al. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-
induced cell death. Oncogene 27, 4221-4232 (2008). 
 146.  Yuan, S. et al. Voltage-dependent anion channel 1 is involved in endostatin-induced 
endothelial cell apoptosis. FASEB J. 22, 2809-2820 (2008). 
 147.  Tomasello, F. et al. Outer membrane VDAC1 controls permeability transition of the 
inner mitochondrial membrane in cellulo during stress-induced apoptosis. Cell Res. 
19, 1363-1376 (2009). 
 148.  Godbole, A., Varghese, J., Sarin, A. & Mathew, M. K. VDAC is a conserved element 
of death pathways in plant and animal systems. Biochim. Biophys. Acta 1642, 87-96 
(2003). 
260 | References 
 
 
 
 149.  Zaid, H., Abu-Hamad, S., Israelson, A., Nathan, I. & Shoshan-Barmatz, V. The 
voltage-dependent anion channel-1 modulates apoptotic cell death. Cell Death. Differ. 
12, 751-760 (2005). 
 150.  Madesh, M. & Hajnoczky, G. VDAC-dependent permeabilization of the outer 
mitochondrial membrane by superoxide induces rapid and massive cytochrome c 
release. J. Cell Biol. 155, 1003-1015 (2001). 
 151.  Galluzzi, L. & Kroemer, G. Mitochondrial apoptosis without VDAC. Nat. Cell Biol. 9, 
487-489 (2007). 
 152.  Tsujimoto, Y. & Shimizu, S. Role of the mitochondrial membrane permeability 
transition in cell death. Apoptosis. 12, 835-840 (2007). 
 153.  Vander Heiden, M. G. et al. Bcl-xL promotes the open configuration of the voltage-
dependent anion channel and metabolite passage through the outer mitochondrial 
membrane. J. Biol. Chem. 276, 19414-19419 (2001). 
 154.  Abu-Hamad, S. et al. The VDAC1 N-terminus is essential both for apoptosis and the 
protective effect of anti-apoptotic proteins. J. Cell Sci. 122, 1906-1916 (2009). 
 155.  Keinan, N., Tyomkin, D. & Shoshan-Barmatz, V. Oligomerization of the mitochondrial 
protein voltage-dependent anion channel is coupled to the induction of apoptosis. 
Mol. Cell Biol. 30, 5698-5709 (2010). 
 156.  Shoshan-Barmatz, V., Keinan, N. & Zaid, H. Uncovering the role of VDAC in the 
regulation of cell life and death. J. Bioenerg. Biomembr. 40, 183-191 (2008). 
 157.  Arbel, N., Ben-Hail, D. & Shoshan-Barmatz, V. Mediation of the antiapoptotic activity 
of Bcl-xL protein upon interaction with VDAC1 protein. J. Biol. Chem. 287, 23152-
23161 (2012). 
 158.  Scharstuhl, A., Mutsaers, H. A., Pennings, S. W., Russel, F. G. & Wagener, F. A. 
Involvement of VDAC, Bax and ceramides in the efflux of AIF from mitochondria 
during curcumin-induced apoptosis. PLoS. One. 4, e6688 (2009). 
 159.  Shimizu, S., Narita, M. & Tsujimoto, Y. Bcl-2 family proteins regulate the release of 
apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399, 483-487 
(1999). 
 160.  Tsujimoto, Y. & Shimizu, S. VDAC regulation by the Bcl-2 family of proteins. Cell 
Death. Differ. 7, 1174-1181 (2000). 
 161.  Rostovtseva, T. K. et al. Bid, but not Bax, regulates VDAC channels. J. Biol. Chem. 
279, 13575-13583 (2004). 
 162.  Shimizu, S., Shinohara, Y. & Tsujimoto, Y. Bax and Bcl-xL independently regulate 
apoptotic changes of yeast mitochondria that require VDAC but not adenine 
nucleotide translocator. Oncogene 19, 4309-4318 (2000). 
 163.  Baines, C. P., Kaiser, R. A., Sheiko, T., Craigen, W. J. & Molkentin, J. D. Voltage-
dependent anion channels are dispensable for mitochondrial-dependent cell death. 
Nat. Cell Biol. 9, 550-555 (2007). 
References | 261 
 
 
 
 164.  Albrecht, P. et al. Mechanisms of oxidative glutamate toxicity: the glutamate/cystine 
antiporter system xc- as a neuroprotective drug target. CNS. Neurol. Disord. Drug 
Targets. 9, 373-382 (2010). 
 165.  Burdo, J., Dargusch, R. & Schubert, D. Distribution of the cystine/glutamate antiporter 
system xc- in the brain, kidney, and duodenum. J. Histochem. Cytochem. 54, 549-557 
(2006). 
 166.  Murphy, T. H., Miyamoto, M., Sastre, A., Schnaar, R. L. & Coyle, J. T. Glutamate 
toxicity in a neuronal cell line involves inhibition of cystine transport leading to 
oxidative stress. Neuron 2, 1547-1558 (1989). 
 167.  Sagara, Y. et al. Cellular mechanisms of resistance to chronic oxidative stress. Free 
Radic. Biol. Med. 24, 1375-1389 (1998). 
 168.  Cheung, N. S., Pascoe, C. J., Giardina, S. F., John, C. A. & Beart, P. M. Micromolar 
L-glutamate induces extensive apoptosis in an apoptotic-necrotic continuum of insult-
dependent, excitotoxic injury in cultured cortical neurones. Neuropharmacology 37, 
1419-1429 (1998). 
 169.  Choi, D. W. Glutamate neurotoxicity in cortical cell culture is calcium dependent. 
Neurosci. Lett. 58, 293-297 (1985). 
 170.  Henke, N. et al. The plasma membrane channel ORAI1 mediates detrimental calcium 
influx caused by endogenous oxidative stress. Cell Death. Dis. 4, e470 (2013). 
 171.  Tan, S., Schubert, D. & Maher, P. Oxytosis: A novel form of programmed cell death. 
Curr. Top. Med. Chem. 1, 497-506 (2001). 
 172.  Kazhdan, I., Long, L., Montellano, R., Cavazos, D. A. & Marciniak, R. A. Targeted 
gene therapy for breast cancer with truncated Bid. Cancer Gene Ther. 13, 141-149 
(2006). 
 173.  Wei, M. C. et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to 
release cytochrome c. Genes Dev. 14, 2060-2071 (2000). 
 174.  Morimoto, B. H. & Koshland, D. E., Jr. Excitatory amino acid uptake and N-methyl-D-
aspartate-mediated secretion in a neural cell line. Proc. Natl. Acad. Sci. U. S. A 87, 
3518-3521 (1990). 
 175.  Liu, Y., Peterson, D. A., Kimura, H. & Schubert, D. Mechanism of cellular 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J. Neurochem. 
69, 581-593 (1997). 
 176.  Diemert, S. et al. Impedance measurement for real time detection of neuronal cell 
death. J. Neurosci. Methods 203, 69-77 (2012). 
 177.  Wu, M. et al. Multiparameter metabolic analysis reveals a close link between 
attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency 
in human tumor cells. Am. J. Physiol Cell Physiol 292, C125-C136 (2007). 
 178.  Gohil, V. M. et al. Nutrient-sensitized screening for drugs that shift energy metabolism 
from mitochondrial respiration to glycolysis. Nat. Biotechnol. 28, 249-255 (2010). 
 179.  Walker, J. M. The bicinchoninic acid (BCA) assay for protein quantitation. Methods 
Mol. Biol. 32, 5-8 (1994). 
262 | References 
 
 
 
 180.  Plesnila, N. et al. BID mediates neuronal cell death after oxygen/ glucose deprivation 
and focal cerebral ischemia. Proc. Natl. Acad. Sci. U. S. A 98, 15318-15323 (2001). 
 181.  Plesnila, N. et al. Nuclear translocation of apoptosis-inducing factor after focal 
cerebral ischemia. J. Cereb. Blood Flow Metab 24, 458-466 (2004). 
 182.  Rarey, M., Kramer, B., Lengauer, T. & Klebe, G. A fast flexible docking method using 
an incremental construction algorithm. J. Mol. Biol. 261, 470-489 (1996). 
 183.  Schneider, N. et al. Substantial improvements in large-scale redocking and screening 
using the novel HYDE scoring function. J. Comput. Aided Mol. Des 26, 701-723 
(2012). 
 184.  Schneider, N., Lange, G., Hindle, S., Klein, R. & Rarey, M. A consistent description of 
HYdrogen bond and DEhydration energies in protein-ligand complexes: methods 
behind the HYDE scoring function. J. Comput. Aided Mol. Des 27, 15-29 (2013). 
 185.  Stierand, K. & Rarey, M. From modeling to medicinal chemistry: automatic generation 
of two-dimensional complex diagrams. ChemMedChem. 2, 853-860 (2007). 
 186.  Chung, C. T., Niemela, S. L. & Miller, R. H. One-step preparation of competent 
Escherichia coli: transformation and storage of bacterial cells in the same solution. 
Proc. Natl. Acad. Sci. U. S. A 86, 2172-2175 (1989). 
 187.  Gill S.C. & Hippel P.H. Calculation of Protein Extinction Coefficients from Amino Acid 
Sequence Data. Analytical Biochemistry 182, 319-326 (1989). 
 188.  Mertins, B. et al. Flexibility of the N-terminal mVDAC1 segment controls the channel's 
gating behavior. PLoS. One. 7, e47938 (2012). 
 189.  Bergfors T.M. Protein Crystallization(IUL,2009). 
 190.  Mueller, U. et al. Facilities for macromolecular crystallography at the Helmholtz-
Zentrum Berlin. J. Synchrotron. Radiat. 19, 442-449 (2012). 
 191.  Kabsch, W. XDS. Acta Crystallogr. D. Biol. Crystallogr. 66, 125-132 (2010). 
 192.  Krug, M., Weiss, M. S., Heinemann, U. & Mueller, U. XDSAPP: a graphical user 
interface for the convenient processing of diffraction data using XDS. Appl. Cryst. 
J.568-572 (2012). 
 193.  McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 
(2007). 
 194.  Friedlander, R. M. Apoptosis and caspases in neurodegenerative diseases. N. Engl. 
J. Med. 348, 1365-1375 (2003). 
 195.  Guegan, C. et al. Instrumental activation of bid by caspase-1 in a transgenic mouse 
model of ALS. Mol. Cell Neurosci. 20, 553-562 (2002). 
 196.  Waldmeier, P. C. Prospects for antiapoptotic drug therapy of neurodegenerative 
diseases. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 303-321 (2003). 
 197.  Arnoult, D. Mitochondrial fragmentation in apoptosis. Trends Cell Biol. 17, 6-12 
(2007). 
References | 263 
 
 
 
 198.  Danial, N. N. & Korsmeyer, S. J. Cell death: critical control points. Cell 116, 205-219 
(2004). 
 199.  Autret, A. & Martin, S. J. Emerging role for members of the Bcl-2 family in 
mitochondrial morphogenesis. Mol. Cell 36, 355-363 (2009). 
 200.  Grohm, J. et al. Inhibition of Drp1 provides neuroprotection in vitro and in vivo. Cell 
Death. Differ. 19, 1446-1458 (2012). 
 201.  Sasaki, Y. F. et al. The alkaline single cell gel electrophoresis assay with mouse 
multiple organs: results with 30 aromatic amines evaluated by the IARC and U.S. 
NTP. Mutat. Res. 440, 1-18 (1999). 
 202.  Culmsee, C. et al. Apoptosis-inducing factor triggered by poly(ADP-ribose) 
polymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation 
and focal cerebral ischemia. J. Neurosci. 25, 10262-10272 (2005). 
 203.  Wu, M. et al. Multiparameter metabolic analysis reveals a close link between 
attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency 
in human tumor cells. Am. J. Physiol Cell Physiol 292, C125-C136 (2007). 
 204.  Clerc, P. & Polster, B. M. Investigation of mitochondrial dysfunction by sequential 
microplate-based respiration measurements from intact and permeabilized neurons. 
PLoS. One. 7, e34465 (2012). 
 205.  Azarias, G. et al. Glutamate transport decreases mitochondrial pH and modulates 
oxidative metabolism in astrocytes. J. Neurosci. 31, 3550-3559 (2011). 
 206.  Dessau, M. A. & Modis, Y. Protein Crystallization for X-ray Crystallography. JoVE 47, 
(2011). 
 207.  Benvenuti, M. & Mangani, S. Crystallization of soluble proteins in vapor diffusion for x-
ray crystallography. Nat. Protoc. 2, 1633-1651 (2007). 
 208.  Chayen, N. E. Turning protein crystallisation from an art into a science. Curr. Opin. 
Struct. Biol. 14, 577-583 (2004). 
 209.  McPherson, A. Introduction to protein crystallization. Methods 34, 254-265 (2004). 
 210.  Ku, B., Liang, C., Jung, J. U. & Oh, B. H. Evidence that inhibition of BAX activation by 
BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. Cell 
Res. 21, 627-641 (2011). 
 211.  Steuber, H. . Personal Communication (2011) 
 
 212.  Stoka, V. et al. Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-
caspases, is the most likely route. J. Biol. Chem. 276, 3149-3157 (2001). 
 213.  Sarig, R. et al. BID-D59A is a potent inducer of apoptosis in primary embryonic 
fibroblasts. J. Biol. Chem. 278, 10707-10715 (2003). 
 214.  Bleicken, S., Garcia-Saez, A. J., Conte, E. & Bordignon, E. Dynamic interaction of 
cBid with detergents, liposomes and mitochondria. PLoS. One. 7, e35910 (2012). 
264 | References 
 
 
 
 215.  Hetz, C. et al. Bax channel inhibitors prevent mitochondrion-mediated apoptosis and 
protect neurons in a model of global brain ischemia. J. Biol. Chem. 280, 42960-42970 
(2005). 
 216.  Kale, J., Liu, Q., Leber, B. & Andrews, D. W. Shedding light on apoptosis at 
subcellular membranes. Cell 151, 1179-1184 (2012). 
 217.  Roucou, X., Montessuit, S., Antonsson, B. & Martinou, J. C. Bax oligomerization in 
mitochondrial membranes requires tBid (caspase-8-cleaved Bid) and a mitochondrial 
protein. Biochem. J. 368, 915-921 (2002). 
 218.  Roucou, X., Rostovtseva, T., Montessuit, S., Martinou, J. C. & Antonsson, B. Bid 
induces cytochrome c-impermeable Bax channels in liposomes. Biochem. J. 363, 
547-552 (2002). 
 219.  Terrones, O. et al. Lipidic pore formation by the concerted action of proapoptotic BAX 
and tBID. J. Biol. Chem. 279, 30081-30091 (2004). 
 220.  Gonzalvez, F. et al. Mechanistic issues of the interaction of the hairpin-forming 
domain of tBid with mitochondrial cardiolipin. PLoS. One. 5, e9342 (2010). 
 221.  Jalmar, O., Garcia-Saez, A. J., Berland, L., Gonzalvez, F. & Petit, P. X. Giant 
unilamellar vesicles (GUVs) as a new tool for analysis of caspase-8/Bid-FL complex 
binding to cardiolipin and its functional activity. Cell Death. Dis. 1, e103 (2010). 
 222.  Jalmar, O. et al. Caspase-8 binding to cardiolipin in giant unilamellar vesicles 
provides a functional docking platform for bid. PLoS. One. 8, e55250 (2013). 
 223.  Korytowski, W., Basova, L. V., Pilat, A., Kernstock, R. M. & Girotti, A. W. 
Permeabilization of the mitochondrial outer membrane by Bax/truncated Bid (tBid) 
proteins as sensitized by cardiolipin hydroperoxide translocation: mechanistic 
implications for the intrinsic pathway of oxidative apoptosis. J. Biol. Chem. 286, 
26334-26343 (2011). 
 224.  Petit, P. X. et al. Interaction of the alpha-helical H6 peptide from the pro-apoptotic 
protein tBid with cardiolipin. FEBS J. 276, 6338-6354 (2009). 
 225.  Raemy, E. & Martinou, J. C. Involvement of cardiolipin in tBID-induced activation of 
BAX during apoptosis. Chem. Phys. Lipids 179, 70-74 (2014). 
 226.  De, P., V et al. Characterization of human VDAC isoforms: a peculiar function for 
VDAC3? Biochim. Biophys. Acta 1797, 1268-1275 (2010). 
 227.  Colombini, M., Yeung, C. L., Tung, J. & Konig, T. The mitochondrial outer membrane 
channel, VDAC, is regulated by a synthetic polyanion. Biochim. Biophys. Acta 905, 
279-286 (1987). 
 228.  Konig, T. et al. Interaction of a synthetic polyanion with rat liver mitochondria. 
Biochim. Biophys. Acta 462, 380-389 (1977). 
 229.  Konig, T., Stipani, I., Horvath, I. & Palmieri, F. Inhibition of mitochondrial substrate 
anion translocators by a synthetic amphipathic polyanion. J. Bioenerg. Biomembr. 14, 
297-305 (1982). 
 230.  Stein, C. A. & Colombini, M. Specific VDAC inhibitors: phosphorothioate 
oligonucleotides. J. Bioenerg. Biomembr. 40, 157-162 (2008). 
References | 265 
 
 
 
 231.  Han, D., Antunes, F., Canali, R., Rettori, D. & Cadenas, E. Voltage-dependent anion 
channels control the release of the superoxide anion from mitochondria to cytosol. J. 
Biol. Chem. 278, 5557-5563 (2003). 
 232.  Yao, H., Felfly, H., Wang, J., Zhou, D. & Haddad, G. G. DIDS protects against 
neuronal injury by blocking Toll-like receptor 2 activated-mechanisms. J. Neurochem. 
108, 835-846 (2009). 
 233.  Inoue, H., Ohtaki, H., Nakamachi, T., Shioda, S. & Okada, Y. Anion channel blockers 
attenuate delayed neuronal cell death induced by transient forebrain ischemia. J. 
Neurosci. Res. 85, 1427-1435 (2007). 
 234.  Pamenter, M. E., Perkins, G. A., Gu, X. Q., Ellisman, M. H. & Haddad, G. G. DIDS 
(4,4-diisothiocyanatostilbenedisulphonic acid) induces apoptotic cell death in a 
hippocampal neuronal cell line and is not neuroprotective against ischemic stress. 
PLoS. One. 8, e60804 (2013). 
 235.  Himi, T., Ishizaki, Y. & Murota, S. I. 4,4'-diisothiocyano-2 ,2'-stilbenedisulfonate 
protects cultured cerebellar granule neurons from death. Life Sci. 70, 1235-1249 
(2002). 
 236.  Maeno, E., Ishizaki, Y., Kanaseki, T., Hazama, A. & Okada, Y. Normotonic cell 
shrinkage because of disordered volume regulation is an early prerequisite to 
apoptosis. Proc. Natl. Acad. Sci. U. S. A 97, 9487-9492 (2000). 
 237.  Tauskela, J. S. et al. Protection of cortical neurons against oxygen-glucose 
deprivation and N-methyl-D-aspartate by DIDS and SITS. Eur. J. Pharmacol. 464, 17-
25 (2003). 
 238.  Xue, J., Zhou, D., Yao, H. & Haddad, G. G. Role of transporters and ion channels in 
neuronal injury under hypoxia. Am. J. Physiol Regul. Integr. Comp Physiol 294, 
R451-R457 (2008). 
 239.  Geula, S., Naveed, H., Liang, J. & Shoshan-Barmatz, V. Structure-based analysis of 
VDAC1 protein: defining oligomer contact sites. J. Biol. Chem. 287, 2179-2190 
(2012). 
 240.  Mader, A., Abu-Hamad, S., Arbel, N., Gutierrez-Aguilar, M. & Shoshan-Barmatz, V. 
Dominant-negative VDAC1 mutants reveal oligomeric VDAC1 to be the active unit in 
mitochondria-mediated apoptosis. Biochem. J. 429, 147-155 (2010). 
 241.  Zamzami, N., Brenner, C., Marzo, I., Susin, S. A. & Kroemer, G. Subcellular and 
submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 16, 2265-2282 
(1998). 
 242.  Shoshan-Barmatz, V. & Gincel, D. The voltage-dependent anion channel: 
characterization, modulation, and role in mitochondrial function in cell life and death. 
Cell Biochem. Biophys. 39, 279-292 (2003). 
 243.  Schubert, D. & Piasecki, D. Oxidative glutamate toxicity can be a component of the 
excitotoxicity cascade. J. Neurosci. 21, 7455-7462 (2001). 
 244.  Pusch, M., Zifarelli, G., Murgia, A. R., Picollo, A. & Babini, E. Channel or transporter? 
The CLC saga continues. Exp. Physiol 91, 149-152 (2006). 
266 | References 
 
 
 
 245.  Shoshan-Barmatz, V., Keinan, N., bu-Hamad, S., Tyomkin, D. & Aram, L. Apoptosis 
is regulated by the VDAC1 N-terminal region and by VDAC oligomerization: release 
of cytochrome c, AIF and Smac/Diablo. Biochim. Biophys. Acta 1797, 1281-1291 
(2010). 
 246.  Öxler, E. M., Dolga, A. & Culmsee, C. AIF depletion provides neuroprotection through 
a preconditioning effect. Apoptosis. 17, 1027-1038 (2012). 
 247.  Bathori, G. et al. Extramitochondrial porin: facts and hypotheses. J. Bioenerg. 
Biomembr. 32, 79-89 (2000). 
 248.  De, P., V, Messina, A., Lane, D. J. & Lawen, A. Voltage-dependent anion-selective 
channel (VDAC) in the plasma membrane. FEBS Lett. 584, 1793-1799 (2010). 
 249.  Shoshan-Barmatz, V. & Israelson, A. The voltage-dependent anion channel in 
endoplasmic/sarcoplasmic reticulum: characterization, modulation and possible 
function. J. Membr. Biol. 204, 57-66 (2005). 
 250.  De, P., V et al. New functions of an old protein: the eukaryotic porin or voltage 
dependent anion selective channel (VDAC). Ital. J. Biochem. 52, 17-24 (2003). 
 251.  Cheng, E. H., Sheiko, T. V., Fisher, J. K., Craigen, W. J. & Korsmeyer, S. J. VDAC2 
inhibits BAK activation and mitochondrial apoptosis. Science 301, 513-517 (2003). 
 252.  Setoguchi, K., Otera, H. & Mihara, K. Cytosolic factor- and TOM-independent import 
of C-tail-anchored mitochondrial outer membrane proteins. EMBO J. 25, 5635-5647 
(2006). 
 253.  Fannjiang, Y. et al. BAK alters neuronal excitability and can switch from anti- to pro-
death function during postnatal development. Dev. Cell 4, 575-585 (2003). 
 254.  Jakobson, M., Lintulahti, A. & Arumae, U. mRNA for N-Bak, a neuron-specific BH3-
only splice isoform of Bak, escapes nonsense-mediated decay and is translationally 
repressed in the neurons. Cell Death. Dis. 3, e269 (2012). 
 255.  Jakobson, M., Jakobson, M., Llano, O., Palgi, J. & Arumae, U. Multiple mechanisms 
repress N-Bak mRNA translation in the healthy and apoptotic neurons. Cell Death. 
Dis. 4, e777 (2013). 
 256.  Doti, N. Personal Communication (2014) 
 
 257.  Drzyzga, L. R., Marcinowska, A. & Obuchowicz, E. Antiapoptotic and neurotrophic 
effects of antidepressants: a review of clinical and experimental studies. Brain Res. 
Bull. 79, 248-257 (2009). 
 258.  Malkesman, O. et al. Targeting the BH3-interacting domain death agonist to develop 
mechanistically unique antidepressants. Mol. Psychiatry 17, 770-780 (2012). 
 259.  McKernan, D. P., Dinan, T. G. & Cryan, J. F. "Killing the Blues": a role for cellular 
suicide (apoptosis) in depression and the antidepressant response? Prog. Neurobiol. 
88, 246-263 (2009). 
 260.  Yin, X. M. et al. Bid-deficient mice are resistant to Fas-induced hepatocellular 
apoptosis. Nature 400, 886-891 (1999). 
References | 267 
 
 
 
 261.  Zinkel, S. S. et al. Proapoptotic BID is required for myeloid homeostasis and tumor 
suppression. Genes Dev. 17, 229-239 (2003). 
 262.  Mohammad, R., Giri, A. & Goustin, A. S. Small-molecule inhibitors of Bcl-2 family 
proteins as therapeutic agents in cancer. Recent Pat Anticancer Drug Discov. 3, 20-
30 (2008). 
 263.  Porter, J. et al. Tetrahydroisoquinoline amide substituted phenyl pyrazoles as 
selective Bcl-2 inhibitors. Bioorg. Med. Chem. Lett. 19, 230-233 (2009). 
 264.  McPherson, A. & DeLucas, L. Crystal-growing in space. Science 283, 1459 (1999). 
 265.  Landsberg, M. J., Bond, J., Gee, C. L., Martin, J. L. & Hankamer, B. A method for 
screening the temperature dependence of three-dimensional crystal formation. Acta 
Crystallogr. D. Biol. Crystallogr. 62, 559-562 (2006). 
 266.  McPherson, A. Crystallization of proteins by variation of pH or temperature. Methods 
Enzymol. 114, 125-127 (1985). 
 267.  McPherson, A. Crystallization of macromolecules: general principles. Methods 
Enzymol. 114, 112-120 (1985). 
 268.  McPherson, A. & Kuznetsov, Y. G. Mechanisms, kinetics, impurities and defects: 
consequences in macromolecular crystallization. Acta Crystallogr. F. Struct. Biol. 
Commun. 70, 384-403 (2014). 
 269.  Chayen, N. E. Comparative studies of protein crystallization by vapour-diffusion and 
microbatch techniques. Acta Crystallogr. D. Biol. Crystallogr. 54, 8-15 (1998). 
 270.  Rayment, I. Small-scale batch crystallization of proteins revisited: an underutilized 
way to grow large protein crystals. Structure. 10, 147-151 (2002). 
 271.  Smits, S. H., Mueller, A., Grieshaber, M. K. & Schmitt, L. Coenzyme- and His-tag-
induced crystallization of octopine dehydrogenase. Acta Crystallogr. Sect. F. Struct. 
Biol. Cryst. Commun. 64, 836-839 (2008). 
 272.  Lee, E. F. et al. Crystal structure of ABT-737 complexed with Bcl-xL: implications for 
selectivity of antagonists of the Bcl-2 family. Cell Death. Differ. 14, 1711-1713 (2007). 
 273.  Petros, A. M. et al. Fragment-based discovery of potent inhibitors of the anti-apoptotic 
MCL-1 protein. Bioorg. Med. Chem. Lett. 24, 1484-1488 (2014). 
 274.  Zhou, H. et al. Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding 
affinities based upon a new scaffold. J. Med. Chem. 55, 4664-4682 (2012). 
 275.  Perfettini, J. L., Roumier, T. & Kroemer, G. Mitochondrial fusion and fission in the 
control of apoptosis. Trends Cell Biol. 15, 179-183 (2005). 
 276.  Suen, D. F., Norris, K. L. & Youle, R. J. Mitochondrial dynamics and apoptosis. 
Genes Dev. 22, 1577-1590 (2008). 
 277.  Zamzami, N. & Kroemer, G. The mitochondrion in apoptosis: how Pandora's box 
opens. Nat. Rev. Mol. Cell Biol. 2, 67-71 (2001). 
 278.  Gonzalvez, F. & Gottlieb, E. Cardiolipin: setting the beat of apoptosis. Apoptosis. 12, 
877-885 (2007). 
268 | References 
 
 
 
 279.  Kagan, V. E. et al. Cytochrome c acts as a cardiolipin oxygenase required for release 
of proapoptotic factors. Nat. Chem. Biol. 1, 223-232 (2005). 
 280.  Gonzalvez, F., Bessoule, J. J., Rocchiccioli, F., Manon, S. & Petit, P. X. Role of 
cardiolipin on tBid and tBid/Bax synergistic effects on yeast mitochondria. Cell Death. 
Differ. 12, 659-667 (2005). 
 281.  Gonzalvez, F. et al. tBid interaction with cardiolipin primarily orchestrates 
mitochondrial dysfunctions and subsequently activates Bax and Bak. Cell Death. 
Differ. 12, 614-626 (2005). 
 282.  Yethon, J. A., Epand, R. F., Leber, B., Epand, R. M. & Andrews, D. W. Interaction 
with a membrane surface triggers a reversible conformational change in Bax normally 
associated with induction of apoptosis. J. Biol. Chem. 278, 48935-48941 (2003). 
 283.  Lucken-Ardjomande, S., Montessuit, S. & Martinou, J. C. Bax activation and stress-
induced apoptosis delayed by the accumulation of cholesterol in mitochondrial 
membranes. Cell Death. Differ. 15, 484-493 (2008). 
 284.  Iverson, S. L., Enoksson, M., Gogvadze, V., Ott, M. & Orrenius, S. Cardiolipin is not 
required for Bax-mediated cytochrome c release from yeast mitochondria. J. Biol. 
Chem. 279, 1100-1107 (2004). 
 285.  Polcic, P. et al. Cardiolipin and phosphatidylglycerol are not required for the in vivo 
action of Bcl-2 family proteins. Cell Death. Differ. 12, 310-312 (2005). 
 286.  Liu, J., Weiss, A., Durrant, D., Chi, N. W. & Lee, R. M. The cardiolipin-binding domain 
of Bid affects mitochondrial respiration and enhances cytochrome c release. 
Apoptosis. 9, 533-541 (2004). 
 287.  Van, M. N., Kajava, A. V., Bonfils, C., Martinou, J. C. & Harricane, M. C. Interactions 
of Bax and tBid with lipid monolayers. J. Membr. Biol. 207, 1-9 (2005). 
 288.  Satsoura, D. et al. Interaction of the full-length Bax protein with biomimetic 
mitochondrial liposomes: a small-angle neutron scattering and fluorescence study. 
Biochim. Biophys. Acta 1818, 384-401 (2012). 
 289.  Epand, R. F., Martinou, J. C., Fornallaz-Mulhauser, M., Hughes, D. W. & Epand, R. 
M. The apoptotic protein tBid promotes leakage by altering membrane curvature. J. 
Biol. Chem. 277, 32632-32639 (2002). 
 290.  Terrones, O. et al. BIM and tBID are not mechanistically equivalent when assisting 
BAX to permeabilize bilayer membranes. J. Biol. Chem. 283, 7790-7803 (2008). 
 291.  Ott, M., Norberg, E., Zhivotovsky, B. & Orrenius, S. Mitochondrial targeting of 
tBid/Bax: a role for the TOM complex? Cell Death. Differ. 16, 1075-1082 (2009). 
 292.  Shimizu, S. & Tsujimoto, Y. Proapoptotic BH3-only Bcl-2 family members induce 
cytochrome c release, but not mitochondrial membrane potential loss, and do not 
directly modulate voltage-dependent anion channel activity. Proc. Natl. Acad. Sci. U. 
S. A 97, 577-582 (2000). 
 293.  Banerjee, J. & Ghosh, S. Bax increases the pore size of rat brain mitochondrial 
voltage-dependent anion channel in the presence of tBid. Biochem. Biophys. Res. 
Commun. 323, 310-314 (2004). 
References | 269 
 
 
 
 294.  Wangemann, P. et al. Cl(-)-channel blockers in the thick ascending limb of the loop of 
Henle. Structure activity relationship. Pflugers Arch. 407 Suppl 2, S128-S141 (1986). 
 295.  Pamenter, M. E. et al. DIDS prevents ischemic membrane degradation in cultured 
hippocampal neurons by inhibiting matrix metalloproteinase release. PLoS. One. 7, 
e43995 (2012). 
 296.  Chandra, D., Choy, G., Daniel, P. T. & Tang, D. G. Bax-dependent regulation of Bak 
by voltage-dependent anion channel 2. J. Biol. Chem. 280, 19051-19061 (2005). 
 297.  Landshamer, S. Thesis/Dissertation (2007) 
 
 298.  Roy, M. J., Vom, A., Czabotar, P. E. & Lessene, G. Cell death and the mitochondria: 
therapeutic targeting of the BCL-2 family-driven pathway. Br. J. Pharmacol.(2013). 
 
 
  
270 | Index of Tables 
 
 
 
10 Index of Tables 
Table 1: Primers used for RT-PCR .......................................................................................21 
Table 2: Kits .........................................................................................................................23 
Table 3: Materials for protein purification ..............................................................................24 
Table 4: Materials for protein crystallization ..........................................................................25 
Table 5: Sterile plastic ware..................................................................................................25 
Table 6: HT-22 standard growth medium..............................................................................27 
Table 7: Phosphate buffered saline (PBS), pH 7.4 ...............................................................27 
Table 8: Standard Trypsin/EDTA solution .............................................................................27 
Table 9: HT-22 cells – cell densities .....................................................................................28 
Table 10: 5% PEI .................................................................................................................28 
Table 11:  Neurobasal medium .............................................................................................29 
Table 12: Hank´s balanced salt solution (1 x HBSS) ph 7.2 ..................................................30 
Table 13: Eagle´s minimum essential medium (MEM) ..........................................................30 
Table 14: Protein lysis stock-buffer for HT-22 cells; pH 7.8 ..................................................45 
Table 15: Protein Lysis Buffer for primary neurons and brain tissue; pH 7.4 .........................46 
Table 16: Stacking gel 3.5 % ................................................................................................49 
Table 17: Running gel 12.5 % ..............................................................................................50 
Table 18: 5 x SDS-loading buffer ..........................................................................................50 
Table 19: 1 x Electrophoresis buffer .....................................................................................50 
Table 20: 1 x 10 % Transfer buffer (Semi-Dry-Blotting), pH 8.3 ............................................51 
Table 21: 1 x 20% Transfer buffer (Tank-Blotting), pH 8.3 ....................................................51 
Table 22: 1 x TBS/Tween 20, pH 7.5 ....................................................................................51 
Table 23: 5 % Blocking buffer ...............................................................................................51 
Table 24: Stripping buffer, pH 2 ............................................................................................52 
Table 25: PCR sample preparation: VDAC1, VDAC2, Bid ....................................................54 
Table 26: PCR sample preparation GAPDH .........................................................................54 
Table 27: RT-PCR cycler program – murine GAPDH ...........................................................55 
Table 28: RT-PCR cycler program – murine VDAC1 ............................................................55 
Table 29: RT-PCR cycler program – murine VDAC2 ............................................................55 
Table 30: RT-PCR cycler program – murine Bid ...................................................................56 
Table 31: PCR sample preparation - G12-mBid, A13-mBid ..................................................60 
Table 32: PCR sample preparation - Y47-mBid, D51-mBid ..................................................60 
Table 33: RT-PCR Cycler program – G12-mBid and A13-mBid ............................................61 
Table 34: RT-PCR Cycler program – Y47-mBid and D51-mBid ............................................61 
Table 35: PCR sample preparation- A13-mBid constructs ....................................................62 
Table 36: RT-PCR Cycler program A13-mBid constructs .....................................................63 
Index of Tables | 271 
 
 
 
Table 37: Protein standard lysis buffer .................................................................................66 
Table 38: Protein lysis buffer for GSTrap purification ............................................................66 
Table 39: Buffer for His-Catcher Nickel Gravity Columns (PJK GmbH) ................................67 
Table 40: Buffer for HisTrap affinity columns (HisTrapTM FF 5 ml) .........................................68 
Table 41: Buffer for GSTrap affinity columns and Glutathione and HiCap Cartridges ...........68 
Table 42: Buffer for HiTrap ion exchange columns (HiTrap Q HP, 5 ml) ...............................69 
Table 43: Buffer for HiLoad gel filtration columns (HiLoadTM 16/600 Superdex 75 pg) ..........69 
Table 44: Programmed method for ÄKTA- wash and storage ...............................................70 
Table 45: Programmed method for ÄKTA - IMAC- Ni-Affinity chromatography .....................72 
Table 46: Programmed method for ÄKTA – Ion Exchange Gradient elution .........................73 
Table 47: Programmed method for ÄKTA – Gel filtration (full-length Bid) .............................74 
Table 48: Programmed method for ÄKTA – sample application ............................................75 
Table 49: ÄKTA installed method – GST-tagged purification GSTrap ...................................76 
Table 50: Programmed method for ÄKTA – GST-affinity chromatography ............................76 
Table 51: Programmed method for ÄKTA – Gel filtration (Bid constructs) .............................77 
Table 52: Molar extinction coefficients and A280 factors ......................................................81 
Table 53: Lipids (Avanti Polar lipids) .....................................................................................82 
Table 54: Initial screens and set ups tested for the different Bid constructs ..........................90 
Table 55: Optimization of Bid 22 crystals I, 4°C + 18°C ........................................................91 
Table 56: Optimization of Bid 22 crystals II, 4°C + 18°C .......................................................91 
Table 57: Optimization of Bid construct 1 I, 21°C..................................................................92 
Table 58: Optimization of Bid construct 1 II, 21°C .................................................................92 
Table 59: Opti-Grid 96 of Bid construct 1 I, 4°C + 18°C ........................................................92 
Table 60: Opti-Grid 96 of Bid construct 1 II, 4°C + 18°C .......................................................93 
Table 61: Scoring system used for interpretation of crystallization drop results ....................95 
Table 62: Neuroprotective properties of N-acyl phenoxyanilines. ....................................... 107 
Table 63: Neuroprotective properties of N-phenyl substituted thiazolidinediones. ............... 118 
Table 64: Neuroprotective properties of N-aryl substituted pyrazolopyrimidinone (19) ........ 129 
Table 65: Gene alignment of novel Bid constructs and mouse full-length Bid ..................... 141 
Table 66: Statistics for data collection and processing for Bid 1. ........................................ 149 
Table 67: Neuroprotective properties of 4-phenoxyanilines ................................................ 237 
Table 68: Neuroprotective properties of isonipecotic acid derivatives ................................. 239 
Table 69: Neuroprotective properties of N-phenyl substituted thiazolidindiones.................. 244 
Table 70: Neuroproctive properties of miscellaneous chemical compounds. ...................... 249 
 
 
272 | Index of Figures 
 
 
 
11 Index of Figures 
Figure 1: Intrinsic and extrinsic pathways of apoptotic cells death. ........................................ 3 
Figure 2: Simplified overview of the Bcl-family proteins. ........................................................ 6 
Figure 3: Molecular structure and protease-cleavage sites of Bid. ......................................... 8 
Figure 4: Structures of Bid-binding fragments and the resulting Bid inhibitors. .....................12 
Figure 5: Simplified model of glutamate-induced toxicity in HT-22 cells. ...............................16 
Figure 6: Chemical structure of the Bid inhibitor BI-6c9 ........................................................32 
Figure 7: Chemical structure of 4,4´- Diisothio-cyanatostilbene-2,2´-disulfonic acid (DIDS). .32 
Figure 8: Reduction of yellow MTT to purple colored formazan ............................................35 
Figure 9: Formation of light from ATP and luciferin ...............................................................37 
Figure 10: Mito Stress Profile ...............................................................................................38 
Figure 11: Vapor-diffusion techniques: A) sitting-drop, B) hanging-drop. ..............................88 
Figure 12: Neuroprotective potency of BI-6c9 – half maximal effective concentration. ........ 100 
Figure 13: tBid-induced cell death in HT-22 cells. ............................................................... 102 
Figure 14: tBid-induced loss of Δψm is prevented by BI-6c9 ............................................... 103 
Figure 15: Synthesis strategy for development of novel Bid inhibitors ................................ 105 
Figure 16: Structures of fragment BI-2A7 and the replacement 4-phenoxyaniline. .............. 106 
Figure 17: Neuroprotective activity of compound 6 in HT-22 cells exposed to glutamate. ... 108 
Figure 18: Neuroprotective activities of compounds 8 and 9 against glutamate-induced cell 
death. ................................................................................................................................. 109 
Figure 19: Compound 11 provides neuroprotection against glutamate-induced cell death. . 110 
Figure 20: Molecular docking of compounds 8 and 11 into the 3D-structure of Bid. ............ 111 
Figure 21: Real-time detection of cellular impedance confirms neuroprotective properties of 
N-acyl-phenoxyanilines. ..................................................................................................... 112 
Figure 22: Neuroprotective activities of N-acyl-phenoxyanilines against tBid-induced neuronal 
cell death. ........................................................................................................................... 114 
Figure 23: N-acyl-phenoxyanilines provide slightly protective effects against tBid-induced 
toxicity in low concentrations as 1 µM. ................................................................................ 115 
Figure 24: Concentration-dependent toxic effects of N-acyl-phenoxyanilines ..................... 115 
Figure 25: Development of thiazolidine-2,4-dione structure 13 based on the structure of BI-
6C9 (5). .............................................................................................................................. 117 
Figure 26: N- phenyl substituted thiazolidinediones provide maximal neuroprotection at 
concentrations of 20 µM and higher. .................................................................................. 119 
Figure 27: N-Phenyl substituted thiazolidinediones provide neuroprotection against 
glutamate-induced toxicity. ................................................................................................. 121 
Figure 28: Real time monitoring of cell impedance confirms concentration-dependent 
neuroprotection mediated by thiazolidindiones. .................................................................. 122 
Index of Figures | 273 
 
 
 
Figure 29: N-Phenyl substituted thiazolidinediones attenuate tBid-induced neuronal cell 
death. ................................................................................................................................. 124 
Figure 30: 2D and 3D-representation of the binding mode of compound 13 for inhibition of 
Bid. ..................................................................................................................................... 125 
Figure 31: N-Phenyl substituted thiazolidinediones preserve mitochondrial integrity and 
function. ............................................................................................................................. 126 
Figure 32: N-Phenyl substituted thiazolidinediones preserve mitochondrial respiration ...... 128 
Figure 33: N-aryl substituted pyrazolopyrimidinone protects against glutamate-induced 
toxicity in a concentration dependent manner. .................................................................... 130 
Figure 34: Compound 19 prevents tBid-induced neuronal cell death. ................................. 131 
Figure 35: Effective expression of full length Bid. ............................................................... 133 
Figure 36: Purification of full length Bid by Äkta-chromatography. ...................................... 135 
Figure 37: Purified His6-Bid. ............................................................................................... 135 
Figure 38: Gel filtration of full length His6-Bid. ..................................................................... 136 
Figure 39: Recovery of full-length Bid during chromatography purification and MALDI-TOF 
analysis. ............................................................................................................................. 137 
Figure 40: Highly flexible regions of full-length Bid ............................................................. 140 
Figure 41: Strategy for design of novel truncated Bid constructs. ....................................... 140 
Figure 42: Effective expression of truncated Bid constructs. ............................................... 142 
Figure 43: Purification of Bid 1 (pGEX-Δ12-Y47). ............................................................... 144 
Figure 44: MALDI-TOF analysis of Bid1 (pGEX-Δ12-Y47). ................................................. 145 
Figure 45: Successful result of Bid 1 crystallization. ........................................................... 146 
Figure 46: Bid 1 crystals obtained form opti grid conditions. ............................................... 147 
Figure 47: Bid 1 crystals used for data collection and typical diffraction pattern .................. 149 
Figure 48: Purification of Bid 2 (pGEX-Δ12-D51). ............................................................... 150 
Figure 49: MALDI-TOF analysis of purified Bid 2 (pGEX-Δ12-D51). ................................... 151 
Figure 50: Purification of highly pure Bid 4 protein (pGEX-Δ13-D51). ................................. 152 
Figure 51: MALDI-TOF analysis of purified Bid 4 (pGEX-Δ13-D51). ................................... 153 
Figure 52: Functional analysis of Bid constructs. ................................................................ 155 
Figure 53: Liposome channel activity assay as model system for membrane 
permeabilization. ................................................................................................................ 157 
Figure 54: Cleavage of full-length Bid with caspase 8......................................................... 158 
Figure 55: Permeabilization of cardiolipin-containing liposomes is induced by Bid in a 
concentration dependent manner, but not by full-length Bid. .............................................. 159 
Figure 56: cBid-mediated permeabilization of cardiolipin-containing liposomes is increased 
by  pre-incubation with Bax, and slightly reduced by the Bid inhibitor BI6c9. ...................... 161 
Figure 57: Expression levels of VDAC1 and VDAC2 in HT-22 cells. ................................... 163 
274 | Index of Figures 
 
 
 
Figure 58: DIDS protects against glutamate-induced toxicity. ............................................. 165 
Figure 59: DIDS attenuates apoptotic and necrotic cell death. ............................................ 166 
Figure 60: The anion channel blocker DIDS maintains mitochondrial energy metabolism and 
respiratory activity. ............................................................................................................. 168 
Figure 61: DIDS prevents glutamate-induced ROS formation. ............................................ 169 
Figure 62: DIDS prevents mitochondrial fission and loss of Δψm. ........................................ 172 
Figure 63: tBid-induced toxicity in HT-22 cells is prevented by DIDS. ................................. 173 
Figure 64: DIDS prevents tBid-induced loss of Δψm. ........................................................... 174 
Figure 65: Direct interaction between recombinant Bid/tBid and VDAC1. ........................... 175 
Figure 66: Thermophoresis measurements revealed KD values for Bid/tBid binding to 
VDAC1. .............................................................................................................................. 176 
Figure 67: tBid promotes a reduction in the VDAC1 channel´s conductances, while DIDS 
triggers VDAC1 closure ...................................................................................................... 178 
Figure 68: Direct interaction of Bid and VDAC1 after the onset of glutamate exposure in HT-
22 cells. .............................................................................................................................. 180 
Figure 69: Direct interaction between Bid and VDAC1 in primary cortical neurons. ............ 181 
Figure 70: Direct interaction of Bid and VDAC1 during ischemic brain damage in vivo. ...... 182 
Figure 71: VDAC1 knockdown by different VDAC1 sequences attenuates glutamate-induced 
toxicity in HT-22 cells. ......................................................................................................... 184 
Figure 72: VDAC1 depletion prevents glutamate-induced cell death .................................. 186 
Figure 73: VDAC1 deficiency maintains mitochondrial energy metabolism and respiration.187 
Figure 74: Glutamate-induced ROS production is prevented by VDAC1 silencing. ............. 189 
Figure 75: VDAC1 depletion prevents glutamate-induced mitochondrial fission.................. 191 
Figure 76: Preservation of mitochondrial membrane potential by VDAC1 gene silencing. .. 192 
Figure 77: VDAC1 siRNA 1 and siRNA 2 prevent tBid-induced toxicity. ............................. 194 
Figure 78: VDAC1 silencing prevents tBid-induced loss of Δψm.......................................... 195 
Figure 79: Mitochondrial localization of FLAG-VDAC1 ........................................................ 197 
Figure 80: VDAC1 induced cytotoxicity is inhibited by the Bid inhibitor BI6c9. .................... 198 
Figure 81: VDAC2 gene silencing by two different VDAC2 siRNA sequences. ................... 200 
Figure 82: VDAC2 knockdown by different VDAC2 siRNA sequences provides slight 
protection against glutamate toxicity. .................................................................................. 202 
Figure 83: VDAC2 siRNA attenuates glutamate-induced cell death in a concentration-
dependent manner. ............................................................................................................ 203 
Figure 84: Mitochondrial membrane potential is only slightly affected by VDAC2 silencing. 205 
Figure 85: Workflow from construct design to protein crystallography. ............................... 212 
Figure 86: Proposed model of the direct interaction of Bid and VDAC1. ............................. 224 
Index of Figures | 275 
 
 
 
Figure 87: Proposed role of VDAC1 and Bid in neuronal apoptosis based on the findings in 
the glutamate-toxicity model in HT-22 cells. ....................................................................... 227 
 
  
276 | Publications 
 
 
 
12 Publications 
12.1.1 Original papers 
 
S. Oppermann, F. Schrader, K. Elsässer, A.M. Dolga, L. Krause, N. Doti, C. Wegscheid-
Gerlach, M. Schlitzer, C. Culmsee, Novel N-Phenyl substituted thiazolidinediones protect 
neuronal cells against glutamate- and tBid-induced toxicity. (resubmitted) 
S. Oppermann, M.T. Barho, K., F.Schrader, I. Degenhardt, K. Elsässer, C. Wegscheid-
Gerlach, C. Culmsee, M. Schlitzer, N-Acyl derivatives of phenoxyaniline as novel 
neuroprotective agents. (submitted) 
S. Oppermann, B. Mertins, K. Elsässer, C. Krasel, G. Psakis, P. Reiß, A.M. Dolga, M. 
Bünemann, L.O. Essen, C. Culmsee, Interaction of tBid and VDAC1 determines 
mitochondrial demise. (submitted) 
 
12.1.2 Poster presentations 
 
2014 
S. Oppermann, B. Mertins, C. Krasel, L. Meissner, G. Psakis, P. Reiß, A.M. Dolga, N. 
Plesnila, M. Bünemann, L.O. Essen, C. Culmsee, The interaction of Bid and VDAC1 is 
essential for neuronal cell death in vitro and in vivo, 8th International Symposium on 
Neuroprotection and Neurorepair, Magdeburg, Germany (2014) 
S. Oppermann, B. Mertins, L. Meissner, C. Krasel, G. Psakis, P. Reiß, A.M. Dolga, N. 
Plesnila, M. Bünemann, L.O. Essen, C. Culmsee, Interaction of Bid and VDAC1 determines 
mitochondrial demise, Keystone Symposia on mitochondrial Dynamics and Physiology, 
Santa Fe, NM, USA (2014) 
2013 
S. Oppermann, B. Mertins, C. Krasel, M. Bünemann, L.O. Essen, C. Culmsee, The 
interaction of tBid with VDAC1 is essential for mitochondrial damage in intrinsic death 
pathways, The Cold Spring Harbor Meeting on Cell Death, Cold Spring Habor - New York, 
USA (2013) 
B. Mertins, G. Psakis, S. Oppermann, K. Sivaraman, P. Reiss, C. Krasel, U. Koert, C. 
Culmsee, L.O. Essen, Conformational flexibility of VDAC and the influence of effectors, 
Molecular life science, Gesellschaft für Biochemie und Molekularbiologie (GBM), Frankfurt, 
Germany (2013) 
Publications | 277 
 
 
 
S. Oppermann, B. Mertins, G. Psakis, S. Schneider, C. Krasel, M. Bünemann, L.O. Essen, 
C. Culmsee, VDAC1 mediated neuronal cell death requires tBid, 21th ECDO Euroconference 
on Apoptosis, Paris, France (2013) 
S. Oppermann, K. Elsässer, F. Schrader, C. Krasel, A.M. Dolga, M. Bünemann, M. Schlitzer, 
N. Plesnila, C. Culmsee, Novel small molecules provide protection against glutamate and 
tBid induced toxicity in neuronal hippocampal cells, 21th ECDO Euroconference on 
Apoptosis, Paris, France (2013) 
S. Oppermann, S. Schneider, C. Culmsee, The role of VDAC in glutamate toxicity and tBid-
induced cell death in HT-22 cells, Tag der Pharmazie, Marburg, Germany (2013) 
S. Oppermann, F. Schrader, K. Elsässer, C. Krasel, H. Steuber, M. Bünemann, M. Schlitzer, 
N. Plesnila, C. Culmsee, Small molecule inhibitors of the BH3- only protein Bid as novel 
therapeutic agents in neurodegenerative diseases, Science to market 2013, European 
Association of Pharma Biotechnology (EABP), Cologne, Germany (2013) 
 
2012 
S. Oppermann, J. Grohm, F. Schrader, C. Krasel, M. Bünemann, M. Schlitzer, G. Klebe, N. 
Plesnila, C. Culmsee, Novel small molecule inhibitors of Bid provide neuroprotection in vitro, 
Annual Meeting of the American Society of Neuroscience, New Orleans, USA (2012) 
S. Oppermann, J. Grohm, F. Schrader, C. Krasel, M. Bünemann, M. Schlitzer, N. Plesnila, 
C. Culmsee, Small molecule Bid inhibitors prevent Drp1- dependent mitochondrial fission 
and cell death in neurons, 7th International Symposium on Neuroprotection and Neurorepair, 
Potsdam, Germany (2012) 
S. Oppermann, K. Elsässer, F. Schrader, S. Glinca, C. Krasel, M. Bünemann, G. Klebe, M. 
Schlitzer, C. Culmsee, Development of novel Bid inhibitors for therapeutic approaches in 
models of neuronal cell death, 78. Jahrestagung der Deutschen Gesellschaft für 
Experimentelle und Klinische Pharmakologie und Toxikologie (DGPT), Dresden, Germany 
(2012) 
S. Oppermann, K. Elsässer, J. Grohm, F. Schrader, S. Glinca., G. Klebe, M. Schlitzer,  C. 
Culmsee, Development of novel Bid inhibitors for the treatment of neurodegenerative 
diseases, Tag der Wissenschaft, MARA, Marburg, Germany (2012) 
S. Oppermann, C. Reuther, E.M. Öxler, A.M. Dolga and C. Culmsee, Schädigungs-
mechanismen in Mitochondrien als neue therapeutische Ansatzpunkte der Neuroprotektion, 
Tag der Wissenschaft, MARA, Marburg, Germany (2012) 
 
278 | Grants 
 
 
 
2011 
S. Oppermann, K. Elsässer, J. Grohm, F. Schrader, S. Glinca., G. Klebe, M. Schlitzer,  C. 
Culmsee, Development of novel Bid inhibitors for the treatment of neurodegenerative 
diseases, Joint meeting of the Austrian and German pharmaceutical societies (DphG), 
Innsbruck, Austria (2011) 
 
12.1.3 Oral presentations 
 
“Small molecule inhibitors of the BH3-only protein Bid as novel therapeutic agents in 
neurodegenerative diseases”, Science to market 2013, European Association of Pharma 
Biotechnology (EABP), Cologne, Germany (Selected abstract for oral presentation) (2013) 
 
“Evaluation of novel Bid- Inhibitors for therapy of neurodegenerative disease”, oral 
presentation, Group of Prof Jean-Claude Martinou, University of Geneva, Geneva, 
Switzerland (Invited) (2011) 
 
13 Grants 
Conference Grant by Cold Spring Harbor Laboratory for research on “The interaction of tBid 
with VDAC1 is essential for mitochondrial damage in intrinsic death pathways” presented at 
the CSHL cell death meeting, Cold Spring Harbor, New York. (2013) 
Travel Award by the Seahorse Bioscience for research on “Novel small molecules provide 
protection against glutamate and tBid induced toxicity in neuronal hippocampal cells” 
presented at the 21st ECDO Euroconference on Apoptosis, Institut Pasteur, Paris, France. 
(2013) 
 
  
Acknowledgements | 279 
 
 
 
14 Acknowledgements 
First and foremost, I would like to express my sincere thanks to my supervisor Prof. Dr. 
Carsten Culmsee who offered me the fantastic opportunity to work in his lab as a PHD. 
Within a great and ambitious theme, he gave me not only the possibility to explore exciting 
scientific questions but also enables me to utilize an amazing range of diverse methods, 
expanding my horizon to crazy fields that I never would have thought to touch, before starting 
this thesis. He gave me a lot of free space for own ideas, supported me and my projects in 
an excellent manner and always had an open door and time for critical discussions. I greatly 
appreciate the chance he gave me to attend several national and international meetings, 
which gained me insight into the exciting news in research, and which were always pleasant 
and unforgettable events, especially the “NY Cold Spring Habor Cell Death meeting” as a 
contributing factor for my continued scientific progress. Thank you very much for this! 
I would also like to say a big thank to all my collaboration partners. First of all, I would like 
thank Cornelius Krasel, who always supported me within the “purification and crystallization” 
project and always had time for questions. He managed to calm me down in any critical 
“Äkta” situation and helped me to exercise patient during crystal growth, always believing in 
the day where the crystal diffracts to high resolution. At this point I also want to thank Prof. 
Dr. Klebe and Dr. Holger Steuber for the possibility to use the crystallization approaches and 
to join the crazy sleepless synchrotron trips!  
I further would like to thank Prof. Dr. Schlitzer for giving me the nice opportunity to work on 
the development of novel promising Bid inhibitors. I thank Florian Schrader, Marlene Barho 
and Lena Krause for all the structure syntheses and Dr. Wegscheid-Gerlach for the nice 
docking solutions and support in paper revision! 
I also would like to mention Prof. Dr. Essen and his group members Barbara Mertins and 
George Psakis, who gave me the great possibility for collaboration within the Bid-VDAC 
project. I want to thank all of them for the always uncomplicated teamwork, the fruitful 
meetings, the BLM and thermophoresis data and for carefully editing the manuscript! I am 
looking forward to Bid-VDAC crystals and a continued collaboration!  
A special thank goes to Prof. Nick Plesnila for the possibility for in vivo studies, his critical 
comments on the manuscript and projects and the pleasant time together with Carsten within 
the Neuroscience conference in New Orleans and the Neurorepair and neuroprotection 
meeting in Potsdam! Thanks also for the very funny skiing event together with your and our 
group! I will never forget the “frying pan race” and this huge amount of rice pudding! 
I also want to thank all my colleagues and friends, not only in the Culmsee´s lab but also in 
the Bünemann´s and Kockskämper´s lab! Thank you for your support, your motivation and 
280 | Acknowledgements 
 
 
 
constructive discussions regarding research, but also for the good atmosphere in the lab! 
Especially I want to thank Sebastian, Eva and Maren for being my calming influence on crazy 
days, for joining the long evenings in the lab and for all the talks we had! I thank Amalia for 
her great support in paper submission and revision, her big support especially in the last 
months, as well as for all the nice talks and delicious dinners. Thank you Diana for the tea 
breaks and our “each other reminder” just in the right time and always with the words “wir 
schaffen das”. Thank you Maren for all the funny zumba hours, the motivation for the 
powerful fitness trainings as well as for the private events in the areas around Marburg! 
Special thanks go also to the “old” group, Julia, Svenja, Sebastian, Anderson, Steffi, Eva and 
Christina for the good time we had in and outside of the lab, and particularly for all the 
amazing and periodic meetings throughout whole Germany! I am always looking forward to 
seeing you again! I thank also my whole lab and especially my office members, for all the 
funny “pink” situations! Without you I would have never known that everything I touch is pink! 
Special thank goes to Katharina and Eileen not only for their excellent technical support but 
also for the very nice and always refreshing teamwork, and particularly I want to say big 
thanks to Katharina for her incommensurable help with the first screening of all those small-
molecules! I am pretty sure the day will come where the “Joker” substance will appear! 
Thank you Emma and Niki for all your support and help with the bureaucratic affairs you 
managed for me! Thank you Emma for all your critical proof readings of the paper 
manuscripts as well as for carefully editing this thesis!  
I would also like to say thank you to all my “Wahlpflichtfach”-students, who did an excellent 
job during their time in our lab and supported my work with new enthusiasm and nice results! 
Very special thanks to all the friends of mine who always believed in me, supported me 
outside of the lab and who were always there even without seeing them! Especially, I want to 
thank you Sina M., Jasmin H., Julia St., Angi G., Silvia P. and Nicole N. for the funny 
weekend events and phone calls which let me shortly forget the lab! Thank you for always 
fully understanding my rare time during my research!  
Finally I want to say very special thanks to my parents, who supported me wherever possible 
and always gave me new strength to go on! Thank you for your open door in any time, your 
open ears in any situation, your incommensurable believe in me and your right words that 
build me up! I also want to thank my brother Denni and my sisters Anika and Larissa for 
always believing in me, even without understanding why I am doing “this crazy research 
stuff” and for all the nice and funny coming together`s at our parents house, which brought 
me always back down! Cause of you all, I always have a smile in my face when driving back 
home! Without my family´s support, I would never have been able to complete this thesis! 
Curriculum vitae | 281 
 
 
 
15 Curriculum vitae 
 
Personal details 
Date of birth: 21.05.1986 
 
Place of birth: Haiger, Germany 
 
 
Education and career 
03/2011 – today   PhD thesis at the Department of Pharmacology and Clinical 
Pharmacy, Philipps University of Marburg, Germany 
     supervisor: Prof. Dr. Carsten Culmsee 
 
01/2011     Approbation pharmacist 
 
06/2010-03/2011   Temporary job at Hirsch-Apotheke Frankfurt and Central-
Apotheke Steinbach, Germany 
 
05/2010-11/2010   Research internship at Merck Serono Darmstadt, Department of 
Exploratory Development NBE, Darmstadt, Germany 
 
11/2009-05/2010  Pharmacy internship at Hirsch-Apotheke, Frankfurt and Central-
Apotheke, Steinbach, Germany 
 
10/2005-10/2009  Studies of pharmacy, Faculty of Pharmacy, Johann-Wolfgang-
Goethe-University, Frankfurt, Germany    
 
08/2002-06/2005   Secondary school, Johanneum Gymnasium, Herborn, Germany 
 
08/1996-07/2002  Secondary school, Johann-Textor Gymnasium Haiger, Germany  
 
08/1992-07/1996  Elementary school, Grundschule Langenaubach, Haiger, 
Germany 
 
 
 
 
 
